ŠĻą”±į>ž’ ž’’’śūüżž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ģ„Į` ųæˆ/bjbjźź 42ķ€ķ€ģ=’’’’’’¤® ® ® ® ® ® ® |#ŌŚŚŚŚd|Ś<PC–łjÄŻ”XŽXŽXŽXŽXŽXŽXŽĮųĆųĆųĆųĆųĆųĆų$ūhhż†ēųi® CįXŽXŽCįCįēų® ® XŽXŽPłæęæęæęCįx® XŽ® XŽĮųæęCįĮųæęæę:'ė,® ® gėXŽøŻ pC8&śōÅŚ»āśSė ½ķ fł0–ł]ė īżµęīżgėgė2īż® ™ķ$XŽ®ß|æę‚ßdęß]XŽXŽXŽēųēųµę XŽXŽXŽ–łCįCįCįCįPCPCPCdK“ŽdKPCPCPC“ŽĀ ¤f"x#® ® ® ® ® ® ’’’’ Pulmonary Hypertension Introduction Pulmonary hypertension (PH) is a disorder of the pulmonary circulation in which elevated pressure in the pulmonary vascular circuit can, when severe, lead to right heart failure and eventually cause death. The last 20 years have seen significant advances in our understanding of PH and the development of novel therapies for treatment. Pulmonary arterial hypertension (PAH), a subtype of PH, will be the focus of this article with special attention to its diagnosis and management. A successful and comprehensive approach to the diagnosis and treatment of this complex and rapidly progressive disease requires collaboration between the patient, the resources at the pulmonary hypertension center, and the community resources.[1] Classification and Staging For many years, PH was classified as either "primary" or "secondary." In 2003 the Third World Symposium updated the classification system, notably dropping the term "primary" altogether (Table 1).[2] They also stressed that the staging of patients with PH should be based on the functional capacity of the patient rather than on hemodynamic parameters. The World Health Organization classification system, a modified form of the New York Heart Association functional classification system, was recommended by the Symposium as the preferred staging system (Table 2).[3] Table 1. Revised Clinical Classification of Pulmonary Hypertension (Venice 2003) Pulmonary arterial hypertension (PAH) 1.1. Idiopathic (IPAH) 1.2. Familial (FPAH) 1.3. Associated with (APAH): 1.3.1. Collagen vascular disease 1.3.2. Congenital systemic-to-pulmonary shunts 1.3.3. Portal hypertension 1.3.4. HIV infection 1.3.5. Drugs and toxins 1.3.6. Other (thyroid disorders, glycogen storage disease, Gaucher disease, hereditary hemorrhagic telangiectasia, hemoglobinopathies, myeloproliferative disorders, splenectomy) 1.4 Associated with significant venous or capillary involvement 1.4.1 Pulmonary veno-occlusive disease (PVOD) 1.4.2 Pulmonary capillary hemangiomatosis (PCH) Pulmonary hypertension with left heart disease 2.1. Left-sided atrial or ventricular heart disease 2.2. Left-sided valvular heart disease Pulmonary hypertension associated with lung disease and/or hypoxemia 3.1. Chronic obstructive pulmonary disease 3.2. Interstitial lung disease 3.3. Sleep-disordered breathing 3.4. Alveolar hypoventilation disorders 3.5. Chronic exposure to high altitude 3.6. Developmental abnormalities Pulmonary hypertension due to chronic thrombotic and/or embolic disease 4.1. Thromboembolic obstruction of proximal pulmonary arteries 4.2. Thromboembolic obstruction of distal pulmonary arteries 4.3. Non-thrombotic pulmonary embolism (tumor, parasites, foreign material) Miscellaneous Sarcoidosis, histiocytosis-X, lymphangiomatosis, compression of pulmonary vessels (adenopathy, tumor, fibrosing mediastinitis)Reprinted from: Simmoneau G, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:10S.[2] Copyright 2004, reprinted with permission from American College of Cardiology Foundation. Table 2. World Health Organization Classification of Functional Status of Patients with Pulmonary Hypertension Class I: Patients with PH without limitation of usual activityClass II: Patients with PH with slight limitation of usual physical activityClass III: Patients with PH with marked limitation of usual physical activityClass IV: Patients with PH with inability to perform any physical activity without symptoms and who may have signs of right ventricular failureAdapted from Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:7S-10S.[3] Screening Current recommendations suggest that screening should be performed only on persons at increased risk for developing PAH.[1,4,5] Those with first-degree relatives with idiopathic pulmonary arterial hypertension (IPAH), those with a known genetic mutation that has been associated with the development of familial pulmonary arterial hypertension (FPAH), those with the scleroderma spectrum of diseases, patients with portal hypertension undergoing evaluation for liver transplantation, and patients with congenital heart disease and systemic-to-pulmonary shunts should undergo screening for occult PH. The American College of Chest Physicians (ACCP) recently recommended that genetic testing and counseling should be offered to relatives of patients with FPAH and that patients with IPAH should be made aware of the availability of this testing for their relatives.[5] Screening is generally done with Doppler echocardiography, but the evidence supporting the use of this test as a screening tool is limited.[5] Exercise echocardiography was studied in 2 families with FPAH in an attempt to detect asymptomatic gene carriers, and the sensitivity of this test was 87.5% with a specificity of 100%.[6] Because the anaerobic threshold and the oxygen consumption at peak exercise are known to be abnormal in patients with PAH, it has been suggested that cardiopulmonary exercise testing (CPET) be used as a screening tool; however, issues regarding the availability, reliability, and safety of this test in patients with PAH have limited its use as a screening tool.[7,8] Prenatal testing is also available for screening in cases where FPAH has been identified in family members; however, because of the low occurrence of the disease, even when the test is positive, only 10% to 20% will go on to develop PAH. For this reason, the role of prenatal screening has been questioned, particularly if it is being performed for the purpose of pregnancy termination.[5] Diagnosis The diagnosis of PAH is usually made during the process of evaluating symptoms such as dyspnea, exercise intolerance, chest pain, or syncope. Electrocardiographic changes, elevated brain natriuretic peptide (BNP) levels, and echocardiographic changes may suggest the diagnosis; however, current recommendations state that a right-heart catheterization (RHC) is "strongly advised" to formally make the diagnosis of PH (Table 3).[5] It is the author's belief that all patients who are suspected to have PH should have RHC prior to initiation of therapy. A mean pulmonary artery pressure > 25 mmHg at rest or > 30 mmHg with exercise along with a pulmonary artery occlusion pressure of < 15 mmHg are required to establish the diagnosis of PAH.[5] Table 3. Evaluation of a Patient With Suspected Pulmonary Hypertension Essential EvaluationContingent EvaluationHistory and physical examinationTransesophageal echoChest x-rayEcho with bubble studyElectrocardiogramCT chest ± high resolutionPulmonary function testingPulmonary angiogramVentilation-perfusion scanArterial blood gasTransthoracic echoCardiac MRIBlood tests: HIV, TFTs, LFTs, ANABlood tests: Uric acid, BNPSix-minute walk testPolysomnographyOvernight oximetryCardiopulmonary exerciseRight heart catheterizationOpen lung biopsy Initial Evaluation The initial evaluation of patients with PH should consist of testing to confirm the diagnosis, a search for causative disorders and complications from the disease, and a determination of the severity of the disease.[1,9] Left-heart disease, valvular heart disease, and parenchymal lung disease deserve special attention during this initial period of evaluation as they are common causes of pulmonary arterial pressure elevation and right ventricular failure; however, their prognosis, treatment, and outcome are far different from those seen with PAH. Recent ACCP evidence-based guidelines provide an excellent overview of the diagnostic strategy to be employed in patients with suspected PAH (see Figure 1).  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig1.gif" \* MERGEFORMATINET  Figure 1. Diagnostic strategy. Published with permission from McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S-34S.[5] A detailed history should be taken from the patient in an attempt to define the severity, duration, and degree of acceleration in symptom severity. The patient should also be questioned about drugs of abuse, herbal medicines and supplements, and prescription drugs including appetite suppressants and anorexigens. Patients with PH usually present with nonspecific symptoms including dyspnea (60%), chest pain (40%), and fatigue.[10] Symptoms are typically related to inability to increase cardiac output sufficiently in response to exertion and suboptimal oxygen transport. History and physical examination should focus on signs and symptoms compatible with an underlying disease including collagen vascular diseases, liver disease, sleep apnea, thromboembolic disease, and abnormalities in thyroid function.[11] The cardiac examination may reveal signs such as an increased pulmonic component of the second heart sound, an early systolic ejection click, a right ventricular fourth heart sound, a right ventricular heave, elevation of the jugular venous pulsations, or a murmur of either pulmonic or tricuspid insufficiency; however, none of these findings is specific to PAH.[5,11,12] In addition to undergoing a careful cardiac examination, the patient should be questioned about congenital heart disease and previous catheter ablation therapy for atrial fibrillation, a procedure that has been associated with pulmonary vein stenosis and PH.[13] The electrocardiogram (ECG) may be suggestive of right ventricular hypertrophy or right atrial enlargement and may demonstrate a right axis deviation. The sensitivity and specificity of the ECG for detecting PH are sufficiently poor to preclude its use as a screening tool; however, patients with newly diagnosed PH should have at least 1 ECG to establish a baseline for future comparison.[5] Right ventricular or pulmonary artery enlargement may be demonstrated on chest x-ray (Figure 2). Chest x-ray typically shows central enlargement of the pulmonary arteries with peripheral "pruning." Lupi and colleagues[14] have described an index of PH based on the ratio of the summed horizontal measurements of the pulmonary arteries from midline to their first divisions, divided by the transverse diameter. Chest radiography can be extremely helpful in identification of coexisting conditions such as COPD, kyphoscoliosis, and interstitial lung disease that may be responsible for the PH. In most cases, a CT scan of the chest (Figure 3) with high-resolution cuts should be performed to evaluate for the presence of parenchymal lung disease and mediastinal disorders that could cause obstruction of the pulmonary vessels.  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig2.jpg" \* MERGEFORMATINET  Figure 2. Chest radiograph of a patient with PAH showing central enlargement of pulmonary arteries bilaterally with peripheral "pruning."  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig3.jpg" \* MERGEFORMATINET  Figure 3. CT scan of the chest in a patient with PAH showing enlarged main and right and left pulmonary arteries with clear lung fields. A ventilation-perfusion (V/Q) scan should be performed to evaluate for chronic thromboembolic disease. Prior studies have shown that V/Q scans have a high sensitivity and specificity for distinguishing between IPAH and chronic thromboembolic PH.[15-17] Patients with a normal V/Q scan likely need no further evaluation for thromboembolic disease, but the poor correlation between the findings on V/Q scanning and the severity of vascular obstruction demands that those patients with a positive scan be sent for pulmonary angiography to accurately define the degree of vascular obstruction and to identify patients who would benefit from surgical thromboendarterectomy.[5,7] In addition to basic testing such as a complete blood count, an arterial blood gas, and a complete metabolic panel, the initial laboratory evaluation for patients with PH should include thyroid function tests, liver function tests (LFT), antiphospholipid antibodies, testing for collagen vascular diseases, and testing to detect the human immunodeficiency virus (HIV).[1] A baseline BNP value should be obtained because, as will be discussed later, a change in this value over time carries prognostic significance.[11] All patients with PH should undergo baseline pulmonary function testing including spirometry, determination of lung volumes, and evaluation of the diffusion limitation for carbon monoxide (DLCO). Pulmonary function testing may reveal evidence of significant obstructive or restrictive ventilatory defects that may be relevant to the etiology of PH.[12] While the DLCO has not been shown to correlate with the severity of PH, it has been shown that a reduction in the DLCO out of proportion to the decline in forced vital capacity is one of the earliest signs of PAH in patients with scleroderma.[18] A DLCO < 55% may identify a group of patients with scleroderma at high risk of developing PAH. Quantification of exercise tolerance is often performed by measuring the distance that a patient can walk in 6 minutes (6MWD). The 6MWD is a useful tool for following patients over time and, for this reason, serial determinations of the 6MWD distance should be made.[19] The 6MWD has been used to evaluate patients and has been utilized as a primary end point in recent clinical trials since earlier trials showed that 6MWD was predictive of survival in patients with IPAH.[20,21] Arterial oxygen desaturation > 10% during 6MWD has been shown to predict a 2.9 times increased risk of mortality over a median follow-up of 26 months.[22] Screening for unsuspected nocturnal hypoxemia and sleep apnea should also be performed in those patients newly diagnosed with PH. No further testing is warranted if overnight oximetry on room air shows no desaturation. Abnormal oximetry necessitates a full polysomnogram to formally diagnose and determine the severity of sleep apnea, as nocturnal hypoxia may be an aggravating or even a causative factor for PH.[19] In a recent prospective study of 43 patients with PAH without significant lung disease, Minai and colleagues (Minai OA, Pandya C, Avecillas J, et al. Significance and risk factors for nocturnal hypoxemia in pulmonary arterial hypertension. Submitted for publication)reported that 30 (70%) had evidence of nocturnal hypoxemia (defined as >10% of sleep time < 90% oxygen saturation). Nocturnal desaturators had a higher hemoglobin level than non-desaturators (14.5 vs 12.9; P = .002). They found that although 12/14 (86%) of those that desaturated during 6MW were nocturnal desaturators, only 43% of nocturnal desaturators required oxygen supplementation during 6MW. Nocturnal desaturators were more likely to be older (P = .030), have higher BNP (P = .004), and have lower cardiac index (P = .030). Among echocardiographic parameters, nocturnal desaturators were more likely to have RV dilation and a pericardial effusion compared with non-desaturators. Pulmonary function was normal in both groups; however, all patients with DLCO < 50% of predicted and MVO2 < 55% were desaturators. Mechanisms of exercise limitation in PH include arterial hypoxemia, poor cardiac output and stroke volume in response to increased demand, lactic acidosis at low work rates, and V/Q mismatching. Cardiopulmonary exercise testing provides more physiologic information than the standard 6MWD; however, because it is technically more difficult, is time-consuming, is not available at all centers, and may be less sensitive at detecting responses to treatment, it is not routinely used.[7,8] Patients with PAH typically show reduced peak VO2, reduced peak work rate, reduced anaerobic threshold, reduced peak oxygen pulse, increased VE and VCO2 slope indicating inefficient ventilation, and reduced ratio of VO2 increase to work rate increase.[23] The final essential, noninvasive test in the evaluation of PH is Doppler echocardiography. Echocardiography can help to exclude the presence of left-heart disease by evaluating left ventricular function and detecting diastolic dysfunction and valvular heart disease. The degree of right atrial and ventricular enlargement, right ventricular hypertrophy, pulmonary artery dilatation, presence or absence of pericardial effusion, and estimates of right ventricular function may all be determined by echocardiography. Doppler assessments can be used to estimate the right ventricular systolic pressure (RVSP) and to evaluate for the presence of intracardiac shunts and other forms of congenital heart disease. RVSP can be derived by adding the RAP to the RV/RAP gradient measured during systole, approximated by the modified Bernoulli equation as 4v2, where v is the tricuspid regurgitant jet velocity in meters/sec (RVSP = 4v2+RAP). Numerous studies have examined the correlation between RVSP as estimated by Doppler echocardiography and RVSP as directly measured during RHC, and most of these studies reported a relatively tight correlation (the r value ranged from 0.57-0.95).[24-28] In a study by Hinderliter and colleagues,[29] systolic pulmonary pressure was underestimated by at least 20 mmHg in 31% of patients.Other studies have demonstrated that the concordance between Doppler echocardiography and direct measurement via RHC worsens as the pressure rises, with poorest correlation when the systolic pulmonary pressure is over 100 mmHg.[30] Doppler echo may also overestimate systolic PAP in a population comprising people with normal pressure.[31,32] RHC is initially performed for the purpose of diagnosing PH; other important information can also be obtained from this test. The right atrial pressure, the mixed venous oxygen saturation, the cardiac output and index, and the pulmonary vascular resistance all may be either measured or calculated during RHC. If a congenital heart defect or a left-to-right shunt is suspected, one may measure the oxygen saturation at several points throughout the course of the systemic venous system, right heart, and pulmonary arterial system looking for a step-up in saturation that would suggest the presence of a left-to-right shunt. Pressure measurements obtained during RHC have been used to derive a prediction equation[33] that has been used to assess "predicted survival" and long-term effects of new treatments on survival. The equation to predict survival based on the National Institutes of Health (NIH) registry data is: P(t) = [H(t)]A(x,y,z); H(t) = [0.88 - 0.14t + 0.01t2]; A(x,y,z) = e(0.007325x + 0.0526y - .3275z) where P(t) = a patient's chances of survival at 't' years; t = 1, 2, or 3 years; x = mean pulmonary artery pressure; y = mean right atrial pressure; and z = cardiac index.[33] If RHC confirms the diagnosis of PH, a vasodilator should be given to determine the degree of pulmonary arterial vasoreactivity, a factor that carries therapeutic and prognostic significance, as will be discussed later. No consensus exists regarding which agent should be used to perform this test; however, intravenous epoprostenol, intravenous adenosine, or inhaled nitric oxide is often chosen because all of these are potent yet short-acting vasodilators. If the administration of a vasodilator causes the mean pulmonary arterial pressure to decrease e" 10 mmHg and reach d" 40 mmHg, with an unchanged or increased cardiac output, the patient is said to be vasoresponsive.[34] The main reason for vasodilator testing is to identify patients who are likely to have a good long-term response to treatment with calcium channel blockers (CCBs) alone. Patients with IPAH are more likely to have a positive vasodilator response that those with PAH associated with collagen vascular diseases. Overall, only a minority of patients (approximately 10% to 15%)[35,36] are likely to have a positive vasodilator response. The most recent recommendations from the ACCP did not advocate the routine use of magnetic resonance imaging (MRI) or open lung biopsy in the evaluation of patients with newly diagnosed PH. Cardiac MRI may provide additional pressure estimates and estimates of right ventricular mass and volume; however, at present the incremental value of this tool over standard testing measures is not sufficiently high to recommend its use in all patients. Likewise, because of the risks associated with the procedure, the ACCP recommends lung biopsy "only if a specific question could be answered by tissue examination" in patients with PH and its "routine use to diagnose PH or determine its cause is discouraged."[5] Such indications could include the detection of pulmonary veno-occlusive disease, bronchiolitis, active vasculitis, or pulmonary capillary hemangiomatosis. Treatment The treatment options for patients with PAH have expanded greatly in the recent past with novel therapies now available and others on the way.[19] Patients should be referred to a specialty center[1] that has experience in treating patients with PAH, and it is essential that there is a mutual understanding between the specialists at the referral center and the patient's regular physicians regarding the overall direction and goals of care. Recent evidence-based recommendations made by the ACCP indicate that treatment options considered for specific patients should be based on their baseline New York Heart Association (NYHA) functional class (Figure 4).[34]  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig4.gif" \* MERGEFORMATINET  Figure 4. Treatment algorithm for PAH based on NYHA functional class at presentation. Adapted from: Badesch DB, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:45S.[34] General Management-Related Issues Hypobaric hypoxia may induce pulmonary vasoconstriction, and even patients with PAH who did not require supplemental oxygen during the 6MW may require oxygen supplementation during flight. (Minai OA, McCarthy K, Arroliga AC. Altitude simulation in pulmonary arterial hypertension: applications and implications. Submitted for publication.) All patients planning to travel by commercial airliners should either undergo a standardized altitude simulation test or use supplemental oxygen. Cautious use of diuretics and a sodium-restricted diet are indicated for patients with evidence of right ventricular failure. Digitalis has not been studied extensively in patients with PAH, but it is often used in patients who have atrial dysrhythmias or refractory right ventricular failure.[34] Experts recommend using the least invasive surgical approach and avoiding the use of general anesthesia when possible until larger studies clearly define the risk that surgery imposes on patients with PAH.[7,37] It is the author's belief that, when possible, vasoactive therapy should be initiated in an attempt to decrease pulmonary arterial pressure and improve right ventricular function prior to surgical intervention. Aggressive steps should be taken to avoid pregnancy in patients with PAH, as the 30% to 50% rise in cardiac output that is normally seen in pregnancy may cause the already taxed right ventricle to decompensate.[38] Oxygen Therapy It has been proposed that most patients with PAH (not due to congenital heart disease) have only mild hypoxemia at rest, most likely due to low MVO2 and only minimal ventilation perfusion mismatching.[7] No consistent data are available regarding the effects of long-term oxygen therapy. Supplemental oxygen should be given to keep the oxygen saturation e" 90% at all times in patients with PAH given the adverse consequences of chronic hypoxia (submitted for publication). As a result, both daytime and nocturnal hypoxemia should be screened for with a 6MW and nocturnal oximetry in all newly diagnosed patients with PAH. Even in patients for whom use of oxygen may be more controversial, such as patients with congenital heart disease who have large right-to-left shunts, use of supplemental oxygen has the potential to reduce the need for phlebotomy and neurologic sequelae. Anticoagulation Whether it is a cause or an effect of the increased pulmonary pressures, intravascular thrombosis is observed in patients with PAH. Anticoagulation with warfarin has been shown to reduce mortality in patients with IPAH. Studies by Rich and colleagues and Fuster and associates demonstrated improved survival among patients with IPAH who took warfarin compared with those patients who did not.[39,40] There is some concern that patients with PH in association with congenital heart disease may be at increased risk for hemoptysis. Even though warfarin has not been specifically studied in randomized, prospective trials, ACCP consensus guidelines recommend anticoagulating all patients with PAH with the target level of anticoagulation being an international normalized ratio (INR) of approximately 2.0 unless there is a clear contraindication.[34] Calcium-Channel Blockers The development of more effective therapies has led to a dramatic reduction in the role of CCBs in the therapy of patients with PAH. The main role of vasodilator testing during RHC is to identify patients more likely to respond to CCB.[9] In a 1992 study, Rich and colleagues[39] demonstrated that treatment with CCBs in persons who had displayed a positive vasoreactivity challenge during RHC resulted in a long-term reduction in the pulmonary artery pressure, pulmonary vascular resistance, and right ventricular hypertrophy and a significant survival benefit at 1, 3, and 5 years compared with nonresponders. There have been no prospective, randomized, controlled trials of oral CCBs in PAH. In view of the proven efficacy of newer therapies, it is now recommended that CCBs not be used in patients without demonstrated vasoreactivity and that they never be used to empirically treat PAH. According to present recommendations, a trial of CCBs is still acceptable for patients with PAH who demonstrate vasoreactivity (as defined during the Venice Symposium) and have a preserved functional status and cardiac index.[34] The percentage of patients with PAH who respond to acute vasodilator testing has varied between reports,[39,41-43] but a more recent report suggests that such patients may comprise approximately 10% to 15% of IPAH patients.[35] It is also recognized that approximately 50% of patients initiated on CCBs alone will experience deterioration over time, necessitating the addition of newer forms of therapy.[35] As such, patients demonstrating vasoreactivity initiated on CCBs alone should be followed very closely for signs of deterioration or progressive disease.[44] Nifedipine, diltiazem, or amlodipine can be used, depending on baseline heart rate. CCBs with a significant negative inotropic effect, such as verapamil, should be avoided. Prostanoids Prostacyclin is a potent vasodilator with antiplatelet effects, and therapy with prostacyclin analogs (prostanoids) has become a cornerstone in the treatment of patients with PAH (Figure 5).[45] To date, 4 different prostanoids have been studied (see Table 4), each with unique delivery systems, side effects, and evidence of efficacy. Table 4. Randomized Trials Demonstrating the Effectiveness of Therapies for PAH DrugTrialFirst Author, Journal, YearPatientsDuration (wks)EpoprostenolPilotRubin, Ann Intern Med, 1990238EpoprostenolPivotalBarst, NEJM, 19988112EpoprostenolCTDBadesch, Ann Intern Med, 200011112TreprostinilPivotalSimmoneau, AJRCCM, 200246912IloprostAIROlschewsi, NEJM, 200220312BeraprostALPHABETGalie, JACC, 200213012BosentanPilotChannick, Lancet, 20013312BosentanBREATHE-1Rubin, NEJM, 200221316SitaxsentanSTRIDE-1Barst, AJRCCM, 200417212SitaxsentanSTRIDE-2Unpublished24012SildenafilSUPER-1Unpublished27812 DrugEtiology of PH (%)8NYHA Functional Class (%)*6MWD (m)#Hemodynamic ImprovementClinical ParametersEpoprostenolIPAH (100)II (9)45YesImprovedIII (65)IV (26)EpoprostenolIPAH (100)III (75)47YesImprovedIV (25)EpoprostenolCTD (100)II (5)94YesNo ChangeIII (78)IV (17)TreprostinilIPAH (58)II (11)1688YesImprovedCHD (24)III (82)CTD (19)IV (7)IloprostIPAH (54)III (59)36Yes†ImprovedCTD (17)IV (41)BeraprostIPAH (48)II (49)25NoNo ChangeCHD (21)III (51)Po-PH (16)CTD (7)HIV (7)BosentanIPAH (85)III (100)76YesImprovedCTD (15)BosentanIPAH (70)III (91)44Yes^ImprovedCTD (30)IV (9)SitaxsentanIPAH (53)II (33)34YesImprovedCTD (24)III (66)CHD (24)IV (1)SitaxsentanIPAH (59)II (38)31N/AYesCTD (30)III (59)CHD (11)IV (4)SildenafilIPAH (63)I (1)36 (20 TID)Yes^^YesCTD (30)II (39)46 (40 TID)CHD (7)III (58)50 (80 TID)IV (3)CHD = congenital heart disease-associated PAH; CTD= connective tissue disease associated PAH; CTEPH: chronic thromboembolic PH; IPAH = idiopathic pulmonary arterial hypertension; N/A = not available; NS = not statistically significant *Sum may be greater than 100% since 0.5 was rounded up to a whole number #Net improvement in 6MWD compared with placebo †Post-inhalation ^Hemodynamics only assessed by echocardiography post-therapy ^^All 3 doses  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig5.gif" \* MERGEFORMATINET  Figure 5. Rationale for vasoactive therapy: critical pathways in PAH. With permission from: Galie N, et al. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224.[45] © 2002 Elsevier Inc. Epoprostenol was the first studied prostanoid, and its introduction some 10 years ago revolutionized the treatment of patients with PAH. Epoprostenol is unstable at room temperature and must be kept cold prior to and during infusion. Because of its short half-life in the bloodstream (only about 3-5 minutes), epoprostenol requires continuous intravenous administration; usually via a tunneled catheter into a central vein. The initial dosing for epoprostenol generally ranges from 2-10 ng/kg/min, with side effects or systemic hypotension limiting the use of higher doses. Tachyphylaxis is common, and doses often require elevation over time. The exact dosing protocol varies between centers,[9] but it is generally accepted that most patients will have a positive response at a dose between 20 and 45 ng/kg/min. Epoprostenol is stored as a dry powder, reconstituted with a sterile diluent, and then continuously infused via an ambulatory infusion pump worn by the patient. Common side effects include flushing, diarrhea, headache, arthralgias, tachycardia, and jaw pain. High doses may produce hypotension and heart failure, and, because of epoprostenol's potent vasodilatory properties, patients with coronary artery disease may develop a coronary "steal" phenomenon and experience cardiac ischemia with the administration of epoprostenol. Sudden reductions in dose or abrupt cessation of the drug may result in severe rebound pulmonary hypertension or even sudden death. Patients are at increased risk of line infections and thrombosis because the drug must be infused through a central venous catheter.[46,47] Two large studies of epoprostenol therapy have been conducted in patients with IPAH (Table 4).[21,48] The landmark study demonstrating the effectiveness of epoprostenol was published in 1996 by Barst and colleagues.[21] In this study of functional class III and IV patients with IPAH, 41 patients were treated with epoprostenol plus standard therapy (anticoagulation and diuretics) while 40 patients were treated with standard therapy alone. The epoprostenol group showed a reduction in pulmonary artery pressure (8% drop in the epoprostenol group vs a 3% rise in the standard group) and pulmonary vascular resistance (21% drop in the epoprostenol group vs a 9% increase in the standard group) while also showing significant improvement in 6MWD distance, echocardiographic parameters, and quality of life. Eight patients died in this study, all in the standard therapy group. Epoprostenol was also studied by Badesch and colleagues[49] in the treatment of patients with PAH associated with the scleroderma spectrum of disease (Table 4). Again, epoprostenol plus standard therapy was compared with standard therapy alone, and the epoprostenol group demonstrated a 46-meter improvement in 6MWD whereas the standard group had a 48-meter decline. Significant changes were also seen in the mean pulmonary artery pressure, pulmonary vascular resistance, and functional class. No difference in mortality was noted in this study. Epoprostenol therapy has also shown positive results in nonrandomized studies in patients with PAH in association with congenital heart defects,[50] systemic lupus erythematosus,[51] PAH associated with HIV infection[52] or Gaucher's disease,[53] porto-pulmonary hypertension,[54] and pediatric IPAH.[55] These studies demonstrated the effectiveness of epoprostenol in small numbers of patients over short periods of time; however, subsequent studies have established that the drug is effective over long periods of time in large numbers of patients. McLaughlin and colleagues[46] reported that a group of 162 epoprostenol-treated patients followed for a mean of 36.3 months had significant improvements in 1-, 2-, and 3-year survival compared with expected survival (Figure 6) based on the NIH Registry prediction equation. Likewise, Sitbon and colleagues[47] reported that 178 functional class III or IV patients treated with epoprostenol had significantly better survival at 1, 2, 3, and 5 years compared with historical controls. This study also showed that improvements in functional class and hemodynamics at 3 months could predict long-term survival in these patients.[47]  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig6.gif" \* MERGEFORMATINET  Figure 6. Survival in 162 patients with PAH treated with epoprostenol. The observed survival rates (diamonds) at 1, 2, and 3 years were 87.8%, 76.3%, and 62.8%, respectively, and were much better than the expected survival rates (squares) of 58.9%, 46.3%, and 35.4%, respectively, based on the NIH registry prediction equation. With permission from: McLaughlin VV, et al. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477.[46] There have been occasional reports of patients weaned off epoprostenol or treprostinil with the addition of bosentan.[56-58] Such cases of successful withdrawal are very few and there are no clear criteria, at present, regarding who can be safely transitioned off intravenous or subcutaneous prostanoid therapy. It is the opinion of the author that such withdrawal is risky and should only be attempted at PH centers by physicians who are experienced at treating PH, and then only in carefully selected patients with close follow-up. Treprostinil is a prostacyclin analog that is stable at room temperature and has a half-life of 3 hours. Because of its longer half-life, treprostinil can be delivered subcutaneously rather than through a central venous line, thus minimizing the line infection and thrombosis seen with epoprostenol use. Unlike epoprostenol, treprostinil is stable at room temperature and can be dispensed as a premixed solution and directly inserted into the pump without the need to mix the solution or the use of ice packs.[9] As with epoprostenol, the usual starting dose for treprostinil is low (1-2 ng/kg/min), and this dose is often limited by symptoms or by systemic hypotension. The side-effect profile for treprostinil is similar to that for epoprostenol except that therapy with subcutaneous treprostinil is also associated with significant pain at the infusion site in many patients. Topical analgesics, anti-inflammatory drugs, tricyclic antidepressants, and rotation of the infusion sites are often used to alleviate the symptoms; however, in some patients pain at the infusion site is such that therapy with treprostinil has to be discontinued. Intravenous (IV) treprostinil has been demonstrated to achieve a similar hemodynamic response to that of epoprostenol, and the IV form has been demonstrated to achieve hemodynamic responses similar to those seen with the subcutaneously delivered form.[59] Efficacy of subcutaneous treprostinil was established in a placebo-controlled, randomized, controlled, 12-week study (Table 4) involving 470 patients with IPAH or PAH associated with connective tissue disease or congenital systemic to pulmonary shunts. Treatment with treprostinil improved 6MWD distance (16-meter improvement for the treprostinil group and no change for the control group; P = .006), symptoms, and hemodynamics. Treatment effect was related to dose achieved (patients who received > 13.8 ng/kg/min improved their 6MWD by 36 m), however, only one quarter of patients achieved this dose due to infusion site pain. There was no difference in mortality between the two groups.[60] The magnitude of improvement with treprostinil was not as great as that seen in the epoprostenol trials; however, most experts believe that the reason the treatment effect was not as robust had more to do with patient selection and trial design rather than true differences in efficacy between the drugs. It is also noteworthy that 85% of patients in the study had pain at the infusion site, 83% had erythema or induration at the infusion site, and 8% withdrew from the trial due to pain at the infusion site, underscoring the magnitude of the site pain problem.[61] Treprostinil was recently approved by the FDA for IV administration in patients with PAH. The potential advantages of IV treprostinil over epoprostenol include stability at room temperature (thus avoiding ice packs), the fact that it comes in a prefilled and premixed syringe so patients only need to place the syringe in the pump and do not have to mix it daily in a sterile fashion, and the fact that the cassette can be changed every 3 days. The longer half-life also provides added peace of mind to both patients and physicians in case of pump or catheter malfunction. Although not currently approved in the United States, beraprost, the first available oral prostanoid, is rapidly absorbed with peak concentrations achieved after 30 minutes and a half-life of 35-40 minutes. Beraprost has been used in Japan since the mid-1990s; however, the evidence supporting its use consisted of uncontrolled and retrospective studies until 2002. At this time, Galie and colleagues[62] published the results of a study involving 130 subjects with PAH and class II or III symptoms who were treated with beraprost 4 times daily (Table 4). In this 12-week study, there was an increase in 6MWD between 25 and 45 meters in treated patients, but there was no difference in hemodynamics or mortality. A second trial among 116 patients with PAH and class II or III symptoms showed that while treated patients had improved 6MWD distances at 3 and 6 months, this effect was not sustained at 9 or 12 months and, again, there was no effect on hemodynamics or mortality.[63] Iloprost is a prostanoid that may be delivered intravenously, orally, or via aerosolization. It has a serum half-life of 20-25 minutes and, when delivered via aerosolization, is given 6 to 9 times a day. Aerosolized treatment with iloprost, which is the route approved in the United States, can be complicated by cough; otherwise, the side effects from iloprost are similar to those seen with the other prostanoids. In 2002, a 3-month, prospective, randomized, double-blind, placebo-controlled trial involving 203 subjects with PAH and a functional class of III and IV (Table 4) demonstrated that patients treated with iloprost were more likely to improve their 6MWD (median 36-meter improvement in the iloprost group; P = .004), functional class (P < .05), quality of life (P < .05), and post-inhalation hemodynamics than those patients who did not receive iloprost.[64] Iloprost was administered at a dose of 2.5 mcg or 5.0 mcg 6 to 9 times a day. The primary composite end point consisting of a 10% improvement in 6MWD, NYHA functional class improvement, and lack of clinical deterioration was seen in 17% of iloprost patients and only 5% of placebo treated patients (P = .007). Additionally, 14% of control patients in this study withdrew due to progressive symptoms or death, compared with only 4% in the iloprost group. Even though cough and other side effects occurred more often in the iloprost group than in the placebo group, the side effects were generally mild. Given the cumbersome nature of epoprostenol delivery, the infusion site pain associated with treprostinil, and the disappointing results seen with beraprost, iloprost seems to be an attractive alternative for patients requiring prostanoid therapy. Endothelin Antagonists Endothelin-1 has been shown to be a potent vasoconstrictor and a mediator of the pulmonary vascular remodeling seen in PAH.[65-67] Two receptors for endothelin-1 have been identified, ETA and ETB. ETA mediates vasoconstriction and remodeling and ETB is involved in the clearance of endothelin-1 and perhaps also in vasodilatation and nitric oxide release. Many endothelin receptor antagonists, including sitaxsentan and ambrisentan, are being studied in PH; however, only bosentan is currently available for use in the United States. Bosentan blocks both the ETA and ETB receptors and was the first available endothelin antagonist. Bosentan is dispensed as a tablet that is generally taken twice daily.[19] Multiple studies demonstrated that bosentan prevents or reverses the development of PH in various animal models of PH.[68-70] The first randomized, placebo-controlled, double-blind trial documenting the effect of bosentan was published in 2001 by Channick and colleagues (Table 4).[61] Thirty-two NYHA Class III patients with IPAH or PAH due to scleroderma were randomized to receive either bosentan or placebo for 12 weeks. The group of patients receiving bosentan saw significant improvements in 6MWD (70-meter improvement for the bosentan group vs a 12-meter reduction in the control group; P < .05), cardiac output (0.5-L/min increase in the bosentan group vs a 0.5-L/min reduction in the control group; P < .001), pulmonary vascular resistance (223 dyne-sec/cm5 reduction in the bosentan group vs a 191 dyne*cm*sec-5 elevation in the control group, P < .001), and functional class. Liver function test abnormalities were rare in this study and, among those patients who experienced elevation, all levels returned to normal with discontinuation of the drug or reduction in dose. Bosentan is contraindicated in pregnancy. Bosentan is primarily eliminated via the P450 enzyme pathway, as such use of glyburide and cyclosporin A is contraindicated in patients taking bosentan. A second, larger randomized, double-blind, placebo-controlled study was performed over 16 weeks on 213 NYHA Class III or IV patients with either IPAH or PAH associated with connective tissue disease (Table 4).[71] Unlike the previous trial where the maximum dose of bosentan was 125 mg twice daily, patients in the Bosentan Randomized Trial of Endothelin Receptor Antagonist Therapy of Pulmonary Hypertension (BREATHE-1) study were randomized to receive placebo, bosentan 125 mg twice daily, or bosentan 250 mg twice daily. Again, treatment with bosentan was shown to improve 6MWD (36-meter improvement in the bosentan group vs an 8-meter fall in the control group; P = .002) (Figure 7), and the time to clinical worsening (P = .0015 with log-rank test) (Figure 8). A comparable overall treatment effect was seen in patients with IPAH where bosentan improved the 6MWD from baseline (+46 meters in the treatment group vs -5 in the placebo group) and PAH associated with scleroderma where bosentan use prevented deterioration of 6MWD (+3 meters in treatment group vs -40 meters in the placebo group). In addition, 42% of those receiving bosentan had an improvement in their functional class at Week 16, while only 30% of those receiving placebo had an improvement in functional class (mean treatment effect was 12% in favor of bosentan, 95% confidence interval -3% to 25%). Of note, the group receiving 250 mg twice daily had a higher incidence of abnormalities in LFT and no statistically significant benefit over the 125-mg dose. A subgroup of 85 patients enrolled to be part of an echocardiographic study showed that bosentan improved right ventricular function and early diastolic filling of the left ventricle.[72] Bosentan was evaluated in a 16-week study of patients with PAH related to HIV disease. The study showed an improvement in 6MWD (+91 ± 60 m; P < .001), NYHA functional class, and hemodynamics (CI: +0.9 ± 0.7 L/min/m2; P < .001).[73]  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig7.gif" \* MERGEFORMATINET  Figure 7. Six-minute walk distance improvement seen in 213 patients with PAH, demonstrating a significant effect of bosentan. With permission from: Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896.[71] Copyright © 2002 Massachusetts Medical Society. All Rights Reserved.  INCLUDEPICTURE "http://images.medscape.com/pi/editorial/clinupdates/2005/4684/art-minai.fig8.gif" \* MERGEFORMATINET  Figure 8. Delay in clinical worsening in 213 patients with PAH treated with bosentan, demonstrating a significant effect. * With permission from: Rubin LJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896.[71] Copyright © 2002 Massachusetts Medical Society. All Rights Reserved. Bosentan is associated with abnormal hepatic function, and it should not be prescribed to patients with moderate to severe hepatic impairment. The mechanism for hepatic impairment is a dose-dependent inhibition of bile salt excretion that can be toxic to hepatocytes.[74] The FDA requires that LFTs be checked monthly in patients taking bosentan, and if the transaminases rise to more than 3 times the upper limit of normal, the dose should be decreased and the transaminases should be monitored very closely. Transaminase elevation above 5 times the upper limit of normal should prompt temporary cessation of the drug until LFTs return to normal followed by a rechallenge. Elevation of LFTs more than 8 times the upper limit of normal should prompt permanent discontinuation of the drug. To date there have been no reports of acute liver failure or chronic liver injury with the use of bosentan. Bosentan is listed as a pregnancy risk factor "X," meaning that pregnancy must be excluded prior to beginning therapy with bosentan and females of childbearing age on bosentan should be counseled regarding contraception. Bosentan may interfere with the action of hormonal contraceptives, so many experts recommend 2 forms of contraception in those on bosentan. Bosentan may cause testicular atrophy and male infertility, so a discussion regarding reproductive options should be had with young, male patients before the drug is begun. Bosentan has been associated with worsening of peripheral edema and mild anemia, and many adverse drug interactions have been reported, including (but not limited to) cyclosporine, glyburide, fluconazole, and hydroxymethylglutaryl-CoA (HMG-CoA) reductase inhibitors.[34] McLaughlin and colleagues[75] recently reported on the long-term survival of 139 functional class III and IV patients treated with bosentan as first-line therapy over 36 months. At the end of 1 year, 96% of patients initially treated with bosentan monotherapy were still alive, and at the end of 2 years 89% were alive, compared with the 69% and 57% expected survival based on the NIH Registry prediction equation.[33] Of patients started on bosentan, 85% were still on monotherapy at 12 months and 70% were still on monotherapy at 2 years in this study. Factors associated with a worse outcome included NYHA Class IV symptoms and 6MWD less than 358 meters at baseline. A comparison of the outcome of these patients to that of a group of 346 functional class III patients who had previously been treated with epoprostenol over a 36-month period[76] demonstrated that first-line treatment with bosentan did not negatively impact survival compared with epoprostenol. In fact, analysis by a Cox regression model suggested that the group of patients treated with epoprostenol had a greater mortality risk than the patients treated with bosentan as a first-line agent (hazard ratio 2.327; P = .0059).[76] Selective ETA Antagonists Selective ETA antagonists are under study with the rationale that selective blockade of the ETA receptor will allow the continued favorable activity of the ETB receptor.[9] The two agents that have received the greatest attention are sitaxsentan and ambrisentan. Sitaxsentan is approximately 6000-fold more selective for the ETA than the ETB receptors compared with bosentan. Sitaxsentan has many adverse drug interactions (including warfarin) and carries concern regarding liver toxicity, testicular atrophy, male infertility, peripheral edema, and teratogenesis. Sitaxsentan is not currently available for use in the United States outside the setting of a clinical trial. In 2004, Barst and colleagues[77] published the results of the Sitaxsentan to Relieve Impaired Exercise (STRIDE-1) study, a prospective, randomized, double-blind, placebo-controlled trial involving 178 NYHA Class II, III, and IV patients with PAH who were randomized to placebo or 1 of 2 doses of sitaxsentan: 100 mg or 300 mg daily (Table 4). The groups receiving the 100-mg dose improved 6MWD by 35 meters (P < .01) and the group receiving 300-mg dose improved their 6MWD by 33 meters (P < .01). Both groups showed statistically significant improvements in hemodynamics and functional class as compared with placebo. The incidence of liver function abnormalities was 10% with the 300-mg dose but only 3% with the 100-mg dose. A follow-up study of 11 patients from this group demonstrated that at 1 year, only 1 patient required escalation of therapy to epoprostenol and no patients on therapy had evidence of hepatotoxicity. Further, the remaining treated patients demonstrated a 50-meter improvement in 6MWD (P = .04), a 0.9-L/min improvement in cardiac output (P = .009), a 157-dyne*cm*sec-5 improvement in pulmonary vascular resistance (P = .04), and an improvement in functional class (all 10 patients were now class II) at 1 year.[78] Hepatotoxicity has been a concern in patients on sitaxsentan. In the pilot study, a case of fatal hepatitis occurred when using sitaxsentan at a high dose. Both STRIDE I and STRIDE II have indicated a low risk (lower than that associated with bosentan) of hepatotoxicity with sitaxsentan at the 100-mg dose. Another study, STRIDE-2, has enrolled 240 patients with class II, III, or IV symptoms and 6MWD distance of d" 450 meters (Table 4).[79] Patients in this study were randomized to placebo, 50-mg, or 100-mg doses of sitaxsentan and were also compared to an open-label group of patients receiving bosentan 125 mg twice daily. The results of this study have not yet been subject to the process of peer review associated with publication; however, early reports indicate that 6MWD distance improved by 24.2 meters over baseline in the group receiving 50 mg of sitaxsentan (P = NS), 31.4 meters over baseline in the group receiving 100 mg of sitaxsentan (P = .04), and 29.5 meters in the group receiving bosentan. Statistically significant improvement in functional class was seen only in the group receiving 100 mg of sitaxsentan (P = .04). The most frequently reported side effect is an elevated INR (when the drug is used concomitantly with warfarin). This can be managed by adjusting the warfarin dose to achieve the desired INR. Ambrisentan is under investigation in a phase 3 trial for which the results have not been released. More information on both ETA antagonists will be forthcoming. Phosphodiesterase Inhibitors Cyclic guanosine 3'-5' monophosphate (cGMP) plays a critical role in the regulation of vascular smooth muscle tone by acting as a catalyst in a series of intracellular reactions that mediate vasodilatation. Phosphodiesterases rapidly degrade cGMP thereby limiting nitric oxide-mediated pulmonary vasodilation. Phosphodiesterase type 5 (PDE5), while normally strongly expressed in the lung, has been shown to be present at higher levels than normal in chronic PH.[34] PDE5 inhibitors such as sildenafil or tadalafil can block the effects of PDE5, thereby increasing cGMP levels and potentiating nitric oxide-mediated vasodilatation. Sildenafil, a potent inhibitor of phosphodiesterase type 5, increases intracellular levels of cGMP and thus causes vasodilatation.[9] Many small, nonrandomized, open-label trials have suggested that administration of sildenafil to patients with PAH improves hemodynamics, 6MWD, and functional class.[80,81] Results of the Sildenafil Use in Pulmonary Arterial Hypertension (SUPER-1) trial were recently presented at the ACCP meeting in October 2004 and at the American thoracic Society meeting in May 2005 (Table 4). This was a randomized, double-blind, placebo-controlled, 12-week trial comparing 3 doses (20 mg, 40 mg, or 80 mg 3 times daily) of sildenafil to placebo in 278 patients with NYHA Class II, III, or IV PAH.[82] Evidence presented showed that all 3 doses of sildenafil improved 6MWD over placebo with a 45-meter improvement in the 20-mg group (P < .001), a 46-meter improvement in the 40-mg group (P < 0.001), and a 50-meter improvement in the 80-mg group (P < .001). Mean pulmonary artery pressure decreased by 2.7 mmHg in the 20-mg group (P = .04), 3 mmHg in the 40-mg group (P = .01), and 5.1 mmHg in the 80-mg group (P < .001). Placebo-corrected cardiac output increased by 0.5 L/min in the 20-mg group (P = .04), 0.5 L/min in the 40-mg group (P = .03), and 0.8 L/min in the 80-mg group (P = .001). Placebo-corrected pulmonary vascular resistance improved by 171 dyne*cm*sec-5 in the 20-mg group (P = .01), 192 dyne*cm*sec-5 in the 40-mg group (P = .006), and 310 dyne*cm*sec-5 in the 80-mg group (P = .001). Time to clinical worsening was not significantly different in the 80-mg sildenafil group vs placebo and by protocol was not statistically evaluated in the other groups. This study is currently undergoing peer review in consideration for publication. Patients who completed the SUPER-1 study had the option of enrolling in the extension, open-label SUPER-2 study where all patients were transitioned to a dose of 80 mg 3 times a day. Preliminary results from the SUPER-2 study[83] were presented at the American Thoracic Society meeting in May 2005. Data presented were suggestive of sustained benefit in 6MW and NYHA functional class at 12 months, and only 6% of patients required additional therapy. The observed mortality in the group treated with sildenafil was 96% at 1 year, much lower than expected survival of 71% as estimated based on the NIH Registry prediction equation.[33] On the basis of the results of the SUPER-1 study, the FDA approved sildenafil for use in patients with PAH at a dose of 20 mg 3 times daily with no NYHA functional class restriction. On the basis of previously mentioned nonrandomized, open-label studies, many patients have already been placed on sildenafil doses of up to 75 to 100 mg 3 times daily. Systemic hypotension is the most serious side effect, and some people taking high doses report vision changes including blurred vision and color change. There have also been recent reports of visual loss that appear to be dose related and a class effect. Nitric oxide, while not a phosphodiesterase inhibitor, does augment and sustain intracellular levels of cGMP, and administration of nitric oxide has been shown to cause reductions in pulmonary artery pressure and pulmonary vascular resistance. Nitric oxide has been used in vasoreactivity challenges for many years, but the experience with its use in the long-term treatment of PAH is very limited.[9,34] One open-label study that included only 5 patients with PAH demonstrated that nitric oxide can be delivered effectively using a nasal cannula and a gas pulsing device.[84] Follow-up RHC at 12 weeks showed improvement in pulmonary artery pressure and cardiac output in 3 of these patients; however, the long-term use of this medication is limited by the difficult delivery system and the lack of published data regarding its efficacy and safety. L-arginine is the sole substrate for nitric oxide synthase, the enzyme responsible for generating nitric oxide. Studies examining the short-term intravenous administration of L-arginine on hemodynamics have been mixed; however, one small study in which oral L-arginine was compared with placebo showed improvement in hemodynamics and exercise capacity after 1 week of treatment.[85] No large, rigorous trials of L-arginine have yet been published; therefore, at this time the role of L-arginine in the treatment of PAH is not clear. Hydroxymethylglutaryl-CoA Reductase Inhibitors Animal models suggest that HMG-CoA reductase inhibitors may slow or inhibit vascular remodeling and improve hemodynamics in rat models of PAH.[86] A case series has recently been published in which therapy with an HMG-CoA reductase inhibitor improved 6MWD and hemodynamics.[87] Further studies need to be done to confirm these findings. Combination Therapy Given the mechanisms of action for the 3 main classes of medications used to treat PAH, it would seem that these different medicines would complement each other and achieve a greater effect when given together rather than alone. Several small studies have provided preliminary, encouraging data about the potential usefulness of combination therapy in patients declining on monotherapy.[88,89] A case series of 9 patients published by Hoeper and colleagues[90] suggests that sildenafil improves 6MWD and maximum oxygen uptake in patients who have worsened while on bosentan therapy alone. As many of these medicines have only recently been approved, there are more questions than answers regarding the validity of the concept of combination therapy. These questions include the proper combinations of medicines, the appropriate timing to institute combination therapy, the "acceptable" level of benefit, and the identification of patients in whom combination therapy is appropriate. These questions can only be answered via well-designed, prospective trials showing added efficacy, safety, and survival benefit. Interventional and Surgical Therapy The presence of a patent foramen ovale has been shown to confer a survival advantage in patients with severe IPAH awaiting lung transplantation.[91] Atrial septostomy (AS), by creating a right-to-left intra-atrial shunt, decompresses the right ventricle and has been shown to immediately improve symptoms of right ventricular function and exercise capacity,[92] and has also been shown to increase cardiac index anywhere from 15% to 58%.[93,94] Pulmonary thromboendarterectomy[95] has been shown to improve hemodynamics, functional status, and survival in patients with chronic thromboembolic PAH; however, there are few well-controlled trials in this area so the magnitude of benefit is difficult to precisely define.[95] It is accepted that pulmonary thromboendarterectomy is the treatment of choice in patients with operable chronic thromboembolic PH.[96] Patients with inoperable PH from chronic thromboemboli and those with significant residual PH after surgery should be treated with medical therapy used in PAH patients. Lung transplantation has been performed for patients with PAH for 2 decades; however, with the advances made in the treatment of PAH, lung transplantation should only be considered after medical therapy has failed.[9] Current recommendations state that patients with class III or IV symptoms at presentation should be referred to a transplant center for evaluation so that if the response to therapy is insufficient, evaluation and listing for lung transplantation may be expedited.[96,97] According to the United Network for Organ Sharing database, the survival in patients with PH undergoing LT at 1 year is 73% and at 3 years is 56%.[98] Prognosis The prognosis of untreated PAH is poor; however, with therapy the expected survival and quality of life have improved dramatically.[99] The prognosis of treated patients with PAH depends on many factors, and it is still not certain which factors carry the most prognostic significance and which factors should be used to guide decisions regarding escalation of therapy and referral for lung transplant evaluation.[97] Survival in PAH may vary depending on presence or absence of underlying disease and etiology of the underlying disease if present.[99-103] Echocardiographic parameters,[99] the 6MWD,[20] bicycle ergometry,[23] plasma atrial natriuretic peptide and BNP,[104] elevated uric acid levels,[105] baseline exercise tolerance and the degree of improvement in exercise tolerance at 3 months and 1 year after initiation of epoprostenol therapy[46,47] have all been shown to correlate with survival in patients with PAH. Treatment with prostanoids, endothelin receptor antagonists, and phosphodiesterase inhibitors has been shown to prolong survival among patients with PAH.[46,47,75,83] Conclusion The past 3 decades have seen great advances in our understanding of the genetics and pathogenesis of PAH. With this understanding has come the development of new treatments that have significantly improved the life span and lifestyle of these patients. New insights into the best way to screen for, monitor, and care for patients with PAH, as well as the development of novel therapies, will hopefully allow us to continue to improve the care that these patients receive. Supported by an independent educational grant from Actelion. References Mughal MM, Mandell B, James K, Stelmach K, Minai OA. Implementing a shared-care approach to improve the management of patients with pulmonary arterial hypertension. Cleve Clin J Med. 2003;70:S28-S33. Simmoneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2004;43:10S. Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:7S-10S. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141-1150. McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:14S-34S. Grunig E, Janssen B, Mereles D, et al. Abnormal pulmonary artery pressure response in asymptomatic carriers of primary pulmonary hypertension gene. Circulation. 2000;102:1145-1150. Galie N, Torbicki, A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension: the task force on diagnosis and treatment of pulmonary arterial hypertension of the European Society of Cardiology. Eur Heart J. 2004;25:2243-2278. Galie N, Manes A, Branzi A. Evaluation of pulmonary arterial hypertension. Curr Opin Cardiol. 2004;19:575-581. Gildea TR, Arroliga AC, Minai OA. Treatments and strategies to optimize the comprehensive management of patients with pulmonary arterial hypertension. Cleve Clin J Med. 2004;70:S18-S27. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension: a national prospective study. Ann Intern Med. 1987;107:216-223. McGoon M. The assessment of pulmonary hypertension. Clin Chest Med. 2001;22:493-508. Budev MM, Arroliga AC, Jennings CA. Diagnosis and evaluation of pulmonary hypertension. Cleve Clin J Med. 2003;70:S9-S17. Vasamreddy CR, Jayam V, Bluemke DA, Calkins H. Pulmonary vein occlusion: an unanticipated complication of catheter ablation of atrial fibrillation using the anatomic circumferential approach. Heart Rhythm. 2004;1:78-81. Lupi E, Dumont C, Tehada VM, et al. A radiologic index of pulmonary arterial hypertension. Chest. 1975;68:28-31. D'Alonzo GE, Bower JS, Dantzker DR. Differentiation of patients with primary and thromboembolic pulmonary hypertension. Chest. 1984;85:457-461. Bergin CJ, Hauschildt J, Rios G, Belezzuoli EV, Huynh T, Channick RN. Accuracy of MR angiography compared with radionuclide scanning in identifying the cause of pulmonary arterial hypertension. Am J Roentgenol. 1997;168:1549-1555. Worsley DF, Palevsky HI, Alavi A. Ventilation-perfusion lung scanning in the evaluation of pulmonary hypertension. J Nucl Med. 1994;35:793-796. Steen VD, Graham G, Conte C, et al. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum. 1992;35:765-770. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:40S-47S. Miyamoto S, Nagaya N, Satoh T, et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med. 2000;161:487-492. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension: the primary pulmonary hypertension study group. N Engl J Med. 1996;334:296-302. Paciocco G, Martinez F, Bossone E, Pielsticker E, Gillespie B, Rubenfire M. Oxygen desaturation on the six-minute walk test and mortality in untreated primary pulmonary hypertension. Eur Respir J. 2001;17:647-652. Wensel R, Opitz CF, Anker SD, et al. Assessment of survival in patients with primary pulmonary hypertension: importance of cardiopulmonary exercise testing. Circulation. 2002;106:319-324. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: Primary Pulmonary Hypertension Study Group. Circulation. 1997;95:1479-1486. Chan KL, Currie PJ, Seward JB, et al. Comparison of three Doppler ultrasound methods in the prediction of pulmonary artery pressure. J Am Coll Cardiol. 1987;9:549-554. Yock PG, Popp RL. Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation. Circulation. 1984;70:657-662. Kim WR, Krowka MJ, Plevak DJ, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl. 2000;6:453-458. Denton CP, Cailes JB, Phillips GD, et al. Comparison of Doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol. 1997;36:239-243. Hinderliter AL, Willis PW, Barst RJ, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension: primary pulmonary hypertension study group. Circulation. 1997;95:1479-1486. Bossone E, Duong-Wagner TH, Paciocco G, et al. Echocardiographic features of primary pulmonary hypertension. J Am Soc Echocardiogr. 1999;12:655-662. Penning S, Robinson KD, Major CA, et al. A comparison of echocardiography and pulmonary artery catheterization for evaluation of pulmonary artery pressures in pregnant patients with suspected pulmonary hypertension. Am J Obstet Gynecol. 2001;184:1568-1570. Naeije R, Torbicki A. More on the noninvasive diagnosis of pulmonary hypertension: Doppler echocardiography revisited. Eur Respir J. 1995;8:1445-1449. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med. 1991;115:343-349. Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. 2004;126:35S-62S. Sitbon O, Humbert M, Ioos V, et al. Who benefits from long-term calcium-channel blocker therapy in primary pulmonary hypertension? [abstract]. Am J Respir Crit Care Med. 2003;167:A440. Galie N, Seeger W, Naeije R, et al. Comparative analysis of clinical trials and evidence-based treatment algorithm in pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:81S-88S. Venkateshiah SB, Arroliga AC, Mehta AC, et al. Safety of surgery in patients with pulmonary arterial hypertension (Abstr). Am J Respir Crit Care Med. 2002;165:B53. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med. 2004;351:1425-1436. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation. 1984;70:580-587. Groves BM, Badesch DB, Turkevich D, et al. Correlation of acute prostacyclin response in primary (unexplained) pulmonary hypertension with efficacy of treatment with calcium channel blockers and survival. In: Weir K, ed. Ion Flux in Pulmonary Vascular Control. New York, NY: Plenum Press; 1993: 317-330. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension: a dose-response study and comparison with prostacyclin. Am J Respir Crit Care Med. 1995;151:384-389. Pavelsky HI, Schloo BL, Pietra GG, et al. Primary pulmonary hypertension: vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation. 1989;80:1207-1221. Sitbon O, Humbert M, Jagot JL, et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J. 1998;12:265-270. Galie N, Manes A, Branzi A. Emerging medical therapies for pulmonary arterial hypertension. Prog Cardiovasc Dis. 2002;45:213-224. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation. 2002;106:1477-1482. Sitbon O, Humbert M, Nunes H, et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol. 2002;40:780-788. Rubin LJ, Mendoza J, Hood M, et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med. 1990;112:485-491. Badesch DB, Tapson VF, McGoon MD, et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease: a randomized, controlled trial. Ann Intern Med. 2000;132:425-434. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation. 1999;99:1858-1865. Robbins IM, Gaine SP, Schilz R, et al. Epoprostenol for treatment of pulmonary hypertension in patients with systemic lupus erythematosus. Chest. 2000;117:14-18. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med. 2000;162:1846-1850. Bakst AE, Gaine SP, Rubin LJ. Continuous intravenous epoprostenol therapy for pulmonary hypertension n Gaucher's disease. Chest. 1999;116:1127-1129. Kuo PC, Johnson LB, Plotkin JS, et al. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation. 1997;63:604-606. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation. 1999;99:1197-1208. Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic pulmonary arterial hypertension receiving concomitant bosentan. Am J Cardiol. 2004;93:943-946. Kim NH, Channick RN, Rubin LJ. Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension. Chest. 2003;124:1612-1615. Suleman N, Frost AE. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension. Chest. 2004;126:808-815. McLaughlin VV, Gaine SP, Barst RJ, et al. Efficacy and safety of treprostinil: an epoprostenol analog for primary pulmonary hypertension. J Cardiovasc Pharmacol. 2003;41:293-299. Simmonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analog, in patients with pulmonary arterial hypertension: a double-blind randomized, placebo-controlled trial. Am J Respir Crit Care Med. 2002;165:800-804. Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet. 2001;358:119-123. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin analog, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol. 2002;39:1496-1502. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2003;4:2119-2125. Olschewski H, Simmonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. 2002;347:322-329. MacLean MR. Endothelin-1: a mediator of pulmonary hypertension? Pulm Pharmacol Ther. 1998;11:125-132. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;328:1732-1739. Galie N, Grigion F, Bacchi-Raggiani L, et al. Relation of endothelin-1 to survival in patients with primary pulmonary hypertension. Eur J Clin Invest. 1996;26:273. Pearl JM, Wellman SA, Mcnamara JL, et al. Bosentan prevents hypoxia-reoxygenation-induced pulmonary hypertension and improves pulmonary function. Ann Thorac Surg. 1999;68:1714-1721. Chen SJ, Chen YF, Meng QC, et al. Endothelin-receptor antagonist bosentan prevents and reverses hypoxic pulmonary hypertension in rats. J Appl Physiol. 1995;79:2122-2131. Hill NS, Warburton RR, Pietras L, et al. Nonspecific endothelin-receptor antagonist blunts monocrotaline-induced pulmonary hypertension in rats. J Appl Physiol. 1997;83:1209-1215. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903. Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and Doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. 2003;41:1380-1386. Sitbon O, Gressin V, Speich R, et al. Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;170:1212-1217. Fattinger K, Funk C, Pantze M, et al. The endothelin antagonist bosentan inhibits the canalicular bile salt export pump: a potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther. 2001;69:223-231. McLaughlin VV, Sitbon O, Badesch DB, et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J. 2005;25:244-249. Sitbon O, McLaughlin V, Badesch D, et al. Comparison of two treatment strategies, first-line bosentan or epoprostenol, on survival in class III idiopathic pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med. 2004;169:A442. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-447. Langleben D, Hirsch AM, Shalit E, Lesenko L, Barst RJ. Sustained symptomatic, functional, and hemodynamic benefit with the selective endothelin-A receptor antagonist, sitaxsentan, in patients with pulmonary arterial hypertension. Chest. 2004;126:1377-1381. Barst RJ, Langleben D, Badesch D, et al. The STRIDE-2 Trial: Does Selectivity Matter in Endothelin Antagonism for PAH? American Thoracic Society - 2005 - Mini-Symposium. Abstract: A300. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation. 2002;105:2398-2403. Zimmerman AT, Calvert AF, Veitch EM. Sildenafil improves right-ventricular parameters and quality of life in primary pulmonary hypertension. Intern Med J. 2002;32:424-426. Badesch D, Burgess G, Parpia T, Torbicki A; and the SUPER-1 team. Sildenafil Citrate in Patients with Pulmonary Arterial Hypertension (PAH): Results of a Multicenter, Multinational, Randomized, Double-Blind, Placebo-Controlled Trial by WHO Functional Class (FC). American Thoracic Society, 2005 Thematic Poster Session (Poster: K93, Abstract: A206). Rubin L, Burgess G, Parpia T, Simonneau G, and the SUPER-1 team. Effects of Sildenafil on 6-Minute Walk Distance (6MWD) and WHO Functional Class (FC) after 1 Year of Treatment. American Thoracic Society - 2005 Mini-Symposium (Abstract: A299). Channick RN, Yung GL. Long-term use of inhaled nitric oxide for pulmonary hypertension. Resp Care. 1999;44:212-219. Nagaya N, Uematsu M, Oya H, et al. Short-term oral administration of L-arginine improves hemodynamics and exercise capacity in patients with precapillary pulmonary hypertension. Am J Respir Crit Care Med. 2001;163:887-891. Girgis RE, Li D, Zhan X, et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol. 2003;285:H938-945. Kao PN. Simvastatin treatment of pulmonary hypertension. Chest. 2005;127:1446-1452. Humbert M, Barst RJ, Robbins IM, et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J. 2004;24:353-359. Gomberg-Maitland M, McLaughlin VV, Gulati M, Rich S. Efficacy and safety of sildenafil and atorvastatin added to bosentan as therapy for pulmonary arterial hypertension [abstract]. Am J Respir Crit Care Med. 2005 Sep 8; [Epub ahead of print]. Hoeper MM, Faulenbach C, Golpon H, et al. Combination therapy with bosentan and sildenafil in idiopathic pulmonary arterial hypertension. Eur Respir J. 2004;24:1007-1010. Glanville A, Burke C, Theodore J, et al. Primary pulmonary hypertension: length of survival in patients referred for heart-lung transplantation. Chest. 1987;91:675-681. Klepetko W, Mayer E, Sandoval J, et al. Interventional and surgical modalities of treatment for pulmonary arterial hypertension. J Am Coll Cardiol. 2004;43:73S-80S. Nihill MR, O'Laughlin MP, Mullins CE. Effects of atrial septostomy in patients with terminal cor pulmonale due to pulmonary vascular disease. Cathet Cardiovasc Diagn. 1991;24:166-172. Sandoval J, Gaspar J, Pulido T, et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension: a therapeutic alternative for patients unresponsive to vasodilator treatment. J Am Coll Cardiol. 1998;32:297-304. Doyle RL, McCrory K, Channick RN, et al. Surgical treatments/interventions for pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest. 2004;126:63S-71S. Moser KM, Auger WR, Fedullo PF, et al. Chronic thromboembolic hypertension: clinical picture and surgical treatment. Eur Respir J. 1992;5:334-342. Minai OA, Budev MM. Referral for lung transplantation: a moving target. Chest. 2005;127:705-707. United Network for Organ Sharing. Available at: http://www.unos.org. Accessed September 4, 2003. McLaughlin VV, Presberg KW, Doyle RL, et al. Prognosis of pulmonary arterial hypertension. ACCP evidence-based clinical practice guidelines. Chest 2004;126:78S-92S. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-993. ł ü ż ’ Ž į O R ¤ QRČĖ%&•ŌÕ"#qr £¦(/ž”Z]ČĶPSTV  C!F!Ž!¹!ŗ!š!ń!źęŻęĖęŻęŻęĖĆ®—®ĖęĖĆĖĆĖĆĖĆ®—ĖęŻęŻęŻęŻęŻęŻęĖęŻęŻę‚ĆĖĆ)hMsŪ5B*CJOJQJ\^JaJph,hMsŪ6B*CJH*OJQJ]^JaJph)hMsŪ6B*CJOJQJ]^JaJphhMsŪCJaJ#hMsŪB*CJOJQJ^JaJphhMsŪCJH*aJhMsŪ)hMsŪ5B* CJOJQJ\^JaJphf3$ż ’  S ¤ Ź ā ų 7gƒ™²d¤śõšśõšėÜĖĖ¼«««««œ¼ & F¤d¤š$If[$ & F¤d¤d$If[$\$ & F¤d¤š$If[$ & F¤d¤d$If[$\$ & F¤d¤š$If[$gdMsŪgdMsŪgdMsŪgdMsŪˆ/ż¤Ó2gŽÓ’@i‘²ś:xÄŅQīߊ氊æææææ°Šææ°Šæ & F¤d¤š$If[$ & F¤d¤d$If[$\$ & F¤d¤š$If[$ & F¤d¤š$If[$ & F¤d¤d$If[$\$QR&•Ō˜“Žˆ$IfgdMsŪgdMsŪgkd$$IfT–-ÖÖ¶’Ś$€Ö0’’’’’’ö6Ö’Ö’Ö’Ö’3Ö4Ö-aöbÖŠTŌÕ"#q˜’+’gkd:$$IfT–-ÖÖ¶’Ś$Ö0’’’’’’ö6Ö’Ö’Ö’Ö’3Ö4Ö-aöbÖŠT$Ifgkd $$IfT–-ÖÖ¶’Ś$Ö0’’’’’’ö6Ö’Ö’Ö’Ö’3Ö4Ö-aöbÖŠTqr¤˜’+&gdMsŪgkdn$$IfT–-ÖÖ¶’Ś$Ö0’’’’’’ö6Ö’Ö’Ö’Ö’3Ö4Ö-aöbÖŠT$IfgkdŌ$$IfT–-ÖÖ¶’Ś$Ö0’’’’’’ö6Ö’Ö’Ö’Ö’3Ö4Ö-aöbÖŠT¤¦°ĪTV`G!Ž!£!¹!śõšššśõšėåÜ $$Ifa$$IfgdMsŪgdMsŪgdMsŪgdMsŪ ¹!ŗ!Ū!š!ƒ}}$If|kd$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTš!ń!ż!"ƒ}}$If|kd¶$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTń!""B"C"r"s"”"¢"Į"Ā"##&#'#S#T##‚#„#n$s$\&]&Ó&Ō&Õ&Ö&×&ą&ö&Ō'×'Ų'„)ˆ)++p,y,|-€-ķåķåķåķåķåķåķåķåķåķįŲįĮķĮŖĮķ•ķ€iķįŲįŲįŲįŲ,hMsŪ6B*CJH*OJQJ]^JaJph)hMsŪ6B*CJOJQJ]^JaJph)hMsŪ5B*CJOJQJ\^JaJph,jF hMsŪB*CJOJQJU^JaJph,jhMsŪB*CJOJQJU^JaJphhMsŪCJH*aJhMsŪhMsŪCJaJ#hMsŪB*CJOJQJ^JaJph)""'"B"ƒ}}$If|kd^$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTB"C"^"r"ƒ}}$If|kd$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTr"s"Ž"”"ƒ}}$If|kd®$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠT”"¢"µ"Į"ƒ}}$If|kdV$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTĮ"Ā"ä"#ƒ}}$If|kdž$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠT###&#ƒ}}$If|kd¦$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠT&#'#:#S#ƒ}}$If|kdN$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠTS#T#p##ƒ}}$If|kdö$$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠT#‚#„#—#\&×&Ų'+-C2¾2H3Ć3ƒ~ytl~tttl~l$a$gdMsŪgdMsŪgdMsŪgdMsŪ|kdž $$IfT–-ÖÖ0¶’` NÖ0’’’’’’ö6Ö’’Ö’’Ö’’Ö’’3Ö4Ö-aöbÖŠT €-/ /ć/ē/C2D2ŗ2»2¼2½2¾2Ē2H3I3æ3Ą3Į3Ā3Ć3Ģ3L4A5H5č6ķ6^8a8š8ō8Q:U:H;L;¶<ŗ<…=Œ=#>'>Ä?Č?”A¢A—B˜B³B“BÜBŻBźCüóüóüÜŹÜ³ÜŹžŹÜŹÜ‡ÜŹžŹüóüóüóüóüóüóüóüóüóüóü€ü€ü€ü€ü hMsŪ6],jŪ¼hMsŪB*CJOJQJU^JaJph)hMsŪ5B*CJOJQJ\^JaJph,jźthMsŪB*CJOJQJU^JaJph#hMsŪB*CJOJQJ^JaJph,jhMsŪB*CJOJQJU^JaJphhMsŪCJH*aJhMsŪ2Ć3L4ī6õ8¬;(>DģFJgM’PaQRhWČZŹZŌZl]ē]Ž^_ŽddZijiŗlśõõõõõõõõõķõõõśčõąśŪõŪõŪõgdMsŪ$a$gdMsŪgdMsŪ$a$gdMsŪgdMsŪgdMsŪźCėCęEėEFFƒF„FĘFĒFēFėF9J:J;JCJDJ†J‡JˆJ„K‹KµK¹KóL÷L_MfM/P3P QQ2Q3QBQ`Q RRfUnU,W3W(Z+ZČZŹZb[f[˜[›[g]k]l]m]ć]ä]å]ę]ē]öņéņöņöņöņéņāéņāņāéņéņéņéņéņéņéņéņéņéņéņéņéņŠņéņéņéņ¹Š¹¢¹Š,jqhMsŪB*CJOJQJU^JaJph,jhMsŪB*CJOJQJU^JaJph#hMsŪB*CJOJQJ^JaJph hMsŪ6]hMsŪCJH*aJhMsŪhMsŪCJH*aJ:ē]š]=^Ł^Ż^Ž^ bbŻbćb‰dd0e1eeeheņjłjµl¹l¾mĮmęmźm0q4qq§qrrČrĢrfsjsātętÄuvv8v9vfvgvvžvŅvÓvżvžv*w+wWwXw„w…wµw¶wźŲƬŲØŸØŸØŸØ–ØŸØŸØŸØŸØŸØŸØŸØŸØŸØŸØŸØźŽŲŽŲŽŲŽŲŽŲŽŲŽŲŽŲŽŲŽhMsŪCJaJhMsŪCJH*aJhMsŪCJH*aJhMsŪ,hMsŪ6B*CJH*OJQJ]^JaJph)hMsŪ6B*CJOJQJ]^JaJph#hMsŪB*CJOJQJ^JaJph)hMsŪ5B*CJOJQJ\^JaJph8ŗlÓlt$ttuÄuÉuĻuėuōuvśõśõśļęęęę $$Ifa$$IfgdMsŪgdMsŪ vvvv3v6v8vD>5555 $$Ifa$$If»kd€z$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠT8v9vFvNv`vcvfvD>5555 $$Ifa$$If»kdX{$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTfvgvtvxv–všvvD>5555 $$Ifa$$If»kd*|$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTvžv«v³vĖvĻvŅvD>5555 $$Ifa$$If»kdü|$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTŅvÓvÜvąvövśvżvD>5555 $$Ifa$$If»kdĪ}$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTżvžvww#w'w*wD>5555 $$Ifa$$If»kd ~$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠT*w+w4w:wQwTwWwD>5555 $$Ifa$$If»kdr$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTWwXwawkw}ww„wD>5555 $$Ifa$$If»kdD€$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠT„w…w‘wšw®w²wµwD>5555 $$Ifa$$If»kd$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTµw¶wĀwĖw×wŪwŽwD>5555 $$Ifa$$If»kdč$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠT¶wŽwßwxxxxx9x:xCxDxqxrx”x¢x°x±x¾xæxšxńxžx’x.y/y=y>yKyLymyoy}y~y”y•y©yŖyĢyĶy×yŲyķyīyzz1z2zBzCzPzQz^z_zŒzz›zœzķåķåŃ¼„¼„¼„¼åķåķåķåķåķåķåķåķåķ‘ķåķåķåķ‘ķåķåķåķåķåķåķåķåķå&hMsŪB*CJH*OJQJ^JaJph,hMsŪ5B*CJH*OJQJ\^JaJph)hMsŪ5B*CJOJQJ\^JaJph&hMsŪ<B*CJOJQJ^JaJphhMsŪCJaJ#hMsŪB*CJOJQJ^JaJph9ŽwßwźwņwžwxxD>5555 $$Ifa$$If»kdŗ‚$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠTxxx x x;xD<6-- $$Ifa$$If$a$gdMsŪ»kdŒƒ$$IfT–-ÖÖr¶’Ž· čyÖ0’’’’’’öL6Ö’’’’’Ö’’’’’Ö’’’’’Ö’’’’’3Ö4Ö-aöbÖŠT;xEx]xqxrxööö&Škd^„$$IfT–-Öֈ¶’Žõ7VÕÖ0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT $$Ifa$rxxŠx‘x”x˜x”xłššššš $$Ifa$$If”x¢x£x¤x-''$IfŃkdD…$$IfT–-4Öֈ¶’Žõ7VÕ`````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT¤x­x®xÆx°xöššš$If $$Ifa$°x±x²x³x-''$IfŃkd@†$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT³x»x¼x½x¾xöššš$If $$Ifa$¾xæxĢx×x-' $$Ifa$$IfŃkdB‡$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT×xąxćxēxšxöööö $$Ifa$šxńxņxóx-''$IfŃkdDˆ$$IfT–-4Öֈ¶’Žõ7VÕ`````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTóxūxüxżxžxöššš$If $$Ifa$žx’x yy-' $$Ifa$$IfŃkd@‰$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTyy y$y.yöööö $$Ifa$.y/y0y1y-''$IfŃkdBŠ$$IfT–-4Öֈ¶’Žõ7VÕ`````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT1y:y;yy?y@y-''$IfŃkd>‹$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT@yHyIyJyKyöššš$If $$Ifa$KyLyYycy-' $$Ifa$$IfŃkd@Œ$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTcykypyty}yöööö $$Ifa$}y~yyˆy-' $$Ifa$$IfŃkdB$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTˆy‘y’y“y”yöššš$If $$Ifa$”y•y–yŸy-' $$Ifa$$IfŃkd9Ž$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTŸy¦y§yØy©yöššš$If $$Ifa$©yŖy³y½y-' $$Ifa$$IfŃkd6$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT½yĘyÉyĪy×yöööö $$Ifa$×yŲyŁyāy-' $$Ifa$$IfŃkd3$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTāyźyėyģyķyöššš$If $$Ifa$ķyīyųyz-' $$Ifa$$IfŃkd*‘$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTz z zzzöööö $$Ifa$zzz%z-' $$Ifa$$IfŃkd'’$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT%z.z/z0z1zöššš$If $$Ifa$1z2z3z>z-' $$Ifa$$IfŃkd“$$IfT–-4Öֈ¶’Žõ7VÕ `   Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT>z?z@zAzBzłłłł$IfBzCzDzLz-' $$Ifa$$IfŃkd ”$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTLzMzNzOzPzłłłł$IfPzQzRzZz-' $$Ifa$$IfŃkd"•$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTZz[z\z]z^złłłł$If^z_zhzrz-' $$Ifa$$IfŃkd$–$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTrz|zzƒzŒzöööö $$Ifa$ŒzzŽz—z-' $$Ifa$$IfŃkd&—$$IfT–-4Öֈ¶’Žõ7VÕ`````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT—z˜z™zšz›złłłł$If›zœz„zÆz-' $$Ifa$$IfŃkd"˜$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTÆzøz»zĄzÉzöööö $$Ifa$œz¾zæzÉzŹzŽzßz {{${%{9{:{c{d{z{{{{{ŗ{¼{Į{Ā{ā{ć{||||ū|t}u}Š}Ń}G~H~I~J~K~T~‘~ķŁķŃķŃķŃķŃķŃķŃķŃķŃķŁķŃķŃķŃķŃ¼ķŁķ„ķ„Ž„ķyķ¼)hMsŪ5B*CJOJQJ\^JaJph,jč¤hMsŪB*CJOJQJU^JaJph,jhMsŪB*CJOJQJU^JaJph)hMsŪ6B*CJOJQJ]^JaJphhMsŪCJaJ&hMsŪB*CJH*OJQJ^JaJph#hMsŪB*CJOJQJ^JaJph)ÉzŹzĖzŌz-' $$Ifa$$IfŃkd$™$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTŌzŪzÜzŻzŽzöššš$If $$Ifa$Žzßzėzõz-' $$Ifa$$IfŃkdš$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTõzżz{{ {öööö $$Ifa$ {{{{-' $$Ifa$$IfŃkd›$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT{!{"{#{${öššš$If $$Ifa$${%{&{/{-' $$Ifa$$IfŃkdœ$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT/{6{7{8{9{öššš$If $$Ifa$9{:{F{P{-' $$Ifa$$IfŃkd $$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTP{X{[{_{c{öööö $$Ifa$c{d{e{n{-' $$Ifa$$IfŃkd ž$$IfT–-4Öֈ¶’Žõ7VÕ````Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTn{w{x{y{z{öššš$If $$Ifa$z{{{|{…{-' $$Ifa$$IfŃkdŸ$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT…{Œ{{Ž{{öššš$If $$Ifa${{›{„{-' $$Ifa$$IfŃkdżŸ$$IfT–-4Öֈ¶’Žõ7VÕ    Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT„{«{·{½{Į{öööö $$Ifa$Į{Ā{Ć{Ģ{-' $$Ifa$$IfŃkdś $$IfT–-4Öֈ¶’Žõ7VÕ```Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTĢ{Ō{ą{į{ā{ööšš$If $$Ifa$ā{ć{ä{ģ{-' $$Ifa$$IfŃkdģ”$$IfT–-4Öֈ¶’Žõ7VÕ   Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠTģ{õ{|||ööšš$If $$Ifa$||||-''$IfŃkdä¢$$IfT–-4Öֈ¶’Žõ7VÕ ``  Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT| ||||öššš$If $$Ifa$||Š}K~-( $a$gdMsŪgdMsŪŃkdę£$$IfT–-4Öֈ¶’Žõ7VÕ     Ö0’’’’’’öL6Ö’’’’’’Ö’’’’’’Ö’’’’’’Ö’’’’’’3Ö4Ö-aöbÖŠT 56ėī}…„…ć…ź…\†`†(‰,‰£‹§‹Å‹É‹ė‹ļ‹Œ Œ'Œ+Œ?ŒCŒSWkŽoŽŖ®Æ°&'()*3r‘ ’ ’’ƒ’éŌĀ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾µ¾žĀž‡žĀrĀŌéĀ¾)hMsŪ5B*CJOJQJ\^JaJph,j«żhMsŪB*CJOJQJU^JaJph,jhMsŪB*CJOJQJU^JaJphhMsŪCJH*aJhMsŪ#hMsŪB*CJOJQJ^JaJph)hMsŪ6B*CJOJQJ]^JaJph,hMsŪ6B*CJH*OJQJ]^JaJph,K~6d‚……ńˆDŒÆ*’$”›˜QœˆžÅ š¤:¦T«k«­¬®,³ŹŗE»…¼½>¾äĂĒśõõõõõķśõõõõõõõõčõõõõķśķśõõgdMsŪ$a$gdMsŪgdMsŪgdMsŪƒ’Š’!–$––™š™!›"›LœPœƒž‡žU¢Y¢•¤™¤i§j§†§‡§”§¢§ż§Ø-©.©ę«ķ«%¬&¬-¬.¬2¬3¬c¬d¬œ­­¤­„­)®-®¤®«®GÆKƀ°°ņ°ó°„±…±ż³“ʵĒµ¶¶Ż¹į¹nŗoŗøŗ¹ŗ»ŗ¼ŗÅŗÉŗŹŗĖŗA»B»öņöņöņėņöņöņöņöņėņėņėņöņėņöņāņāņāņāņāņāņöņöņöņėņėņėņöņėņėņöņėņöņėņöņĖ¹Ė#hMsŪB*CJOJQJ^JaJph,jhMsŪB*CJOJQJU^JaJphhMsŪCJH*aJ hMsŪ6]hMsŪhMsŪCJH*aJGB»C»D»E»N»Ć»;¼?¼„¼…¼†¼ü¼ż¼ž¼’¼½ ½|½ō½ų½=¾>¾IæMæßÄćÄżÄÅ‚Ę†Ę0Č4ȄÉéŅĄ«Ą––ĄŅĄŅhŅĄ«Ą––Ąd[d[d[d[d[dhMsŪCJH*aJhMsŪ,jójhMsŪB*CJOJQJU^JaJph,hMsŪ6B*CJH*OJQJ]^JaJph)hMsŪ6B*CJOJQJ]^JaJph)hMsŪ5B*CJOJQJ\^JaJph#hMsŪB*CJOJQJ^JaJph,jhMsŪB*CJOJQJU^JaJph,jl1hMsŪB*CJOJQJU^JaJph „ɅɏɓɠɔÉŗÉ»É Ź ŹLŹMŹNŹWŹZŹõŹöŹĖĖmĢqĢéĶźĶ8Ī9ĪDŠEŠyŠzŠ•Š—ŠĘŠĒŠ%Ń)ŃĄÓČӔՕÕåÕęՖ֗Öß׹×ķŁńŁŪŪĀŪÉŪgŻkŻšŻńŻ&Ž'ŽaŽbŽµŽ¶ŽŚŽŪŽßß\ß]߄߅߰߱ßąąąą6ą8ąMąNąkąmą‚ąƒąhālāżćäīēōēłõģõćõćõćõćŽõģõćõćõģõłõłõłõłõģõłõģõģõłõłõłõćõģõģõģõģõłõłõłõłõłõłõłõłõłõģõłõģõłõģõłõģõģõģ hMsŪ>*hMsŪCJH*aJhMsŪCJH*aJhMsŪ hMsŪ6]X‚Ē”É®ÉPĢ¼ŅŲŲ—Ś‡įä`ę²éĒėöėGķIķ]ķBīŖļµń·ńŪń˜óßõ`ųbųlų³üśõśśśõśśśśśśõśšėśśśšėśśśšėśgdMsŪgdMsŪgdMsŪgdMsŪōēœč č,ė0ė„ģˆģķ ķGķIķßīęī%ļ)ļµń·ńkņoņ@óDóó—ó·ó»ó©ō­ō1õ5õµöøöĮ÷Č÷[ų_ų`ųbųļųóų ś śś˜ś¶śŗśÄśČśŪśßś ūū*ū/ūæūĘū„ü²ü³üµü˜žŌžÕž×žāžÓŽßłé8ź8“E,‡/ˆ/üóüóüóüóüįüóüóüįüóüóüóüóüóüóüóüóüóüįüóüóüóüóüóüóüóüóüóüóüįüŚüįüįÅįÅįÅįĆįæhsxBU)hMsŪ6B*CJOJQJ]^JaJph hMsŪ6]#hMsŪB*CJOJQJ^JaJphhMsŪCJH*aJhMsŪI³üµüĄü˜žÕž×žāž«’&ø‰Ju0· ˆe×hP į e ū ś śõššśõįįįįįįįįįįįįįįįįįįįį & F¤d¤d[$\$gdMsŪgdMsŪgdMsŪgdMsŪś š Ē „§P’µ€£9;Ó†/é„J½]ö' Ā˜³m 8!šššššššššššššššššššššššššššš & F¤d¤d[$\$gdMsŪ8!"±"T#é#$+%±%Œ&$'Ž'’(˜)j*[+į+b,É,h- .Ä.p/%0£0Ž1K2 3æ3±4šššššššššššššššššššššššššššš & F¤d¤d[$\$gdMsŪ±4?5A6ü6ü7©8:ü:q;Q<Ł<.=Ļ=Ć>o?@æ@xAfB"C¶CDzD E“E’,G-.Ķ.šššššššššššššššššššššššššššš & F¤d¤d[$\$gdMsŪStupi AM, Steen VD, Owens GR, et al. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24. Opravil M, Pechere M, Speich R, et al. HIV-associated primary pulmonary hypertension: a case controlled study. Swiss HIV cohort study. Am J Respir Crit Care Med. 1997;155:990-995. Hopkins WE, Ochoa LL, Richardson GW, et al. Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996;15:100-105. Nagaya N, Nishikimi T, Uematsu M, et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation. 2000;102:865-870. Nagaya N, Uematsu M, Satho T, et al. Serum uric acid levels correlate with the severity and the mortality of primary pulmonary hypertension. Am J Respir Crit Care Med. 1999;160:487-492. Ķ.‡/ˆ/šī & F¤d¤d[$\$gdMsŪ21h:pMsŪ°Š/ °ą=!° "° # $ %°°Š°Š Šž$$If–ć’!vh5Ö$%#v$%:V –-Ö0’’’’’’ö6ö,Ö5Ö/Ö ’3Ö4Ö-ŠT˜$$If–ć’!vh5Ö$%#v$%:V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT˜$$If–ć’!vh5Ö$%#v$%:V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT˜$$If–ć’!vh5Ö$%#v$%:V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT˜$$If–ć’!vh5Ö$%#v$%:V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¬$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö,Ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¦$$If–ć’!vh5ÖŖ 5Öī #vŖ #vī :V –-Ö0’’’’’’ö6ö5Ö/Ö ’3Ö4Ö-ŠT¤jDdæ"ččšh² š S šDAĮ’Ćart-minaiFigure 1š€bšči ņ7ēżėמ°Mu›ē"Ļ’ÄiŠ nš¼i ņ7ēżėמ°Mu›ē"Ļ’‰PNG  IHDR£Qßł(I€PLTEžĖźeŖ×Öķü%e“‘IšĪ;‘ÉW¢Ņ¬Ōī‚»ąB¢t³ÜŗÜóĆäČä÷’f„Ē’’’äõ’O>£óż’ ‰ž•Š.’>-›@fŒna¶®§ŲĻÉė~r¾^P¬€™³¾øā0Yƒ My,€ĮĄĶŁ@p„æĢŁ ˆ/šPs–p©ŽŪō`€ ąęģīģü"S«8ž J§(nø*w¼'•„¼ŠŁćšóöĻŁā#\Æ°ĄŠÆæĻ ³ĘŸ²Åßåģļņõžż’¦¼’–Š“Āęz—Ļ^†Ę6?£Jn’~©×F‡ÅŠ©×'.šXy›„·É>c“6v¼ī}ś¹÷ėūŸÕ׎ćm„Ń›ŽŸŸŃćŽĒgŸ’ś’ćqozŸo^?³±Ćo7/n^<ūCńÕ _½ŗ¹yÕūųłńēĒ>īe.‚ߟߞܻyÖ{śéĶÓ^ļŁ›÷Æ{/n>ż|ūó?Āč=ļÉļ·ļ>Ż¾Ī§ŸŸŃ[¾é=¾łōģöŸĒoø~żü‡nŸSž??Ę{óBļĪķmļęöńĻ’…ß/zÆ󦑹…śŚ{¼0zŚūó3/Ž+† ¼yńJ…Ī#žÖė“ė ^üńł#ĒoōÕMļÆŽŁ>Ž<žėó«Ū?3ĮėŽÓŽÆĻß¼æżż×7?æ÷üŸŪOļž’ĪAµYĻA†ņśŽūēĻß÷ĄļöYļńÓO½ŸßÜžó³]ģŻÆļ{`ō«Ž„Ē½ŸŸ?§Öéžužc½GĻ׫s£¬n2ߎ60ĀŪč02tžż„G}×{÷ōöõ4|ÖGüöYŲšŸ–ć¦÷‡=ų‹wÆæŗłų"{=ŗ„zŻūõŸŪן~½łż9×ūżW*ÕÆjźF £_?~÷X%F·ĻŽżŚūēw’<}ż¦÷ĻkīF)’łōø÷ęńć×īõŻ’ØŪ’y÷0śČ»FŖ&Ļ^½Qō[ļFĆ¼æ^÷čn^ü¦ńÄēŽÓ?Ōrüń׳æč«n{öēĒ·æ½¢oŹŗQŚ·ō1“I½ĒļzŸōJ|ŗÕAFcŒžæ§’yžBUļńļļ_ܾ’ż'żś¤č˜hŹ?{’ė³ŽÆ/žź{ö‚½w½’µ÷ū į¶KõčęĻ›gOiźžčżłńóo??½żųłĶoŸ{7Ÿ{żŪĶķ»æ>¾{õōcļóēW½Ļ{ÆŽÜüÅøīĻÆ_½ćĻēž–£S~§ĪhĄ…:ņ;oæōnŠ£§æözļŸćŠčõ>Qį>õŽ?~ü釞=’ŌÓ`į5C ×ؽ&ūż»źįµu“•ą©õ>Īņ^<Ö±ĒŒ—3‚`ĒŅė³A—²¬Ķc/ÜŠŚŁbīƒ]öłóÄX½&OŻ]åxmŹz„;ęėū£ ¹Ų˜ak6Õø]ß2cō«©Ōz“­Ä…»Ū[fŒv»8¶ņéj’¶ß¶½öm;B’öoµį~ŪöŲc“ķ ‡{Œöm l’īėŃ£ķ/ķæĆ}=ŗGżėĒĮżß~śrūK<ū&õčĖū=ĮwŁ‹`ėĻš}³# ¶¾Č3ß ĒčūĮh[;Ń®4uƒĮ£ķÆn{ŒöeīMī~Ā¾­»{–CŒ‚ZŻÕ§Ö`ŠĢV³ę²³Čq0ØՂAĄžżļš!Ė¶oė\i5A ŽjƒF'ŌkŃ Õ Zµļ:`+®ė(ĀN'TźVÜQń7źvŖe`’jAIÅ©ųHß5Āž yrž‡a7 Dū1ƒ/­Ę a‚Bģ‡ ĶN?Œ;ģPųõ¾¾ ģ(j­ h„V#hFą@(²©·ĆØ֊ŚĶØÕjÖƀ…ßi£Vćs§¶ĒČZÓlcļĘ j·©4ö¢7ź”%km«[Ų0čØ>„ĶnÄ'J[Lé—eĄ¹ƒN·Åń‰ėĀĒ0:Ŗ­FķČe_ĻŲšīŪ:{„Ć~Š©wé&ŗ±0 »VņQ»N{u=F:Ŗq\kuć6£Øčµƒ @0jÅķZ­SkÕHW‹£>uMŲtĆAh­*fŖFū¶ĪWXųo;ƒˆś@ŁuõGA¤bęGGõ”®&N }ś0ž6Ŗhė8.IćOÖłŚ'ólC†=F Fõ"·Zk]n7ķ¶oė|=ZWØæĒ(ū˜!ķ;½‰tūz“‰RĻvĶ‡„QŌlĘ5?š 54³į™LMū5¹ÉšŻ–œķø“Ķf2,˜Kw'FuMŸŽ&7,i(`f{@Éŗ„Cc ¤Ukŵ¦M՚ķ€!s³Éœ@F|ÕhŠ!j8ZƒĪ [kÖŚśĶTDŲī{®Č›z“S±X•$_„ĶZėØå3$KŲh×uŽĖŒ,sg—Ezk`sÓŪĀHv&UFf&’¢6s2-ą²zTÆÕkŻ8$I—™Ž5#Ķ×°ĆŃ°Ū±;Y6“E.—Z§kĆoWĘ&€m›ś āZ{ £ÖgH>–,łj”¦™s†& +śįb¤yp„‘Ś¼.ŲŒ1 [–,WŹ«>ś*kv8“Į+ĮHhĮ –Œ0ÄŻøŃw3JL÷46oį3T>#}5Ęh ĢżüFG3O®µœÜP=tšMfD}=¢µéŌhŻĘÕjLńŌćv›NK3l GƘč0:ŖuÕŁt›®œkŹ2JB"n2÷6čĀƒøŻi0ß5˜u° •«šśj#eīŪŗv«£ęõ!c4÷š+ŲdŖMą°µGó/9āi§ “81æ3·ļf>źŠCŖG™0r½‡›¶ī ó²äŗ(ķt–‹ę‰öŻµŒĖ?Qłe|×+ģ1Z_‚nš7æ±L±dń½kƒėMA­ŹųZŸoŚ{ŒÖ—”ź Z ļZVĮ#VĢµa‰²°ŠÕŹź¹[ü–“Ć ę+­_“ķ1Z_,ĒÖ5MD]VĮć¶GÄĘxZĀ«uüā7 µZ‚ÕH:²•§b¶=FėĖъ½ ­6ó¶B«Ķ~ĒŒdłzÄ„a¤•Ł‚¶=Fė ²ÖĮó'īśuĖ £°ĆYŲĆꡡ܅\PØ7õv= »q«EmźīŪŗNzyüėVŌėø D”Ōƒ &Š­’°’°x0eŲdCX·UōŃ"ūzųS„Ų×£TÅ4“hĮĢBŚÉ†—Ūc”£Š*>eQÅžćr»‹Ń×9Jc;Oł¾lłźóOāaæŲĪĻ|W?½¬¾ Ė¾b‚ŃĖŻéĒÆĖ.° ä?ęgųśQŁŪų?Ź¾Ā."T%§ÓŁ“³ƒ ¼„;pÉŖxNŽOŽ‡';P`x„j0:=89åį.Ž7š„÷’’`t|~r „†ĆĆóū_`x‚²1:»:99=×|E:>æß@܃K–ˆŃįłĮÉɹ«A~;½œkķŽŸœ‡g{¤–½.Åatč·¶żæ^Pźg¾ŁW­Ė󳓃«“ėó=HK@ŗ#Fg‡WƒƒkŃšqĮń¼‰ķšdų„źvšäź“:›¹Å¼ uåpŖ-Kõ gS½ŅĮµ5v§ĆĖT'?ÄDy0:dpp8UĪN‡é›Ŗć‹ć1“ õŽĪOÆfŪĄ‡ĘŻŪŗÓ·Ąr >×óuēņąģbP鶓=F ū-e dØG½·ēW «ĖŁÉÉÕõÉõ“t ½EäoQJ€H–£½Ž‡%‚ƒė“'tžéJžŅ„L’»œ2=F×¼żo—ķåńĮåŁÉń“”%H{ŒR–U¦ztń÷ĄĮĢ®†‡×Ćó«ŌÓqĒ—{Œ²cōõ—ė¶’:™ą_kÆ°f©čČ¾”“ö’»šĄ·uße]”žqõšō÷_eĶp}śÆvŠU!Õkå0śa} Ķ¦ųbUö%Ń?PFŁ! V­K—P‹t‹_„zķv.‘aō(F+^ź\ł„¹#X?<¹pFŚÅpz&źzG§üņc“ĀŁp FI”QhNŽų{ę³V_› QŚĀĶ0:9;<8§ė·‡WL{/N†LķņŁGĻU„Gæ¤Į}{Óüų­{ŽYŒjŽ™N!ūIĮĶŃĪšEvŒ`Ģ0r»z»ÓtĘĮØ:p„ŌC˜īˆˆ‘’ Ž] śÜf}889>fĘćü|ų«łņō †ŁŁĮŪįåĮĮՄ[Ė涷ōÓŽŁ 1ź+n "ZJņØE$^PkGpŅŽÆcąųlĖŽ‘1Ä'XƅŻ MÜ~_`Düe —Jܵ豹¬Ąčō‚Ėӓ³‹ÓÓ'—ĆӋóóė«óƒć'|:œlü~J[[œĪ:żŁz$bÓV‡²Jˆ0™äu'O$¶õ‰²ĖƒQŌm*ņØьjl“õZŠØ¶”®i×b=—Äõ©Q}žœ]^±~{~~Ī ļńx]?Ŗóó'ćéĝp¶BžĆ¶Sca¤ õ‰­5MwØGQ9‰5pŗqØø¶ŽzŌó„%bśŽ«“äÕĪ"ŹRŚĄ„Źj·£ĮQ½N«cńW€uc ĒÓžŻ0jY¹  ²ŒCāŹ \qeQņ%Gˆ+#hĀjA—`vn]ķiiŽG§ŌjŠŽ5U’Ł"ȗėÜ{S;,Ŗ‹U’ķéāIY¢ä[jcŠ›\×G/.Ä[ķģ=62[bńųc=¹}šŖGē—‹=O¾Ā‘fė:vÕÅ·Ÿ¦=ńkńÉMX­%œ½Bķ®^VükVz"\£§%“)Ś¶VńˆŚ„Gr §‡ā-²žŌń“÷į€³·Õ“šń·į RŪc‰ŌY"Ė†7F7±ĘA"×b|Ō4n¹Œ:SUž±÷’}ĄbEńyóctŁė]hk#±Kxė˜ŲÄæ6jŹ Ū‚NC“mŽōV£F{LļčN »]øŖ:m^PaŌÓvŠļhw”0ģĀ.%BsKTƒ˜ŹŁUŌĮ” Ū›cŗŅeqĄĘ-7Ł:Ķ4¤ ėŃLš’ūß,V0Ü]°ż»FlEE‹“U@ŸÕüūĮĮéįĮĮł‹.ŪįĶéżĶ“śT=b06l$āų×FŃ²CWæ¬b£FlÖGƟ¢ę±^ėų¤.BÅ: mćrUĀN×QĘ»šlŲB7ĘZģŠķmŒ‘#‚3ŚyøåŹĆčĖćóYźQzō—§LÓÖ]ö>œk‘dŗ­kQR6(uük#ŒŌwtk]ѶÕ!q£øVp_»SčxŗT1ĒQ*h°ņPÅ°zä”H(ɅXõČaģĮo`Ņ¬†š$ŪØ4]°½#‚ó›Øą2b䂽Ż6&ˆYȄ®jx½x(ՐŹøhŲŅvāJ›£d18ÕMńā¬ĻcE‡³ęäEmHhS#M×0†Ūžiš°_g¢D09ąŹnMߏ½=1ši8-—õ[Œ’)Õ-ĀhżųmŁ£/ĆŖŪõÆåšĻ˜NµÆ–š8żĀø,ļŒ­@„ņ‹×rŁYŒÖ?XVŒŻfŠj·k–Y &Ö+ķ°”SMēFÓžu©^aÕ#ćł“+Śä‰ūæ§õØ`ŒlŲĻ¬OŲ£nŲFĶH¼§T+&ˆ–c4ķ_—#šUųjb!ä“\Öo{Œ(#G*GĻS‹”ĻŽj1cŽ8ˆśšā×d‡4YfüėRadĆŃÖČĢM¶ÆĘiŃś÷x2Å$F3žu©0Źv5—zQ¶R›ÄhĘænQ¶¢\žśŽó “Ķś×•“t“ÉŸ”“„ØņO“Ļ2ŒRö «ˆyJZ]ļÕ7įo²ĖM ²6˜ĮzÓ#`‚vY4ēŠóčĒ4oI¶4?fér:Ņd»£ņS/©Gh„hāŖk«oš§e}d“ź7qWw&ø*™Qc—ė‘fĻµ4*8ØGnF½Ķ¼®d,ļFƒœüŹÆ<W°Ö}~żˆ™ Ōp’:l1 Ÿą-wńä.‡ōµsC”e²glÓßųĒŚ8F×O†“^W©!x £oŅ¶“é2+‹JӍė®Ī‡Ÿ–žö”xöĒtqyę’š˜żšv†Ü.ų‹ä'‡P=äĢh÷Oså˜økwtFéĀŠw„5Očćų²Ī ütēp­ćæ{iCœ:Hé欋.©“}lyŹ"ŻF§RŽāƒOVFßüšEÖķÉzĀ÷k¹»e括7Qfś/ĒÆ„Ń·yFļ™Ļłj 7tęčųĢwPö GbÅ`”ĖĄŹń¼?©Żƒ1r}įp&čzƒŃ—9Ź;×)2œOŸœ=^] ÆfˆUņXy¹ī¢Ä“~YŠūƒQeĮĮÖ\^Ÿœ>9>6°J,ŗŹ²^D{Q Fb‰'«…ƒÕńšó`ӎŻ£õxķ0Åī–=ĪYPH/NO¶Jžø ā+§_ŗŹ ²Ä UƒQ=ģ˜Ü^-b}ŠāHl-Ŗ^ėƒ„a-*cąbt8Ōŗu‚ØjąNl‚…O‡!QsI©øzÄ’ėƒ³óĆ#Ų%šP›å^‹eo‹^‡‰—Ćæ=Ķ±kū(Ü.$db¼Éå°x°*ĀØÖ÷µ-bŽč)Į¢¢hKŗų¾ņ-Ź‰Ż‘RĪ›ø†O¬b©šu¢¢ĆˆŲ¶–¤KõøCų"‹S±ˆq UčŁlŠ†KÄ;Ń$f³Ć®ģ"» pGQćūO4^"œ¤qńtĪ±īå@ÕQ/ˆ{ą#Ų»¦/ć0B{ø^kąŹæø3ŃMmp’½F *Håf›ŅŠ0 ›’©¬7:a›Ķ×#!Õæ#‹5Æä$Ŗg“„ ©N·„ąhI—Ęm¢!ę3Ž2_9K˜`ÄUX„t—šī Ż"NK Źķˆ ¢zƒ·ÄÕ0{9(ę¾^’ö°ŻTˆ©}ŁjµrHž!hFŠŠ$֋¦ ‚ū…Q»«rĮćĪć^»a#&Ņ-Ę{8]SF‹Faé„jÅ&QŃVF%?Ź\Ē~p”Xņƒ’Æ]Iö;€Ń²¶ŽXņ|L‰•|†‹lF9By—`$qžŒĘ‘S1Ž,/1(^oīœäĢI¶—ńŃљ3PkäŚ8uµį»-aōŲ-ē²®×msP­”ˆśw,ėįÕ÷Ō›žÖŃ«æw„²m\¹ö::Æ•6“°˜DK}m0“Ń8fƆäØ>»l%ÓČÅ>pPO e‰É“SzK4ō°šŻ¶# ,}¼ÉńTĪŠ¬"ĶKź‘ĢJH Q…‘æłC‘t!©jˆ’­Ói2ø¬µ£GŲcŽ$– ĘåüČ<Ó]•M Ŗé4ƈc¢ŪsGGqæՍŗuęRb;@]'ÖąGłA»ƒ-Š Oawåc7“½ÉŹ76gfi}=Ā–iĮ\‚‘4P Œ\l¼Õ\JĶ6œ$M&˜ÄčvØÕžĘƒŅ³x“ąL]÷¶›"›Ńif½rŒ9®ŗ;źĀø¤ `Š•’ōföśi=¬}ęČgq+²Mõȱ5hEʦ)°JQÜ ³VÉjnČx(·oń‘yAŸyęsÄyŁ&tĒĶŽLĢĮpH ēG¤3š2ŅG…‘4!ŅźĆ$s‹ęŅp ZīØĆ؉ķiŠĆŅó!čŠģK o“‰®õ“tł…»-µo22šE7eŲR`Dy‡øEo”C‘ńo]5Ėģ¦;Æ9 E…č[õ5-·P?ź’4õŹ®Ķž·:$dšÕ(ź įŻž;Ŗ FČK’8@F|c˜Ć·^[RĒ×aZVŸjī†*lėŖ]ć[ę(”ė„I5™8Įż—‚°ˆ«Žó(Æ}_ģ.ĻmeøeU7QęuŹĆ蛊"}\ĢT™õØĢņO“wy UŅO«}·ęŹĄXoŁ|F–kÓ; :.M‰ _~æN›gīū’”õŒo×x¬Ī•ÄxXĻŽ$O^)e¹z¤ėƒ÷‰skķf+čB§ź9Ŗ0„ą+L™y•c†\ī¾…Ē•»'ĘÜaq§c¾Č]-nŁ÷.oģ’X– «ÄŹvŪqČ›³ų>†ÅĪ[–™jĶˆ%p6ņ€×š8v­­¼ŠLŁŲž‘>ŠP¾ķ•c»eq–ܼ[™õ(Jå`„}x„]å/–aäö&MSohjÉ ¶ŒĪ -"‰ĘS^=,`‘pbÅČ0²čm[ķó|µv_×bŚBŸŽåm†#dBń ŠĻĶaäöā›“ĀU=Y’˜1!?šsćÄģNŠ…įĄ–Ń»LŅ¹zÄ&7f'+—ķé{f‹ā°7ŖG¦Å·•ŚmM=’:Ą "†B»A«ĶÜÜ4a>\^‰¬gŁA,qCŃOĶ©såŻŒš“H Äėå·6k˜¦h™Š.jj¤5Šž0RČ}¹&šČEń÷L=å_|õ(÷ČusE‹¦„Cm%Cņ¤ 2ŅŠ†ōBY ¦¢‘* £GY Iæž%?Į˜: ›†PY>ÄDŪJ]Ü1·_­¾†-[šu®½ÉāŸp5ߣNMKxś‘pØ­Ł[iz”¶zė$0}ITŌį£‹Bvu­œŒ¼w‚‘ܹM8Õ-‡; Q„Ūų4Fko9{‚b0Śœā‰—r:yŒ¦•/)ån]»V“Mb'ŒjØĮŽ12g|±ŃēµŠ„Óp)Į­¤¬Š~V?DTDę įŒ’¶s²/t+£—…ŽR¦Ģ¾ņ NĖ82e6ŸxAqCc€`ņóĶtz!mr!Ķ7l%q:M‡ēYÉ*Š,æ’H&p|āņ1RŒmŠœ“:½ĀåŻHx2L`üŲbbPÄł,õcyŒöœNkLɕõéo'ˆ{¬ŠÅ$, ŚGAFœy…÷ēh¢kIPŸ…F.R«¶¤­ätŹóönĻ9å×#uøŽa6&….¢Ū,UQ 0Ÿ“PńˆĀHŠĄź†Õž( _Ā”dōK+6ŃjN'#e[ŗµ&ņ‰£ä6Y9Ó^@sŃA£rt'~›æąŲrrō_£“å÷W FD/ £6\J„.zŒ’čEÜA5ŽŅšHc%ė„ŒųŠ]ć„½¦Š»'§ĀšHj ¬ZĒˆÖ 0Š}15jĮ‘ŲŪš|”ŪÜZĶDĘ-3NÓ)±xŁäkÜ!¬K-A$f-s>–ÆŖķĢæ‰~KŌ;øCr©ŠņŌ]hGę1C—ńĀĮļ…½©J02:2a`”‹¾­ćž1 årm1D9¢¬€°_kėj¢L[Ē—#ĶČžaaäĢ ą1onŲŗ¢Ā…u¬Å ”ō( ÖE¹B4Ä}ˆ—»ėÓr7c‡™\7'Ķ–vę‰ßDæÅ:ŸŠņ“ĒbĻ¼Ą†.•žĻŲĶ`„ĶØčE .“ŠEkPhųmØ`G5-51ű*äQIō2ĻŠ`Ķ?B*ŒŌ¹¹l,YM£@Óęeģ|q v\īuu›xŁ&"‘V7ŸÄ0š#~³¬ą`ćt|#]žŗ ķłV$ačšj›{Ę źŃĀw£°ƒK1:¼‰†»N—¾®å& ę%¢5Šž9ė —«ŃÖIlPaŹ†s= a†ŗM¼lš[$²Õ1‹DcO³µ€ųĶč·ŲtzĒšå©»Š^§Žŗ,ȜŽx‰ń[>FV6wŁV·vĖ1ź‰ŒĘad#xj&cž ŽÓ6Ć{łÓ©ę²ĖĘÆeIŒĢB$[|„Ļ2‰Œ—MlZbąPv¶ēHøSŪ,ń[r|dQ¹<¹„±s)=ač²ėIĒ†ŚŗĀjĢĀŒ‚Å„N§Sļdī$GŁj[œ?$Ø܇šÉ½üzTņć¬ØGP£łzTņ=”œżībt&ŠĮ=FÉ;¼n¾Ž0ėTfÖ?ķŖžŻ&#K×/—„׍ģś{ĖõvPŁ_ĻčøøbXo²¤ĪŲéX žkõj…Õ®Jź‘Ę+¬_}L“öÉ8†5ŃZŌRH*Ė˜l6žbB™qźQMŃWZeqéź- FĮ‘cā žŃ1e(’MGÉÉ-DYG¢Ń‚« ū/ŽgŻT±;ŗ-Ūo“ˆ<{Ė–ų&‰µÄ ‰@K—jdfÜÆFäe)™}“©/å&J£ŽMµUƒQęGÄ?Mšģ,:7怭$Ś­ŽzŅb­Šö# V,£¾[v…Q—Y@¦Ÿųgē#}£ÄĀT‚žVIHlą+„vŒ[«Ö’Å Ē–HjbLxrXĖ‘&ėL.F1s%Ē±„=¼_²G]vą„čkŻ£%ßWƒ‘–Ä©’Ģšą^į)a¤į„sŁRhUTĖŚ…`äĢgƒŚŹ*ÓOnĪÉšwęī/YŸÕ»ćMĶюLPdŁąŠĶ\93Ō2Ÿ9ščJbm1µ,ģ©v=!Ķ©#žŖĮˆz„]hµDkŸ<“W0–ó®ŗzDŠ¼¶ķańćąqYmćÅQH[§i]cײØe›„±o.ĖÜNĀåŠŗƒ&dŁŻ—ĶŠ(„ķˆ[ĖxŲ›¾‚ūŻLNsq¦ńzłXhĻ±EŹ6¼_6õĄÜ éCNI‰R%„­ŌyŅ„鏘ōŁzļ¦}2Ā+Ę Ģ¤&ÜX C–f”k–µR*N·cÜZ|b²Ź¾ — ±–Ķ_‰ZK— įŠ²+™S‹RšöāGS]FĻ„ Œt\F\+¤Ā(]Y”‘ŠyŸ„Ł.$ę\ŗŒ†›r  Ö9•QīUēY F‹ łqdbÕåYĘõŠĮhųņŪ_ —śo™rłe£ÓÜQł0ƒ×yÅܽķÄØ8¾ 5Äōś]‹°›zž:ļ•¶£āų‚ņ–Ė6·Ē“+/Ź,åćģ£ł‚¾Ū¦ ‘ó^¶ŠŸ!įÆ+/hc³T9ńXpŚvńœ$ķł‚&¦ÄvŸ/ØšÖxK2ÜĶˆ«sK b‹occ•Ąé“ÅÅ|§[ŪFātŗŗÓ­/8¹ U“L‹&&žn1ÅĘ0:Du·`N§ .5²Ū²qŻ‡ŽIĮÕčĖ¢JjƒłükA™l¬ Ļ{EŠEO>ŅO,Ū¢.żĖVa4,šmļ“æ¾]zT®rā/‹(ä§īŖØwy“ł”;§śmŁöÕj„·Äē¤åā6“ÉQ§×$–ÅgXj‘(Ü9ŁfŁĻ”Č9-€W›Eö曋O¾sÆĆ!_Œ ¶±•ä”na¤\ŒŹŸuö÷Ļ ßåBzBWxc7‰;é° ›™¢ūY‘m)Ą»&gSÅü+öŸ8āb£š–ų\i[ź„‘@pa%°Ź;!Œ€t$Ā«U\N „×ężŲ” č8Ā )Ī.\Œ3»ć:H±•ŠŃŗø¤÷·6‰oŁŽ^\Ÿ]\žžĢ·'™¹Žéfe0¢Yq'€©Ć”“óÆŲźŠÓį#$:ß½ó¤öNīåw®ąuŅ@ Ļ(į0J(·¤PZšwd: Ó©é #8hH=?,ŒN®†.ŸĢŌ¦ Œ|ŲĀøk4”£x äØoI=U坏·pAĪ/Ȥøq="¤Ü»tć”ČGg$x¼$[†äī™xDv°ny ø7s¢ŖŒŚgœ“‡i?)¢äø:ķ:uøŠqCīėѓÓįŪįńńšģķō@Ęc$†Ēˆƒx"yĒדėDץbÄ.~Åž'):?Tq+5z—Ä+‘PhR7¶ ĒĄÖ†įČ0Į‘„rD„ō[=7§§–PJmy)V©»mqĖšŁĶŅ7ŚžBŃ}jž)}õÉ“ō¢,UQX¬b04z5yN"BČgī!Įö=?98=9ø^„Q¤Ą9z{įÅmfŃv ęs’äĻ»M¾ŽYģæ"ö\ź:ųšćXžć¢Ņom¢ Pč憖ŹB-ķTŪ·_–ĄÅż[0_`7‘f«Ŗ?±“nņ-h_ŗÄ8Z„“Tt­³@ńŖƒ®rF¾¢YĻĖŚč—}o”4„ÅMĢyĶ„s£K—* 4£4ÕaŠ¢ŒüĆguĮ5ĻVłæØģÅżńߓśŲÖ Š›OŒYKĆ(S1–šø"Œ ¶ŖÕäåDQ«_UpœÅļ‰“[ė›c.e/Ń\G¼„Ļ`$OģĘXn8«#Ņ——É£õ3 «R4öVŽŅméõOmźotŽ4ĻĖ\G0: …ƒ+‚‹NgŗķŅ„IgČwKļlü…ĀĢ'īg׬[EõHż…n£¢[ŠŃaO¤NVźā ‡üĒ¢śéņ YgČ@°æcŠ„3ÕbFs]jÆ °ÖĘ ¦ kk„ĮˆŪėļų…Œ]Čž+¹£øt—š$ ¾ŽX‚ą,M½U„Qźūɚ0<\¶]±`ųįÜåG¬5ā@Q÷­ŗ…źcŸ0Ą6€øm‰B+ŅŽ†ÉčŒŗ;°¬( »@žv‡ŗ¦ĀˆØkq5 vø’%wźĶīR“dpä9ŗ€=F'Œ.ĪFķ–7W鎟m‹w°2LXĢ¹>‰ŽWčD3R­÷…īŒD4Ū™¹I²L›Ų'Ā:¬Ż˜)b“3y]F{ĀØN¬³ į;d–ŠŃ79^šŒ§ü”#o6¦!Ÿ1µmVĶĮcŒ:£”izĻ„|.‘#£¦$'Ž÷„QūČMV¤[_ņģ„b4,__l‘ē$löŲN4`9łœ±Ś9ņ9¬ViŻ‚ɘ|NvoB>§Ž3!Ÿsõ9@«†;ņ #ķY=brHm]KkĘ×o”¼\Œ†%»ņ~µ–0Č=Øur²%“Ļ«#Ÿ é“D>ēmV“<‡ō•'Ÿ³ŽÓ“ĻqŽ‰.`ėDÉ30L°Ė““ Ā(…vR–ž“sČ·•ŒŃšå£LŪ’ž)õzYĖ»ł©Ž|NĪ]Emec”qš^8§S¹~²E”°:Ÿ¶Ėß»pŒŅLVSŅ¹ÆņÕ"Ž¾ĶÅM ĒhųÆū9ńÅBwéĀh8ü:[·e©—DģF»Äū‘|0:?žßŅŚĢ]nF—‡'Ćó«¢£c7S %\u 0ŗ>8¤³ėĀ£ĢK(®d¹ž\/‡{Œ–½[€ŃŪ”(ģ/ömŻ¶£³!n¦Ēų0ī·Å%°1Œž\~øÜ÷@©^Ėat€Ūā¾īl7F§½ŽL^Ŗū}ˆ‰6V†½½įšīŪFgŅŻa†T_#V²‚Iė—ĖXn8]ŅĶa4,¼7*ÅCKkWƒÓ•{–T…aōņū/Kß¾_©€ō²|“–'Kń§J[FßVR@+éhž•{e-Ӊߧ*×"„Ń7•@4,\§ōåQ²ĻKä—EŖ¼ ĀØ¢ņ V¼Ås÷ąTŻ6ćō–Bw›q"Ž=N óÉ8PŚ0'·{‹Qeī”Œą.Fyf›Ćˆ0Jōg)_Üą$ĶŻ”‹©ip›6‹¬šQõ š–Ø%Śv€ŒU į£łŻĮhJģrĀ½l†‡,qg—o·)//ŪʌbŠōšHFgĒ—Ēgpégb[€QDŌ°‰o{1$©ģ8 ni‘m_lAŗ_}ī†!Œ8Näą³é@²£ÕåJH tpSw¤b’ĒkAO#?Eä¢ !s:4Gw| •¶ŹAŁ5ķA.ĘĒĪ4FĆ·—gēWOĪN®Ļ§@Z€L"³‰ŠyGcł»Ö¬/Eķč³ā9&0jÄuPw#œ9AO\¢z»Š™ŗ“äŻkb 3Œ Ī0ņRŹGī‰™’H>h¹jÓ3ĮōįąāģąÉōœģF5U›,ńm'*…‡Óą™‡ ē«Gś·¹öøEķfwwµ­«‡Ķ®£iņQŁ¾õ0i{kĻN””Ā(nK¹ÜHĢ”„Cn)ńbõŲ—ĒĆ·Ē‡ōI—«Ūŗ„-靾ø·c†©žž0 5ĀįŹ‹Ź†+AŠ¢uÅx¦¤ÖQ—RŚ—”t殑˜‘¤Ėp‹=‘‹MG{©„˜ē;;ø>¾R,ł’žČų4 Ū¦śĶŻĄˆØ8Ƈ1€øčmvZ„VœŚU„ŒxLü#Öė(œe$†OL!DeMKš..![Ā­hüæQų¹6š¶ÅŪĢønĮ°ūš^E{ŒV[ēm]^Œ–›#„NžētŻĢZbµ»Æ qX•ÓŗØzM„ y†©ž(]YåKõmā śWåÉ"ƒ™X“ÄjaŽ`h€É2,¶¶‹ClØY}9<¼XH‹œj^'O¢ū†ŃāŽą°÷ö|u[GpP3AKœūa 8¾aQ3Ķ@¬±‹!Ś[EĀ¤;H‘Ļ‡ĒųdģF§Z‹ZŁ”Åk‘žČq-ÕÄP J6Ł`“ b,&vU“·Äƒtqöäģ zäó™!fžŚ²üœŠ1āń5 7ū1׶bTµ#&v\رµu >`Yq|Ć¢&+·bYćx9™ Ż±»ē xų÷ł)3SW×Ēe¶~cÄŌY_¤©ā˜Æ5%īA“4šóIµåÅH”¬F« Zbc¤Śˆ­Čų†ć‹dAęa¬­GĆSS49¾\œŸ]@g]ŽV1F!Ó3fĄRĢ2k–LSĖĘ›jĖŃ|ī9‹ż\©yÅ’łśāśśąšb‡0“3xāōꭅ°‘f‡įTée›wXł¾$oÉ0b™D³ļ§‡„śAW\˜Ņ³č¾éšōŚ-¦Ę[,ē¤ Ķ.°„Ŗ·ó‰’;8ÆĢLŖ#÷Ģf^śņķĮØx­e=ZAU4“m­¬ķĻ›®`cŒˆµ®d+ £ģw[4‡Ę¢zäׁµĪ8fŽŽć¦ęXd“ŽTkœ„Æ;Žč{ĪrcTUc·ÓÖźŒD:‰—#FĢ3Čć“`ä’xBļÕ +źv#¹žHMĀżkE(gAĢŁb%÷9‘ ŖsZQ‹śä’hÆ)E-¦Ŗģ¼emŻš TÓuŌ2ķ2FkjÓÓO()śōć½…LXh‡×Ł[ųg<`ŒRŽµg“MZŃÕ4v;„QEŌhßNŌ„=FY›…J˜Ń¦"7Ŗ±v¦]A€ĶWÄ»ēŠüõEŹ‘¾RŒŸ '&¹œ}„ĻöįÕńÉÉņīwFMyįCž^œ°‚óņūĢfqĘ~˜“¢ ļUQ“*Åčä —W'Ž~ĢŹ³ü‚Ÿ\\Ū÷WgO.®Ī‡''ē3Ƌ :¼ØhÕ·—ŖKĒj4.NOĪō=ĖgŚ½¾ŗ8¼¾:_éu|EÕŪŲvPÉĄ®JŒ(ķŽŁÕɉ·Īż|žqĆ'ęg#Š4}wĄ%’ä'g'oOW¹ œ¤é¬ŹƒšøL7†ŃmW‰ŃLYMĪ©žåq¬9=Ń@!ćöķ/• Ń³Č?~·š™cK0že.ķ\…G[ó‹U«.Ū‚QĘŚ0<’Ē壚•Č,u(I»Šyā^bt|p‘ky­¢Ł¢<­bžø‡9{5Ļ¶„ Ćō»„Otļ0:<ÉmÆVDV“«qŅR2¤{†ŃõÅyžu5Æ¢5§>/6^ĢsN*ěŪņžś¦²&HĄ:ĖL(Īó=Rø±w‰ĄØw×» *Ļ9>»ŽR ®ū„Ńńg\ 4&p?“hL¤źV^Y®E`˜µWÅ Ō "hBGŠ‚ł>›fpT‹F$(ä ® yīū¢Ęŗ”č ‹‚G“ å^ƒŽ’³zŲ® U@zQŲrÕU SSķŽżĮčų ™čĖÓé‡B“šP¾±)ŌŠ Ā)ĒóÄG-C£$p? ZJHPTĮŽ GRku‘w;‚łĮ0ņn.äv;ņ™n· AƒHüµ €wŠ8Tv£Ó“»‡&8Œ(LE“VžNUOY€;Ŗ×”ļ˜Ä(!A±BWxN8ŖGņł‚ŻĘ¤‰ŒŒō - 8ļ’dµ¬ŻNܓąPŁ1ŒrŁ«sÕĶ0³1ĪÄķŽ”øĶ£ĪcÓ$éŪ£A‹Ą›1Fj+t» P§ź‘ńŁ rŪ®£léė‘r§¦ś—B°v N#ųŗøSÄ”²Så³Wē[Ä¢«ĒF’#^±)nŽ–miś„į…öGŁ¢ž=•BŌ’yõžæQĀƇ'ēł=‹ĀhM ßēõ•ÖŻ¼ Œ^f,ƒYŅ±E/ćŸ©Güߞœ\_å\Čx+«H _VQÖ"X‘ˆž¦ £õ߯=²˜cĖzƒ%ą°*Ė 0ś:ė#­Ć؎–ųlžķč’ŗdE0ßo#9<āƒ*aū©×`Ö+Õ7ĢW5ł&įI“[K>˜’$Ck×?!ī»&8}QYU€Qę0±Õat,x¼³Y<ĒŃ!Ļę0bąĶŲ«o?M3Tē€øPä¼*ńdƒEßóŁ˜ö BQŁcU „‰ģöATˆ¢DäCÓ¾hj”be‘śÕ½g…š,y¶Į–ėpóó õ>šęöćć"ŚQD(u32.”!ź‚HPœW¾cCŠŁTĄa¢'źƒvD‰hߊTŃŁ]ģaG„~ņÄ ¢øqŻŚz$B“ÉĶÕ£ł÷,¬·W„ĖŽ£ ‹ęÖcO1h Ē…ā0‚ū°ćHPF9–U‘Ł¼žƒvD‰8ĪÖĶ_ŌšŠ§¬kŃĒ%R]= Ž| °(ŗ#Z ń¾čN¦fy½ÜŻĻ½gõF·³¢ø+FQ7īóŚéG“>µ¤Ó1öĒ…B½ą܇G‚ā5‡Ą|7nĄ£ė U'ŗP!%āzó\żHģ¤ŪŲÖń“˜ø)z³›`„nS&a·-"Č£vÜėėžŻ»)#¼‹}?h5°Ā)®ZM Ł¢ÜŚ£ †å-Āŗ–.™Æ”Iņ£=8 9b\†Ę…¢· .Ē}Čqc@äØĪ1ŅĆXŒ;Q}pTˆu±Ø$¤Š:¢&BY¤ŻŖ«GšB4›†zåL; ¾«cÕ¼˜ĶŠ‰Õ„]œ<{#Œüm§›?kt%Ō±čP4=ć·»Ö£“%V}ŗJ1‚ĄÄ1Ž†}JŲ·ušķF"Ū6h€Ø?‰LÅj&•®V£¾±r‹RĪŃ”ģ1ZßP¬MįĒ PY‰ĄDÖĒ@ō¶0Ā™iĮ,bĖ¢źéV³ÕļiZ‘µ•ŽŅt›Ż¶*‹Ņ±XC"ŠE¹µ lėŖÆ )ÆXa=JyGƒVĻ7Õ”ˆŠŪP0¦bL»s[ēĘ#nJzjSĒ4:“š)ķĆ/JWFRtH¹1.µķØwŌMö—ŸšŚ1b”KčˆeTŗx ōüt÷ ˜Öh:eHÓh–§ ‘ļRśéĪ­ £t·3™ŖMĒ”~šs÷qćķøōƒĆ›ĆĘĄ¢h‹ØF6žf Īø”™ƒōSŁŸzĮĄhÖd]ņ‚Ø7–²Yū“w®GĪru ą²Ņl}ƅe`¦Ø7TÓÆś¬½įŌ 6€ŃjėĶ9Śha_”ŃŽŲā0 ;°š{Œ!†+~~Ē–½3˜6©qX•°:Œ“&\c‡#SźThĶ¦FH|ŌŪ]ģ„&ŹRќÜJšęL=ėŚ§÷9Ń\·žŠxė6Õ!µ‚Z\k,«J`F“ÖĢ“ķ.F¾ÅHÖõ›Øęø&•³`ŻDĀ’Ź0å»s=J÷Ī#ģSõV]=’’ĶĻn.%ķk"˜Ł‘ģÓ"WYŅÖ£Ŗ‹>õõŖĆy5¼ ¹1zœę fNµŃŒu0źŌ[Ņ^³ćX­²OečfÜ*ŖGļŖˆäÕa4}·L}g˜łMó¤wÅHjó’ó}Ļh¹un<³`€ɛxŖŹłdS„)õliīŽQæ5lś:Ė73Ōł0dżhŠ@+€ū6?AYŅi ֎G˜VJ%KWYŲÜD³„5 Ā:Łżx#Y‡ä ^ż‰$w†ņģsW†Q†y7§’×{ō@wÅČÉīÅ,šÄ‘Ųņ-ÖAx‹¼ŸŁØsĄśĢĒ Ę'&µ:«@śĒĄŌxōYr"%ö/¶pŌ4g;ģ+­#‰gæəśAqPF2Ž‘ģbCŹß”½Ö›d(o£l•"Gźb0ņ.½Ž[ŲIY »fC"K¬£²4¢µ:ʤM[V1”“uܶ›Å·5ó CŲhņ¦`ŃvŒ…f•Œp§æ²z”£Ō³R Fø4h½ŌÜŠ–“[2,ĢÖkmŚŗZF,ŽØŠh¶ŽV“5PJ‘Ó v9C˜5żčDŒd~ ’fŲĒBŁ;’‡½ō£Q܄Ęūņõ‘żJńi—qn@&˜Źzø¹įvā–ę]‘Ł”ŠęŹĶ](né·Yŗü3·mū«8fÕß"~8QF²–ĖŲ%; rÉ^ÉĶPŽXÄõåߤ~VŽk4ņqƒØ‰a÷ō cäÆč¤ī^²ÕŪ5©g‡IO¼é‡\{ŁźźŹ«Šņ°’ךrŗ¼8 A‰©WŒ4¼Č”4¼ É”ŽoĢ‚^—¶ČŽTÉ~Ķ?Ų–a“¶äÓ'Ø#šqšgzH_œ†—¼™ä„¦œ r@0' /kŪ„>D ’Ó›śI½O),ū‡Żc“~Bei æVī†BVč†­"xæ5§Ėkī ’*Ź½ŅšJ0B{:vMDdĶ¼ˆ…b4±~’mE/ÅDżŚ$³‹fUÖ#æöBx!Į‹ļxæ5ÆĖ+Œe4Œä„†īhĪ‹MĪoø„IīĖI³•ÜÖQu“¢4'ā©ėĶyžMšQĶF/›Ī§^²\˜Z¬¾p?U›ŖSŃ:Ļ4'Ųn~kN—W2¾,M„Žtzqrs^lĪńMŽjrx[“Lxēz„+ęŽVIäņW«²Gs"6‚|9óAMæč–Q䯧…X 2ø–Žy—6ƒ÷>iĢ9±yŸä¶ļ›!å2rü¦–¦t=f2”ŃÄKX]=š~óĆĀ§ųļŽ‘DĪĻO&dēŪ\½µ¹ęĢēHņż=¼5d§‚Uóģ¢eŻš®}/ŸBĀ(1™ł¾ž¹ŒĘü–ƒ®‡›ī“ūVų{§į¬JYFZ%q®|żAØŲFĪ|D=øÅtż±ĪóŪZsüc ĪEĢ:Œ,V]é&;ņ}aē2Ņ'GĄo9čz“‘ŽÕ0yŚMÕ£bp™ĢåĪ‰łžvF«$ęŹĒ 4 MuLa[Ģ¹9’|lĒ”/ŁXķ¹µ¾$öŸR“ĻĆomr„öäūµZŪg4ęč·t=&q•Ń“u[ˆQń·¤Ó9N\{~-£‚zTĻ·łĶƒ}¬å°V«) ōŒpżRN**×ļ—=Nqcļa%č_gÄe2ł÷E•f9ł,}“1Ŗ€}µŲ:ųŖ ĢįOŪČ_·®H‹’Ž“£å+Ć²ĻZJ6,²_ØēųņĒ² :žĖi FƬT,ł‹<ė™?¬xT=¢¾­dō™”/V|?4Œ†ĆÆæżrĖ¶­”T>°¶®ąž­¢ģ^=ŖØ` ¼Ģ£ ³¤¬ö•T°f»ĒØĄĀ,)«=F%lŁī1*°0KŹjQI[`¶{Œ ,Ģ’²ŚcTRĮ˜ķ£ ³¤¬ö•T°f»ĒØĄĀ,)«=F%lŁī1*°0KŹjQI[`¶{Œ ,Ģ’²ŚcTRĮ˜ķ£ ³¤¬v£—ß’²ÅĪZ+üR~śā‡I'”ĘčūƲŗēlSś •łŻÅč»m*ń÷2V™ßYŒ¶Ü?h?%āŲ»ŠŃ7÷ŗ”s&¾«»ŠŃV»ß§ØD–ÄW¤]ÅČ č$ō¾r›ć`0Ž†¼ ]²Ķē‘$¼+‹»„ŲUŒ\1)4<$Łą"ŪŌŻˆq¤šN,r«A ~'ˆ!iŖ¼ ĮF kVĀŠu²błÉ¦Y—<ś`„MYŌ$āœCĪ‰H8R©WZ»…8sé“5Č„ó²»Ž‘(¤ō£`ū(čˆ6!źĀ³"qbśŽwŚNd^ņlF,ēĢG„ŹNoKl,”“ąĆV»†D-&Gn_*…÷Ky>j“<³;ŒU¤UO ¢‡‚\źQßØEƒ@%U –•æZ/£LčŠfŹńr{cŒ<ł‘cX ’4Š‚ētź"¼UžŽ?É#į9‚@p„‘Ņ O¹±AŒ¾łī‹Ņ¶œqä®4Žh~Ā<ŽŚaŒŃ‰Fµ¦[s“p*8Œ$ļź‘qĻp 1u7€C=‚AFZščnAgŅ†IĘiŹ'y@q#zQµśz) ²E8#N›å×ģ lėŹ V^ą¶b~lī©WŠŖ²CpÅĖ?֔7…ŠÅ[zÕÄŁó ÄØdŽƒ\5i®ø–S•­˜I)W¢<֒”eléŠ3d×^XėDx~É3œ¹<¶ń„āźŃ£ŁĒ«ł1¦$bØŚĮ9‰X;sKŻd–_ģ1ŹSSēĢadŻ±‘)‹€“=‘ć‹Ćbń±-õ°ÖCOIÄĪB~7ŒęMOQ5MnӖ&]Ģؗ‘ęøߔĶŌisź„x _ńŹ­Äz$:°ŽŖ’$b YQƒĢ j‰Xõ²ü÷%"Åsw½£“ĆÓĖć¹Ķrs®.Š¬@- Z¦ļ0¶kŁ®Ńź¢|ŌÕ.$Šu+e#¶C2žQŖ&²y~48‚:iG'>»` A'H|a:ó+ģ¢CĒA=ŠCdjĄåŻqOÅĘĢå['4£(Œ•bńV.Fč»(ƒ˜A'¼ŲŽŻĶųāžö±@€}#Ļ7sĆk0:{ryz~r9<8ø˜@Źņ€–;hH×]?ؽ `ˆj–Čv­®}†ś¬Õ@ZŁ0jv:–^Lé Ēa÷vD¼öŽĮ˜FZ/>=„ß į‚¤“=Ļ™N Ś]ąąš(o/ÅÕ-;—7”zĪ‹[Ź±rŒ Q•¾«QxSŸøÆČѶĮØ\‰XĶœ˜“ˆEęHOy|×ėŚŗ·g§> ß^Īb„0¼4%¤ŪĢ§jt„mÉxķ,—Ā_NäĄĪqōüöD¼®ąČH|ŽQģA~čĪė½Ši0Ż…P šéky{y.ļ0Ā~•¢rŒ–Ō܇²Ą­Åhxx2<>^Īb„qĆk ™®~«”ʼn*¼•YĆŃźŚg)}€‘uLĮŲ9RŠ—’ŗ4]=B;Påq,ßNĶ&’€¹'ķqž}'ųĮXiŠF—x”·šVÕDdB$¢ĖėqyZŽUc”YŗeFvö„ZƒŃéÕpxrp~xrp6‹‘„į4’U īfUŅÉiķŠXGÉķ»ŒźĶ£‚pØ2›’0jĢėØM?Õ²žŃ„r¶ Q'TŖ,܂®UFā­–¢VÓZZ0cąF›,sVC8ÖŌ÷4Ū_U‹ģ`½)‰[ekEZ‡›žŸĢŠŃÅ!­_šRš±:„L¤;Msź8›ÉZ¬„`Ł% {$ÉŲŌø~4žgÄ؆A”–Ń“`ĘŠ%D·€Ē–)dUHC!·Ŗvu0ģ6JāV ay`Z66+F½ŽŪs‡‘©Ćc&:!=ėžéä%•'é=įÓwR׫GÜØõéM;KŚzNaO¢}ź×•“ųūM‰Ž”üģ#bN~¤ł‹ŒŸeHö$ģĒŗ&$‡ī‡ ÜRŖ”ŒzdŠYµ°…ĘŖO¶°ŁźzHoxķi[UsźjŲD%I0Ņ:Ü“†Ć=ȶIż­½ŻhęuQg-į˜V—±ø¦9 ²7]<  [ėƒ,k0BaOĆķ£„nŚ¬š÷ėjxŃ5ōP?^ÉO»}—„ōčs[ÉKĘĻŲmēAŽÖt»ĀHŁ+Y?ŽFZStE=®³øŁ–žƤ¦ęFõČVÕ8 ƒŗj$I0Ņ:Ü4FŁėч«c{O=»½„ō¢n3@ĶĶ0’vü„.ž>HJĻŽÆKą ^njNŃėé9sŌlŁń®—įc=Ńél ćēš?9įׯ=„¾’„]ģ+£„ŖĄJÄM®;Lę”£Ėó¤?ĀOD„.!½7 č"ß&Œœ.žtó(M}”ž vxŒ^vŻ'‡©]š!2=½.b|’š3%?·‹t…×£§U‹!?aŌźš­U×Ø0ąÉīFźgÓė eÅČģ%WŗtŲtŌŌ`Mo"†‡“„Mš.žDųŌUńARzļ™Āž)ķIĀ)ģ %鶊g/~¼’ŸŪeśŚéчL“J@Q2~–EĒ¦į˜ā{)Āšd=pZIł2—Rh× Ś&FWł1Zg¬(*¼~ę¾Õ€sb©cĆ]V±Ū5X=ŒR¾®[›¬ŒJyŚüõؔŪ©0Ӈ†ŃŅžĻŁ?“Ū:+vŻ÷+PLī"]o\FZżEWŪĢcŒ>ŗ{›č3§NÜ<šĢVL=#åa7q LīÉ Ž|/ęKŚ9^85*mxE¦ģżG×KīBė° ]˜eGnv[ Õ:Ų@ź×#?Ļ"œ!)ę”Óŗo±Øø‡ä/9«•š¹Ēö—¾q7k›˜œ¤Ī‘'āŗļrz4ӆ½:µøE²Čʏ­€›ķ&ƒI;¬`K_ÆÓd™µ)ęؚJŒž£lÉõIĻќ‰±Åń‹HąÕ:īB:Ś–Š'ŗ‘v1ג¾§Żŗēŗäł“ghŪ:®I•M¼1e`„Ū3ÉĢ`ĢnN6øōŌŠģb «•³˜UZ·`ĘŗÜ֊²y¦D|QIZNŠ4ēĒČ'Śęåģ¢ėh/Y€-ĢŽę@FK³Ģ)=ʑ½ŽÜŁ¹^É-ńĻ0kU®ÉīBņN$ė4Z®ÄĶ`R‚ÄņÕ*¬ĖĘjÖ‹¶ęō1m9•Q»Éčß0ju;vsŽ7·“¦Yēę–«oŗÄ"FŲ•öÅiŲü™ć„Ö¬Ķ‘ĀŹ„=!įfżDĄh.Ńļ 1÷v0xf1’Ÿģ3’ Y§4Sœį=6”oń1d.Ģo»–,ĮˆI%×Ö14Ń–‘ęĄ\Õ­Ś‘Ŗ¹Łą\œ€Õ)¾īœ|/)ŗ²Č›Ü— £Ķ—^byR6?Fę8Įt’{&¼×”ų^«…ßq*±yPرéwÓLeĒ+ģiĘŽzĪPbÓš3¹>nXīhōę-bĒ­­£ī+{ylhņ?Mżw”±óÖ » ęų:ĆJLĖµuŗsśĄdĀõø8Œ¾¶£bw ĮH×ZŸlp-;×ĢÖÆK”œ¹õ“¤EŽĀ`ÄuNü‘…n>U“Ņ0Jī¬äæĶorÉÕ£ śĮ÷VFĆÅ”§,é³-Õ@[å½YĢ„7œK}[ź£äSą+õ–ŖŹ¼@Œ†ß–ÄżE>¾¤m1ļ¾nEb4>Jæżē’œ>ķ£Gkdg–6w ³ÅYŽ×­XŒ28öŹŻ ōĶ bjX9i3&FķsTV­<*0.ĶŽlāēč–O·q{ŁōsK%Š˜ń1Ćdæ2.½É*ĻÄäĖ–õĄ0’Ś»ĢQ¬Z Ģ:Ę„³7x(l2ćŪyŃÉ<‘±(r,LYµ˜2.aĖ¤ŌÖBTąœjĘ¾„Āž(MéƋ"L“GYiB=*«ģŖŹwQU%’:;ŽŃ/łKf{Īōę{õ|AÕōGåĪOUc¢2æ« ļ'Ūķų‰ŹüĘ0:?ŹŸ““­\‚œ**Ņˆ„gc]Åz~5µ_j÷¤1OŅ¦0ŗ>8¤³k‚YĖŚ^ŽgfāŸ’†ŽŅŁF'‡P*\ĖÄh8|łhĖŌćÓŽĪ·S 2›ĀčķšŒ/ŹkėŹŖžÕē»)ŒĪ†§§ĆćJ–)Ŗ/Ō‚Æø)Œ ~ŒĪnŃöĆ»ĒhŃ| T3“ż%Ÿž÷õ(}Ym*å£M•|śėī1J_V›J¹ĒhS%Ÿžŗ{ŒŅ—Õ¦Rī1ŚTɧæī£ōeµ©”{Œ6UņéÆ»Ē(}Ym*å£M•|śėī1J_V›J¹ĒhS%ŸžŗUctzłöķå$wś[}°)«Ęhų”×ūš`K;߃WŽŃyÆW¢/P¾BŲņ³*Ēhų÷ßUų™|“%čv›Ņ&"åļMõœ”žŚ>ś„Ä@÷²]TæśīŃLUŃń¤NpŻkßG{1y_:ÕcT,“y¾Üoüi½ÕŻĆč‡²£*ņ÷ŃaīŻŪ9Œ2(”VQŲyÆ1ɲsmŹßÉXĶl«™pV)aNYåĘčėJ¬é;1×A™±Š„f1Qż“é\y·V† Ļę,D+™pŒ^ŗ&¢0³MĀåÄčĖŖ·?~æĄpX„œ{V{léøĆaj²y&ŸÄDcjńGŠ6č ¢±ŌHqõwøiŚN¼vDŽ ¢Hką¢E½OD•b®UU|«]Č5;äŚÆĮØ Ļ¦Ń·":o,ŖFĀ*&N…W•Rcquāˆ¹Õs°ø?S(}ugūhżņW9+ŖÕ#ŃNŠĀĻIŠ[SL4^'ÄŃŅšĖŽ:Q ‰FN¼vLŽ Ē¦8X‘Ī‘h„c®!|«06¢eįF“ģŖq,ŖNĆF‰źAŹ0āµNČŲ˜„.`ĪÕĮ»b“”~9H Fa2Ģ¦XMĒ‰‰f„‘‘­ŖŽĄRcI’)č"GI ÉQC#­!D–5Ļ\C‰)8ŠwU©&lŪ0¢›č$ é[įQARɳ·Š_UD­rPĒ*ż,ć÷]1ŚPŠvg½²sr5kĶZ¤š$]3QRƒ˜˜hܞ(jō”ƒÄ¼4ōD¢¦13'^ėÉQkmĒĮAĒ)>UĒ\c ÄŚŠĄQSˆėѬźTŖ¢ž„clUJŚ:$F‘IK¤Õ¼¬š1­ŗŃåLW„»bōåtvSÆ@:ų¹Ŗ=ׯźéf¦9¬Ķ9S‚Y ©aĆB5ŪLŁÆH\FHFw#xx}wē5ØׄP^C™ļÜ·Kß­„pe¾Ņ–žPFāw‡¼J\ńü˜ŖŗŃ“Ó”vė"’§vwÜpˆĘ@üóā]VӀźĒN¢ }>BŅ^³ƒžx>zōĢ'ŗÓźėŃę, #ŲįVŌ°É3öyŒl$%‹!Ńxq4u¬¢+ī4tĆPā]v£#Ńū:8!“֝Ō[ßc”¦\šQ„j B£ˆcģ›ÅHgĘO?mÜņaäGD6ÕGæŻčˆqUŌ×GG<ÆZÅGLšiī03˜ä§ļˆ-3§ßįjåL7Ć+–RÜc ˆĻk±YlWKłd­-¬!n ½øāmš£¶Nüļ„@/"yF4F/Æ1–¾Ą¦Ō˜‡iiÅśŃ0y}ĖAš?õ`jM>-ŁŅcD‰i¼Fė«,ūdF‹õ­­ÅVąU ¼”­0jÕŚ-³{#øæPf§ ±uŚTu uŽōįx;,sGĶ…r¤ęYE/±[äŠÄmfeŻ Ć(ė…³§Ÿzć3`T«Å]$ņ5„ *1ŗØÕŗ)‰Ó†­v"e+óT:%¼AVŪ¤Ēg–Y>VĶćN?’©dZ<’±‹zØāŪ€Iœ˜ŃŒ^šøfūfß Ć1‰ņ·1ß~ŒŌÄhv'Ņ`Ä “’b ĮhŠ@Ā6‘²M0j nč1Rwj6AaÕkFēH2¶cŒœ² ?ō­cŒĄŻÄN7‹Qö×ćNgdĄˆzĐ2ī2Tģ3qĆš= Ōj=F¦xĄš“²M0Š˜l3%†„Ņ`‰WģĶ.VIuŽ}eIm†ZÅHVt HÉWBŖG4ŁV=Q>ÉžŲ…Õ£ģ—¾Óé1Ź™–iįŒĻÆ×7Ć-])F÷YŅ1ØiĄ%õל§ŽÖ`tpseźĢV%œ˜įˆrŌ"ī”JŒX1½Ę8ö‚29ÖhŁ¬šōūšę¹ÖaŌė]^§Éē>¤©#æ4 1Ž@AÉĖś` ›Ń#g+­óÕāņ—ˆÉ’ÖŠÉvåźSo#q #ĢŌZß fžĘ[[>œ§hė&Pœ”f\ Ć(ńös/Āų@] \³ó“nø˜iÖ²ZŒKdÄŹĒ5n“yŲŖe`t-/WŌ¬DŻ[Ņ+ļ“”ęZµ0@܌#(Ŗi'¦3d ĪY-Ņa„ÉCÓ0‹]J–ź„¾c±čH¹š=ėH-;Ź ®rø£’Oć_+–n&——ˆš®roģ«uēz:gżV)Fėo'uŠōćŗ>Kwż°Õ śahF9¶ˆ×¶CMI”;ŃxY“6Źä= ĀHó$mäųXpźR‡ķ„R¶C.ą ŠėŃŖ\Š$!Z‚r² ė¬‘i3śī””Ļ Ķyčܹ³8&żĮk»ŃČ¼4ÓŅĶß ƒ°ÓEMĒÉgR½5/ˆ¤ S‡]jū ”²·b ÅśŠ?ŽČä-}t«»G5¬³pŁšŠp:“föj1·Ķ2»\UFgéøĪYßW‰ŃŹ©ˆŒ|śztdc“z#¶ŻFQ»ŽéŌ»q+nK½VŬ©5Ķņbr2 G[ŒW ‚!¦&ZļF¦œ»±2aGŅµ“\qÜGĒ¶+p•°ą„-ŖØłŖw=·ļ0Ņõø¬“óä,?’Õ9ė›Ž*1Z7éS¤Ēˆ±‰–q5&Ą§G­f"—9ĄÜįøvš >ųĆŌ3>źpč~ō„eĀł‘rįtŽ““ĻFB¶ēŅčŸūR((]Ö B“7–) ģ>F”iō%o»Ū*ÄōÆQa)w£ĀŠjc…ć¤É •zŗū·y‘B[”lc/•y³6F[ś¶ncE[Ų…‹Āˆ¾5PÓń›6}xzaµõ|–t²v$­Ŗ ¶Öy`śŻ,ūééh¼YTzŚķv‡v[ąY¦:I£¤±p”ŁlļV F6³Ó`=­ćĆÉ8ŌĘL|ĘiWÓūŽŪT}‹“Ē\[8ī ĪŸF‹„V½Jo£¤Ry6ebtč$¾‹˜‚õ[zŒ""zķŠüėĮ,Ēh»uŹŻŪ¹Ž‘³¼ س=“°ā›”u;”Ėø÷”GšÜ °ń«[,s{+śg"“Ģ9‰ļzyÖųZøÆ0Pė#éŽni}UÆļB?nč€Å`Äńķˆ»* #y.ć0¢2ī‡‘9ך ÆĻ3õ0¹1,”LDœ²‚®uN1E7ƒ˜°.tö}#ģ±„Į™ŒŁū£°Ż<ŠŗĶ°ÉR¾žõ9}7µ's§ŪŁyŒŌTŠÄ1MU49…g®›¤²N(¶žžĻtM5M‹µBĀ9܂ żÖyŒ;ō7$IX ˜’Q…8(grßÅ£Hź¶®Ž ń=`FmŠ§ŖŌżėį0²ĀØÉė°2f£ųUŖ~ˆŌŁD*†‘j/¾ōć×CļxQōFq¼źGH}½ŻĒ(uQlmĀ]ĘØźąµ’@žq3ķŪ4óU‹ž=M[·‚–ƒĮdō®XĖ™Ų–tÆRŠ—a+[E{¹¶4m(6*×ó¬8i2®RŒ¼­R*FƟŠ.®Mä7ŁŌåćgČUœ§‰l•I÷µL¦ æĪ”åv&žźīZoł0ź3ź5[E”¹¶T æ½÷ƆiˆŖ¬G±™&²IŲĖµ„Ćhųõ¹rߚ“¾›$9į™sõG’ŚĢćLņJ¬†ė›ļųāžn?|?ƒPNŒ^n¤5™iRVŖH–« 71ĄżbīżŚāOõł0VĶ“ųÅS#T¶3‰rb“3ĻdŃö£“ĒhŃL l‰lßV\öåxöå(“ŠOŁcTqēøÜ£…Vń){Œ*.š—Ūc”£Š*>eQÅžćr{ŒrZŧģ1ŖøĄs\nQŽB«ų”=FxŽĖķ1ŹQhŸ²ĒØāĻq¹=F9 ­āSöU\ą9.·Ē(G”U|J„”±¼šĶp„ĄX‰€ļw÷Ų1’§fŌ*ÅčųļŽEö×(ó›PŠ*ŌswJÕ2§ŸjęRKNøč•-ąĖ•6„šX L›Ō‡=½Ģ oźļ}-֓²–ł|ņS—×\Āņ{£ éŠX‰”ÕW“ ‘•öGł±MęŻŖQ$B9ćI=Ų…čƦ/µjS¦×‡=B€„ƒõäf܏GضĢ}³¢¢(#”Š²€·1ŠGq‹ˆcR¼“,y¢£&Ųu–ęZ€>lµåžåjī©Ótµ>¬jv%oh"ƍN#Œa(²“”ĆußHG5XbD„ķ ™¼q„ō”2)XWWČHJZPŁ’LT¹ž'IŠ°ļĀ©Ø™ŹšXĶS°Ż]vųõw‡`}™6²eŒ‘É®,ׇå}ÆmŹtBĘL“TŌ£v{ąæqģø0MIŪ®Ļ[%µ3T`ÜÅČČä`K {łWlĖƒÆ„ģ{—ķ®å‹żæĖĻ½[K‡wæŹväP FŌŲ“s‰ŗŃ<±øõ׋·E,äėŽŁ©śæĒhĶ`××£3ņ»ØI#Ņ|Ü# 7€„2$#i©Č:ƒžŗæ3t¼&RWēšO‚Ąķ™” i’‘źhõQīš@§ƒoG-øū]S ,” 4²ZiDZ}rrčˆŹÄ /Œ>H*r§?ä›NĀӘh"yéX§Mر®R"=I¦{E¦ć>ӏŽ©!]ŠånÕ§3:0–A•ŅY»EäÅ]Ē½‹7~Ö”`ŚõŚ&Eˆ×4ń}A‰+Zš$čqa-Wprh+˜h>ØōGqhXTĶDÉsŻ?‡‘cĶU¦œōGsśz¤ŗŁ–wüÆK°I§µ¬ŅSq%%Aå*ÉmiœiT†¼+¢®’{•Œ,ā®Ö8š„¦›õƒ«ņSg!~I»ŗ¢Č@MPh}¾ŗ‚0 ŽK:jaĢ ųŸ¹G5ZjŽœ¶Ŗūą„"5Fķ¢¾éŽöšHR”śd‚‘$’$Źø:3w“)ĀR1M‹µéucÄ8X’BQ単˜„¦‹iœ9®d“AŁC2²œäżs{d=Ż8ŒĻ¢ x·ō,ŽŲåfDSÖ„‚0Jy5—lłŪ“ę=s6HʶĪkėH¼ŒéSŠ5Œœģ#hߙĆQė"!eōļck'łŹI®qŠæ‘*ģtć0> ”ķ«­Į(“‚/lėK¶åßŲ Ī®Ģˆ‘)Ā2ƒ&™X¬NŚ#Ō[Mb‰źFdŖļķ„ļߢDŽUrÆ5dwuZ°6½ĒžĖŚ5®Ź»«}HōŠ¢jĪŽóÜ9X³yjŅ&źQ¦J·$qśž(_PÄ=Īå‘Ó˜Ż}Œī¶xS(V9o„tŒ e-š5c°³Æ/™ōõh}^Ūž¢tŒøI#r€°dM5¬č¬Ļ $1Žā³éB2}É0œĮjŽ¬ å„·£³+–ā·½ģÓŽ_ł!ł( Hō"‘xd™‹į¶^$ņF§¦ ©ļ"ō5C±žī×`tŲūūäŌå²t®3żL'†RrG‰€““ģ…³Mģū @b¦ĆüB’ØłŻåIĒ‡õO“ü^ĖĒHꧩšĖb[CćŃZŪÖČōS{Õ^Š›”~įŚmĪņn°=Ė5×:ņˆ’¾p՘ ™€Ö³ćVĒWķXjƤ‰ØįVź\ct'UķMQŻäbu÷Ś°³ØžZ<ŅFŃa:E’,ȆA‡,q°Œ‹““hŲB Z“¢’ ~üJ0’¤ĆÖZ6ŒGĢ“Cēf„QŲÆÓ豤œFŗ}m=ź½=wOŹū€< š¬RjåŖT_½*f愿@ó å–,j8¶, Śģ!ŗŪ5QŲ†Ō]%k+n!ĻFčnŌFzFģ'3~uœ}+fźŅ„õj‹%h%•2#A;Ré™ä£4 „žę¤¢¤Vļø#ņQN9Ģ¾3ÉC†ÉuÆEp>Ahy„ה\™žk'b:£)'ęh¼]źŌ^©į#ż&ęņĢzņ!oü*[E³vē»ĪfUŠeR©Ļ°ŪŌŲµe>Éå$Z,A6»š sļ“©NW\f/č?ĒĖ&—¤_qßkęTMŻi²Ś”¢T]$©Fʼnø½×m„†3įŠˆŌÖųVÕ9+ęź$é‹j“źy›ę³Ž®3­§²µ~©ĖP‡¶®eß#F3ķÆ1Q7j¦ ƒE“TĄĪŒm„õˆ'Ź¾„Ą/żŲ;ˆš4pš¬RP »Ó¶ō‚®U56ŻVjø* Sģ‰U:KĖ™®IÜśMƒ5 R–„Š/‰ĘŖ źƒIŹź°Zn !Ņrū Z©ÄĪHŠ>0ŒfkąŗīĪÕpS_¼M1­,«3Ÿ8s4‹ü_éżQŹ¶+k²ōõ(kĪŪ—~Ńöa²¢ļĶå_w}NZō)6¼Ÿ× ž°£&‹K"¦’qä“Ł‰7:Ō¹’ü,Ź$Uš1ėV`d‹ ¶®"ßč\/rź¶ĪFų*@ӆ×čA‹¬N‘„©“–Ię…cÖ³ōpŲGĄ6`ÄĮ—n9©Ž¢žÄ„“į±ęFy(22 ģłg5ƒ# Ł»ƒžk#$„ö£ _½$R©Ū$ĖzŹ“uZŌ4ŒĢ7ŗ\Œ2QqČfŁU4k9 Ŗė5#'3ĢŚŸÖ 愇Q”e°՚8“:yŌ&#p<:ę¢źmÕņ†p°ńēi l«Ä¦ģÄłL‚i^׎Ąˆ’~"_MŖŌ±ķµģ„9ķäk–Åf0jó„$Œœ½²Ć”ŗńŽ·X’GĒYsņµ))²’•£ÄXPŲł^8' ż%‰ŸĘŅ©~8ĀČÆĶ:ŒŽš·¬.‘Õ5§F¬]ļēmpė7ƒJ朾1š;łŚ-Ā{ŠŠĀ¦č²Äé1Š)U-”¢L•Ā¢d’‡‚āóŸNf˜ĘĪ ųqć§ķ¤‡ē0ŅˆÜD¹¹wµUš%rsC‡¶żvsD F6—¤É%fœ 4I?FTōŸØČܒ—ÆŻŒXS’W5>MęgKS¤!s§[RŃĬ“0?¦Cč;™į± °fpéa¦w6ma›fåŪ)”D —O+d?¹h¹č?.Gn¦Żųs-­]»e™IśÉĘœ/}cÓ>Ö×KŅ7ŅÖåeęœ pµł,ŅĢūuį=FE•dyłÜ£ ÅMü²ézT"ó9ߣįFtÄ~L$6~Śé>Of’ŪY±U–~ŗkŻ£Æ7Ņ© ņėGĻŽ–d†1;“<Žn鏵ČTwĘhųMŚ„ß}›”Ń_€)X,ßG–ŗk­#l–N³Ė$‡_ų.²@KČėī„é6“Ę—™Ŗ ,ֳȔ<ā³­zŽƒķ`$—zOaÄl¦%(ł¦¢*Ev÷1jāźMHG­£0 °Mh‹Å$eÜ"^e”‹f„¬æŲīc“¾ ¶=Å£mGčī±’› ¤»źö—~ŗ;Ü×£tå4ŸjÅ\š‚Æ/ĄŽ­iåæĢ±p÷1bÜĶ4{*$ &ü€}”~|l&‹qMņ=žŽ,¤Q3".|Y|°–'†•Z^ø=Œl1GĢX,„ø;ÅįR2n ®lŹøµæG¬Č9‰·»pgµķŲ˜ˆ‹@g‹$²@®’$VŸźł+B.g «Ś«D,ųĘķWkEćå0‚•=›bćĀxk4=ӃĮņ$l"ƈŻFĒ—™x“¬ˆłk~¬nÜykqĖ‡ÓŚŠĶ±ÓŽĪR=°Ķ2¶r™¹ģVĪĶ«ÜՙdŻ5!ųbM×}5Ū±_föćab$ē‰%ī¾Č p#e7dt ć– r3nõ×cäĀ• Ē-µKHŗVdål¾õœbÉ'/ŒX+c$B.ē1ņ‰ŗT%q’Ńxł¶NQ .€ŚcŚ]Ō(ļ~=2Ž­¦˜±b±ŌįĀnSA·ō640āøą/¾Ś­ˆD~S uŽcŽˆK¤ƒQSĮTāb”qŪ±mx6 ­£"äŅyŽ¬E‰Ō։Āś¹6t.žąĖżå‡ p©-‹YVŒ`’H5–P"üƒ2ūĘuŅʆ%w±8‚q÷ėQj¶6į£­…&¹±ųTÓŁü›Hu•&&_œę%žnė«HŖüa—ŪŗG©Š`ėMŅ0ēŠ›ŲD–śšæl}ł§øĮÉjTµŽDź’ĪŸš„cŹæ×ŪSæ{õhųņ‹{7’Ė“ƒĶb4~{Æ«Ņ/f‘Äh8|łčŽnó­üŽb”æ;ŪĀ3÷m!(£­Ūž‚Ļp‡ūz””°6”tŃ† >Će÷e(¬ %ż’},‡WU+[3IEND®B`‚ńGDdpJččšh² š S šDAĮ’Ćart-minaiFigure 2š€Rš5GĄŖ¦ Åʋ(ĀQAt’G.u Fš GĄŖ¦ Åʋ(ĀQAt’’Ų’ąJFIFdd’ģDucky<’īAdobedĄ’Ū„       ’Ą’Ä„!1AQaq"2‘”B±ĮŃRŅ#šįbr‚²ń’3CSs¢Ācƒ£“$D”ŃR!¢1šAQaq‘±"Įįń’Ś ?łÆé¦^'ÕŲł<Ž†>>^FNLQĻŒĒŖ}»d ±‹‹×ŠłéZĒ§J¼/ iIu}‹éļÓļ¦øæÕ>v<¾;7Šå=ÓōüBÉqż‰qŸ$µĄ“{Ś½ƒ«Š~iWĒL+֞æ¾Čx£O%ztƧņł‡ ś1õ‡/ŽĆģ³:L||Čš$/lŸ—Ź”Eß&ĻeŽzļkżÅ€”ļ×+˜ÅĖyU į¾ƒ–ż5ä°ųŁp9>G˜cČccHgd1bĶ,Ģö“#]±XŠ ų]2—›%+\iLGŌ+JaZāĒĶśy›•Ÿ‘ČbĒÄįˆ=ģā'O{%}¼hÄ%÷€asŚZ]zy©^˜uc_}qč?ō‡œ—™o '!%6TøX‰_(’XbdĬL~Ę9²·kœ—±J­ni†8W©o\pʘ«‹ō«’š^W\žóœN#N@t­õś Ÿ ZĒ Ü@'ÆZ~E:ō®õ>Åzu§WśEõcš„”€fœŹ8Ē?¹ł`7|žß³ī–z½½źŸźµOäGóö%‡ųÅo+ś=õ'Āæ’~NóAåŹćį‘Īž6Ä$2©Łķ“‚RäąvŻŪJDncZąJŽT¦,%t0zƒŌ õØ5nż.śŌ>FŒ Ž×!āŁįł¬¦‡ĀŠA»\דīø¬~ü>>ģZż™|=ų+Éż5śĆBs†%ƒf™E#ĀĪE?,čČ>°żß‡Nµ4óĘø|ńČƆ]~_ķféÖx3ēĆ6IćpßČe¾9c{Īä9¤‡ÉĀ śME<ń®>…|2¦? ų槒SdsŁ|bŠ>Cóy¢YāŽ8a cÜēČ÷ n kö©Æš4¦>ź¢ž)c€ĪGō«ėŽ÷CZqĖ"ÅŹ‚y$‹1ķvFĒ—˜„{ŚÖ¹55øVƂTq’„X·+cĪéå~3åƒ+X žŻ,ŃdHĒ–Äč£as·?"8bF\é)7ü|¬G{œ{¹O:Lø Lvd˜ŠNŅ$kYÜī%S„#sNæ®?E«ąÆOŠ«ōĆźŁ£Čµ”š|h¢—*?"lfļ™ø­/žöĘŻX£±Z½|ńRž:?L>Ŗvy1·GøāūølŹŁ0·9ģÓD¹‚GJĮ}*SļĒoqöe‚ÜĻŅo­1²±ń[“4óKŠ’ĖecŹŲ21ć2ĶCĆöBčćĪŽEķQKˆV˜¦¾ Pź¦y^ \vꈤ‡236^4ŃäcĶyatrÄē4£ŚZF ź+HN’ōRp¬}O$ż%śŁ“AŽĢh&Ź•žŌųŃå@dœŚtū2Ū¼{ nqß`…ojĻņ æŲ’øæKžØ“)ńa hń?žäs1’$q}ļĖ™[XvĖé-]Ąō©ūńłžĒŁ’ØæN~©ś{#+’Š³xńņ™D3I¦kŸ¤dnsšÉšĒ8ź<ĀĢ<ѕz"~Gՙ­Y=AźPzƒŌ õØ=AźPzƒŌ õØ=AźPz—Óü¦/&NN;ņY&6N0Ž9D$~jĄ]øĒ/ŹŁ DÖ©8ćE”,*Üq­9x¼ÆŸĒ»5æOqrqxŠ7 DīµŃžćžÆh±©ž…^•„­iZV”Æ­qoŒ+J֞”Įdß­2©ń>§ƒwņ8¾Ą+(Ė…a‰°<Į ckę„]£Kœ@T-ÅžæN=3?#ū}^šœ7źOĀqœgĆęĀ3rĘoē£ä909±KbEvū~ņƒ×ØB‚ŅšJUʵ§ģˆł©aJf³›ż\Ōœ;‘›†YŽcä3qŸņøK#½½’4¶rĶ¤Xź%V#oō×ÄĖĻõS ‰śgõs‚ą›Ā^'ż›"ILŁŽŌ9b@dĢÉ2ŹĘ‹K|µDķė,zśüæ„ĆĻHįÓÓę;śĒé¾7č¾sŒĘn^wÅāÅt32)}ģƒ9m®zÄ$rmŽ©éŖĆĒ)RTƾæį2ņF5iī§Åšē?S$ē2±y|ųrĪćb3ÉAf4’Ä cÉ|A»·€T°;ip]µ¬<M0§£9y¾®µõ1ę?X"Īį„Ƌ‹t9E,p±ÓļÅĘ~S'*XbŲ×,¬Ė{Zó²Č¤Ucm…qĒŪŚ‹JćaƒęµŌęzƒŌ õØ>£…śļÉāńųŲƒcĪ?ģ)• óZ!f? ļBūĒ‹v­Óę½rVŅ•®8ūņų:©sZSÓŻķT>™żoĖį8ž üDy‘ń1ĶY|„£1»·įļłWé®įkRv“•k\}}«ū¢?M)L==©ū(śgõ›7‡ā0xÜ®5¼ˆƒ2ió¦’b×ebdG3_†šXōi“*Y Æs„ŖgmIVµĒžÕ!qZS 1(‡ėųY›ĶņOć䗓śƒĘä'v@Ł»>@öČĘ{^ŸhŪ»ÕŻŗUėįéJcŅ˜d§ŻėZįÖøŠĀżRÉĀĶ9øųd7‡Į€¾]Ķkųiqfl¤l„§äP›µ)x­¾4Ć}sĒTÓĻ…qĆŻL°9Ķżmlł1ĒeĶ…4¹Rr˜™|ƒękŁ™ŽügƎl‰¬dĻ,s˜÷ƒÕR×ē’õ¹łfŽżXāxüŒš8¼ü>;Üv4Ųüˆn`k²Ÿ’ē¹Ę ¹µń¾7«vŌŹŽµĒÓ­qōE<ō¦R¾ŸÆźoÓüÉ.å>˜ĶÄŹĖŹāqqņģüąfčņXŲ–P׳z°Ę§Ā¦> GŅ_Ŗ%ę„}hyĘž³ń’E‰Ä¶Ė‡“7Ģł¦ A•®– f@ĆżĻ`——½Ī½|åm_\qõżzÆKŠzašÉNgź’ĮżC—’ė¼Āē21œģL×ĒĒć>>>L¼ó‘0É|ĀO~Rble»Fßn8ŁŠ—®¾?cšėņe?-%’¦’ž©š_ļyģ?MÉņĻ™Üć¤Ės˜ųņ ’ āÅ6˜'¼^®/!Ąt§ć× 1éOEžż1ĒµõÉž¢`Éōģ’Mń|Sńx“‚0±LłiŚēgĒŸ$Ņ½±D×ī0ģ kZƒ©«GĆ_«ź­zćž°V^ZaōŅ?ī*yŌ?÷,ØqŪżÆ÷ēńßļnöŪ"tH›’szōŪćS§_LsD¼øŅ½=pɎ­Ų½AźPzƒŌ õØ=AźPzƒŌ õØ=AźPzƒģĢĢĢ åRŠB7ųWĮpv›3–Æŗēļ7öĒE ås6btž•Aénæe8;M™ĖSŸ¼ßŪ Żłóęø÷!š§i³9js÷›ūc¢¦»“wŹI’•¶ū©ĮŚlĪZœżęžŲč±ĢåYbK¼CGš§i³9js÷›ūc£±ĮĢLkżN qąķ6g-N~óltzpģX\ü¼ż®j'ģ"œ¦Ģå©ĻŽoķŽ…żQķ«qć|§£ęŚ>ę pv›3–§?yæ¶:Ōܙ>§ž›A’Øpv›3–§?yæ¶:9ž’Ė“n÷÷·øc?¦œ¦Ģå©ĻŽoķŽ‹"ś;GĖńŚŃū©ĮŚlĪZœżęžŲč$sļi,šéaµ©ū)ĮŚlĪZœżęžŲč„ÜĒ.?óÆ’ ?…8;M™ĖSŸ¼ßŪ<ļ(5ŸćµŸĀœ¦Ģå©ĻŽoķŽŠĖżDēg+ś}ø’¦œ¦Ģå©ĻŽoķŽˆŽsźś_wxĒōӃ“Łœµ9ūĶż±Ń!Ķóīłr?ų#žšpv›3–§?yæ¶:&Ž_ŸvE¼YōӃ“Łœµ9ūĶż±ŃsyžT”9 ŹĆū©ĮŚlĪZœżęžŲč±¼Ē$\¾ž’ pv›3–§?yæ¶:/w'ȁ’ˆ>Ę’ pv›3–§?yæ¶:$ŽG<ߎ#Ąµ©ū)ĮŚlĪZœżęžŲč" ģ§H÷•: jŗœ¦Ģå©ĻŽoķŽ‹dĶČcI( §i³9js÷›ūc”>W;ČÄI£Gś[ü)ĮŚlĪZœżęžŲč^>ŖåĖö¶U’‘ŸĀœ¦Ģå©ĻŽoķŽ‡x¼¶cńć{äĒę³Gī§i³9js÷›ūc¢įČfßpžąķ6g-N~óltU?%šŌ ”‡› |Rœ¦Ģå©ĻŽoķŽdę¹ø“O¦¾– pv›3–§?yæ¶:*’|äŅŁ įgōӃ“Łœµ9ūĶż±Š<œ÷4µ¹'žäÓNÓfrŌēļ7öĒEgžēŅŁ'’揶iĮŚlĪZœżęžŲč”ßR}BŸ›óžÜÓNÓfrŌēļ7öĒD]õ'ŌDzrÓ’·ōӃ“Łœµ9ūĶż±Š3ž«ś…™żø梜¦Ģå©ĻŽoķŽŽĒõWÕ(Ü¢ūq'żąķ6g-N~ólt7õC®üŠŃ’·ōӃ“Łœµ9ūĶż±ŠKyīe”Qy’‚1ūNÓfrŌēļ7öĒEoś‡œü9 ŪŃōӃ“Łœµ9ūĶż±ŠĖ źIfĒŁć­³¦cZ|‰iœ¦Ģå©ĻŽoķŽ‰O™ĪĄæ˜l°¶F5„ā‚Ōąķ6g-N~ólt'?ŹŻĆ%Ģ lGö¶œ¦Ģå©ĻŽoķŽŻõ>÷$sŽ„²2é§i³9js÷›ūc£‡źØF¹ięČ’¦œ¦Ģå©ĻŽoķŽØłĘė—øöĘ?łiĮŚlĪZœżęžŲč’²óĒ’ō§ü‘’M8;M™ĖSŸ¼ßŪQóäŪ*ßūq’M8;M™ĖSŸ¼ßŪ?PóélÆ’ÓNÓfrŌēļ7öĒG‡?õ Ó+’ĒōӃ“Łœµ9ūĶż±Ń„Ą4©Jõž8y°Aš7ó…$wē„FŻ§@ĪƒŃH­6 “eź( öĖ€xq’‡½y’f!dLtc«€½k•µ’D~yŻu6½čū]Ā ä`‚Ų#YNŽ±żĘ‚2c€HK­Z_ō’¤PtĢø·scöPHį4”łžį@Dx偏R(.¢PŽb* ²0`Ŗ×¼čŅhä¼0śÉü7 żĮ­>–ę(‹‘$…Dģ”œ‰B9Gņš ÉÜŌxC@tę“’:ī(.›C,;ŲAø ĪäąOė.6 ³Žć1b¦u2dü§łZ“[Į–G=Ā$i$‚-­?/,GÖCBō+ALÓ1 6‹uėń Ēø“öš }¶ ›ųPW+ä'ū`4v‚ÆrfŸSmöP\ŲćČwö#÷ŠXŽĒęhh óøLCg.į”ւ§ąŗ;0yPVŲž_“‚c@Kq‹ŹPyķÄ`O˜Š ł‹¬`h6'Ŗ āęOɍźĪĆvŸ…Ņ~C)€€#Čp’Ć?)ņ4ĻĘ䎄Ž4 Įt6#„}ūh: ’(,ØA@C1Qj ņ@‰©ŠŽƒw3HĶųPQ— DŃ°X”š½nŒ½ ?ćJŲģkbč(r|žCŸķ@}ØŚ.F“ åĖÉ-tq½Ą;ēz•?Ā€_ĖssÜŠVģt¹ū((,‰J jČĄ’ė ߅3äq OųĶXĆ»łA3†ö7Ż‘ā&’;ģ(*o-ĘBōné^?ō°ż“Ÿž”ƒģµ‘ł?i _''-Ÿ3¼@°ūØrä:K¹ÄwZ33U„䎬h8rŌ¹|’øł”¶.µŒI‹ŃŃ½Æ‰C@Ņ7oZAė@ĒX!_ 2OmźĻķ†é” I‘÷žÅV®“ny˜},°ņHäd²Ā÷:īx_ §!’K) o”léń$—(źžŹÓWiŪŃm@Æ39ŃKšĪĆS@®Nn}’”ēņZŠżž -ŸR䎌= ųŸQ6Vv1qصńeąLĢĆöŠ^ģ&HĀę8Ū—D éˆ¦†€y£ÖÉ@8Ē.!œtJøXQc‡<ŽF‹¹4'µ[żņ<ˆāoĢ÷~ļ¹üÄ8ĶŪŒÄ=ū»ĻĀƒ/ŸÉäd<™\|hŽi7Ą›XŠy¹3ʶ$v ¾ÆzɵŌvņ”ĶÓŹFPHą[”  āRl ”~ķĀ[½L#“Gī Ń`Ī×±Ŗ.:ƒ@É\"aøu»Š6ƒ>A ›ĪļJ”4 r§ŒŹ\Į;Šéƒ^Ōm@óFm ā¶'JĢ2Ģ(Š=7 [’K¢/‘Č„\ļŻAœåsClŪžŠt ĖęČ\®[÷4 ÜO©Č½±1„ZCŁ€ÜX7H…Ö4 bĮ : Œ·F}£ŲP+’¾²PtÓļ cÉA?¢`ÓvŽʂłqŽĻr½Ę£Ī‚ŸĖĒ(æö䯊łŠ.<‘=ŌńéA“€ļ( Č!ķcÓębF×b„M$Fķ¤ōčhĒŸ'“ßu– )=WĪ‚ÉāÅ?ŪiP«„Ø(`‚Iv†õ?mܼyKÉÖŁ‰”ń ­ńƒÓ’m·ŚQb/ćA‘0]ĮĪŠč>4½Ł­.hüV&€oĖićAQŠäŠp°¦«ŚŌNŠ AÜ8€yqŠY|č:8Ł` ēHīŗP/ä\ż…’Ē"1¼RƒœęūŽßwŖ4 ¤–6õO…råmxŪzŻ•)w‡JœHK;Šk5śßĪ‚9 Hy½ŽiÜ@©½‘5ą€Ÿ5ØįFŠ¶'š÷ kĒ†µčāÅ6ČŲ;Tžō Ū 3Ąē0–»nš‚hŒ1īśŽjlś\]Ļq÷œ“ąƒö÷ »Š>ÓƜCƒŗŽŌ ‹OeO“Žg( nŲ[ņAĶ“qsµ4 ę P\„b—]¤ÆZ [c“smuZć–8Ü×H|t „łr¼ś„; ŗĢ¾—4§ģĢ{²4‘Ü^‚ČgĒp8Š;ć³Ą “ž½ nü]ń‰¢ ÓgŽ¢‚”Ćk‚ŽŌɍķŹšµŚ `‹|.Œ‹²ćŹ‚xrɏ!Dößg“ÜyŠ2äe˜ÖŃŪAż«A1ɗ¹m5G¬X²Ćc#®…ŪŲ,«{P-(Ķ±½č/Ł»-ĆqEwʀIbŠ›-© ˆ`i,4ւ`u „ģP<(*Ūb¢‚§@ā‹sįփĻb5>Ć@ŗV—9ĻO* °1¤t»Óūzīč“ &tXŠŗT §Rh2<ŽTŅ=Ī$ÆZ ÷ ų7>@-kš™­Œķ ņq*“ ²säsPY/a@ņå&äŪ­FL»‘oŅ‚Ųņ'RIUéAoēē Ś|¼h'+0s#ZB”)@Źćīh!«éB©@Ö1Æk—ŌĮļ@lć.½Øć²IZmbtż“!‚ɗ“Y'óĀ’Fė<»½ØżQ@AF€Š.‡ŖŠųÉD7:Žōē{Ī=ÉšķA“åÓŚ %wWŹƒ3š[Bļ…ĢŒ˜£r§ˆ:P-Éä^āEČ:(+Ē‘Ļ>¢ƒšŠ d-hV€wČÕM’@UJ ™Ÿ0ŚCĖ@Š-9ylŃ&6Ÿ“P8Äå!qMŇ£_§żįA°ś<9qä°!ZīžK@Õųģsö‡”ķ@&f;š ^.ŠżŌÅčx\GŽ«ē” ›X@ƒĪŒ»Z$†)_śd •¹øĄ·Ü` u „q“ŽŠ{!ųP,døYGo:ѝģļAäµ€ óŪA(=“PS3Ɛ ®,F½Ä‘čn£¹ ,6ČŠtÆØłøļf3¼µU4Z W#ČK.„@(M*‚Š¢€ 'i]qŌP0{^KJ§N“™RmŚƒģÜ ŠĮų•J öĘBøś’ŌģąŪpzP‡# q½‰»h4˜°²Fļk÷„ ŠFČĪķS½, Oø%.­ ŃcĢöqņ-ƒœKP 4 ø·Āē¹ aĆJĄć…ĶŚh”.hšA!piōø&“žzÖ³åžēZ ¾kć»HWĀ(ēī™H>µķĘ/`>7 µ°¾Å؃Bh#ßOĄ“@$’qHÜ ŌP CCÉAŲõ ƒŠƒĢxQ­¢hāŹą,h fTEĶ$’M¬-@YÉÄ¢‚m»Q÷P7į‹ d€•ŃPżō(_‹CūŠ=ĮÅhs}@— >V½¬kYźzšč ®3qG/ķ cE@(+4äĄ_‡pQ(3üĒļŹøėkjf<ū‡uU Y`Ü\½Hė@·/=‘¼ˆŲ źćzåĻĖsH/×M @“N©¼  ¬:Ršw [‘,cŅćA`ĖČU.D aĪŚ€°jH g‹“Žńź&?;“P6ĘR šąęč­+jPŠØ;P=ā¦ •Ž=;Zƒd@sY&ŖĪ€lŲŃķ—méwŸJcø·R4ņ  6Å:Šs`AēAzZ‚²Ą”n½(&@KŠN)Ak»õ4q'ųPVą:Ppw ėqMh+Ļsc…Ū®QRƒ#Čäā:vó ĶęKU>Ź9S„GŸł…|¹Ś“ŗŻ W‘’ŗP&SĪ‡ĢPł^nh8'$!6 ¾75Aq×J ŚÖ¹åĒ@-ē@[Yŗ2攳R‚ŅZČīI4 x·€4ėsA¦ć™3Č'Oę4~.cŚ¤¢Üw s‹–^ē9 !(|ØjX’†€čßĶĖØŅ‚¢BŚƒĪ6A@£‘œIōBŅ– łoŌXOŠg9—!Cüh3YEū\Šē•P7%æ¼ńvéqjdFvnŚTXŪ„pZ_ÖķV÷4Ķöāœµ‚–ČÜļ›„Šø’ 9²9ĪŚ¤t a‰)ki-rź P?Åä³$­trłŠh8ŠĢ§±øÆY?ōŻgyŠn°äc“ug„Ą÷ öd!ŲĻž"€8ˆH°Ö€ū%Ø<Ø,OMh:h=“ø‹­«Aē‚”źh, .!­Ö‚ęĘ-ÓS@›—˜^ u=7?6 OR4KŠgó3¤*Š‡­Ā÷®!~Ź’5å["å  VØté@#ĆĮŅŻ(+sŽėŻ4 -'Dš "–Pt ,G!fĄF·:Š#V šēÄa`IŻHmߧø—ęÖęO[Pk±pć`t dĢcģčA6cad16£›įŃ|(ĆŚ¤_­”§m›ˆŅ‚2FąŪ”ń MČĘĀ@`+u4Ng…®s‚­œh0œŽ'±#œ±§c@„Ī-w„” u ²—|ˆMż:PEĻ ŸYs ¼Ø!Ż.…ÅÉ”ó ¢h÷’é©W½MƒB䶔Ē#DńCŽ—Ż®Š:Š0ĒŠF܍Ą %ų”īxK“ø÷ˆ€ ’qUF¢ƒiĄsI9=eźOMŌ“ ę…ŃNŅŪG"ąh/…ŹŒ:€£Ź‚ä •ÓŹƒ‰AŽ”„Ō¾TōŅ‚/rŪķ ˆh .¶D~i?gAAW!‘&)’Rw>ĶhŌŠa9¾RyÉü  Ø2ł³y7ļ@Æ# 5PkŽ\Ņ9H}s{’ uŽ¤PüYšā\-­Ķņc¹N‰Ņō~QŽ¢†‚¬r·ÕŽ€¶DęĘ¾‘qAtR5ņG`ŗP4n,-iöÜMÅ1qÓo MSģ Öń¬ŲZŅ.ˆI qŽčŚåy°P0ŽOqĶõuTš k€Āā OL'jŠZĒzƒŖt6Ģ\āSķ _<WŖP"åpŠ‘ų]ÓĀƒ)ĖaCżä;N¤yŠc³šā›ČMzP. ›p“„± ¹dĘĀņZZė!¾” åd»š—\PG%ĮRĮ@T ƒ L(M†‡ZbtD®6M(C‹ZĀ\/»[P~Rņ j˜ļ²|zŠŠGdŅ¶ä‚f¹U­ ī| čņāA«t=č.’!$nb_VžÄi@1apkŪéxŗ§^¢€†<8¼PNƒ”>ę]( hŖ“ø„»ŠI±[æz¶-ņ¶?ę7ņŠétŠt<[ź|‚ü¢‘ų;|(1܃fsˆ#h6½,ÜV”.q·jRµŒu$P $„•i*PR÷øµmĻŒ]'Ph–+…z@<Œ„č)ŽXmŌuµ˜ł[cŁ³zč”ÅÖń Ļņ……Ķ”ŻE+9’5ä¾÷± W$NHc ={P*Ķʂ+M(«EĶœŒŒ8Š7s»@ ¼ˆ'lq”ī.ĖqŌæeHēh+%ˆ¬Gj†ĆŖč“ųĻĖ±Ą=į„±õ m<±Ķ·ųō¢P čä/s” †‘@ŹA{\…łŠ.6_¬\1ķSq@ߍ‘ī w&ƒG„ĮQ,|hŗķš ģa¦4T"‚™\²4 č ŪPW$Võ'•žN0×45 ršŠba Ü æę” y®1Ī›qŌ¬āį$6G…l‚ÉøözIDP@µg‘ćDA×!ī·Ė„L®2RŻį–ÆZ‹+“4©Ō Š^ÜwF““ōEģ±ą›Æš¶X$x±hŠ^Ō1ķ³·»·A@× +%²ĆųuoŁA¤ĄĪĒ•(öüą+~"ƒKÅÄļ~7õ“ØAA„b==śŠU;Qķ$\ųPqo…ŚvŸ µšn“6żnh,kM¢7Hķ:]ĒµFFĻ‰ ”É"”X@‡“~c€n·Ł4½qÄb… ŻĻõ8łŠIį°ĀéS²ź|Ø2ü·';UøĆcGĢļÅžTL¹Śā\I/ń¹ M—I:”ļŽ6[åy;Aó §†U µRm@Ųo:č/@,˜Īa±}‰OØÆŻA² JµWJ [YźzĄPN䯶>¦ŻĶ„ʐLē>?OĢÉ pų^^H č ĒŃ“„ÜÓ~ōcĘÓ,ˆ\uNōqŅbPEpDJ:0Ö²Ą; żō q§c‘„U¢Äémh cZ>ŪŠ6‹o²æå(– ä€!_²‚Š/ ŗŠ’E“ķ U™˜#˜0¢’BŠPüŲv ¤Zć_* %|®Č澎Ÿu9óŸ¹ķ/Pæ/zLrn‚ā‚ö  Ć.9T‡l ‰u> 9ŽK.2ĘJäo؞T Ī@{T蚓jŪ”Ę:ģ> ›ŗ|(:ÉWĄP ¾ŹńŃ zFīśŠ2Ēl„ ¤źhįĘĄŌW%ÜGŪ@×Dö€l持ĻdÅČ÷Żķ·ūEˆ£ƒd:ąŠW;QĮćGėę(*"‚ƒĪ>‚WAA•'Ā€¬`( ˆI™Į|Øw÷& €P/ē'Y„Z26ü/A“Ļt³“Ńų¤6oÄŠg¹ f°Ņz†»,>Ó@ŖY™q°üĘō ņ^ąJ"õ)@²w9÷pįz¤%æ*åAC”|„†€I£cIUµDĘĆ”'Ź‚.,k•×k®;P6ś •Ó<+#DփU ķOKCP((9+å,Ü 7P“‰×qł\z‹²‚Ų‹„pgĢ”š1}¦‚Bv `ĒļrI=t dĒ85‘øµµ4 "Ro×öP5ĘŲų„˜=i{ŠrV€U,EA (*ŹˆZʃ;ÉāHéƊķ@æ ³I-‹…”¤Š-Źå^hi]I43ó²=ąšĖyŠs—kć(øŠ(‡žŽIhjh£_* ßŌlŽgī]@Š?—aŃAĮķūˆ\ŗŠwd@ø‚Gį†y ¶±ˆN©zø’<¼‚;OÜ|ģ}¬nßõ (ćl˜ĉųAæŁ@Ļ2ÄčzƒŅžD­• ŸķÆŪA«Äõć8ņ”;Õ ‡āmĄņ Ž‚&€\‰ĄkŁ”Š|h'Žā’‡ZēA~4…¹zÜP1cÕą¦“ łX£‘Ī.;œ?B; Ī{žT o¤ß yīłµ!(åĆ ¼€:­ØĶ+YņśŪցfNC@.ŻÆ…ł²:ŖÜP 6D €ŖßŪAS§{Ópš‚§½N· ģLsŸµ,/ŽƒaÅć6>;ÜüD•xP N‘Ź_“ń qłxŸ„źņ>ß*OtžéØ@±Z| ÷ui³F¾fƒYˆĆ µØ=č.ĒĒ x½}$Š1kāZYzŠ\Ęö4 1āŹ ƒnorˆh+•®(ŃAčŲäNšŠrv ”N” åČŗ„ž[ ²#¶ m(åq±‡€ļP:%b“E+$‰XŗPgsā—Ž@ üh*lolŒkŚ īPrxą‘Ī½ū³`G ŪÉ%®6K„²p!1ū„A!:P€ē!ŪÆj #di2 üĀōA ‡ŌąI=R€čĘ‹ō€ų^öž‚5"ŌšyŒ†€ŁG»ņ»Tó ÓńóąeļnOä:#A§ćA +Ł/į@QfąSęøó _įAĆ­į Ostš + ŽzÜyP֟CQą x‚3Ü?1Æ Q’ā÷tļ@§”n‘b|­As]źŚF×h¦ō9S·sT§‡…JĀ 9ŻV€ĢmŽwØ0§öŠ5ƒ¦ń?É®é@Ē ™L•»B9PA¼įó¢{Y7mõīE“éõé@æ-Ž“zMēACĖ€)ÓJs¬Z°€P‚Ü(÷¹Ņ›†”oq‚C’• Š!äłń”0nz|ŻC:y§y{ɑĘĖ@“7 ŅļtS@–lR×z\\Óš _‘‡·6ćB§ļ ųųĶ%ZŽ¤ŠS!Ēd`ĘĻ3APČ(£j­č:é¢s@Øģ(%¤•póļį@Ļ‰†0ā÷=6 jmĪ~øč.„šłQę%$øŁÉ©>TćŒÜö±Ā'­.E +² ˆūˆnń×įA¶Å™@Ü8:PD3&Ė! *P‡,ÅÅÆzÆŹ;PŽˆąP_œ\Oøī4Ņ€¦„¾„h!(źųŠE¬M~d¦Ņ:k@™ņäėŅ€¬¹CCPø£F¶ ]•<cĮ•ūR€˜ó¼E+Ś#‰ “ŅÕŃŗ-Sq_Ł2vó Q9•¤°ü£„ū18©,#ć@¼r;€(”Œł}µi]ŗyŠuœ§Ź^=]H 6¢…7 6ūč/ˆ”j0Ž ’ ½Č@N Y(Ę{‹ĆCNļ !„*śśžžTp¤Ši˜BĒ ŃĶėę(5 “ŽĒńh~`l‘¾'uŅ€@Aéc@6Ld„%ūŚ¤MøėAkÜŹā`‹ŒŠ¤łŽƒŁŅŗ<¹£ū’YæʃœĘ1ÅÓ8Ź÷_h° ²$FŗvµŁ^ā”==I W”ųÉ°ŁŃBP*ɁīęBM¼ØO •Ī³łØ'P”|4 ÷øĮA›ŠRłcSµ7h"ģ–±ˆʁŽČ~8Ś Znoc8n؋A#Ś/ņč?Ą œqC*7w¬jR‚Ł0_;@C„Ņ‚Ɠ¹ŹĒ­č …īPī7t c œ¾4 qŽ€;å=Ø6_NdœhĆTHŽwaŚƒT× #ß@6X2õ4Z€W’[¦““ģ bČĢ164ĶßēŪįA~[›6ē»h@æåA•å9p{qü¤č.OC’ć¤d¤ø†1×R>\ńGgkw«ÉżŌ ę‰ĮŽ!6õ#üØss‘ŠŌ»Ņ‚Cוžö”ÆÓģ  Uū®Gv }ųć¢ M…ļ—x²ŠZųĄcw<4‹¹Öւ©fˆ†“æŃŃ:ŠWł‡Ū0PyXšŻ»Ap¶Ó”4ń\³órNcc!¶`°UփG „ö]§ƒŽĮ—'e‚4:P6‘™0°”) 4b{w$” ¹®Ź ±¼}T °Ąp§¹ bÖz@oų4±‡n“s‹ÖƒÅ µ~ @"Š!½“­iVŻ½č‘ĪCŅ€W—£O D_phr9S‡°Óe/@&;ēŽFJOĻt)@7%–łeĀƶžt åap.> ²$ya®pŌéj ęv0Ž{A=: ŸĒ(iÓU4Ķq”Ņ‚Qä5Ńģs‰O”-Š7$ęķ³[Š°ī ‡Ø %ŒŒSŌé@×q >Pt&äOtcŌ± Ņż?˜^ÓŹŽ”H % ’… (ū/snŠ ųųū™~XĘóš i ³ļ•·q KŹf»*W†’"gÉühO$0°ģ'ÜźN¾T rĮz“Öž$xŠ%ĖjØ`’T:'~+ƒ½9nÜh—<ø’£Č)J¹Mœ¼»ŪyŁ¤@;Ė‚ć½¶[‚oAr¤r‚ŌŌ—,ķƒoĔŹöŅ|Ø;īīšä"“„niP\TŽ¢÷Óń4å:P[j ¦0Œ°tr”µ«ŒČ…¢4³‘ zZŌ‰Dńø) HoĀƒøŃŹŃź*jĆ½h Āˆ›„|v E›éZŠ—Eń ó˜½Ō (ņ¬łŠgä$›[Ā‚ŽČI_ h:h)“Üx]?ī(ę²6ķŌCį@š`\Ń`]eO óK²BRĒ^”ĪctN{›u²Zƒ?Ź°÷“īw^ā)äg°pŪØq'T ½Ł¬!±ŹŽł|Ø(1Ę%øOå4Ä±Ę \ŻH-8Æ86†ž*˜øbGļwÉeCs@īŹŻ­h „œŅĄĀMĒXÓæXö’Z÷|» .R’ (äX×8õ¤żāĘCc‘ą]ÅĄS»Łć%p³žCwuC­_;$FĀʔq°ó I<ĪÄ_#\?øšs© Y“>Å ½€„ģ”xTGßA4‹ź©@£™>˜Ą”“@–Vȇ§īx h"\ch=M'„«qAD‘õA@4įžÓ‹ 8 v S.ł[źˆÕŌ óbŲv•k“J˜d‹‚/@yyaŪdøµØ3ä.–x"ģ)ph3mĘsH{oÜE6’ķ®(OmEXc#ģƒ­žŹ!h,P7…'ųPZŅKšBtcē¹‡T4šł&HŠē«N››ü(cø¼4®ķĆCAØÅS‹ķŸ˜ ¢rvJŲ-,Ę`?1 ¹|Ųćß$®H›bš“ŲP`9CߐļōFĀDqŻčŽ)3'3å$å\Ų;Z,\įr{Š4ād!OćqւųŪŽRŻŽŗ„Eń4{ 'Ąth=ķ„ƒk[Ś‚™±¤…ł{PAųR p©J [ŵ¤܅Jõ ė8¦’ n‡ķń 'ņŃĘĖ Ä @;°å{Hc]ó ²8¦3B MĪźŁĘā†‚éQĒrX ÆŁ ˜øDĘ³uŗ§Ū@ļŽÉžHŻ¾ūlŌµĪ/ŌØ 6"’l}]Ø c‰o«”€Ģs„•hĄņ¾“ĘB€.Z ĄŅż4 ƒ‘l,½h+ÜĄ]ø*ė@£–‘ÖŖ$P'–@Iæ…śŠVL ÅωA[ż—¹ß„xŠA­ĪMąt½eĢč”øŅ½(ŹųD…čˆ~R5 ?Śš6¹­õ&¦qk[Š oŅk 2±ķ#Ņ‚ŗŠ$äp¶qźŅʃ9•€čä5Ē•qńņ ²čī5»]ŌP0Ētn»]Ø](;ĢOō›:ƒŅHĖG [Alm·z)( Ē{™ų“ųP;įłnVĒ"˜ÜB‘ØńAĕ®Ųö8»B4"‚€Ł§”i#ģ p܆Ē‡4ļ 66’OĀƒē܏$sr y"ü­ģ<|čä±óäīu‰M”.#ŽFŲŚ=Gę$kā“}Hiģ– µøĢC~45R‚ƒ»Šh/Aķ·½ čbŽƒÄmPCh:(†ė@,’åä”0?‰’gŹq¼k{]ŌŽ/aĶsɑĒ’ (wÓN!=Ó®©@6wŅ•ŽMr:* žWŃł­ÜAOĀ†Cø>B%Ó½oćekOö\Ō7pč•²ĘņŠ¤t± ėdq{_Ōwµq<4ļäümā‚ŁŌ ØwS@~ĘŠā=GöPl~•äæø0¤6qXcŌP=ä×ņR·§‡Z >Øäæ-‚Ģ”|ĢŻ!ģ: ³ś@źzwéA¢ąøP ÷„P]r{ų Šc26£7¢ō !±€‰Ao¶\h:[}”,$© ‰ŒŽÄŠHDćm{PI°7ń”4DŠzh*ö”žŹö‹ėA^ŻRƒĶ…ÅVƒžĖ‰Ņ‚–;7PsŁzŖZ‚×ć„Ēŀ5­jł÷ ¶Kܝz%xb”­PJ6ø\­xĄ˜Ōć@_—•FĖū…Ó=Ė“ņ KĖ0— ž“Ÿ,€ŁĒŹ‚>ńu)sAp¢é¢P{ŚČY¤/SAdTQŚ‚¹Ņ.Pgņ  ™ĢkBŖEߔhqŽß3@6_ ąo`)m5 W‘ōÜE§Ś²ōé@žN?#[‹‹HķAę49ć{Pģ aö  ć½./%ŃåÄšP±Ąƒåz”LꏊEŁ+h ĘżWœr99ļfƒÉ“ż/Ęøf{óq T ś Ū!  ¹±’h&#Z†wւ`&ŗŠI:Z‚+¹=4P,5 ā.·Z–²v&ƒĶˆØ[ Ė܉ń ćaźGĀ‚ob5×½ClOZ ™½³a„qą½”š „h ‚B ąˆ®G šöŚĘ;e_KŗP.ö–ĆĮ(Äp0©I $"\_„nŚM”wQ@,šJ_° IÉć佞4 Ś&$īp Śōo īrõŅ‚ߏ““R‚n* KPpŅćµ$¶Ī€wĀįÆʂ—ĀŅ "ō¾4ŠŠy­'ZŗĘ×J Šó0=ļSJ8h(ø;å{PŽżÅ§’ ADK^€Y1C]eŲ—ļ@4ų,”=»‡q@įż¶;Ł“-ź<Ø’ęŻšv>4įNZõ'ČŠ} ƒÉ9\d•s jłPdr “;’‘6{És» Łpų ĀĘla»U==“½5Bmn”0©½Ø:\4E=Rƒ€’GN”m‰_ŗ‚[”„ U „vŪA6GmŠOcSKŠx4č‹A9X©±ūgĢ­ŽĒ.łĒz 76\ń4céAĖåV‚NƒiēA|p6ÅGŪAk1īæ ±ŲXŻĀū¾ź Ɯį·”P†‚ŲšCQ:}”mØ9°)(“‘”Ź_Ż@³: ›Ż(lEJü¾=h<ų€ m ‡“[”8ąßļėAć€m÷PU$*"AS˜­ģEN.oŽ‚§ĀRŚPUķ°ņ ĢBh8­HķAFN,sµbŪƒühl{$tdVćZ9Ļc•ĒMA½\Xē4©ļŅ‚2BŅŅŪŗąŠfy~%ĶYįj’ź3½fŽ@»VŌ¤g\y"ļźh ŸĢ“!MŲƒÆ]E«Alj…tļA'%…Ø<Ķ|~4²žŃA0‹}(,Ÿ“Pu©šūØ-hj\ jXŚƒ£j›ßĀ‚M ļęEH…~d? ³ŚPˆJ’h$ōé§J#v…4jt¹ėA\āCŌ†öåAķm¾æ}€ž“ŅĒ­QÆ[÷ gŻ ŗw ėŻź(~?¾‚čŃ  µSĀƒĪżÖ …Ņ€“÷õ[µƒ`¹ø²Š¹ĮlÓ槯AĻģm ¾*šŠDöĀŸ dsģ zj¢‚¶»#w©¶é¢ŠY'²YźAŽ€ŽP–×J ĪŻ„tėAYŽėŪZžŽŻ(*rmōüR‚%‚ļ  1°Ī z^ÄØųP D{œ\ļWPå×ćATŠ­ļŅ‚`Ģ$!Ķ%¶øM(œGźCéüKŚƒ5Č³Üs¢/žcv½¦“ >–2 ¦† ĶB§Āƒ’Ł–WDdpŻččšh² š S šDAĮ’Ćart-minaiFigure 3š€RšŚVė “‹Šæ}J÷¢s•••’¶V½ Fš®Vė “‹Šæ}J÷¢s•••’’Ų’ąJFIFdd’ģDucky<’īAdobedĄ’Ū„       ’ĄS’ÄØ!1AQaq"‘2”±ĮB#ÓR3£UŃįbs5šń‚ƒ$%r¢C4EScT”ŃR!¢1šAQaq‘±"Įįń’Ś ?ę¾š]ŲZuu½ĪćgįaoowqsgssĒ#-ķeŸN™…kÄb¾‡ĻJÖ=:UįxkJK«±t÷§Ż5µś§¾Ēw·ZŽķ[§šz~ ”d¶žD¶æ’HZąZ<ƒåFŽAĖŠ~iWĒL+֞æ¾Čx£O%ztƧņę/£a»Ū°Ūy,¾’ŽŽņ; Ū'ĖŻJ"‰ļ“G’Ē>ŗŚĒ?Q`&œśås¹co*“7@Į»zk¹Yķ²Ųn{¶šĘ7p¶¶ĪČbµšY˜ä6ęF»EXŠ {1¦Róaä„k)ƒHų±…iL+\Xł½<½·¶ŗæøÜ-cŚlÄuńÓĪ¹Æ—o儾p .{KhŠ3Ź»ÓĶJōĆ«ų«ėDū_HwÉw–ģŅnnS]Kei•ņ‰%†&LMbcō1Ķ•ŗ\źc¢­ni†8W©o\pʘ›‹Ņ­Źiv{h7[ o÷ūOœŚmn„oĄ\ųZÖ8˜ˆn¢j锚“qkšöC BĒļĆćīÅÆŁ—Ć߁»ŸMzĀŽĀsf%ƒmeœ—E#ĀĶʟ,čČ>0ż_w.*iēpłć‘_ ŗüæŁĖ’KśĪĘ{ųf³i;m›÷ ·Ē,ocmā™Š<‡4āŁ"x ĒĀTSĻįóčWĆ*cņGµō’©®7ė½‰±Eįaoów¢YāŽ8a cÜēČ÷ jĆJkę)ŗاŠXą™øśUÖ61½ī†Žą“Ū–EkuņIćŪ“ģ/1J÷µ­u3*#q­_Ø'śWÖ-ŗ¶¶dóŗy_lł`ŗ·–('†7K4W1å±:(Ų\ķG Ÿ‘±%–ćéé ¶Üū{«Gy›{· ĪśKøŒLu䖩N’$kYĢź&“įHÜÓÆė‡ĻŃjų+ÓōU[śaÕ³Gp’*Ž'C4öŃE-Ō }ÄÖĶ×3mZ_ųŚYQČÕ^¾x©O †=0ź§YGsmd{Æ›fĖØs ožČķ4AŚ˜$t¬åQZ'ߎ>ŽćģĖ·ž“u„µÕ½«mķīfžim_ņ×Vņ¶ ‹xĢ³Cpšżŗ8Įsµ‘€<”Rā¦)ƂTQõLī»¶ķ½I äfk;»i£ø·š0ņĀčå‰Īi£ŚZF`ꐝ%č¤įXśÆ$ō—­™4ģ¶‚k©_åOmŌKY<§O¢ķŗĒ‘H£sŽ¼ qĮgł_ģHÜ^—õD—Oˆ:Č[Gkó’ĢåæÉ_;åĢ­ø,:eš–×P<żųü’cģČĒQzsÕ==iqu¹EYiiŪļXōŽĒ{Ń{ęŁlŪ»ķŸj µŠ;čfdRł×8nŪ\śÄ$u4ė­<*°ńŹT•+ļÆĆųL¼‘cZ{©ńf·ĻS$ß.­w{ųn¾ŪZ2ŌÉĮe“’Ä c¹|Aŗµ€jX¤øW*µkÓL)čĪ^o«­}V;Ē¬_lŅŁÅµŗ‰"–8XéõŚŪ>é“Ēu,1hk«+.ŽÖ‡¼čĀ•!V6ŲW}½Ø“®1¦9Ŗźs€ £eė¾ēk·ŪZ µ6ū[¬L¦ZŽ“BĖ}ĮŽ łĒkt×|X®JŚRµĒ~_U.kJz{½ŖGLśßw²mū“öˆļ#Ścš+²łKEćuk³Ö487å_–z†$ķi*ÖøśūW÷D.~šR˜z{Sö1Ó>³^ģūEŽŪu¶·q^M=ōŅLZė«KˆękģŽ F™.„»NX)µ%Z×:{T…ÅiL0ÅQ_ĀĖŻļr~ß$»ŸPZīŪ„īø5_ČŁĻ+ĆåM:¼\Ū’½|=)LzS ”ū½k\:׫/T®lÆMķ½€ °Łģ`/—SZżš[Y›)”)³ų*)«3Lb¶ųÓ }õĻSO>Ēu2Įs{ėkg¹ˆŗīk)„ŗ“t“»Ü3^ĖĖwŪ>pŲćdMc&ycœĒ¼4Ø4„ÆĻ%ėsņĶnõciŪī,c°ŚļģlöėmÖÓ[ī!·®ŗ}Ėžē ¼žf—Ęų\Ž-Ņ¦Võ®8֝k¢)ē„0Ā•ōų˜Ż}Méżä—n1›iuwu“ŚŪÜ-Łóš£¹cb¬”Æfŗ°ĒSŲ¦> GŅ_Ŗ%ę„}h¼Ū}gŪ$ŠÓhž[-…ĢŪ[.Ķ0XŚ Ø%t°[2Äņ y{Üģp<ó•µ}qĒ×õź½.)é‡Ć#7žÆķ{PŻ’õØ’/—t¼ææ’[¢÷\ŗh„µŻģŽ3 s=ģ®³S‰4ĘimYGūW®+qHלӎĢuG^Yo—Īu„ėćŪķŸß%Żłø˜\¾a'Ÿ)162Ż#O—ląK‰Ļ_Š±ųuł2Ÿ–’’Õ¤¾©ģ_Īī7Ųzh Ļv|Īß%ŪœĒĒuOØ“ĄŁ<āśø¼‡ĄcOĒ®cŅž‹żścŽkź¹ś‰c'NĻÓ{^Ōū]¤Ų‹+S=Ąšv¹×ńßÉ4ÆlQ5śŒ:ZÖŠq*њןś«^ø’¬—–˜}4§Oū‰ćŌ?ęV=CküæŹž|ż±śüķ^Oņȝ) kó5׆žÕ1šįZuōĒ4KĖ+Ó× ˜å»@@@@@Sśģ’ņtä[žZų.ÓfrÕ÷\żęžŲčŖsżOų’–œ¦Ģå©ĻŽoķŽ…~§õĻŹŸņ-’-8;M™ĖSŸ¼ßŪśŸ×?Ōš’"ßņӃ“Łœµ9ūĶż±Š?Sśėś—š-’-8;M™ĖSŸ¼ßŪõ?®kž„ü ĖNÓfrŌēļ7öĒ@żPėŸźĄ·ü“ąķ6g-N~óltÕ¹ÆśŸš-’-8;M™ĖSŸ¼ßŪõ?®kž§ü ĖNÓfrŌēļ7öĒ@żOėÆźT’‘ołiĮŚlĪZœżęžŲčŖqżOų’–œ¦Ģå©ĻŽoķŽśŸ×_Ōė’"ßņӃ“Łœµ9ūĶż±Š?T:ęæźĄ·ü“ąķ6g-N~óltź\’Ržæå§i³9js÷›ūc ~§õĻõ?ą[žZpv›3–§?yæ¶: z›×G=Īƒ‰ņ-’-8;M™ĖSŸ¼ßŪ}Oėź_Ą·ü“ąķ6g-N~óltõ;­Ļ’%ł’–œ¦Ģå©ĻŽoķŽ„ž¦õ×õ,?Č·ü“ąķ6g-N~óltŌīŗĆžåü ĖNÓfrŌēļ7öĒB‡©½r1våü ĖNÓfrŌēļ7öĒASŗāøī_Ą·ü“ąķ6g-N~óltõ7®)ž„SĒš-’-8;M™ĖSŸ¼ßŪõ7®§ó*;ü‹ĖNÓfrŌēļ7öĒBSŗꟼx’‘ołiĮŚlĪZœżęžŲč©żsZ2öł’–œ¦Ģå©ĻŽoķŽś×?Ō«Ėš-’-8;M™ĖSŸ¼ßŪõ;®kOꥷü“ąķ6g-N~óltŌīøž§ü ĖNÓfrŌēļ7öĒAž§uĪĢ»æßņӃ“Łœµ9ūĶż±Š?Sśćś—š-’-8;M™ĖSŸ¼ßŪ=NėrżĖņ-ńžpv›3–§?yæ¶:õ7®E+¹SŸą[žZpv›3–§?yæ¶:=NėŸź_Ą·ü“ąķ6g-N~óltŌī¹ž§_ł’–œ¦Ģå©ĻŽoķŽƒżNėŠū–?ä[žZpv›3–§?yæ¶:śŸ×4’Ržæå§i³9js÷›ūc ’Sŗąå¹ßņӃ“Łœµ9ūĶż±Š©ŻqŸóœź‹ķŅės»“2Ku+¦”°aWą åÖŃw :ą|g“A Ń=¹“ą€Ø1ĆÄĀ„}ˆ#Ž€łP­@Žü‚†Y” vUą€{(€cTTÖŌ ³Ūz{sÜdkm­Žš~õ0A·Ł½7µ‹L›”ŗ™‰¤}h5v¶V6Qˆķ!l`}źT yŅ9Ē€‹‰ć\)ī@)Ž(?܀Ŗ€ÅP1@}¼%¦(1ģ@zA?RžĄ€õ#QćĒ©ÜŠ ]ø ĒŲ€€©÷ -5(c„š MiÅPžäĆ* S14ĮlŗI fmøx4ŖO¼ĶÓ,Mv€‚ž÷£v Ē9Ę3 ?²iŠ ĘķéµÜZŸ`’=ƒ&żä+Ż§q³ylš¾7  ‚'#@Œ'ķ@t@‡µ1ä€q@cż‚h€±ā€éŠ »nÓ{3b·‰Ņ8ņŃCŲż:³·cn77%ĻÉi ö ÖĀŲ-¢lVѶ(Ę'€  Š€ų ē’\)¬s° (m¤Ē $s@¶ķó; q»t€ÕĀ­ XƒŖe€#ZHÉ76®Õ” įš€AŲ€«ˆļ@dŒGø #D÷G3š’ź3,O454®hBqXQH÷ 0€Å½įAĶµĒ0P7qmiwŽę&ČĀ)ˆĘˆ3Ļ¦öw-t»s‹$„|¢~¤-Ļ`ܶ÷˜®`sÄ:†žō…„`Bą€šā€#?gˆ˜ @$Š  ŅtĒG^nÓø­€«„"ƒéAŌ¶Ż³oŚ­ÄlØå?(s«Ÿµ čIŖ­™ŽųZJ qķ’8ų mŪ­™ńO.eń²&āāŹ³*€Žä n’āM1@‡\FIhÅlķ>Üx pHŚj Ļ@’ŃŽ>äę³ēŠŸģAYwfųhišŌØ©Ļ’š q­(‚ŹIØ W4ķń³¶˜ išąAi¼Ķ¤f”ÆmP%ö6š eö²Œi€ä§±Ķ##L~“q@@ 0i܀VŸŽ€Wō\.9܍@¹ÅµÜUäM’3…Nh2ļ¦¶ÓFė±ę“$Äiō ē†Ūuc1Šā7FįūBˆ#dB§¹3ÆŠ€źP­.u'‚ ÆHtK®ÜŪ»ąčķ† Bīä&EL‚łpĘ4µ£ę€Tž(ӊ’`€ Žä“@Lµ°t†Æš„QĒ ¢£ļÅ|¦ĄsAGśƒQÅžkµ obŗGøE8s@Ž¶ų± åJ e¢&WK«ŽĘŠ¶¬Ķė–ā YŚųnå'IŅÜM¶l“5¦WŁģ@»­®öFųŠxŠ’b »–X™Ø“Č“ M‹]S#MA„ †X0e ć•-ŽįJT v9(؈Ɓ s”Ć·…P/C‘Ń ųH”śŠ"[v?€p¹)6ó_ķ!9„…ą4@Dr@įR€z‚46˜ęP w zŚG6FŅ¤’u7IŲo¶¤øhøkN—ŠgČ āĘŃu¶^>Žį…®iĀ¢•  Eq@9 0 Ā•ģA»č¾‹·×ą¶ćaAŠ C4±ø5£@€QqÅńĆ$·š@ģŅJpsAe Œ0ŠæÄńŸŲ‚\ļ—Āч‚{6C$bM@īAK;ØāĘ“’8 eĻl^)^Ö7“„ż·FtüÄyćW’5“põ1ćˆńķ@ŪÆmóūĀYŻY¾G¶IZhš8f‚@1²ßĢk=õ@“3HØs®h·Š[«–CIt® hꃦ ”Ų- Ūķcošw ½Ļp©JĆÖņåM^і”É„}[¶ĢŃęZĘęņ @ÄŪMČą÷Y²£6ŒŖ‚-×ņ=Ź@ŪFĒVŃ²4ŠƒĶuŚī¶Ū‚ŻEńŽŌ ź/£MAĢ ¶sŅöŌóī@ēœŅŚ»Ā2#&Ž(c²«ŖN8„ņąßØ@qLĒ5ĄŌ;€( ö±H+…~¤%Ūž*ZkŲ‚ć{¤Šs(.įĮŖ‚‰@Ŗd€q@äd4T|YÄģd>Mq'Ś‚‡®zf-źŃÓG…Ü .AÅä€1ĪkŽ—Š£ŽŃQOb ŸDō‰¼—ē.Ś[o ńH:AŅĮ„Œk{jćT4”Å™žhŃ^ė}°‘­ų‘“POĀ&łM¤Ō’b ¶[,ó~4§Ėˆžä·zõ2Zŗ;ĄæˆN>ÄŪĶ’q»q|Ó9Äć™AĖ!?²ŚŽ`Ɗī¹ŁĮ ›ö —gÕ»<ų –“öą‚āˆgf¦9®ļ4Õ:¢$ŠāqOę—1 K%f9ńģA[wfų†”‹PE¦(#’ā€É±5šIv48h&0µŠÜ4šš iĻ‘¢9qČŌ!/õ§›ktŪūq[{Š—€0kb  Ńō‡LĖŗŽj†Ž:y źķdqDŲac` hī@xP Ś€Ø@ÆjCĮÓžä­¬Ÿ)80 “†ĘŹF*P=ek{y?“hĀOŽyČv”0ķŪv×ā˜üĶŃÄ~Č(~šČ~{r›å­š*Ö €äs­õ^—ZmQŃ ®¼y å{–ļ{1’āR÷eVĀ^Ē9®n`ꁦéÉŲ 01Ć„6¼ŹXé\(ęéh®nw„„ kKˆj½ŽØ4=ˆ.vĪŖŽöįŖŚéń(4V>°u…­)x÷PäIąƒc°śū½Üi¶»”±īš‰+‚ {ß­¦Õ6†Čłg :š¼"Ø)ī½}Ž.šķaĶ“±Ų Én~„ī×os‡„ø“Z×4}M»\$ÜĄ ‹%õą²øźķ(2JcŌI"“% {EkŸˆŅ“@l.&ø”ŽŻŌ;ƒõA+ƒGŻ®6ū/©‘KH7©\<֞=Č7;uÕ¼±¶āŻāXˆ  »ł6Ü3Ģ‡‘‹9„ļŽ1Ź)ŠW;hu]ĻV½®c‹H „x œPӊցŪT¢{cŠ¤P»ź@Ō×&A¦”· w )låŌŽn¤\n²0ŗŚŹæ r/AĄzĖÆw~ ½|ÓŹąĆƒXr¢ ›ĖŽ5$q@’ī“ØīĀ€Į”Ą/i¦$fDeĶ¦u]NQf$b~ ·qƒ—: '9ƒÉ pŠbUsPhGĮ„Ō†śÅ“T™”^;8 Ø$×Ø"BEŻ\(€Ų1.į˜Pū"˜g‰@\P Ń”( ˜ ku84ę‚u±wˆā9 Ōt¶ÖĖżÖ8ž)~9Ļ -A{{,W›¼“¦ĀŲe `Č ó’«=m6ł½¾Ž‘cmHāŒhsęc«¦<ŠćB€Pœ½č$Ć$ŗhücö “cLčĮÓØPĶ9`{etnsp(sMpĖŠn­' ų IĆ 8Šżī!¶'Č o Jp§Ņ€a«$ –j Ā`sœJ’rA­éžšįĶ–VéŒń(7¶;e½“l §Ä@ĶĮœź†ž\ŁZZ[ØA Ļļ= Änt, qģAŠŻ:&ž×¶  ĻwC'—(#šM䎍šˆjŗW艵"øu5PwcĶ=„Ž”>ä‚q@œAŖķZ\ē»¤Ō O€*pA”čĪ­æ鯎Ūw1økepsN`„–“Ü­·]ŖŪضĻ ­ĒļcnqŹßˆaĶKkż”[Å»@ĆĖøA«ØŹ¼c†>Ōo#WmP!¹ć’ÕJé Tꁶž|•>”‚…#rą€ØN$@Ā\9Ń“a±ĀGš ·OŪæ¦_yJ\_,[C…²;įw½h±µ½øŚ.w=ZcˆA™Ż,kw-“ƒį8ššA¼µņŸQš”Nb¼0@3‘@GµI€«_bkģ@¶·‰Aga#Y’…„vŗŗ†Ö1WHö±£±ē{ÓžßZ°0Ž„œ}[ßĪįŌSA‰†Ś‘“pĄ Ąŗ¢¼jöVKW“ q].§1Ä zŚāKyƒŲć§'½ØÜa…d°Ć”TS y Š£’]īA¬ŲmŻy·\XŹ5PV0~Ķ[–^:)p,$;ŲæSØ0hĄw ¶&øš“fŌ ”ĀļÜącˆ@ČĢp@¹t—U†£: ć¤bNAć£ś9Ó]\·šĪ-:U½ ‚ÜG(¤Ó]}Č¼’­ 9„»a­§‹‰ļA# OĮ ½ˆøcģ(»¶ŽxŒoįOjA×=:ėi¼Ķ#2E>¤Ó'įi®hq£E*ƒA“ŁYŽBxą#LūTnöĀ)ėt±õŠ‚æŽyfmš·`~Ä #K#ä€4‚ŚĶ­¾ķÖ·°Ļ “ŗ'‡5ÜA§ö­ģuKŲļšŗ·vĄEyĄÕ™]InėŪwvį9łŌqA•¹²ĘAČ(„c˜ņÓń#\B”©§ 4ä;P@p@\ł S[R DLš5ūP\FÖ61Ā”©AŠšyŻD%pÕ¤o”÷‚u>šŪ; żÅĪńiv‡w ņęķtė‹Łę‰Ņ<øžō ų’V7fĘƦZFķq».h”8x@ŪŖŽI·™²@ėwć\c<ŠåŽ§Ō4Óµż·p»±ž)šā4{Ē=÷k‚ą7w“nØeoāӁ!n) N™Ą† C}Ć,‚uĮ©Ī•¦”8Pkś3¤åæš;™›XkZ(;߶Åocc`‚X€iĆ¼ bāÕÆiĆ‚ ¶Śc\*A§5åļ@*,8Ž4ą€Į5ķAGÕŪTw»{‰m^ŠHēT.źɞŹdā€7ŹŃCįÆ.Ĭo#ŠFFŠ]u]¬mŚ­.ą†šQŠ xŅI'Naš†ćP5!Ōą/Ķq§ŽV“ÆĄk^H:’”Jw>Ć;ĻĖ_“µ­9k¦;NĀĆ5†į“Ķ‹“»@<ĄĮ2„Ćń4Š×˜A[øŪź¬ńA[kō #JN¹&ø <=œP.0óWZ Ÿ·°’ēŸˆąOŹ7Tg—,kŗ*!o°īwī{Żå1üiÅ<õow½<ŪF»ńn Āƒ„<ų‰8œŠ ¼œ ī@ż˜"xÉ©hp­HÜŲīÜ×6±š8s¢łö¦“yq½©&ęܲ auÓC^LS×p!.ö»»oqœœ1°’ŁÄĒu]š8f ÷KZĮŪ%”Ņ‰)yHÕ{=¾Ń³ˆĆšćFÕ72ŽAB{±ÄDęęj\‚^Ķ·Køī1ĄÖÖ¦®réĶŗ+KhācpcF\Šh€3É¢ÓĘń¼ r@ējk܀»Š`jēh’“ˆqAĄzŠŻŠī· äó^ź €ų^ār"”1·Y šA½¹Š;Ž†`¾Hˆp¢ ……å®p`ng»‚|Ę“oĮ–\4ņMyÖŗ‡äN9d²”k°”!¹;oßlīZā4JÓQŽƒŌ;fāÖīÖW¬żŻŠawi8½Qbl·Ū˜²l‡Ķ¹ų „‘šŲc“ ¦t:d”ą§Pā!ā‚TVŃÉ¢@&Ø#iŅH9 q†LZĢšEå“ ä>šbS?ƎNæŠ ķŒ/¶č{Ę¹&SŪ\pZoŒ›“vÄį AĖžvhp8ā8 fųAk‹\9Š„—V°nvŽt1£™•hƒ;$eÆ- ‚3 b4H,¬7«‹OƐ `vlv>ä–»nŁøJ%µvš¾3Ą ø½¶žŹ;sWiŲƒaÖ[sÆziķ²±ŗ©ŚqW±ģ&¢œŠ³[K€”f|:@KŽĀƒŠ“ŠŻ5%“M½ž2%•µ“Ok<;2AaQƆˆM[Ž|_`@ŌīFß©’`€ >Hųq@bƒ,²@ 4=˜ įŻv<­śp5‚æot7pMo `atdq<U‚ęÜø{lz~ķķéŪøœjŽķAŽ6Kw¢GˆŲē¼š@żż¾Ł-·œĪį}(A q”ą€y®Éšź““œŹĆŠ­[+ďrItm’ĪōuŻk-¬š]ÜA¦ėśI&×ø3Ķ—‘Ģ ĖŅ½€ŃeōT:j ģ؁” kßJ…r@+ģķAc·Ū†nūƊ •=ä xģ8»ƒ¦īņvM¶Ż§[Ē‡²µAęOTnŒŻOqWT0†ż1$ŠÓ4 cģ ƒ]Ū’,{0ĄŽ` rÖņki[+ G4’ Ž UėGĀ0ALm„cŻŪ„ąd‚1óŖM®€7#Åö×ļ·—\GH®=Ø/Ÿø>h8?ŠĒ4“÷ é֗=·Į×­€ņ1AĒ:ƒkŗŪ·;ˆ'\HŚN ±‡É{¹ƒgŠ=!ó³ ėØėq‰§‰ęƒ²m°BĘ6"ŠO”— ˆ" ģä ™# ¦Æ$eÉsŚÜr# a¤½žaĖī÷ qÕ 4€É§—WŌ8æļ¤×*f­„ņ&Ō0!ŠēŻåńTn(5 Œ[tünĖ]^Ä ©\0©@‡e•-–ó>2ö š±M(€ó!“h3(‰„¹Ž(;×¢w&ó¦oģO‰Ń’ńŻJ čė<ī³“’å”ĘHąĮH#¼}ؽŒ:#Ī“AMqcˆä‚8śs@}Č·a|Ķnu(.ć¬Ó/bяßv=ˆ+gżSoփŖļŌ¶Œ¦"Łƒ’(Aäž»æ©ÆkI åH5”øœPØ tŪĖ 84‘Ģ zv$®Ō߆ĒĖMtĘKŹg:#®9ūośkx0Ū†¹ßļA–ź¹¤½Ż_+Ŗāļ¹vŻ†īźX`ņÜ#$:GÓ ģŪ=„v–QA£XŠŚ{3AiÓMX XÜĢqehHą‚£sh·{Ēj'įA»„­ #e°K,ī.80 ”Ü°@x”ŽÕÓæ4ր ÉAśq ³œpķAĆ:Æuuöķ, Õ­%­ö ©ŹŠ “AcµD×_DÉąātŠó8 ŁõŠČ6öFĄC#f=ēājTćŠó”Ż"…æjĒ3ćp,&µÉ—>Śrąę铃‡§ņÄ 60d8 ^æ8sA×½ܼŅ꩚‰˜h2Åg½f®Ü[˜ŽFæØ1 5c•såŠ+CšAå\PR]TČC½…BĒØ‚Ķh©¹ Ÿkląž<»PO/4‚§ v *Ń®qäPV1ŚīŚNEćj±Õ. ¶ĀŸūvxü(<“ÕŽó7ūÓZÖW}h*$C…NlĀ)’…”:¦ßo9łŽAMįs…OµĻ™!iĖ6žu@EĆ@@XaLP59 X…ļš2@ä , ¹Ō5ƚ xļ ˆµŽwš™äP[E³Ś_Dnš%ä1AW¾tĘįµ=’HĶQČ*Ģ@ģĮēE3ĻÜc³Tt©$qAŌŲtŻ4ż’1@ć­ć‘„;ń@ŌV-k‰Č šŃ‡2.Ōö Ą ēžH@īā‰'oœŲėā9ņÅĄbh€Š ø ' “‘Ÿ7V’™éIĻ½Vć鞣z×J×ŗ—T? =Č9Žé·M¶Ü>ÖFųšźĒŅĶšāŅŽ{éšZn SĀ‚ŪŌi䇦äŠGį§š gHķż7qf÷noi•­%šŠ ¶žĶŗ;¹ š{}Č*@³G5­o Š7P3B(b°Ŗ8öN…øņzŽĶĄŅ’6žō¬ŪęlŻ;»ķ@[ø’ AĪ­\|¶ŽB„÷ \€ąp żh!_“eR>$/&hiĢ ‚‚ĀĆāķą‚~Ŗ“ŠcöÖ4āj1ö ÆŸĮr\0”=Č:ŸP»h°” ź¶f?š ņ—ZÅ£ØÆE>łABÖ7ć'\P9qrelmĮJ dQÕ$;€ę€ø7 Šk… āĘø“gÜpqՑ(·ŌŁu8€Ē“ Ōķgih·†)ĮŠ»{u ¶ÖĒrŚXf‹[1'ģ@Ü}3eb ģ†ŒjB (¼QGÄ8d€Ū1i:GB[u Ņtøó@čx9ó@nĒŠeĆ u=œP6éXÜČĆÜPB¹ÜXŠZŽ# ‚%¤Æ–ż…Üy »$†ØŌ¹al„›qĢŔjrĮ5×Iķ—×bźī0ēƒPŚ‚ī(c†cK(ąbżQ½c6fĮ›žį@ƒ–Ū\ˆš v> 8 p’2G;*’BŪZv 2q KSTōFd Ļ4*ż;Ż”9łĆŚz—n¹ņŗSt#qR£…B M“€½•@ųh m>µk¶įŁJ9+°ł„¾"3<2ėbĘęų²č†ŽFSUExQį€­19š@¼$q­yę‚óC\3‚›3~g¤6‰HÆį?Ƃ1śnbźk±Ą¹P‡!‚¢„ YŠ3ˆ}ģ T0¼;ȁȠļŠBŽP4"q8 7åJš dµ”µ£Šųk‘A·č>¤¾²¾e”Ņ“g!Ņę» OƒŖ²®iģ@ÅČ6ģ/aŌk‹{Ežc $1Ē0y …¹ļ;u¬žy@,ą%Dś¬Ųę-e°1@KPiö^ŗ²Ü@oīÜį€ÆܞŚŒłW’_ŗ8·µwŽHü9Š`§9 ÕļkkĢ€P?jCgdppb8{hšq&½Ü 3ą€Ę|‡Ų€s 6“@`nh9ēŖ°µö‘<:Æk¾šƒ—˜Icœ«s4  <Š.XžĀŻ8ƒĶX*Mph1¢ÓLxņ@øĪ—U¹ øé¦×{µ’1æZIĒpcé+Ņļ愃;Y4ČĄsćÅĆ%$šeT ܍LpöÕbĖph»Š\Ö»1¤ jMOųE=Ø">I*8Œ~„£”8š$š"n  įš‹Ó3ü×BDŚų­e-äX›]Ę9ƜD ÄfjWŻm±]^˜-ÖFóń3»lv›PüiŪ;Čɼ ܲ D°P¤ j8seıš0ą€¤•Æ‡KŽ 1§ÄŚ‚€å4~šŌpAŅ=0“¤.š”Ō’©Žńāi‹Į‚ƒ½-Z5s5'j8œ»ŠVO)29‚¦¼tÆObmĪß}j(ŁŚZö>œ B c¹˜Ćģ·šåGPŸb ĒQōy³ƒł…ƒüūš¹”ń2¼ūftŎ œ}ØL0Ē ĻsIfŠ‚ī0Ķķ$9Ž£ Š…½iÜvˆ7żÄ@Čy8aö ówØ[9³Żäøhü)AķA’sė–hµø|M/ 9£&÷nņKCsp!K,hŌI#Ÿ$ ‡ŃØ‚ŽYå ĪØ%īZ-ą:Ø¢§†h8ńįTw}"Ō8œAĶv«Ūć¼žpkĮ”'įīŖ %®åir–ńPqŖ !ķ# B9 nćČ“ «xąƒ˜uöęĘHŲįĄ5ÄūŠb^ė“ĢŻTØ4Ä aĻšGbKÜ9š hµĢuH”ä€5”ŲTō„­<Š‘Z %®£€@ćœö‰'ƒ²te·Źmƒƒ]ļAo#Ėc„~"jy •4ÄŚŒHɧ~ŅØ‚6½śņP Šō¦īŻ£weĪ³ä»Į3?Ā{t=Źū„®Łeŗ`Äāq@[=ŽĪ$s Ü4Rąč„Ā¾ō>²é'ķÓ:öŪ\Ig¹IĄJƒ<‚psƒq®p¢W°—5ÜóA¦čūóu²O¶9Ւ?uå܃ ×ū#®¬.£Óų±x›‡$X·CČpÄPó@RRī@€×§ŠņäĄiĮ†ŚēXhm9Ń—yO-Ōx F‡Hķ-”H%‰¾? xq@šĆå ™÷¹ mʆ‚Ø |>.9Šr-MėFŪ‹ÉxkµéPGžĘąš€gUp֗iš /A^ÜŽXā"‘®Ō8`0(:ĪדĖzZöj×\IÉÄ]-ą..„9·ĖµŽž.? š©A6£ kÅa‡µ=õ¬c‡n³}esOšįĀ¼rč®dÖ\āH9š °Ś7ėė $R:„ŃĀøƒ_^Ė 5UŻŲf‚Ā/R”Į®Ē+·Ž¹øt€±Å­n!¹ūŠb÷MŹ[ū—O)Ģ“D]p]oå µjÜ*FcŠ Įb®4 5Į®†ņ`yü7iqʎ@Ļ’üó¦t@b•z >°7{¤QØWŽƒ³ŪĮåFČŪ€  xs§Ž6ā%™”†™“T ™j8ÕØų49×!Į(1ĀØŁYJ’ÜFh;‡ iĮÜPkv±|,łMČ»%®ńi÷šAŖzPY1»•‹µķ³ųšFl׈ö Ķ#\(G0‹·x\Nį˜@ĪĶø?mŻcøišWKĒaA¢ź‹VH{)@.¦"ŽAĮŗća;~ęéāōÓx›L9 Ė—š“Ä I–Bq4ˆ æRIę‚vŁp-„l÷ ¹€ÓĖꀮ#|÷ÅĄÉ [†/šŪkŒĆl·$TČr䂎y_3ĖžāP%Æhӂ>F–Ö€x” ƒļ@nuŃcĄ8āP<éžüKH÷у²§: źž™tcĶ.ēĢa^ (:֛{8„“Vž"0'¹½Ś“‰ķ4āĘYĮ¹[Ėa#P|‡q¦0³›Ė'M-ž':3Ųƒ Õ½søĮ3ģ-ÜXęŠ=żć‚ ÅŻĢ¾a¬„āIÅSÄ#’'µZ\Ž8q@ń{œ',PH·‘­x2i€Ai\ēj&£šˆ….­¦h&’ńQiē’ Vv\‡¹øč§ä†Fŗ……½„Z×j„H'€@ąiŌ+īAŃ}=Ųƒb7Ņ7šW±ä©ĪÆĀ+D Łƒ©Ņ;\Ļs*ąėhZŽc  ’ŠŻ"‚‡ Gsµ¼7ös<Š»īœ iī@ūZ>‡.HłT·‹G‘܆į·Žģ³8¹ˆŗī ƒ ę¹²¹„Qģqä/dÓkāxxą‚ŗš™¤ŽÖ”~Ÿ¾VŪ„'[ƒ3ŌŪ/mn,^Š%ÄÄć˜(8µõŒÖ7rApŚ:2A"=ÅÄŠg’ ,ņįƒ[Ą|‡įŃ?‹4­¹ÜMtś­L ųį?q+ÜKŖ\qę,Äē‚ NņžĘFk…jīhsCF–ššā±iGcšÉĶŁ œĒ9¢ŗEOf(Œ’Ę°j9’ƒsŅp[åyįøj‰„V½„jŲmm¶1Įŗ\[ŽA%±:I|X IwÕD!‡Ņ(=Øl2‰Y_Ōӕ }uµĒwg÷n$MĆGNAĮŗūi‘· Ü#oį¼i—±ĆŠ ¤3In,q#ehœ[& hg€„P(ąBŃś.-Ó÷kT …¬$—V€blŽ…ļ­ NšZ\:ŚvŹŃĢŠąP*õ…Æn,xØö U…䐹å§N¦J3q–3ā!łŠ8U|ĮŃ Š$%l{\»žåLn \{8 ģÖvńZZGm¦2@s8įĶŁ÷ “ ÖŅ½”Ā?śŚ4iÄ9ĀØkI” A_jI$‘ʵ=Ø$<œFDFH*Žģ1ļ@±‰į\čFA3§o?—īš\»ą×„ōż“A3«6³c¼J궶óÖh\ ]Š‚†F²g4čAŪc²µŽ#k@c|¶Œ¦AĪÖÖÜģ–÷ kAcŁž PIm¬n`tT×ÉÜĀØ_ iA"}¾gBŠŃ_ģĒ›‹ż¢ö¶æ„^1 nh9¦éµ2āŅHfhto\9v ćŪ¾Ż>Ły%¤œ1aę8 ‹œµ5i­Š>6µÅ„”ĆĆ^=Č©˜@*+Zv 3‡w$ „@ȌP$?ŽhKµcĄ ›jņč„küAŌ÷ Df܂*[^ųā ŗ“āūh<׈”sȧŠ±Ņ7×`%‘£ę‰#1T…Ą øeÄ EØ×!•ąŒ¹ ™q«¹å‚·:ƒ‡}IŪ¶ĶĆpøZ“¾JćɽåźĆ„¶}™‚MÕĀźģų›mģ(9œd »:܁8ST ŹœA(«°¦C<'[Åtā@ A¬Św+mómfĻŗ8Eq„•ŃįžÆJīūs’*±ø‰Y‹KyÕIy Æ ūP1w Ō>`}ˆ“¹}¬Ž[Xōܶ™P“ŸhA‚źīŽ7/uå‹C_Jŗ!…{`'†HdtR·Inm(#œQµģEAĶ¶¬ńo JÄ°Į€’Ż¤ƒAGÓļ@¦įƒ½ˆ$I+d†63 ?z Ÿ§žšßoÆ÷6ū®8cȂŗ¼Pį\QlU“JdīA«•3ę ŠŠ” Œ“Q’µé?£7;ģŒŻ÷ČĶ¾ČĮ©€ąé 3¢ÅŌRŁmvPŚŪ@Ųl­Ąeµ³G,cŻówƬļņćū±ŽH-,6S$­6ńUæzG]č:MžÕ%¦Ź×[»ń5g<Šrmāźā}ĪwܚĪ]‰vzFTAŽUŻ—t¼Ū·Ķm!cė‹GȄś›rÜwk†ÜIPCtņAšÓY2h›˜ŚÖ4‚q.0aŅ¾cõ„tu ž1õ€ƒ×HČĖA£Iń„.·Ńßu£4scx :šę‡7Ś6„šÜŅ)T( <?Ž‘¾SĶ@häP—j “Į·¤śQ÷S²ę埀1”āƒ©ķŪkŽĘCo˜Ęōūk6ĖBłĄÓįćķA›•ĻqĜZ\\;? ę‚ģŖƒE°: ²ŅmŽldo‚Ѥ}źgģAMqøŻ^Nł¦q|©sĪhSyóKi|țLtåD³‰h;iP 8p@U Ēˆ5Ē$ ÄŃÄe÷J? $ q@Lxn?x|=ˆ4;GXnv16=^l:ųš ŗ½/Ōlw’Įeø;'7—v„żó§÷¢åŃ\Ē…*É«\ŽÄׇ3[~!ˆŠčēÅ=ÄGrŻØ(é1c]Ųܐk'ŻÆ®šc‹š†@;C¾xŪ-œś~;›Bć÷kÉ:ø¾{o%Ī«ŽN§&ØŸqtįŗN#ā§óČ`.4m=č/ŗKŖ$Ś·Ģ’XĢt\0ā(xūt›­Ęk DÖīYČŠöƒ•$ąźŻ.Ö"d¦5­÷©¬¶[=WNk®^*ŲžÄ{ŸR· $‚8ām?gWւ{źĶĻuˆ2ź]MmhŚ>„‚'ŽEģź‚?Ź°“¤wQWĒ+ n܃9æōtƒ Å ]ˆ œƒucwa9Šā#²u~ÄØßsū¤ C‹‹Åq¦H$ƶŽ\ŗ‘DH8Œ0Ay·tVėrę‡Ęę³·„}'ø‘ń­+Ž&Cš„WgčM§k‰Ż&˜b-Ś|5ķ¢ #ó“!°EšD܀A–źž©··…Ū}‘W K ʝˆ1,Ņņ5»jź “g³]ßĪŃe „pĆPĖŚPiöæO÷{‡ÖęD‰äƒ@?ŗnūFĆ ö½œł“J¹»8’r (2&G9ĻVæµÅa“ ‡ °ö ^ œīh3¢ˆ²FjĆD ūŽch$Į~×»KČā‚[× ±ÕÆ€;HČēĮ[B)Ƒ@mS PœEOq5}1ÖĮ Ū/Ļ›·Či^,'ˆ@½łÖę9`ŽFĖńBxŠö ĀŹĒyĒy ™.tt­[Ä I‰ĢĆ6Œˆ@ƒ$øx lĆSŸPZķÄÉĆŚĮ#ā1AÕ:zŽźįt¤l„0§¹­õ¶Ļć^HÖSē:ˆ3[Ÿ\tõYcŸ 5Ä5 Øz§sÜÉűF :X)ō  ŒyƒKŖHĒhkšeŚ€FIiŒœ+…P b,…Į§9 č¾oĆw±~Åzk4M&ŚCžž^Ä{ö÷oÓ[wŹ[9®Üž38‘Že,Żw[ĖŪ§Oy!–W`1į܂+'ye)¤1@(Cp5ģą€¦žMmģ‰ąƒ†?BżćÉheƖ;iŲ‹ī—‡pŒ6ęē œsAH’H$™ō…®ÓŸ4-‡Š¶HZéb28¼pAŠ6ÆFķ-ŚŃ.ˆ˜M(4QtæGm1ÖV $h”ŌI$÷®ŗŽqųlm†į`hÅ–V×7#Ī¹:ZŚ—=’ Ŗėxm¢~Ūµ88h–lĻm Id—[¼NĶÕāƒE°ōÕöē3–ęZ<ŁN˜o2ƒusuµōķ§–YG‘[{FēA÷ž{J ĘåÖū½Ė] dĄįO*1Lj üÆcŚM+Ī¹ n7ƒƒ…@§ø)āV”É0‡|X– ĻWŚgÄ ,{Šp­ręm™Ć'L0@č»” k@>rSxf.øqĻēįJåö Tsź‚ĄO;ĆtČtœ1Ē dMƌ{PHmƒ°P °’ŚgĒ³‚œĘÖ“"¼2öˆ÷ r×wlx™B߇µÜq»Ē˜¤ó d‚·rŽon€2ĢēøœI5 AYi%ĹĒŲP6k ­+Ļ „ŅTÉ5˜8åR§ÄŌ0'Ķ“2™¢ ½t,ś·o‘ēĖŒ½Ķ{€¦’/©÷)·>”»¹¬Zō3•‚ ™[GTŠ”””ƒŲh4sˆ.š³ÜĄÖęŃP>öu@Tn§8a^@ZĶ@£†Ėa5&‡ˆA£Łī¬ļ cu‚˜e_z m§¶šW˜Aec|ųt’x{I½Žnäo— 4¦‚±›Névņt¹ŲāH¦h&}—eŒĻøÜ3ĶnP‡ź÷Ž¦ė‹ķŏ¶±gĖŲä89Ą ĶģŪuĪåzŲ"'šjqČóŖ““ś{¶Łµ›UķŃÅŲŅ!Ž‚VūŌ»vŅĻ—²ÉxŃ÷w°qAĻw Ę{Ū‡Oq!‘īĢ÷}ˆ"·*åSD q%ĀøŠÓ܁5ŅpÄՁĄ–óĒ€µxqÄ}(3¾Ī9 1ƒIꀩD * rŲ2ćš2G<7H­>÷ĘIqng½y^čg‡ĒRę¹Ģ{ća.“ö ׄĆÄx÷ [Ė[Ē8 døJśœŽ<ŠH{Ć 8N\ŠDĻĄų “Cgó@Ė¢l“h$±† AÅ›nźū‹x„w@\B0«°sOz QÕż:HkÉQ@GŌk,¬Zēœ‹‰r Ūī½ź;Öƛg!hiŽ‚ŽRłęÜ9Ņ¼āē8Õ7,Õ-‡±{f䯵Åįŗ„ä‚鞢n“Z a/—Ā‘ąHķ9 Øuü2PøŒ]\q@Įŗ€×*š(ŗ„iĒµ:ö ęÓZźäoÜ#ĒÅQĮGß>GQĪŅŠxfPHvćZCA<(*Ś€Ū’9ŒŠ’(ĶŒŠą€( ä2ĶŁĻ>'2žHųrć_„‘ęŚk’‡ūŠ<5kžZ äѕ€Hxć÷’ƒßČæ­š„š×’ąŻ£+GńĀMčŸųųłóŸšģ[ņ~żaց3čæĮ_Ÿ?æż÷.C’õ‡‡‰ąŪæÕōßįoģŻ’jB‡­žć»¤„’Š,éę?Ž} ??8’!~śm²=źw†UĪgŠ?Ą§Ļ?¼yG æ’ķļO~’ōžß7šīļ·o’÷žó’{ūž·>žööż§æq¤’÷ß’÷¦ž÷ķ’~žüń·’żöém’ŁĮŠEjĖ?“X‰Ž½#?>`e#uģĆĻļ?|~‡N-„Ÿ?撁TĮ÷æcµūųóļ˜öć_ļžˆ)’"|ž(üjģūŸIĶ’¼ū’ų@®ɹ8ƒžł üüūļśæŸ>~€æKī7xĶ’÷÷ŌOæ½ĆR ŸßĆļųÕ’>æłĒƒOßüūŪoļ’īŸśŸļńfļ>æł>|žóĻĻ?ĄošĒŪĻļ’ÄÜżśéĻ??żśęÓ?ŸžåēĻ’Į€w?~öįćųžśšéĻ_įWLłéO!_oą öO˜]xóéW!ż›ĻļąÓųēĻ7d¾2’Æ%šśļšļ›ż¼żšęÓ߈Ėļ=¼y’óaB÷÷ūļ?~ų—@ĒÆŽćWæ½’¼}óīĶ»’½ƒ¾Ėōæ_±ž½’?|śż€æ’ł3||’éĶē7¤žüś'V¼’>’õéóŸæā_o>ąŒćwx÷žÓ‡ĻoßżŽxūßĻæ~ď>’Š@ßüś+āGR?†÷Ÿß½ł~„ŸßaÕÅÉ|e$m ’’#Mć7œĖżūūĒßE,³æ{s4żųļ›·ųł{ņÕ{ų’¾CyūžŻ§7æ}ž_ßeś3ü’üśūŸŸ’ūē÷7žõėŪĻŸžśõ?ütÓæ"j†u žüõ×?+ÄēšWo~’üöš°æžłś?¤r¾ƒ7枊żÉ3¹ž©˜æžGźā{r«÷}gļA_š„„ćżw]Ążį)»æąÆ>’ü/öõśca#ń÷¤³|’ %łńÆߎżöžķĒž[śgģw†Ž~žłÓ?ļ’ūŸ÷ß?Ųģ’!½{ś;ś?ļŽżõŽ DčŸ?üõ¼ż“üšóļšögĢ IłöÓ;ųżŻ»Ÿ›ø1ÆaśŒ#Ēzūŗūś[l4äæżNĘōæį=™Ģś‡ŚĻ’&“¼7šĆ椳ü÷ӇO8ŽžūĆ’Ž¾żü÷o8¾÷+ˆļ3ŽÓŲ Ć»æp‰uģÓgņ!Nė¾B’õOĆżH{x÷ߟ?’łß_xŃ?æ"zܱ÷~÷įĻ>Ą? •öĆGü ĄIEµō¶TĪväŽų{÷įoßüżöĶŲ‡žž7Ž¹ožžłļ÷8¶¾żė·p²ōę7xó~ūżż'œ½’ļķĻæż…’¼yūææ˜)żE\d ±’‡Õ Ź†ÄæB’į€??`…ĄÉāĄ'’÷ ž|÷īÓ'üčĆƟpüłųłgœē5ūńŸ1Móē¤§uļm°·Zśło~Fšęš¼õĻĒwä³wøĢz‡Ó:üEHOž&ż~3åmIsSącsEÖÜhž!<ö×_Ļ6 ¾Ō»š¹ ŽÖ+ܵū¶Ž%‹ĀDīĪéFŅg ō ż®Žoµe÷÷Ķ­›‘ōU}Cļėī£Äw²D’o$®FŠņ’÷’Døå6’GV#č 8yŻōōGXš•G-}ż–Ą#|å-}ÕdŽä>—ĄœīĒŽÕ¹tEø˜ɽ.)Uߊ°×{XÆü¤趇Ušm ś1S=`*`azą,ŅŸOt’®ģµžNįæĒµŹģUŅ=Üč.&yDŠõ.Qrź©ĒĮ†»ƒp9– ēRķÄĶ“0Ē‘‹ė91o$JŻot'S<"čīą$0™^^źJĀ±šó©¼2pŃŲ°³“7ƒŸń%ėzŸ;šąAG`Yµģ®XS­hĢr¼"aĄROŌŒŚā¤”fĒø…LĮnµ@Õ©Z+ā5ńWpDKl1ś’4Mćäś­Ō³Õ„nVsņCįY ŸōšģÉxü¬$ž„ø4 r…µ”żJēPŅSšpf#wU“ėų§Ļ¤„øW÷āŪdņ¶ōøĢ’šœÓź‡ÅEH…'—(@ž¶8ø’V˜°‰(P'±×ģå—Ś£,€žÕī])ČL2ģŌś}(fK‡ 5F,˜±‡Æ$Aā`Żą]3 ÆqD”O›rœEų Žģ±ė£“”{FŻū}ą-ä‘ĆĮ–Ć°-ŃŅŹ$6a†9’”ā»ą¦•B:‹æīĀ¶ øżsŠõd_ŹgB褏P£īż>€—²›8ń¾Ŗū!A³j±_—«³~ -ZāĻ¢8fO«°œ{õXšåTj†[!LnlŸˆM8ą¦h9÷30“ ߇—n“ĒG5¦—wvrPŲŁÉī4N ³³²dRÓĪ×ĎH³ˆvvp꤂_6Ääļb£QČŌÉ;;B£Z€¼ø‘Aæ§% d;':ēæÆm·æ²T-½cŃä_.Õq£mi·æĀ»Æ©GŠļ+¹ä{ż…w_/} Š ™B*ß~ž••’Żó‹’=ųzv’:øŹ2›ĶerYœĖ ‚7ożOvh[Ÿd |^6w–č.Wˆ ]DÉV:§/K4|sé}^,üדŌi2§»$šøyĻ‘\Ēéؓ>P襔Ŗ‡šģš_”}\ŒćŠūŠP­µ~!Ē­ø+Bvä(²GDĢkį~~ä'[ŸØ¹,ČiąōI›‹ļÜGz‘U@¦XŅ3ż~įP£@ÖY½:ĶxĶŅŗ<Œ^©Héb +ŠjؽŠž€= m[­H/‡ŗ^gkø ‹ūµŌX‹^Į>Æ/|‡āäņü·ß‡†ŗL%Ū+Ē_guSb.įĄ£ Sé ĻnˆĪi‚Ź'>ÓzO¦§fYKzv]+I’–ž˜šå*Ī°4f©B8}o]yŗ‚.¦^į®ĻŻ— Ż O‚?ėӐ“ĪZ†’tƁįanņ¼]ŹĮ.WRøē9w:&I…IK_r»y©ķ5½+Lńz^„­–óź6wžƒ…ŽŪäEš­Įś¦=¬ ’3Āš“XXŲgKĒ†y<^ ‡Éh^@č– %«„1z;wēńP­7č°Nmā°~äB/p‚2„ļet‚nÉAk! >Ä :ėŠppŹ–½Q T@‘Ł»ƒ±IB2‚ēč•L•MĀų†½9‘«­ižNłY”{— {ó/¹2łœĘøū ś7AĢ jLgb’ceÓ˜yJ›”VÉKÅq{ŌvN¼Ąī'6¬Üō %(K&hL2Nż^ ÷zl“YL-»ÕdĪžß¦vŲõ‚‡':~©čęW z>RfųAnŒsėƒĀ‘ÜŻ— }×",ŅŻåĆT˜É"Øfp®ę.ļ2ŲėŅäŽī.sœ9*ZöŖĢ¤°ā~*…ģ)“Ī„,µ¼{µ ū”yņ9ĆLāeūu1ŖÓAÖrbIļŸXź–iŃāĀÆw,»Ā<>OŚū= ?æÆuKY<¾ "KāøÓõKűַ±CXēzą"éų~kW滇…aźśIDžĄeCōĄ_P+Ģ>ŪŹ½Ų\ŗ~Ü|7½'÷|¬ŠÅŗ{č6²9‚~„zĒļłX”’1jéw¼f;{%Ń~a+K–ōSeKĻČéąŖłcu˜ÕŃ4}Į#Į£ā’([:€…¦żWµč łG ½øN_U¢{,Ģ­oXe¢ó†Õƒ‡ß”„ėé-µ†žŚƒ~Ćt£©ÄŪN:@īó,>hŁŚŚzŠļ·ø„ė¼"ķä1RŠIÉ=.‰¾OŁ#‘÷˜·õGź1²!«ēŪŲ/į,Ž£¦‡k×Ę)—ēb>Šjév“ą-šŽŃ» ĪQbu_~­©:č¹łBaŪ~niZćę2{¼x·Ź“ >ó '#ÖP(nŚ˜*źrž$Ļū§ŠģŃ–Ż’©Üć„Yx<ĘĄŽŁk„č–T“„Ģlz­ 5?ĒrŲµx²6†ēhĮL¬=…’ykÕļŽIŹąˆ_£3~o:żG żŽš¹•ŒŽ ßJ±Žķ›Ž ßm>·’»ō[)Ö»}Ó{}×}ęՇØźŠł(Ų;“²¹Üī,łĆR»ėķ7v —ÓÖ Ć]Š”ļęOųž@Ļ$š‹_Ō˜ņ‹— øŽ^é¬ĶØ;ļ &’Õ»ÜÉŁ’[EĆe‡éØ/Ś›×zv\eZŒ”—ļrVõŹņW©Aū“{ŻE>xÖ”Pn@ O ŠH!E°O ī€Ŗā1zBĢĘwóP.B”<=9ŽL®pāW!(œė1P‡šÅ–fd3Ż}§ “Mē½ I=ø<}Ü4B×7[!…߈³Ś)”ĒČ|j5<Š©āAm!ÓņQ·š¢™rgĻ'D ( ABvI:©B.91!žƒ4 óöĶå~@/Pı×o L¹lŠW6ščv“‡ Dfė–"øė60Ś6W@¢XĖ¹eµ‹L"7f€˜zŃ½  ĒÕ*~\66-Ł›ŹA”šk¶ŖßĪ>‘Ʀȩ[œ·;żŽqNļĄiŲ%Ė+Ō ”Ék›-’„u±ŚćņĮB&–I\ĖüĖ­°E6ń$Ŗ¦¢ÉŒDĀJgĄŒ½XL—×lę08Óöōœ³“yŁŹl&M/”ßVīō†ąćiž>fOÅc'ĻMč.‡ƒ‚9WѤUOć”HĘŖg³>ō6;–šŲ|j›ØjŁ+Fč²¢ls2ypčSZĻ“ö÷lŻä[ÄĘ{¼o4“Ų”ĄöŹKSU4' $Ą [šüśé†ŌķŅźń™ɱ²ß Į‰lĄp»TzżŌNoe-ÉY¼½TytĖlė¼š]Q ²:®ÅY?Xøzd#*­ żÕå}ßĆÆĒż€žĄµ| ÷¾ŻŠ1_ŗTM‚ł9õ6Hć§Ä#Ų XżįŹāŌßżĢɝŌr ”ÆŚ_›`6)øŲ¦NĄó#ņópJĖU• døåµ'@ašœ3P£€%½ū*%Dłą]LŒ[µv h7€ģ™žu…~Š”fök;Ė钱ø óH~jL1Ķ4(ąęAM1žł©…q HAtC„ņĮę8l«æm#žv? Ćšp oId‚u2hz„;IŲ~s”ė`Łžię0Ācd­Čø6KSQÄB•ėŽ‚ä™4®©=(ćßKĆ./œ™Fč6_ōŠś“ü«]Ļ—Š¢“ ØP”€žÉĮ†0F7”gŠ•Āg25Ž–…„ńP89ؤ/Š…JuĢķB\*¦ČQ­ĀS’ÉU ē ³¼Ē„üVśÉž·—{$®ēKčŽr–}ĻXi‚Ø:m{—8mp)ćwŗ¹ŠÓ’‹×‰`qŚø$f×qUŅŠ‰—Ē)‡AVg=žųźrU/śĶŃEµY˜@U›ĖūŠuč—K6X ūŹeŸp”9‰#Y[ąĘÉ-cBŠŽiš5ŠāĪ'ŒQ&s<$^×r ®]”QĘ+•ā2„Ō<”Yć§Ųˆ&Y›_Vv¬)°OȜa±!£å”‡śÖZAGŗ°o-÷:ģķ18 ®‰!ļH§ŖäP»ą(”;ƒ„šŖeaŸ(:Y°Ųėšā^䰔RĢf;5q£ 5MŽ)Õr„4ä„…SęājIsZ+åk2łq—~R|Ö S¬„«{ĢE#Ö “‡z vpʏŻxŚŹK%°«B­X®¹€@J„FļR›LŚ]J-IĮr¹ 䎩Zߢž=Nēļ ō¾[C8n0Ųn×Ń¹‰k>i|:f= “}M.c¦'O¾ĒŽ&K:HÕdŅ}›b< VVE=éU8žk:›Żf6ÆÜūC’¦åxÆ6ōļ1ß¼Wezē3ŪæĒČ>ĆÄHīs ¼źßcdŻ-Éż.eóč”‚~7¹Üj®FŠoµxļęĶGŠļ&—[ĶÕś­ļŻ¼yč©“Ż‘ÜļØt6³č}5(›É}.õďżī½æXŚÉż.™ üŃĻĖČc䯍ūČÕ#õŁG =Ą¤hĪ<ēd?Æ4‚ŽOi=“#čd?Æ1‚ŽOi=“#čd?Æ1‚ŽOi=“ßz½óNŽŁŠÆ„}©×€ˆ‚ż8‘Ų³ |Ō Åø-|1ˆEķĢ/J%1N>*}ŁŠ”Zuē¢uåŽ$«' …±å%˜Į“n«" Z‰ŗiāR±Ūla“~“¢ż’{\Ņ–mUõ\Ė‡ÅÅēx.{Ī™“+šž*¤TöĀK†Ć»+vĮFī†•ļūCwr—v‚K_= 5hĖ]ō"šÄcb”q“_’ź]Hfå%<łld™xEÉ'WŪ„dŸĢ3ܕīD2›š›Fń·2bīn @ĘĘ3lŲ÷‡nj:UĻß¼äæ¢Õ³¹–ó+M^ŪQƒ“„j ėq4ƒVā˜ö€Øo§I/@’»uĊ0‡.f²¤Ø K›|.y“+ĄČ„ Ń¼mŖ’*¬72HĒćńßšų©ś[¾Ÿ³V/Ž»N¬Ž3@üģ ‚]Ś>b,’O~ęXR+čÕV51xń¼`³pēGˆ­†Ćź—o¾PÓÅL »/Ęd¤»JRU‡9‚.śfŸ‚åQŽÓä‚©:td`ät»k2–ŒDāÉŹždz’5‰,Īšœa„Fæ€tcUl`>l} Ļ±W õ(Fķō?…ŲŠyÉø™Iš«Œ/zP€2\NøÖt8ļ¬5‡Čm+{acp7¹qh1©¤Iõ–/Ÿ‘¼ŠÅHļŅ„®Ž²BTØ'X=Ųœ2 <Ż&ׄĪÄ:5Aü“wś¬ƒ!Š±Ų“AI5%ėä’ļXeµ.ŠÓ¦Eʏ%õŗbōĖzR²g+~wZcÉč3½ŒNV°Ž„#B&b¤Ķ=8čŁg §!ŸŖbš3 žW8*Q.”Č,ŒAž»ł\P ‡če(W^š•øÄkÉ^P ;‚xæ)SčĻĆ GŽ¬oÖ7щs>±8¾@'·µŖƒ ‡˜}¼/œŠ”·ņ‚‚%-® ]+¤{!%"/vŽr)­'!w›Š—6u˜L’’č<Ēm Ū—–ćlćŪXEŻĄ}’Ņl#“Ō€I—§6I £ öčłcōNC9ŬČę?ŪČ'§E¤K‘±/L825Ö@ĀįŸk¼Bį¤ü­„«‚!=mE ÄŖŲ §Ģ2H:åśęt鄖“¶ŗg“²ŁCŚw<Že…#ūędņČ %{\õ“.qj .°1Å°y DŌ'&VWUx)¤žŽ ’Ų·0XĻh÷¾ę8ō$aū“”Ō5BŸē®$ŠŸĒ‰QŁ/š¤ pģßc+œX=ćÅÉßƄ>ļĮWtŠG°AIÖÅ Jćį+t‚~½ŽšŁŅ8ÜZhż8ļv„SĖ“čŃg.|ūnYģ…–ŸŸbO×i—LćęgĖ^œKGy½·°eĀ ©³yµ‚p›ĀŪŗEFš?}Ÿ^›ć5Ąéē7Ę£ĀjŽ@WÆį/+“ąņĻŹ‚”W¢;Ŗ @tvĢĀ2KGęłĖIČńÄĮ-ė„ĪĢ¶÷§–š”©€éꟓéCļA2›VĄŃEÄ3;Ś)Æ/±!`W•4z²Čl4}Ļ,’Ł!¼Ä×5¾ųTköž°&rN ®O“SVqÉģw@fZņ\RŌčÜXÅ欕ߐ’ķł„Č³Ī€åՒ4Æ°CµĒ×óšjŻ½­ÉMB N(źĻeČc·(–XŶkcÓ×#ŌóȒŪ:Ź^kžČƒVćÓ;Ģ3į«S ™Qf­ ō\¹*sž.=QĀžŲšćaAo"¹-QåzW!.G+¤GhNä“ÉĖ;=ƒŻ¦ÓU/Ų:}ø„sžn Īߋ“—Ƥ)a% J2(ŗ«^©‡ų^™č¦Æ³Iy’śž›3żēyčW ŽĄ‡ž•orĆōoRĢwė!#čw‹Ē7ÉĶś7)ę»õō»Åć›äfż›óŻzČśŻāńMr3ōĖn¾I>Gb Ä.źæsFE"<žŠÅś°_q®očæäW\Ńwv2’xd‚CģKļ×­/ō ŖNĆ?܁ŲŌ=“W†”fx"Ń » ›4ŖĆjÆĘĄq,žŃ®ä¾G øś ˜9pø6׊…°3˜–.k^ŃĪÉi[uk:_}’ÉĶ‘¦ZD"¾ß¾˜nœū?ÜĶųķY«VÖžÕė·¢…ż×æāµĖćbü¬Qib,^yNNՂ}Öw’ė”ĒŠ¢“IÖĖ^ćs)ĒÉ‹ę>łrp Vā©jH摦yFČų*Q*~Ü"jŚIe%UWsG‹‰}9§2é žH6”4„L„'Ź$0ėitģŻö÷›Õ]]}’‚1TĶ·nĄ2»’©R§%Ŗ[cP`ŽÓˆgÖńT°ĖAĒ½}¬‘ nhēå~‹jöŌkĻ$lĄ8]jé_ KjŚąf“Ž2”ÜAÅd‚" Š‹€†@Å4Ą!æ2LcōžŖɵ-]ˆbBɋ Ռ:ū¶*wZąŻ%Ó’”aš][Ų„k­i©?‚~¦±DŽY{‘ ¬YOe[ŠČŽ.ż“‚ÖØ)UGÓ 9_--óČæßnĒ5Šsī5bčŅ×F;0Ļ’Œ%¦ŖŹ^œ„E(Fp­īöłšCśśY÷žŻ'ī%܎Ģŗ ¬Į9sšt|}Į#Ŗ&¢§1wvÜh…c‹?i™åō×F‡“śŗ–žĖd…Ś˜!Qwć²™,Y¹e¾lÉ}©¬ņŃDī§ę˜žĖœÕXJbļPZ°ŠH±į_vµ¾ėöÖ0öŽwEŒźÅö±Yœou¢Sµ.L ĻIiŠŅ%f¾ßŒ­CĒ0 č™m¢ø¹ļ7F §Ó»É]22ŚG±ķ ¬Äw9WŽäUĻ®-q4Ķ ž{­¤XšFūōū!CŽfÖ_|/Ż×~.å4}ŽIÕš0Ä;ŗ˜ćš§®WJTӓÅ}į@›õ1čhµėŽĮ ›¾Ó³†éīv rHŠo7“Cŗ{u’åōtr’tˆ÷ŸŅK·»M zåąfr|r³ėZ^ĮnńU3K¬īžHšbIdֆØtӂųŽ¹d_œ/Žvśv»Æ’5’4¼¬· Ēæ·„Xp³u»¢&Ī”ī©dĶŚįå¼]p¦ų]…8H½eQoŻņnńö#讜^wļ£–>öho.åŗ÷­_“5ÄuÖćéŽ ‡ÓĖśļxˆ}£jQu›¬Ž”Ē>čEM³MÆÓ÷Oxžól½p?ā‘Č½Ł)½üzėĆ<Ć{<- ȟ77čæÖ|Ļ+j4†¾–Ü#čRåĶdö…Ģq³;\0ģėŸĄ7xś¬N={ƒĖ[—:š™¾GŠ½1ĆĶdāÕĶ®ęm*ł*7yŁŌĶ2O®~Ö Qu ŸÕ“Ģo~ļ†ŠožƒŽ”Ģb–^­“BkµrpŠŠeW:Ø …ŅØTŠ}½x§v1Y—üvߑėžā†EŅõr’Ķ ’hm¼ößŅÕS+ć²s©D³žhmźŲ‰Ŗ÷Ņø›)µÄ/ĢčMŗ—H÷½=išTzcAģ|‘°]IÖĄŒäŗ²rO€#“,b°¢^„;Ņī)z}Ö é+ōĢ‰ĀSē_V¢”0h£Ø 8.@`h$“ē³‚Ł#@·5C\ö$Ż‘vOŃӃnč±BÆ6u>)”Žō[“É—-蓤Hv$ˆŻÕ°}lvwGŚ&E}wwo²żŌ”ŗj \šo©jģ3L*Sœa®V€ƒŻJöx·–=9ié]”CĻī0{ūķõ¬¤6č²Ļ6­ ę$é6qIŹ»'łę{ŲÓ«Żģ€cz•ųY†Ž·Ą¼\•”œAo*WŃ"_'|Č¹ģļ}.7ō§œ!¢ö·ŁPƒ’»śl ĻEÉČĘäŃ »Ā]ųSPšŃüÖZ»ĆĒ {"W²ņźˆ«éĶą‚ Źį³å«+š”} ējŲœU·‚HžOw`f Eań^Õøz†"‡ŅyŽü)ˆe*ÓtŖynY$ˆ‰īčfXĶ^d čm~CWkōüyO9ēžŽ1ŅP¶É^x›0O3ü/ąę«°Š¶„WdčŠAEćc„L]œ·“I!ļ·@ xr’o“f ć’Ih¬4ś6jųB;ÕŻ™,gzbś’P%õ$dlAK<śÕØŗa^§›!{‘ §85ˆĖõqi~ܑ±`Ą WUH,6č˜Äś¦rŽ•Ąm ™ŠP/aE [„ šāxƘĀeÉ—Ą)dt‘ %揁ōŽ!Ś.Āńš”»i1ĪTŠXÅR‰ĆŒcć¼m©š‚vÖōčĪÉ~ 9›v|:§Ė!W1,Z|±”Gm’,:ĒkycXš’D¾¬bŒSˆµQ­:(¦5OcG‹0d­+`b\”ĻQ$%Ļ­ <®^Ŗę=Ō”^×”Ā¶«ƒAg§“‰JĪ+Éč b~ÓĮ‹Šs#[ŠÄtųܕxsćō|Œ’Ų.†ß +° ń¾(qĒk0UBĘYYF>VāØõ ”?„åĘMŒW¬ń5ķ¶qp“øpiųÉābdaĘd€¤Ł0'}±Ń‚Nµœ”ix˜źIū¼,„˜_ÓµVØ2Ņ¤;»,C‡Tˆ,æŖčfjf'ÅĄq­éoø$j.ĖkZō6W?h0“żœi ³īEHHģÖ¤|¶—&(¹Į4†1x!ƒ"-w`\M¶|¤“óŽ&tŻš½įœZ“ˆC<0Ž XŻ~󖮱؁įĖeVźą°ć®šVĄ"=Į`æK¾4V@#_Ō¹€Ä§Õ`xĪfK'Q¾‰ t‡VK)~Ŗš›`ÕĀ€$@gh‘µŅÅąŠŪµÓ›6 t Ŗ˜!Š žƒÉhÅ©DL.   ,:łām³,Ģ°¹§S¶]Jb¢ -= ±Čxr \zØ(–P’Ę-ć€F|”Ļr°ĒUāÆqb“”d­~ B×ņyŻLmƒÄØ>ƒžŖåę ”ļz4dŚ‘Ä^LĀ ³ŖfßæĶŚM:ō"/¬%ÆĮ4Eāģ^ĢŠĻ³.ņB7{!Ćø9˜įŠl(Ė)›-t^l l(ęYXŚĄ‰T4~*Ó”8ą‹čŒąŪ¦ŠngLĒĢ|ć€×Ģ"C>’Š>Š¬LāÓ%NŠÕ&šÅ@d8ˆ²Ų}‘\ÕȐÓfńu2œŽjŅąwĶB†'teū)ōƒ€.M¾&-åyrĢ¼½æū×`‚§"š,¹ą¦¤9ŻK…ŒÉŗ~c_¶a„&˜ ›ŠÄ·ż6…:[2IŖ¬g“Uš"¶č¼ovĒ«œœ]ĶÆPGłqŖĶ2yčŠĖFvž Ä æ5iŌ'÷f©ŁRœ7„Ėqó‰ĖTv›Ü1MJ7QšŠ©Ä{¢„NŹß4ZpDŚX—)č4«b§Æ$z²nOmKÕDŪšż8_&e–b JājC\ĶC–ķ§P/įFŒ Wé|ŗ*Ž ŌóāRŗ9Ķ`Üøõ"×A|Š“ē%F9fÜÄī¶p\>”OĕT›ĶÄ”CĻ”sĀ €Ņ„F-UC?ų÷Īq¦.CŽ#ļ…oV,Z0§é|UČ?8ČnH_ŃR,Ō "CY#`®ÖK‚KOį®WäA@oūf·÷įŠ”ß^VŪßy½’AļæĢ®½b ŁūóŠķv#čŻJØĻļļtŻ°÷Žū,£'oY‰öÆDqć'·æAwč”jžf¢RŽģzå uä؛<_5{³Ģ“«•-+Ń{=öźfŚ ŗäĶī0į¹™;WĆ ’j‘ŗĮÕ­‚›Xo6ø{żĘ]Œž0‚¦„ŌxćRų żøč’ŪīŻū_÷>›*ĆĢš”S¢£‰Vtx£ėDäųż–å~Co­±‡QF­īżIģF²–0¹ntƒX¬„{1ŒwźtūlŸ3Ƈ~Ó²v桝—ē­yĢĻh» jīō{ąä?ēxāwÜl”żkĖ‰|łĒÖ¾ūĶs1$’śŽ•įnžēĮīPöŃ4G3ī„øŠßpĖüšęłō]…[“4Ę¢;-šš]’·~Ó?hzyh^9‡Öh–§Ÿ|ėrčūy>ž| Į¾/’¾øĪ †”@/Äi:ŁFūüłĖ2Ņa‹Å¶99ä{Ž¾›Ė/E˜ā,t(Š!D± ļy”MɆ,››Ć½į« Ŗ÷!rēąb{a³ ~õŁ•+ĶÜz–Śčėõ»—Ō/[…lnȒņ³”©¾Žšu*—ćƒ_{våĖÖX :`ŗ‘øŸgotż×P­ś°×Nm»{]ł¶)D}A’;Ķ]Ž’āŃjlķŁMdķŁ“›\Ž×®]Ś‘Aæś{Q]Š é泚»_eżö”ß¹S¶ōŪ‡>čŻ3{iĄkB/åÕō¹@ās;jÕÆŽĖ“U2_œCåę[XLi®D<æµ1ż Š–b¶ī-Of¾¼§•¤wJD­1{’;® +@/FyÅóšęW“8ƗA XÜüZMø` |õė}l¦ŒsĒrøŖžbDū§/ŅQ;Ętębį‹ó-AOoJŌ6n¢­ üµÆgŠ!öIÉÅæĪ@a®ņ³«ÜčpJl £_1„ĪŽŲauüė;²"(Ÿ³'7 ÷1¾£Œ«ĒŽs†ŽŠÆ=Ę„2Lµž`ūb|KŠ½äČr]ŖoėC-ūu36Ć­@†';”†?ō½Sģę²æŒāå£]«ÜÕm»w)]…r r÷öu*ūBaŒēÓ c% }µ Ń “ŠGč!7Ųįę`‹‹ ¢Ėó0®©ä/ŃöC‹f@3QŃ+My›Z]‘©:ŅܬMÓ3\¼¢YSc ėp}_¶`/£XugÄz…vlūkFČF”pl©Ōóću©ÜFšŪīlŅņ‘ųĀnmX$¼s&¢²a}UbVŻ+$Ę9ä94’CW‡ąē§é ]%;“Nµķ#ŁKŖIņŠ½ķ¤"ėkįz>› ŪE1zVm&Įķ‘z8ˆI4Ė.±ÉSyĪĶoĒĮ„?äŃ0Ń ÉĶ\ŅÆā^{(‹"Ī€fŹįĀ¦<ė ¢U~ņ- ¢… —™ß–ŗ™qzŚ,ä – ųњˆ7čy‡†×Ö(՘!~>»RQn†viłł 5AšŸBƇĻ®“xøčŗÖį܋qXē]cųĪcŁå€’ƒÅ$c4ÖlA/” °¾ą$I7虤ŠSēū~¤ukKÓż«ē2/¤č×=>žJ²ŠŻŅ—Š'‰-¶NŖĄĻ¢ĶvyŃĘ8ˆŲµ 7ėIKŸ›Z, ;ŌÖ@cē35å–x¤dž+Mr½_ŖĒ~‚×+Š Žį“HÕ²ųUzö^ŠųJ”’ņ ;YgŠŽ——5Āņי€U‚×~tū©tTqöĪ›f°.q—DęMčz½ƒ‡ž”C„f±9¤Ó:µjŅ€O¹–PņĢ ’r——ńŽŻµ’&ŒK”¼ąI¶ FJ ŒAiŠ•“Æ"/hƒŽkß3˜cåŽu˜v¼œ”ŗ6“¬ŠŃŗ”x[@O°±NL“±7 ya”{įnž.ččźÄ’z]›MĄwSŌh ¼œē­aV)Ț,K@ļ@YÜĶnTC:'ō×AZ:µZąö",X—"E˜§„°)“lßp‚Ļ*¬8%Ī’ŅĄi4·]Ģ“Ńņ©x5 O9t0‚ī4„wFg›Ū`ƒ7b—_ ƒ‰īy}Ś­„Lč ŌŁJ«J6¤Ąī%¬gx¬õFHŖ!¾bŻV“:Ģ½Ś»N#£‰­čt Ģs9%W.œŒ`e,IhN Ž)qqĶ%­ĖŅzVĻESY‘l„Ų ·ef5”€cJ V>ĻŁ†œęęr6ZšyJ¾‰¼n {ŗ¼ĻyEüĖ”—Gžƒ4ēÉ­Ņ”Øō܋tą¹ķż9¢ö‘Ł|†?ĆüĖZŅXJ†Į«›e2ī0N%щRĢ¬YĻWX{>i-ūÖ³~½ZqæŹ?ædæ5č MNGĒõ™šFŽĪÖbĖyˆw.čÖó‰¹ņ3oŁĮs:b–?ĆŗHŸ j¹ ¹Z¦W>é=‹Ī8¢“¼ĪÖRSō4$¦`wMÓ&]q£‡Lč4\¶č²@ŽøĄń‘96BźTÉf į”Żčej[FŻg,ÓŚķö§ŪA/3čø†gN*µ“ZŅ*1®ąŅ!2œ:ņĒ•ž*€Jz·trrP9HWN°ÆķÖp„tšń(rJĘæ=Lfßpn źš‹t¼%±Hg²=©2•ŹA%½u)T iöO×4 Ån¼’>®UöĒĒÅq«ƒ)vCĀ.Ńķ“t¼ńüQó„ofŽ+8Ż ļ,>>H7ö ʗ!/VÖQŁ«.Õ:ńļ=EV?…˜+‹łŹ>T8%¶tÆx ÄÕ°”‡€ż%P\%ŽNčŽ'–aŸĆµS2V³ˆ]ü€.’”Ć%>%‹iXIŗØj¹éā‚“ķŽ{ؼ}$±6ĖžDɎEōņ.k‘[ƒŽSHŌ :,Ęf‹;°ģēķŁübuÓnSVN¶ĻæšäŸÕøĶŌæa7•4ae;1q§`¤­–KjO—ŻOō3ōĖčTFIŗd«.Žā³;×rų½ąńģ›C×.õ”ʧ[ėŗzxŠÅi Õ8¬1ā†C”BĻ€āģсESH‹ uq6Ż€lˆ(hŠT é'sÕ4N)ė(ć æxź¶€›uĢāŌ¹ŖÅåS#§SĒOg±C įļ}€¦qż%śĶ‹HÄõ±U3Ģī=ŸL”G'v¹^×ømŹcżj”Ųd Õ£ ś”f†’½Xģl(u”.®0=ęšj²”Gö›šŅ+¶ylU\®T.or÷š=ęÜqd‡kŗŽé½>kHé†]ÓDzŽ[ĪČÆęĻ=ž³übļNé/Ż«Gč 6*T³ OūŽ“›ÄŻo’¢Ēm„nņ`”W‰26Ūø;Ø āŗ]«wĄūyÜūv5H)S^XÅ}µ§2µ“ ¬\¬=$Ū¹ĄŃŹbĪÓž sqgvķŻŲĮ¬pąrQņčŹø›Ü5č—ökלY" Š£Gą§`—¹żO &²K˜˜j.QJśōœq’];Z£lJĀėƒčĮŚĶõ¾Š½XŖõ‚ŒK.~Šś‹G›$V®ź!ÜŌ:f¾”ɹ„jÜZĶč_Ō!b–“ø{p55Ł Żµä"ŗŽk ¤o„qĒ`Ņ‰Ē"¹¾”'%k7’Ķ‰×7ŗ~mģ’ĘĄąŠ·IuęŸĖŲē@ŁAK§uĮ½ņŲ–{\—E7«‹XVƒK” ‡9ĒAߜŗūn­åÜ÷n’Kć9qĘÖåĪó4wŹ:æüÓLŠ§Y·Ś ū|PĘĖ č~ŹZDōD‚Ö‡hĆ²Ōßp@©KÓ鰖į46Ś.£@“ZL ]©ŗ™¬Ēnv½JuiĪ78ō9¢ļĒc›°Ņū|ķŗÅ>^½i(c{Ö½†­uÜK‡+Ä…s8įDńēR÷^Õµ57Ćī]6ƒÓ³ŗ÷iJ*²”‡c+¹—Ųāfą°eŚA‹,<Ė,ÓóÆŁY1ų¬W¼4Ł'9 ƒ”Ö z§C…~Ö'ēŽ÷Š§Ūė³^(Ģ§‹wŖ„£ź¦…ÖŲŁrļŖ‘=Ō¶ē鞎@ś‚ŽZĒYb/¤Ńbē”~*:€ƒ7”'v%ØX§X¬:l€Ō¢jÕ÷(7ŽĆvĘƒNIˆi€¾Ÿbļ”ŪBww4īēéRŽ]ĒUÉŅŖW[Ž¹—§.½÷Å.?±ÄļĻÓ/+qķ“ĢT„„™ģYn]v’ZśņY©¼Ÿbļ”$ŪBƙ:yvģēéR>fōSŅrwQ j)“^S”)«Ēó5ą,EO~‰"ę/hčÓ» =SJŒ‰»L$2)Q"ŻOæs%ßCÓŌ¼ŚV¶Ń{õ²½ŗŌZ§åk?x¤h_&jmµE4(YöŌ«®¢©{Ė6rÜŖ]OZŲ„@ę=ŹĄŠ'Q%ĄŪE×äå›śÆ2tØŁžBĮ”X®m©¶‡®”u˜ĪōµĖŌ­B›]q¦uÓØ'%VœĖNž;U,ÓŌ†ØČÆd“.`=‡œl“×Ox³®dw%Ų/wø„£. uĪÕG‡ŅJŅB8ņåCĻ„;“‰>ZzyFćĄøĻ(³+PtŻ8…·9`×!ŻŃäöC0³Z h4»RG=8tÉ»7błĄ*¦÷æ„KĶķĖ§č7–ė/¼tbŗJ±‡4ׯäöZzs~‰Xš#ļM¦›ŗ÷ģ\{eä{ =3?įĪJ%]v2Å/ę!'ZłvŠÓVų‰ TŪė ɒŖK:…-ÖrĪ £‰%šÓ­ĶµŌc^ģ(q^s:˜wL½ō)`3÷ØmÖĪĒd—_·£-ŪQŪ­ŲŽ _¾ŌŁć]:Ī“_ÜĀNą’—·WöXœų*;u}rģjól>*Ād}›óŃ ģū²gĄ×Up#Ē„mš‚ōŻN;=vlĆŗ•.ŠčĆ#t€§Q)‘·…<Ė)Ų$—Ą„K\»ą0Ē Ėpą1ƒĢCŒ ÜtŚĘ6jĖKŠū VGčõå?Ś{oŠĆā§tegåzŪUq=uµĪŃNĪŪ[“¬Į ×ˆCMź…Ć=Éų; Ū"R”^ć«ØĘŗ/ķHŁų–EW¦}żAJX€.ćŃ!*ŽrM/x悓1D”Y{D,\L]‚f 3ƒg hTr¢ŻjÜÜRq”Ŗk#;KŠŁjUÖ®pzƒŽJ°Ä9jf’QB=Š–ØLõĒžIF…^ĘČY«J¾WóoVæŚĻė±é”²o¬§L=ćŽvd` -uŲĒĪŖY°Ø2Q™­·&ćnS«ūŽŻ»ż51Q £õž!ՔĀm%Ā4Ķ†=ŗ‚C ÜĒDŸ9=¾ī %Ą³ĉæg\†\Ż{*?’Ø3ōŁD›­ŲŽ”cĪm|"ąŸzµ!~ŃG;ģ|"®Ł²¬o‚ŽčXg(󞑆0·”ŲČøiĖ­Bļ¹8nœ°čašdų ÅĄÖ® •š#ŸPįÓa‰š‹‹>ō,ß$VnxĪš4€)(F3‡ ^±¢ēģ®óøX('4ŖŽq”ē‚mšD_ŠÅ“4æ=&Gƒ“s@ƕ“#Ÿ˜F£ūł˜O|ž5ÜĶÖéFžŪNó  ’ŌŪr#š}@Æøg°]i“"÷,Īßj Gī§¢f“BՓa„©‰ŽfOē÷DnĶ‘’9R1Ś…Tjå%b‘vG<~ 3ču·ģ><·BŻĖĢ¹łn”gm“bū‚^Ać;ŹŻg›g;"“dĀžČ >z üĻŠ“5»Ė’!f™Ü7śq÷ś€~£Źu£‹ÆńDįh£—Õ+ōė]ÆĄņ"Zc‘sTk‚XŖ™šžœvĻZ‹>LņpĄ‹óģnƒ‰śz J=Š˜Ž,¢ōVU¹zF×ģkĪKŠŃ³„2*Ünš§©ųŠ®…-‹}0j’Ńč4<Wš3‰¤ĘMļ?„„Ržé.ÆOy7{ŚNAæQ#ļŅ½¬\]i÷½ąŠĻdA£Ēµ‡#Œ¾”¹0ĪŽ-zœ¬ŸŹEŠČ&į ¼wŖ·HõĢ¤Žr¬×¤ŽÜm&ŽW_p}P§#_Ėņ:GCč®,C{„~™k»K÷zøŠ„°/9ĒPūr‡>²5'ņµq¼¤µ™¼®ĢŲzAß]; C§pōBāŹVģ`Ščē~Xņ`”«Šæ³®óD±sÄ 9¢ •jÓXT:7‹`|¤Ļ„~­K±aWh€1}X„ŪÜē”B/˜,č„¼ūĀ™ö1‹¶ź51ī¹Žó)ē\@’|Łń ay%šŖūFw{×Bo.ļM ÖŅ‡Y*tŒv j¤f֖śqF2īā„“ak\Ŗä$s)©yÜū“āaõÖćC`Tž¦¾WK’zēÓ—lļ5tż]^§Æ“2Ę'š•ĄęEču} ¼tbé4īI”)Ī­ö€i‚DųŹĢ AA0Ų€J²×C×Č.MåŚBw?Q„—öåm=O=eæœd:Ģ{rS ÷łĀ[xö›Ó©ņė£uźméõɍ5;Łū”ó`ŻÓĄ›3sč'%ŹĻA”@ßIą1'ļˆG¤ŅŗĆÆ°!ˆč“1p"tćC 3tõÕnYæz#xéL”tu†$äøÓŅFjŠÆ³ ļ&äHŲ1Ą˜(Ļń€½Ź]#ö!Žé© wmn.póõĪõ%:0ōMTŸÅų vŽ@Æ°āE²5éÅq[U&ŠlAŲ^h#tŅoņvZz&,(d}•6ŠÓØ€Ć‘ę”K9ŹPL7N Ä`æSך„·€‹ļƒ±Pā2rŖ€Ēo[BE Š#VløuŒ8 Õƒ‹śzy2ĒÜw3L!šl,oŠ–»xüM·óŲŽ­]ōõżĄŠµT¢ĖĒ [‚0‹ĘŸ§Z¢¦£vzqN“ƒ»\üŖŠP¦ŗ ÓL[hō’Įą2·2¦ƒf®+t;6Š”W9æ™d6WüNX§ģxRģdÅÕWNÆ2@/ń®³Ą{-čŚ E`>÷/ŅÖeęBį°K×8^{ī“š¹³ˆjē210tŌS Ÿō“’ÓåK‰†> Ā2oĒ”¢VĶ8^Ī‚jS>ˆł9Ģ8UĢK÷Ī“ˆ~©Ŗ7JÓöHE«ŽƒXÆz]—_čśī2Ū·bŪ“t+Ż¤¼øĄ3"žąŲOō9Š./čY¢źöIBN ƒīŃ}iéY Ķ!øŒ? ^7Ō0¬PS®Ę`Ąš6Å?8ōc¾U=oµŪµƒCwøś\v3żŲ}^Čwč]ŗ EŅŗž ttÉØšl—³ć9Š我8G\5yš"@ÆÓćkĶUhé~)z‰ŃcčVj² —.Óq0Š‹`¼älWøjpčšl½7˜n`Æū~pčØĄŃ׃S©d@éżdūBŲŗ™¢oņ“…ƒ–@ĻR8ąź8\G’°Į‘Ż*9ģ]"by02’ «ō4­Ē'Q*°ā€ VŠ›(‰%jaĒ£ĆméPp²ŪOŃŽz?¹YŚnŠ S\I“›½»ł˜T®(éś1- ajēvÕ2Ą0Ś/yģēÅŚ¤TÆXa‚ ä›scRC ń²AęxŁ5NŌŊŽµ²Ī¢ ‚LāŪčŖ_ié¹UÉROb·ö’ŠśņėŗV/hŶ]§×Ē­"18"^©Œąc\„–Ž”ƒ§zʁGkŅW‚j©>Đ›#:TDzĒŽ(T£0Ī‚‰ēZ8‰Š•°Óx b›b2 ².ø$W —t.§m˜¢Š‘ŠwŹĆ€^ 4×[M¹µ9GēŻ ē§æhĻźņe±G ēµbo ŗxnŗGÆ+-=æ.ōCĆ]‚^p-~]ytÓqF•87ē½-č½#{\ŠKĻĘńXZŠ57i‡$Ż”§‚ē\3 w)÷!éSÓĄÅÉĻō·œė’ÉīŠĮeżczĻuųŗ–~Šfˆ ŪK„õĶÉåmŗ;Ō½£ķZž3~—b é`īk¹}’–NĀŪ |×ÓEÆōĘ«Įe[ķ‘ĻČäĻ'P”G;„7NĻčęŒ²×­”wzr²ģBdČÅŽCK‡ą×™k .ćƒ_śåJgė÷*ōčžņ8/šnŖÅŠ qET~n—įV/ŗ>“)+¦Ķdwŗ“«»uš –‡)½@¾LåōWĆwõü‰Ś³©ī9qĒ„- Œ«ŠyAy—Ü(ÖE»b™b: µÉ}7dŅ9Ø!ė<:@rŠüTÖCš² ü8SšjyøCŠauL]+D$ĆŻKģśA°Ļ£€µŅ8DēźW »…^<Ė]ŌłņzŚŗEå%¼Qŗ,Ė'}ćÜóĪ&'`Ķ½E"WTéęBTI·z1æ)=ƒ†bw­„³}½W/Ša½Ł:n*įAŪ<ų t9Ż\]+āØp"Ž‚f5č©P7g{b:@ūwsLī‹®ńŲo“NÖq—øysWi„[3Ö»ŌŅoZęmÆļ ŗūk’~“LÜ*t ÜōpzŲŽN)e1*Ų&læ"Š—ĆtZYL,»Q4­Ŗ"tļ*ŗŅp](Ó/7}vķ­B‡e²˜[ˆfI`)Ćī¢%¬[ś“ ĢxÆ ü®N v2+ZĒÆ «É˜„«¤ ĆĆ ]śpż čĢX›“ž«ĮķBO{żŃē &啈¶Å ōį)żņ„; ˜ŅI_JGbÉēI_†āć‚BGŹ0F1¾ļĮ†.ŖVģ°ldŔhnyŽNK/ķQ3#cŚ“ųņéžĀÉ(­/qMį^BŻ÷¢ž…=ā¬ųOb‚±öŌ½ƒęŗ°]=Óæ]čh•ś\‰#tQ?Ÿ‚Ŗ“Z’Vą©»8É-“ʵEcBTŽŚĢ©ē‰¢nNÆv” l‘īž-īnśn Ā0k¾jŠ¶ Į/Ś€©@<_ē؅l7ć^SĘNĻļĶ÷pÕĘp,…[;m„7čeS'—L=Ē„· ½Ÿ¼\—öV oŁDUŗłŅįö““Ģ/ׄźįĘøÄĄt]§ļ·Ūœ7u0é :X‡ˆö1C'¾Ćˆ”X…)˜q›dńāø5(§ÉHĆÓ@V$Aa*J —ł1Ø­²^šGżP«.Ę-ĮÉŚX¢‘Y_Opīā¶lca~l*†–Nć‰yæ"~.ńKė>I"ž‡ēVæ!ōc]'Ÿ×µ Ē Żˆmčœx•†VGÖAÅל|EÅ\]o†Bk%Š!ĘēōM' nŚ&ĀÉę3nÖNļ“ [Sąt‚‡d"¢M¦Š&ŽŻÕ POUĢÉē‚¤M‡<æzSč°ÕnžŃgz[ŠŪhĒ÷™³‹ÉŸÜĀyśQkc@ĢJŃ;X•k‹.½*JĀ_Ŗ³;A“¹6>軓=F‹‘–~šÅ-Fn?Pk/ĮMCB†ŽØLKØüŽĖ*ėe£ ŽD)rCYæXĒjׯz«ŽŻØ0oz)q(Õ UÖoz‘<¦ķ䉱ŠØĘEĢ–“Ś$0\¾ĘŠ×ŃĘ%nA3GT‡IKĒHéPŁ!{NĖaģ.ęč%6E £QŃ+¼ī’čŖ‹ū±ŚX i‡€bOh|hśv³1˜Ö‘ęMØßōāRĀ3TY4 hHŹ¦ćyŗW‹÷䏶x>RĮŻ_'—: £nåž m:ō€p¤&=‹m”gŒŒ1re®„ŗVÜwšz’k°‹':½CįUN³J»$KĄńŒ™T8`£ƒ;­'rńÜü’v ß¤’ŚĪJO·b/Uą‰ö&ōóÓXšĘ±—RˆNLŗ§4Ŗ‰y{׉";#q ź¶¦Ī°Xż*Ŗ7†±ŠØĆ(½?/A"nWˆk±9Š7†ź’–¶©M÷ĪåNh}ųüŗćčyĶƒwZŁĘY_÷ŸÕ}‹Ń‹;ö#č}įķ%¾=ó‹Ž;7ęĘé ī*mnHē¦¢#č·Ē±Æ;_€Īę?ĪĖ[ńŚś¾AŪ ¾BŸ÷®ļCcJ‡óīŁü×C5o¬Ē½—6÷'S9±a£„W9‚Ž7³¤vx{薌2Ęåy²Ļs@ײs©Õ>”^z©?„ˆCw ät½oččŌ#ĒFnĖĀå’‚Ķ“<šįł=ČRšĒ‘­¹£9ĶĢJõźR½‹I•Z§f”źĢ‘S“ ģ»³;źh!£”®>/鱏¹Ń'RĶ-’£ō6ż¢LĻd#č}CĀf„ńŒ“hqQZŻ»-Ų²WĖYe|«ŁT…āä“é„ķ°A97!÷ŹóńøŒŚŹQŗ壉ŠÓ ¦D…`Vt<¦ńL5X³œ{bŒå^ˆBŌTt[–_[>hĪ *Ė¤‡AļœK¢pä^.Ž†…‹;pf£˜[ęƒÅ"oĆ¾dŪašYV®%`L‡NkQ\,EEćE/HĢ¹£œlB>Ó’”-<™ŽńŪ#Ė§/Ģ'w¢_·˜8NGŠū‡ua‹ė†›ķ—ž+“ōbąK åzū–%ąĀX|Ó>2“Ļ…Ļė·ÖąU™Bš‚9 čńų^EC•’ń(³%© Ojb@2²éFüF\`~cGżU[OŽž„FŠ€~—Š—Ī<½įˆ‹w†ūÅHK2!ÄÆ) $žĮ46dTL =]Ńń˜X–VŻ°½D {$e^³ŠÅē g|ōŪ8Č= ōņܗ3ŃÜn’ƛĖx Ŗ)āZ«„Q”t’RbŖ4ķ)ŽÅUćvŲ6³1³Ćƒ‡}3ŗ,¦ę’‘¢ßZ2Oˆ= O%RvoC?–{õ_LŪ£ć#čƒŗktMĖ.ļ_ŖŽ±yg!ÆżIŲ•łCåŲU9ŖŹŁ†Ju<¶š'Ÿ ć/Ń!CŅļįjō)ŗ5m„gEņTÖ1_ÓĢŸäC_öżš·bĄx„2ų=»¹9x:’“¹*ź&öCL‘ µ°)čór%å?˜č‘3 ]o!¹äøė_EÅ:ģ²-ĘL½$;mĢŃubŠįsS’—X3-ƒĶ>|IJ Ė{’ ’1ČC„k‚••tŌc–Ąkśœė&R4…©ŽgŲÆZerŗ„ū„üŃė’ B Ū;˜<]¹g%}ų’AĒĀCčś@2Ō¦ĆÄw·~)Ʇ cxk?ūģå:ųф§äPˆ”°ĘĄDŠO^ńøa*ŸŅ//€ÅCbŻżB†v3z‰'¬ŅĖ`a³”±KŠāe%Üåx†@w_tŌ20Ök/ĢĪĮØ{'Żōŗ~Į^—>0SN†Oƒ ŌK¹‚ˆƒõD&ÜI.U7Ŗ.’IŹĄ£/,7”+_éĪ×ųŻq āćYM&““ń)?3»\\ófęy W\_32ÜŅŖ Ę®Ō»Ą†@Æū®w/ŅhקŸ¶Ū/wŽ§—ĖF9al–Ķć¦Čā"Ģó9°r©$GiøbÉ}d2“x³žŲKÜtMx!h(%K0ÕģŽ·åŽ8Z5 ‹›ĶhÜ/0vė~‚¶0ŽM=h11ĖaÜMĄxvkx]— nb¼ä÷LĘgrPq÷EC””«öüč|å: ’č涩'[ń:ge›‘^™p†sppyańåŃĒs™tRģšŠrĶ°Ė?‡‰Ų¾ĘĢ5¾!”J[žņr ¶eÄ%ŠĪ>p®Ę\Ģ¢d¤äq*gcAĖå8łĘ*ęÜō ˜Bš„Ś _Ÿ§O·8©Q/uƒéść÷ęĖś…yuNŚ¼Ō"#CV)õź3;nM¦B–snG:{ ‘VÄ椠ęPe2uåédnVušqsLŽRƒ¬ūG”ēÓJĶł9_&A'“Oukø啗­ēA”ˆX3§f¹DšŠĒžz§žÜWZf(>_·‡A¼h(Ļ'§L® "ōFPĒ(ęŖrÓɚw< ™ō«!<QĄ E%ćvš_˜Ž>ŽœC®ėmŒ›ŠÅ¦sFKå1£|ć$Ķ'–ńĆü˜\Ī‹*VQ<¢äĘö^FĖł·µ©ā˜†Ł=-ĖŒóSŗ°ĢM9l¼śm­¢kīåŁv]ĀŸŗ³²ˆ[>£½w4€"ž6rœI'œ‘¢}J¶ å2¤2Ł\>ƒZķ; &É ’ēTs)W&6,ČQ\„TJPĒüO/1į8ŗŠąl¾©ąD6QхĪõŅ:ZeØÆŌUÉ<¬Ē³q}ŸĆ`Ą¤ŅµžÜÆ«zÓLÜØąTņxV\ą^M@ƒv,Pp2.³n—-šØQXIV}jHœsY¢ņ’Žō.0śz Āæ9S—RR?MóõxlŠ§h¬0’K¶Ė@¹u?āÆ%ļ/GĀDM³Ę,§A&;Ō’…0ŠŹV#å–bHÉō÷ ¬RšąKXü½Ø ÓÉō>ĄōžōT4ߧ}Ā¹}ßvk½%¢‹ {Hž»Źķ7¤¾Õ/ģń.wTRJåDe‹Æ$t™Bņƒīdt+Ł Ē..AĀ²=ŽŃ@F÷Gœ¤ĒIčšq½w’·šņ«bäĪ’OMFČO$f§OjōY‰āĖ1NqĄ'żóŸ;uѦõ² ķäU“楑ĒŠNšÉz’cܓ=~mgŻ›ūf6Żµ¤!åÓ5ėŸZ7ÖZē _EYÕHÅ_g]Y‡„£ØĖjĻvā•"˜õ»Mz^ļŻį™3ģĶOUČļļ ŚŒU§V¾—Ł‹.䱗ÕbŁ®fv-yŒ•Ł€½Ÿ48ŽCY=ć˜/hBłI&›Ókhs&IČļ²*čū’§ō+Š„ {ČÜZć— 1mŅ¬uq€Iw¶‰:„%ī&ŠŃE²N·ŌC=ėµļ©hM>ū×-€ō+·…§ŚīÆ~’±żz P肱lÜlŻm¾ļ«—lŁŹOĒ’ fpM÷ÆÆUuLč¶ēMÖGŠÆ@£q‡­Č¢Šg­ųH^tE“Seššś•žæ“÷Ąf|„*Ś$«čCā„K#ćķµ°(ŽøšąM­÷M”c®˜Č–Ē$é¶ŌėŅŲ÷¤ÆlāŅ®ŻśÕRŪ¦ń <+“§7Z^! ōeZzNĒłœU›(H¦Wu*†Rė²jw„m¤7^gŲ C…3AŻP ćrģ5nZ{"(Ä|öTžŲ„poš’Œ ·i*ZŠÖW(1Ģ”o(":Łƒ·µŃM%€”+8‚ā.ˆŒ*qf Äsk` CbւC‚.<ü$2åJÄż±C”‹—Žż;4tŃÓ1.“,“=ęAæRldO]ēµąj—ų‘ū ]B“ĶQ6€­uĻĄ†» c,T|¼ŅŠuÆ!`ó&Ć Ÿ˜-[£!°œŽé–—4š“zć"żj©^·hTZ¹ā•U¶7É^žT*wšLŽ _nÅCņĮ.ÅcĶ/ń=ĘayŚ¶#MhL`2Ą>ŗ%ß|²ė€©Wn¶ž 7ė  :X`a¾M łką •ģÜó‰q—l*±m6 N†Ī$žŲŽžžš,YWŽf9źģG®=ūō”hµÉ¹D  żĄ'«‚Ųf&.ŽUƒŒ]Såēd9xnÖ¾ĪIuŚ1éIrm7«ł]āÅĶ†!!Žחė» ƒŲgÅż¢+…ĚīÄĪ¤D\Šõä’_hŌŅŪ— z •Üvzŗ¼ƒ'œł®Ÿ*øg2µ(MCŖD<¹¤1aF¬B£ā†8W*ÕS’ø“SŹ—Äå’ŲŁ„½]|pŠ'1ŖłPd½s1ę’smT‘2¦ŽŒ”gŗłļŗ*p8䣖~]1Dóm¦Bwß[¬½°źŚŅWM7p{1£–Ž ‘o¦ō°æ7{Œ^²:‚āzÓ ‡č³°ÕzŖ=5¬B=}ĄōPŠån'­×C/ŗ|ēüŽöš¼k“Œ ƒƒJ“\wMµ lü Hpė„³d[ĒĒqSōYė˜śšä%0vŁ¼æzc=1œŲ‹Ķ,Ž £2ģŁńX“4~ä'•®‘šYŻ6nÖÅ»“=I˜[nE:$½śžæ‹Ņ|ŸM]€. Ļ õēÉłuAQŁ† Z„žōeTäŃu Dō7DĀøć¢YQ8Ā¼³Õ;č‚? ;‡svŒ!—ŌųtJ§F¹fV¬%ČŚö*8 aóµh®žcü,šUŸp;%A æ Żż}(ׅFŪ‚®ž–.a“_2±ā µ­˜Vk6bĻīŖm†W¶4Łę|Œ–w‚č™#>U£MQŚć¢W”“LŚ¶øā™qŪī³j|3 Jō.pt†.Ż ć„õܳGŠčnŽ9q4 J–¬ŅZŠ)'­Ģ`TŽ,=ć2”R¼˜2ļŠ«¼ Š„ō†Ž9t 3‹?Ó^ĄńĮō #<=W°QÜ”EÅś<}­FGčnź««ĒQKļ¹ŗŁ§č†mć˜ī>^As‘ŅķšƒYŒĢę¦3u­i¶:ģµ„thYMVD‡‘›ćš °x6ĒĮ?žgƒBĻF—ŪE ģłŻŪ&9%@TMčy:éJ4ŽéxĶ°ĆŠÕI(/70p ķWLu)HĄW‹‡BOĀ.ŠŽ)6V‡¦Ź¼b1ŻŒ;w¬T…¹Š>„nįÆ]h‹Z'z—(ł;( žł±Ń×H\Ģ”Č`ŃG‡ņčkoŅ„„×¼±Ŗ©Xix#æŹb!ēōœ=§¦Ņ'ŖĘØi‘Ā 2Sģ&åSŃ-X#@Ɍ< Į#6™Žžć1śN’§4;źÜŠ2ÕTq†ucčX£3 ±gīÄŠĻŗŗNTœńźŖģÄāąĪ:<­Hżģbæ:|ņ~O”ļ6jéJ£~ fjÕĘńN·Š{b¦X©āü\„>|ŒĖ³R(VźčŖ§†;°ŁŖ5Ņ <%zt•zuÆyšę@ĶTāɓգ¾ŹŃ]wcĀ²† īĆÆ_æP%ęĖ3½R06,6ē˜14Msƒ»½D’žBļÖÕÄø¶ćvŽŚī—œŠöv7Ģ5CÉwQ¬h  qį9ŁÕI†ė«®uoM7}ÄC(t‘±Ÿń±µŻ¾-0]JX„ś“JßŲ—P@Ųu˜¾ŖäĻ—{œŠģšö÷(ō”xē–N¬VKžøō¬ ŹM-GŻĆž¦ąz82‚~ƒrl®ÓĖ &Es’ā1“Ż]37‘½ŹM®>»¶™­ōCĒ5æ™XæĆŽ³ŻŸö÷‹=\žŻäāÖcc­‹ō!@‡²ÄJŶ›¦ķ…=:ü¾B”¾G-żĄ…ĀŗwA4sžKVRWļŻ›ŹÖ ótķå$ŗųØ{æY Ÿß{ÆzüŻl¾?ō–’Ŗ»Ś½’ŅÅoßĶh éj÷זŽCzČŪEńu½K¹ļł%Ö».K!zĆq˜7Ļ-Łļb÷~Ē[zł'»üĪK”x“9'…„å§×ģĮöŲŅoeGƙĖ;}Hš·¾&`ķ|ŚŅŗžüv/XŻTņōCGŠoZ“mÆƽLv„N ³j#Üq¦Ó4KuĮģżœ“Š+‘;¼Ūś­@‡ĀOĖ¶n„;AWh4²š”"ƒŠ&%FĖ*Fƒ:œe©-³4RČ2b•,IµNø –jJz JJ(3;īćŒčö«Po’WĻy”»š–#č·÷ē¶dgj·Ń ŗaC… 5­nų©ĻDc+‹ķYČ%©©ćč‘:8G‡iÉnŲj[–ę&B²čÆO=é "zi›SƳótĀ8NdÖĢ~Īlnėwż¶ CŹejkEÕśüZĮƒžOŠ,ƒŽrÄ©X0Å1 įr¬˜×šé@† ĆzX ƒ¼ęxƒŸĻÕfXP J'£Ób^”ž\£ÓKT÷qDüGŪįō[ƒŽC4]½}č1É”ž‡'…†ūzm–¢B- !>ɘ'čo4iGćy1+•£G…%+˜*ęa@XC8$õčĄZŌšX:in ß"tØ®Æj×µ‡^yš& ŠōLĘe® oź›‡bĀæˆSy=P«pvŅAļ5^€F@ę`!†Jž¾µvœ6°c7y[Öõb¢ÖNFŠo:å+‘vŚCOt1ŚQąŸX’ØŒ;€X¼<ĶOō²:ˆ»Xšø•YŪyóÓÓķ|x|gI'£«ŸŅšŹpø(&ķ™šŌ„Ģ°ŁV{żV”ćŠj–5×`_¤-ōŌ‘²€.ŽŃuåÓē'"w6ļ„a!lœÖ†Ž™5lĀÉ×jTŲS:sĮhĶ%½giņ”mтž­ £ŻMó;pÉ7J• šOvą7ŹOr¤]×BĀö-¶Uj®fįųøRų8«ĢĢŗÓPKqšž £DĻ’]×ć"®ŠĒ|hčė ŪSÄŗ8D¶Žk;—MńFŠæōÓ8Ś&Į‹O¬7”G¼čU!õdCX‡y™ˆšhĪ÷ tXߊM[Ē¢ń¢• ū¶Į®y&©moG˜°ī\ņĆfRį L}ā©W„„Ɠė:˜Ÿp˜“ąóSʋA’fŠ+Ķó<Żō’ņUZŠgŲÜ.ŸŃ³ąęÉŽ»Ž82>ƒ®`ėĒ‹óu^źą‹Ē| ]”+IȊ –@×ĻņE5K»t°$j XŲā™¤VhŲō£ü 2‚žĶ ‹ÕśżÓÓS#ū^…^@č{}ƒ„y•™k¾VćZ:9==pEx©’ĶģšU†āałĪL$@źZįŠ+ŲOp°¦ƒāx$vlF“µŠYōq¾ōČōożģAyļ¼4hÜPĻ®JŃuś$īH¬žMĆĪ g—õĄļ;ōŻ<„ł|ą(“šŹ“JZÄ|VM@—2,#t 8)“¼–ņ$°AxŌŅæ9åK¼4{—ŅĘS閻ĢŁĀō¼“-…ųĘT<1Öt9_±h;1ʖ‹¬,BŪō|]JK]rʔ‰'¤u6Ló­§Rz¾$a5s^7gĪs’]k²ģņĪŒĒĄģ/¬%/jnZś7Æ”ē uČnĖĄĀ„#:¹šrWeŪ7ĘbAAB,‰ż€ŽVå”#™Į8R·B= „\ e{“p4%•,hm·bW¼¶P5DBć ]+°śRŁØZ¬æšitŹöĶ‘_Y§·Éū4uźāßÖ{圾÷WµōŽĖjH)»ļ½«ż‹cŖėŸv¢ܧĶśPö~›īŠ1ŖX·ŪaLnI:?‚>xŁ xe/Š¼u— ÷XPĆK¶‘K}_ɶVpwÕTyxE}wīd2æÆ$Z}ĶśŻ©ß,'#č߬ØļĪƒFŠļ‹o–“ōoVŌwēA#čw‡Å7ĖÉś7+ź»ó ’®©£æ·YIEND®B`‚Ö$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö,Ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTŠ$$If–ć’!vh5Ö(5ÖŁ5Ö1 5Ö‘5Ö‰#v(#vŁ#v1 #v‘#v‰:V –-Ö0’’’’’’öL6ö5Ö/Ö ’3Ö4Ö-ŠTä$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-Ö0’’’’’’öL6ö,Ö5Ö/Ö ’3Ö4Ö-ŠTś$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTś$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTś$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTś$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTõ$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTū$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTš$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö5Ö/Ö ’3Ö4Ö-ŠTö$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠT$$If–ć’!vh5Ö(5Ö5ÖB5Ö5Ö5Ö-#v(#v#vB#v#v#v-:V –-4Ö0’’’’’’öL6ö+Ö+Ö+Ö+Ö+Ö,Ö5Ö/Ö ’3Ö4Ö-ŠTĆXDdąąČĆšh² š S šDAĮ’Ćart-minaiFigure 5š€bšXVŁzć+ŽP­LÅiž’ćW,„nšŪWVŁzć+ŽP­LÅiž’‰PNG  IHDRō_ÓĪ•€PLTEqqqāāā}}}šššHHH333jjj¼¼¼źźźēēē’’č+++ŽŽŽQQQčččaaammm¹¹¹VVVŪŪŪ···YYY“““ČČČŁŁŁŌŌŌŲŲŲąąąÄÄÄ]]]EEE###ÖÖÖŅŅŅ®®®MMM———ĘĘʄ„„ĖĖĖfffĀĀĀĪĪĪŠŠŠxxxzzzĄĄĄ¶¶¶AAAĢĢĢ<<<‡‡‡±±±¾¾¾999²²²0Yƒddd‹‹‹ØØØžžžžžž«««›››„„„¢¢¢ŖŖŖ¤¤¤   tttŒŒŒ™™™’’’˜˜˜”””ˆˆˆvvv’’ņŠŁćPs–„¼’’ų’’ü’fżżżģģģåååüüüõõõūūūśśśłłłļļļųųų÷÷÷äääņņņīīīöööóóóōōōķķķ@fŒ€™³ MyĄĶŁ@pæĢŁp©ąęģ`€ šóöÆæĻ°ĄŠŸ²Å ³Ęßåģļņõ3f’’’¦&gbKGDˆH cmPPJCmp0712Hs¼UąIDATx^ķ‡_KōčYźņ¤ R”&*ˆH‚ōb¢bŒś’¼ßCéH3õęö«óÆæ3 ((Ā‚`0į|ī5°ĢĪĪĪwź™3g×3łår€A½ń§Ń7üoėŸf.üž/śųĖåĒ/ńĀMč×ßśz}żņæ&ū–|šA’9Ė@ś7ōūõõ‡æ§ś——?'‚§«6ōߊŸŠŗ’Ž„žjż×_qMŁĢéę?Ÿ?~ĘÆ?w^„«O“ģY»3®|nC’Œž»~łī#†žéŪŸ’}žķæOæC’üšįßO×/’żšéŪĖÆß>|śļOčé’žūļ_Bčæ?üūžśė·æż÷aųä@ĮĀ„åå{ü ŃĒųĻg(løŒ}~’éóõGh|`hAż}’é%.‚Ÿ~ƒb÷õżoöėļŸŽ…æć/×_©æT‰żō—L*ČĒ—šå3¾g&9Š†~ż½’ķ7 żļ’¾~F"Č¹očT’ß>}ĘP’ūörżŗž„~ƒŸž½~÷7ō’}}÷÷·oŸžžś÷OŁĒėw’ Ļ×ßæ_æD’¼ƒ?®?}‡Ō}łćū÷?¾¼ūćÆė÷ßAŽ_’ƒŽ!ōń=‚kŸæ¾C_ŠļŸ’ųž}|§Ņõ½ƒö ’‹Žżń… ’īś#śćśėū;<^™ÉmÜ@’ żżī3@’ˆ>|~÷ߟ€ņļz÷éżgj@÷ē§ÆŸ¾~žC‡Ÿ>ĮOß>}ś†>¼ūųīćæŃŠyśĻ(gŸ>£—üö”Ļæ}¾~śćŻõ;\~¾|‡‚÷Ļõļ\’ߎ}†Ēočć§?>_ųų$ąĆ?ļæ|…K×_č»/Ÿ” ~Ņńś}ŗžųī=üżŠŽ„¢ ¾āńŹLz@‰žÅUćŒåžžķė7LņģO„€{³7żś÷»pżžéśżżäƧ’½ūvżļŠyś½D}łķūõ?żöīūļ_>\’ńū—ą"n¦æje }’ņå;‚qż}|łz÷Ūõ‡wŌĆ~’ė;čįĀł½ūņŚœf|’G\0æüƒĖā'Õ§”“÷SßpSÓaŽž†NįžüĪ»ßŃļ/Æß’ m=ÕĻž ™ Ä?įĘņś›ŹÉÆæūųķӇÆĆ×ōkhwߣæ>\æ’ćÆO’|ēżóTūæpėŽ„ž‘‚ž×ĒæÄ(śõēß’Bž /ß’†>¼‡Ōąžųˆ~ūųń}7¤õw(Q׊sĢ ÷.»·Š?@ķčø"žöīÓ’DŸš`žæ÷ŠÕ^żņŽ”—ćĘņļ’>’żżõŸŸ’żšįśĻoŠæ+€ļśih†ŃĒßŃøŒżq/Ā°īś—ļŠ‡łŠ;{ōńŸļ_Ææ’ó;Üō×@;“Ž?’ė3śėėK\h?…Ożó„YMļI„­‘ūōł%“ī£?¼ūóĆ»—Š†žö'ō¹ļž|’ē§ėß’ūšū·—0Xz÷ ½ū€¾żöé?½’ūįż·ßįŸwžżs„‘ŅļøĆÖjń?P¬ą.l@üśĖæśž  Ž/B@“šśžń楄Ļ_ž€žēėõ{ē5Ūń÷¦ł÷ÜRĢš÷Ų[5½ó——TŽœ“·žłś_ūÓ¬0¬ƒTxü·ūĶ“’¦RąksFÖŌ 4æPżņ„­4ø)w/›©”Nź¦-ŽŠ$‘ČMą6a&CꥊŠ?Āģ}¢5{øhŖnf2T }ØŲg§2’o&æ\Ģ ’rČ’ß’c€Źm&æXĢ ’bĄńėĪ Ļ ’‚9š ¾ņ¬¦Ļ ’‚9š ¾ņ¬¦Ļ ’T9.UWWĒGLæĖēóbMIr|>Žˆk‰ģ-;Ō‹B²^©°XõźOõźż_ꧬ鄐PĻó¼nŁgˆ]õ‘¤ĮĒaĖD:ēӖ’H$ĪHä ¤TJ5ruę'.?ōZ¦Q%ĻIé¶ił€Éµ±E2‘`7™LöåŻUbś©œXRŪ½Jļ›ƒ#‹Dā×ėe\īĪNĀk_=ē_² ŁŸØøš«;¢\ĆÉĪŃHŻt™včKJ?—yŅįŻĢŃ|T0vĻś}$ \Ė8øļ^»Ņ ®«ņV ¹Že_f2'jb: JÅ4C/\$œf O^ōw~ÆóĂ!Gš1Į©ŖkHHØńälI,Ā? C”3GŽ˜ ”MŽo Lš\ čdGEśÅsČ×_šé…>§eˆJ\ÅFÖʖ‚Co¶Ūõłķī‡šBl”šŗy ~8±pX(mB7&©Ę¾§ī-Q!ĮOzĖ”BOē¼ nHų˜¹pšoä…Öd¾]P·÷hļ±Ž ·m…µ @÷Ž6MŚB āiéČWGČ¢¼(FÖŻć•Ds}•µŃ¾=&į“ē?ŠĖ&®‚7`˜N/o‚™rłÜį …˜©±ģ…ģ²TxØ)vča"–Aqē‹7É čĶ‘…Z_ĄŠe¹;mĀżd½„{°G/©Oj*”Nļ6 „^MĆ’Xų Pó„¦õFe’yÄē˜œnAæ.Ńō:kWQPō5Ē’n³²_s@'ŽI†™Fč‹f mĖ:Sų–‹.õfŒ™g ²óˆæ" L2We—yRWžĄŲĪ›\-słČAvƒIĢōĘiQhŠ©O!t–(Ņ TG„H„bX]f‰©PJ VŽ& =>ą#­ŁÕ&ķ’Rƒ •¼Źėø*iĪŹęĢ‰‰&šQ‘O!ō0³ėœ»vD¢|Čļ "õšG{)ĀļåÅG½öäoֈhÉ'厦z]·Š•ŹŠ(ĘØ”Bt]0¢RUj’€|ž‘‘ųš÷<ŃÓżLr·Š ęBīˆdˆČ“3ŽŹnøÆ{¢Ģź1ń唂?eąéƒ^–uŒÜńŖ ŁčhŽČŌ,Ž¶‚Õc(=¬šī)3?+Ļ¤»d÷Ō)›Ź.+²Ž±;*liR¬ P|/9ėčDą@9Ē“Ww„®’āüÓ£¾}āōÕt“Ų:ŖqęūÕ,qńC‹ģŗx‹÷C=A'‘…ÅѦ^ė®)ÖĻL!tT²čŒ7ü‚AÖ9?ƒŹ¬:Ø6ƒ•Z åsO„ēä{ ”Z²ĖlÕŠ7=Ż ÓåĀ¢)™š\qļĮH///ĻÖ½bŪ×ó©ģÓń0ķĀ-Z›†™Łœįźjõ.uĀe /ؙ©LlŹ>]µįISYÓń{šĶnļżõÆ^ń1·„’±^\ķ9µf»×+Ž 1dÓyóōtµIŲ£īZčÉćEŠ÷c§‰ Oų^‹#¤ ÷P³QĆéųį%u`˜bč(WŠRlēĘŅœüœ‹–īåa/螏±Bv"-N»žæĶ4C§rūr=%fXKwķŪēń87ß’ŻƒNJ#n†bŁų\öæM=t°7­ŖĆū Åi\Å‹]ÅP„įač”j½P"¤±‚aį ›ėżĻB¦:+ĖŖWWµė-Y5Z•ŪįØS¤÷3÷¶sO9Lź ŚDs,—¾8rŹDĪ°‘,<—:Ž,“Ó=#“¾^Ž×‰õ>Ćīn—e[lwWąyva7ŖGē'k¤7tĀ‡¹a"ŠÓ,}©5BCVņŪ²!ę „R¹\®WŠ—äÜŸēŻ;ŲbHüf6[a³I,n·ū(Ā³¶E#æ‘EJ«Ż\u8V7_˜@Ž"ą„BĀfė īZdŁ“®\2+³¬l¦k¢|żn+[a_ך“¶0ż#Ōņ6÷]ɚsmÉÄĻĆ’2×nD!’y§å^ØżØĶŪ’¼Ś•…OØß¼]~kā…üĪĮ_qž>ƒ~—9ß)NlŪµ“eÅ8ś6S@oŁ|čI*«ÕEŻ-P±ŪbWĖ”¦žs²ō=_Vƒņā15ż‘+°Fs¢’菜AȜ%ĘlCJ‚ "œ¶©B[·4†_;ÓŠĒ? )źo$ńĖBĻӟŪļ›Š(Bfwo½ĖCĢ¹ŃŠh¶ŽaųĘ½ EUy/Ó~ŪŽš£Ń7]¶–])²ĖśźOEču¼=»Øn®vTģ¦mµč¤–®o[ɜšÅ<ŃÕ:ę¹ēn_ųÕøŲGogq«$]Ü®ķbœÄe#[Ņz׊ŗ”Ć-#ŒĀ–ŸžcōšEpśW„ž l7ģŚB|׏cÆ£ ÉĘS«ÜĒ%’-.vµē§£o y<¹īÖō‡”ōšØ¶”}3ŪrVAD {yćA:K©E— Žų²„Ī‚‡­®śCæ“Ż_Gū¹•3֝āö.žŅdvCō]i€Ēš—Ģé.BžAŠły«Õ½Į’RŖŒtā0:čÓAü.Š·cč‚" „8GČØŅ,ā&߃¤½„?ō^÷üŌŠÓ–Øj]€µó…$5żŽ'q…ÉqxßѧŁ§“ĀŪ„mānMŸ3pՎØIZŅč™Ü¶”²Ąx.r’i‰)“ņ’…õų)K å=‹Ö[˜3č][ų6]H‡ ōŖ(JŽ$UW„»ø±?1ŌH Ÿł¦ŻƒŽŲGøĢąĪ ¬Œ^“ūß”KķT—_ÓözA%5Ā¬cžšØՌ¼D?eė zgŽÖlx+Y‚Hå”FåŹeŽ›;bkYŁ}Nyté9uYw£…»]\‡~B2Įę½G”ČÓŪ%3ŠƒA¬³NƒR»xBé:ąc¦9E¦K › fąØ>ߎ¬6÷Øé;Ø.‡IÓÓŪŠĘŻ<)ƒła”BUÓ#rMĖ\Jxœ¼’yó[;\Ē@¹­£å„ŠžÉ”cDQ÷ö[Ė*¼¾ŌōlŽŗ°Įpł)ɳ¶˜§Tū4HīA/)OĀ c„­Ė¦P˜$#”.Ó!§é{v—#£ŹT™§ŹÉN;Ī˜`¤%ˆA)Ūļt *}V\ņoFŁ6Lŗ½įc²Īy ōVšJ#ĒĪšžLrtW‰īAņ|ržž‡xN0;’ÄĪ®ź›•ą~ķüNsĶ –Ü5|2ĘV\k'ˆ¾Š¤'Ėƒ‡DzßD:lN›¶Į÷  CŹĒ0ŗW9-éģÜoŽ„žKÄŻēsš:ŒBm©® ŗ[k>.jœ’³§\P ńõ%b£¼Q =[,‚>¶%÷›÷ńNĆ=³ōr]įÜ1Ćk²dŠß U›Ķ{¬½:Ē:ķł¦ac5Ż4ō®ż$Š9¼ˆßŹWļ#ūäŽŽLTļæ]öÉäŌ¦Ē­4ŃÅ5žp3č=jŗKHVƇsXą„šw5Æc%‰åęÉū»YĒCä by^ŠƒŁĮ›J‚„`®ŖĢ‡Õž\ •ūŽéīCēy°šŁ!ĄėÉ» $I!Ņ)3wĢ`ģżd;+ž€7õˆ)†.æoŅ"§ćĖeu+”Œƒ’fk4~£É+™żUž÷ §Ć5.&{ŗł95GŹIź$QWtŲZdtW:*€§‚8ģs¦:—Z/é’E=5›3Īń™LL 9*Do·æÅģ=č9Õ+9®Ę%GHµīĶ²LJ\wwŗ‹Ņ4 ž«L/t ƎÅĪåjGš0ĀŲ˜TĖŃ„L{»OTčøCSŚ4•Ø¹Ā`$gwįŖY7"­ ’T±F®-¶Ąjŗ]y›:ż>;öÓ =¾-wŠ&ó8ģTŠÕ#“9\ķ89-ĮĖ–°ØŪNGm£JAÖó 1}‡čŲēųs„•Ń”ßŅ¼ īWÖ<ØŹ»©é™|I¹¦÷ųOTdUM?/óqkäÖĪĒk,ńUƇ4”׋ĘC†Ė%ńžµ»>c-ėĄ,sMO=ræųĄōŽ vņVÉ{h±ū`!R"’)Ž6§sŤwīwÓx”7$SéŪ^³æµ’ąvZF aę°-Ź¹^[äʞßSįx”£-³“©xóV"t nāYŗ=Ē `?7†$0xµvōģĪ;Ē ŁÓł¢½SU<ä^:ų¬Uń憎²ŌĘ"’|Ŗ„ĻŸćÄq'Q|õ±hk4zŪk]žåžS9‡“ŽzšMŁü¶iæ‹c`sS)§_'։oS&ęZTĆŗĀjāÕ®žó‚śŲ”ćķ/S&Hłd'jŲJ»v:eDå:ĖĘ°·ŪšžY=Ÿ@MŸĪhØwzQˆ‹š-hĆÖ°IF<әćoŽ§ō=Q¾¼łqGé±½q©µŪÓįĮjZßŗwŗ&Š¼OoÄ±Hƈȧx‹¶÷5™ĒŅnü€ģś„ ƒ±cyõHę‘ķ©)Ē’#‰źÖßć™Nń1čx(—S/‹<ŠeĶh3>McĒ#ŽG*mć»é—ƒNe]uéĘuĖ#l.½ōuś,M>Ļ!|śr*AX&5Ó©å1֖Ā©ó.„”ŽŌ©Š—b^$R‘¹FB¾ęTZS)ł|Źrb ·N_/9Õ©Sīel SGņ5†T½Ę°jO÷Õʖf+•ŗJõšSÅc0W£©ƒsˆēĀRn¦œZƒŠš<¤¢~ag¤„Ź”…bDĻ-§ cŠįŠž:…&Ęįłqź˜ŠŚ™²ŚSnįkĘÖĀV*QĆÓÖRˆz™Š:NøSŪ5¤:DEm:J;ĆyėĘ»”] É|²×ÖŅp3õõŌ¾³U×cb‹óą¹lTķj&ŚŠ%z÷’ŲZgė•&Lė֋…\Å*s…“.³)ŹÉ÷=\\Z5³ßĪ›ĶŽ^ę`z$j±Ž­±yJ³^»ģQØ×\6£LŸP‰\ė&—HµģŃ9lz·Zē ¬ėõó8j‹Ž/äś"WČī2{CTŌ)µæµŅl6Fõ:5ÓĆhGķe³W<:ˆšŪŽ:ģYįŅŖMoØĆ8ź0D½Æ÷Ė¹¾#ˆzĻīQQÆįØ]G«fóŪ0[Ōķéˆ%<6ėő…!7«Ģ‰š•=91æIćkČūŽĖՖ/Į€¤XȱŠ™LµņÕ *VĖ™z5—f±P¦ŹB¬b6ÓØ‚•b0X,¦³Åz®V­³Õ b±rł"+W*փåĖ<Ų( ®›ØkÕRwŌeT…Ø+ķس]QWėAQ›©¾u.UYŁ`^¬Ü½ejź…K]Č Ń9³Ģ-čöy“ę4ÖųĶ>½# 39GTäóG/°ćpZužśˆÆĒŹo¤Č~yč8×ęufE€ąśéĢ¼‹ķš>ƒ>R‘›š›Ź ū² Ī cŠ >ƒ>5Ų› jģC_-é©oÉtńgŠ›×StiŸķLķÕP.¢ŅŻ± BH;¦f£BļożX±DZ¹=ėÓoŠ]ÅŹćÖ½¢\XąXŖŖŪĮyš)Ą{jZ2*t™wüöćD+žAؑÉ7Š¹/Dµ›i\ģ“ ]ōĆ·Iµ}aĻjz/öē¾ƒ *‰.I1Vā½˜µ+ |›AŸ¢>yŒIįcčpžÅ±Vv“57’nżtAļŽĒŽ7 ³š>FBˆŖ N‰b^€;Ś½=D¹ ŗ†IK”ƒÓ8ƒ>RcŒ²%r±ģŁ‘ ÅlŹ)©mo]ŠbŻ5—ō1š@T—x ‡ŠŽlJD<<ŒW'5é‰SļīÓkģešzūtbÓåGķča{m—¢¢²bļ±_¤¬ģv1ĢĀŪƇ–Ł@®O–åVvu|TŽ€GŠW„;–Z¹b +iėTė;¹ģ€¤#-č¤O”#© ı6Õg"ųw,dĖš/_E5/8ĘėÕ‡”ģ“”ō>™¬_V (™ŽØ² —Ų÷L„oŽ‰}wō>Ļ”·U·Ż¼oy@ægÕµ”ŸÅjųO03īh ō4˜k§!^üó«VÕĻRå$H 3śžśŠ«Ķ Ó©œwĀØ“Ī]č鈞Ö6™6tŅ@|f)•‘mÄŪXv žéP‹Ņa“X„¼d’!y<°œāE„ņ`“¤Īµ[%$}µcDĖØB…ņĪįL?Zļ1ƒ><ō„ˆ=œķ1O/+Ø#^ÉĶ@.eF‰š±¢ģ¬YøbÕ2Čmńź(Ė4#Æ\]"f“čÓŖ]Vµøŗ£@ģƒ‚ÕWāqŃ+OqKÆŁW cĖĆÖ GŽł}}Č ƒ3N§ŗ÷ūŹ™37Š­»Ś#Šł,­ø ,f€“Dż”Bƒ¼"“Šeˆeēqģ¤ˆ@jķ¾ÉĀHčɊOĄo–ņ ŁE(ŅēŃYŸ>4Y7ōŠČÉ 4śŲŪ)›Ģć02„Śļ· N‚+AHĒd;(čl\ÓeŁöœyīDfuķ¹ą’՝Š°C#G©sj—ØŽJj¬uāv¢t^(”J¹Q/—‚d¦†Ŗ—ˆu†*( ŹY”†P¹z­œ­‘t•€³Ü (tļ½ŹVńDhęfjXŗ9<…įXZu4Ļ˜XfŠ§&Ż$Ż@æc÷īmžBü Ģ ÓĶį) Wg8Xī-Ü2÷]fAŸB˜t“”¾hž) ĻŽ¹£¦Ą®«G«éµƒUī½}:§½Ńņj[;ėIŹh3«*“|Oz²Ü–RŁĢFļtŽĻé7īWӕ)©Ź¹ÖĖč¾‚8¶“)Æ[ŸÜŌ©Ķ¬xc‡Z‘ĖG+mĒR=S=ƒ>LŚA¾>nRū@×ŗ`A­½ŪńĄ·ņ¼«ujĶķÕWŗÖgµ.‡kż  3č“IŠÄyXAŚ:Ū’ nFwöŠüņr…ˆ8 ń"¼ CD®ē1·Ø–1BŹ“Ü ėxžu¤ZFėę8ׁŒĒ§`ƒL¬£³Dċˆ#mŖ§»„ōaXŅ›Ž’e ü0ōz,šŹ+ń‹€   -EZ·…"dT ŁK%Ļ[«gĒjõµœ8Ć÷ŗģo]HéBZŽźˆS×g”²LEö1Vņę=5ē•ÓĖ÷Õ/}Aø`5u‰ZCÜ:( ”FĄ†™łŽęač>*”Ōhe'·£]Ÿ^1,jH34ļrÄŻ3†BU¾Y(gó‘^k2|_QķBėŠ¼‹”jQN ½¼$“äi Ø^nÖą•¹ūņsCÆē²µK’”kā{k"¶a7y_v“¶Ā¹ętāa„2*w€Øä|>ŸU+Ó6q½—³¤ė!—$}šw=āYēäµ²RÖ7HŽ±ŚS.šoB·2™œ4 ĢsHo5‰ßĆjAיŒ¢ †ĪŻ[ń±IÆÉńŹÜ/]Ī7Ś„‰ŠN„±c³™]zCŪłW§Ÿ˜ūŸcQŹāf®­„œšŸÓ™rīs#–ć½ĄŗVN}.ŗšó€Ķ\æÜ. ¼ķ‚²VŌ@:1Ņ@įȗ J“č2^t?啔` 5l€¾‰kŗ§‚”›Q‘K:Ģ™ s£Ä– ^9ą›~fč¹t”VOoÆzßī0øf³NĀŲ:Ł Kģ[·_ży7ķz$vČŌL!Ļ …V­v}x½lqs%"³(•z²K3¬F9GØ ÆŪˆ±¼ß”ĶĪ8z}z€”"!āėvöĄ(NČ,ēJūė {^B Ģ ėŠB~©P&øMŁOĮ'Ň 5āéŅ·E¦Ž‘T±%Õ GĮßkņųܛ÷B™oŌ®ļ3ü"Yj+ar¬fĖ,V6DF’^ ļ.»ĢīCW J4V|9ąåĶÉfŠéCĻärėQ±Ģ¹¬Tń›ŒœqF§Īķ9Å–Ś—ƒł\e;ü ²†?`ˆ˜*Ōåm6äéčuXŠ«X,^™5ļt™gÉÕC¦HUń SŚ1’’į†ī7ed÷o#ś?’ӑ“¹8ō!9Æ­9éK–ę¶h(Š‰Ęü,”÷”­Ū oA×@ĶŅ” ±®EŁY4kŽéAēÆ3ČŽŖ’%§`čŚóDš›“ŗ æøZ‚KÄ®Ēå»>XÉŗR|ķ厎—Č©£k)Åńņ³Į>”~%6‘čP€ķ+f5}0ō|M»Ćõć(xHՖy—īˆ.–(ŽÕķY=NMµs’$^ ™“ÄāšO@ąč15r'{o^#µG"œČPCw¾Ą[HŸ…E¾S^%Ļ[„+bū‹§•ėSė~ä"ĕE…4t!ŸÜfŌ)Ó vcĀ% ¶Īmźz †žŁ‹3p‹®}Ė4@™#Ž*\5qšŠ%»=ēį8!­Dę^Į?­®["ĻNÆåŅĮ%~²!¦:5;„ ŽĪ“_½²x½Ådźą0U½Ä,“‰lūĢ@`]%'ļ=C?`¢ ~qŸw>ŚGCµ «®Ž{ś:ü&–Ŷ„*Ų}1›÷®¾g²0éĘ>•Šs«2‰q Č;3!É¤K,|&ÓĻż/@Ļé½ąž”į©… ˜¦Ēe¶lnįš¾Ӟ : ¤0šĢœ-›-KĆӆ›Fč¹øž¶.eT/¬—Įʊµi(¦Ö0Š·*„ÄŁ(ż€Ģżß’ó?’ó?ØꣁmŠU]ęń˜ % ×†l4l5ļƒ ‘œ«-UĢĶĮÜŌÉBO‡t„­å‹° ĎpŽ pLf…±,—Ś`ßž8å’/&žpó.Ž%Īć,5öö@ʶɧś}%FĖńĒeXćõ󞚹q&z“ø¦śŠ¬£ż” ĄŲ!¢AĘ]¾½’  Æ>³œćģ/©*ž?’āżæ’óæHČŁeæ@LŲ&ŠęŲ¾•“ ŌązČŅ«]=}A›Šhi:©ŻČwMō·s{ŽyRĮBüRŸ&a±P¾Ģį"UŒrßø0¾šžŪÄ!Ś’ÅčI“•ĄFbÓ +?Ģ£ ć*q©^ÕĄURc€ž=ńt;¢qć™>č—Ü®YNäj÷5¬i8\Nŵ.²Üš!ƒš:®ćM” C^/C,A®Ø[}7Ž˜ĒōAÆčŗ-~U®+QYŖŻ łlˆa ēŲ‡FŽ4‰’oWČqA?¦ĢźlģœlŹdś —»Ę¼%T‹ĘœČŗ‡\Š€C“¤5–Ā®e+¬ *d+uX&d²:õŖŅ½ˆĆõ1Aē‹š©r°MĪtÉōAG,Vz¶$Żs2õhsycāņq? 3*ŠsŅ835»/1%E#Gg:š‡QEį1™N° Łw×ńq’9cW –³PĄNɐcCśƒ„ķŹz ”£ Ńm“XšØPĢūµĒØĮė@,v¼2„ņhŪDgžnrej7ŅCSū"©DkŲE{Ł’C³B7Ž‡Xcæ-5r™åf=6*J0š‘ū`ē‡J„ŻJą4BG¤_ÜŽ‹4ĖJT ,Ļ”%>rģĀ0o…Ė8\ĻŅ©˜&WÉÄA=®v~bō,-§oķČ­Wķćč<®¦²Ē†bŁ–KW,‰ūćWŁšĖTBGz2IŪ8˜Ė‰ Nnŗé01ŲÓīÆG»,P! śŪ$Św9x'tl¢n¢’]@!;”TbFGóyę¶øażńŠ§Ü0²@)ÄRZ•¹/€žB Źt =² Š*v)ŅŲļįģ`q0 ņąłŽL¬ķ4ČØö Wxl:ƒ>0#3å8Wv°>¤żÄŻhM.܁7”ĖĄ#ŽŁ[ƒ–#ÄÖ L0ļ²éūŽĶ,Ä×ŲÕŻņ”Qć†uN–Wˆc.—)}ŒęĶäĮ­Ż*Q'lżJ{I$ģ¹Õ«WšĪEōJÄ«Yöū¹¼‡u3čt cć’„ÓlKØ«£-“Ö#Ō™ŗ#‰,¢Ė”ģUĄ .e÷pŖŽŗ™ĪFĒ2åD¤Ū ōF¶ 7Xõ< Ā±²ō² J~»Q_ź6ŗ® v[Ų~Ņ”÷é·’NW“ÅéɲIMgŽÖ“éuĘJ>“Īfa ū>²Ł:•ŪƼōņü| ōŖźõńšˆŽDéžŗ·tGQCĮ.­IDŗ*Ń*£p†qÜŻåI;“ŽéŁ@§ŽcA½p3ü§Qķ=C„Ākw| z;Øéę!æܦ9żī=X ”8µ–PŃQ ·›÷˜Ś”-p&KMSTqiī“ė0š€,¬Ąo ¤Ä†š8ŌĶÕ`¢ó‹;…`Z”Wj$!š”¦ӝ2‹°˜Łf…ū0ņśxĖbÓłŲ©Š¶šø=›å»ņ œTńį–NYÓ]—ķ ½0gT)-)¶lė•·ZiZB”6tį®Õ׊héUtÉ !øwåäJt6ā%Å VŖtóŃR<°xĄYŅ˜BBāe‡ ZQ{QP d‘R¶TŸrbAO¦ś…œ—H°-ćCĢ1ƒ€cŲŻ˜÷“Jõ> ŠnIÄśšµõɲ;Šó¤q=qļ§RŠĆš¶q„/79æ½ŚCEW% ŹĖ²ŪK’ŖÉÅ ‡ź¾um*w (ŠeŪā)C/”&O1`8Ž˜ćØŌ– ŒYį˜PD„LnääęĢ¶ ‘©čxo%rŹ §ƒ«^§īĪb'±åd+„pł»WyµZ/ōsČ+¾ņӇÓ’/R£B¹Jf‰Ó4=~ĘŚŪ#•C^~üŗ}Wåņ¦Ćāu”9†>"Ó uU¶^„ ®žYlŁĶH 6;HÆf¼F„¹ŒšK ;€Œ”£“!Ģm§ zVųF’°„rĻjK&ÅQa0čP®’.lL·„ó¼m•P~Q.ߣżD®tzŻ܅Ņ™\®ŃnĒī7[L‰˜­Hķ¬vT+Ņƒ÷Võ,a7Šsf,•^ŲõˆÅäŲ¹p0„īŌ }s…½‡ žpÄhŃ%—£Öt¬jŠ«Å; ‡D®Uē± ¾³|KŒe”°å,CĢh§ z.2Śž³˜Ļ”CUו^X&¬ZS"äÜZc2©SFŹy»¼¬Üęi…DA åfPū^X$ˆUXKD"GĢDĄ8—kŪ«Uä#•DøÜĪÓ£ø·‘zÉE. ń1§€D8ĄE®bˆP‘Ķ·øzƁ ĆZ°ŽqÄį“&ä²"©)ą(<(9B!É<ĶYU '=Ē:w“åL© »å^ķČƞ+ßvœ€ŌäóJJ¶#Nƒ!ÉŲąĻS€7·%w .}·°e©”„ak^4sm6ÉÖÉÖq8x”Z ’$³9¾luĎįŽm·ŠYb˜‰‘lEÄā¾pK3¶-o©}œµ2)‹ĘM(•B ™QĘcj«¾­°KH}8+ˆ d3 "օ(ńf‰·PÄ8ČKdg2&ż2*¶‰‡.lļ]dŠäUR¦Pčt:±Ų/†?šßÖü~ļ™˜A¤ø+ŽŁ$T};Eśō1I‡FŽj’Iaš¬P3Āą ø€u/ ("ņź"‚©^^ŗ\‚ę…†?ć妼¾6ü+Ŗ-TØ (]x¶@Gź'](NI‡ä„G®čPłČsåŌöŹ]W¬™»#%į‘Y9`ŗ5§ø=»%śo˜č]Jž‹6M„œČBŃjękYx%+]%ęą¾F}ttn¾=‰–f É0F¦N÷ź4ęéió• ÷Ä\(\Rvŗ‘ɤ`ˆQs3#ž ōŒZĜKŌØī„ õ„|_e.Ö6óČīönœ˜īhs¶–•MąT° Ņ<ö˜ÖÜ+4 ēŲŽŽ/Ųż īz@75ŌŠTéŻfÄsŽŠK®”sńŃ„“ź‡Źŗ$^ur֐œ 9.Ōß1żW+†ZGhēHֱŒ{ŅuL­<<:ņŽxčYNEč¤ē$xI0č÷Ģēō"ļµÅ©{ŠÓcRĄö;#amē@ń±ŠŃQ_/éĆAµÖCz¾Ż³iŽI—(œJ2”=3PöŪ;Ā ƒ;5 e0ØÜķ²ź&`××£%—Åk.RÆ7bi‹{Yi² …ÄeķŽźå£”ƒŁåøj:!ź7x>Š='9H†aV Äŗi“ŹTlÖō•nOÄXwŅ*>“†®»7Š{p —ß×v½Į ō†tc^Ž{9=żbˆsöā½Ż‘>œm4ēé¤g'XģŌaAŽv &v}Ad¶at”ÓuE?č4 i‘ī4ačć=:B×*śšy“” åŅŠ¤—{Į­Łče@ś,Āƒōw£¢ ½ČŁJ¬ISi|ŌBbf*Į­d>0ęX©ŗŚŪ»ŠY*žZ­ŚHc·n„½‰Ž‹S”šŠ ¬dIŸe±†*·„u[ ņęŚHŸ)Bż›÷)yzܬ÷“6t6ŒP·F¼µĪõk-Ūn $nģ)øfQMĶźš‘n>ŖFé­уž3ŹœŹW'Ųr?āĘŁJXšĮ@ ģqĶq6Ü9Lų.ō¬bwE»aĀŠŃĪ¢0ŌŽa1ӁA›ŠĻvĢ0ƒ ™Ž$L:æCņā±É~BĶ9žzęųA÷žĶ—hA÷RžÉ‚¹¹-±p5¾œ@fIĆŌ %OĮ–‹M"ŖXÜéRåM§›¤Æv¤(|P(_+6P1pó fŃŖ5DŚĄ Ē›÷ zŠÓU’\¼`ó «“‚’Ä… œ+ĀoyĶēŻkŽŻøŗZÅNĢ”"F†Öb z›yś¢G€ĒŒs“ź’h‡ć „4a’O]Ø`ĖтĪhé`d;åFīĀ¹Ė«5Ģå8q%Ż¶Ģ[61榛ēX4®-R`j%ä¦olpsV£ftt„ND`D‘Żä ¹Œ„öŁ#ģ‹ˆ™Ž!=č7yžöŅ²Äŗ} IūQ{ēąÄŲ± ®éŪĮƒ˜Ś °2ņčš3d2˜i²P…ņę÷5=-t@V ŗe·Å.7æĀĒ“ SR„‚~]Ž„œčŲ†T"įŃIéķHi&]gČ ³[*F"t8åT\ŠGų°\½"ŖŠö€^ߙ»öz ZŻīĶ5Ļ į°95)¹»5ō†ģ*^źĖāÉN@;hØ3ükĄ6ŹrĘȝ‡*A¤ąQqw `!œ‰[Ø~Tč9f ‘zā"maż“9…Ž= ›ü÷ÖīæĖpŠ‹ėćŸß>QóŽńźtN·…:·īØĪgaåQ ’¹¼øĄU2X‡ƒõØG…žĘؑąj“ś2ėÜīCÆāóq ĢŖŅōJżĄōB"0µ¦d¼ž(~Ą‚ ŲK ܀šŲr¦Æ6D¼ŁU—ēŽ$ei,Mā9ą=čAf„ŽTĢ¼Y5l}€QóŽÅ»Ę÷t:? ōüś@ƒŠLDĘ|pæ[Ż{ž€ r9sÆ:ÕMĢļā®ūōUšsG•‰ęŽ»[ĮĘE·"_QuĖŠji!|d¼su‚_Ūę"Ļæ¦lVčö“7d¾#>ßCm\öįfü.ō¼¢ei[ćĻuĖ@Æg„×¾”ķHū¾?EóžŲLč=wĻ>~0ŹõTŽ½ŒĒk-čķqVŠÄ„©ŗŗ—Ņ3?œāōŲōp’¬¦÷Īrcūgx"/¤–åĀ؛š@7” ŚŠ—K6ŻmĻ÷š0[~§FąöØ[fŠ†ž*UŲ-åtŁ U  Ź‚±’qĀFAOŗC!j™;ź€%-N†Ł–4ācīŻ6ƒ>œEĆ|»‹K„Zße;4Ā6MjQ¢_BfŠ‡ƒ‡“µ©ė±!UCÖvø:n*pĮoˆ?@fŠAæ»Ū×²Ķ‡Ć]@”’n41æ5j“Ż½ė© ŠÕ>nĮä7ÖsÄę …fŗR<»ćŗ‚{Ū.©ŹYØŖĪ#ćąĶG óvļjŪ¶ØŖŽthB˜›‹0£HšMY ży*čE·@ś°Æn®§żź[‚AQą ÜwVėTŠ‚:KKĄ FLNé)s©¾Ņŗ4yµqēöf·~JĶÓŽ>bšĶćµHp6‹+NŃą%Į:bŠZŠČĢD ²!'±ači銜‘„×č¼2śÜ¼Ą"čērĢØo£{jčŅ«ē¼ Ž ,bŲøH©Ļc—ÜR_#ķ{–õĮ<±2żFUķĄhÖ-nzį2v)ėę6tA,&e€l ŗĢ‚ä°ÜMbč²vóŽLäg ‡ĻŻ’;= ÓūBĻČFß{Ż—Łāš®įT=1ō•E“×^[;²)č™ vĒ5”WZŠsŗmĘßHÕ,X$Ļ(ɇ›5}ŽČi4vÆ2‹OĀœ[$0ō ś\očg§Š3—{š:ō…®” +Ē/91sŠ,eü½‰qĢŠ×“o?N’…œ÷-žWew_ĶŃÆ 9ŽZŲ3ĆŠ#/ē2/H CN°d§Zŗ‚Ž§ wł2YU4GO±ŹĖ·(‚Ņ¤ŪY vÕą[-»$p€S½PMįAē»*0T™dd߽܎¬īōœ“÷…n¢Ś–ń‹C0śüžń©/t~ź!Ć®ģ2ūõ¶Ņß“*8eæ±łU fE9tŪ. õ…"š>Rœkd²›‘U» ‡®ĀjvsD•S™Ż<ž›Ś[§ /ZiįĄó°V¶Ļlśł*¶Č\÷eŠY˜‡n'µ āžōsJPŃŚŲ34††¾wZ†Žh“Ę =Ļ}h#‹•ƒfŗ„žÉłlµœmŌ‚N"©ŽbU²—õ2«XŖTXe Ž9ĻfØ~Ń­ĶĮĘĄ „³|ćŒl·ŗĮ¹:ČR¹¹Ü ³ ~­žIK¬2üßhŌÉr½R,Ż æ÷V³Śi®BĻdÖCLŠ—f/t¤² Ņ¢v„‹å’„ķ¦Iģ`¦łś`ų>$A c"s鬁Ö&SŚļ0lĄ1CÆĖ†ńU ŗėĆŌÉeŽõ9³¤hs9l~Sįß²šõ/Ż›Ę iĢ£/5ŅMóĆUżż Yē'3v?ćŒĶßģhY1nčČŖ·h~ąldØ\ؼPDśŌ¹‚æć0”"ī8ĆÕŽļÉķ˜Ę-l‰uć³ÕīˆédgĖ²3Ī˜% 1ƟZŒ€-£5Ģ,¬Œ:X½½=žćƒyJ…3.5­kyŅõńÄĪó²°G%:Ż@¢O“2ŲąśceŠ'ōBu [!1]<]×qé’n2Č-gbčęüóŽrÄ Sęc/oÖrOŅ' pD7‹»Ćå<]jĘŃ"yä]Ļ:¼i9L š k>~™kPĘ ©ŻŠc—xłŃņ¼ S¹%—2üfŁ²šÖ†#ēoŚ xć¼ ųĆåBĒGœ(|ś-ée~"3LÅ;™%‘ˆčé%®g z›%W$“D¬Ł‰h·ų‚;žģĒS=…œ„ńDōØXž/t0{c9,Ÿžė•œm;tu°gļó“”mbMÓļųœ”ĆkęŅŽm†K ³šˆÖ"ÜļžpŠ’Ó•KDw"YåLfÕnČ“>sčŌŪ Ā¬8ŲxŠ.ŻĢ‰ąc Ę/öŃų#!ʟ:¼6‹”Ÿˆ=nBČzxKķģŁćŒķ0¶®g®ū†uÖM;ÉCüI Sļ¼`t‹Ģb‰IżČ6ōx°›”ņøøźnŻy¤‡Š¹ég‚ļ{Fš~½>%]mžP8‚4œžÉŲH”=ödU “_ö'ƒļ]h^·Ž§·ĖÉōŠm}I+SŒģY¢®WųźZ;}?tźĶJBS&RŲvxņ!ŽšFyĀé±LŖ:īė&±hG»zwüI”ć_>—ī1Ų># ,× ƒgņĮŒ5ā‘9&„Õ'8Y“›Aæ“A8eSµ#Ó»k&«0×gNWY4é|";Ś£ä3Źė(ÆdS!?oMæĶŽ|ya#ī—čD eO)ģ1[4Fu.Ż©jR-;¤ee2f8#¢_:•1Ł,y¦ōZüzG —1,Æq,PŠisł|ā„4;ōØoˆĻ{į¾`ˆēŠ śĖ@æÉ !]>Üq6wEŚlŒ“čśäWA¼¾ÉlŠ£łn _śHŁōŲ›j¾ń{o=M3č£ēż;ƒų“€©‘ō§@A&£Ģ1ķ3č#fÜP·9#ź„‡z ķĄ3č“³jō€FuNķŌČ śäQ¤–©Ŗčcv?2ł |ŽOŲöe§+Ł³š>q5OxāĻī3čĆå×”_y~üö†īdĻ €qØ[ų¾>n†ŠilgŠĒ–•½#ŹȦ­¢ĻrfŽĪ§gżęUg5}ĀŌż©)ŲĒtēgŠ' }i:¶7Ģr“ÅÜ{Łüćw£ßŻYMŸhz¦c{CļšžÜń)ī„B:](3„<Ź”rØT¢¾¦K”†K„R&˜/„ƒ„BžG…R.˜ƒÆ…RAØ\!_s8ü”†›Ņ\ŗuAØ>QgpŌu¢ĘńtFŻŗŌŠ: OėH5N^GŌ8ŽŽTOdkæBSęLĮnō‡kŗ…»LøżR„«Z±q^ŪÖĪüƝ6„šĖUIm "dŪ!Nl!aŠ+5Ś$ ó\ēbŌvøøeŪBC² “1…QŪĮą¾Š8m7„QŚœD+j55C²1ł‡õ)µqĆĘøŁˆ-ˆšĮåYmM€»FDmu\Īåjy ‰ÜksCŌµÉ‘²9“µ’hį&äL?OĶ•Ø“uŌvBXüį©mG=ļ_#"¶Čʼn-QŪžŌD|Kō”žܚO”“›w.œ²ą÷-«ŁzŽ¶GÆ>r)>&”š$Œ.×ŗ×ŖŸxü|‰Ļ"¹V—Žp‰„nŸDČuķ,°]¼m³Ž‘šéäWČv…2ĻĻe^{dBæĖiTų–lżö¶Ē,?qéä6ˆZęI8\zkÜĆ^XóŲų\ˆŚģ2Ł=śĶˆ^“čö1 źČ’KÆ °õʐO'“xB¶>jy6¤³:įQ~ż¾Cį‹BŌė<yĮķ/Ų<'g"_G I\XÓKl®ˆ\fNō:)>“<Ų”'€QäXŸą)Ć?¢ ½-ĖŁ|°–Ķ¤ĮQo.[ĄR°œĶ³Łt&[ ę³eT¢BeŅ7—JĮ¾©‘IײéŖqäØx²5ø± ! šk3źf<ér3źV<éB+jźįŁtž Ռ:›Ķä²YHO;ź|.įØ!‰8=é2ų‚K™Z™ŠÜ ēo€ÖĖ„Śjߎ&‡C"Ņ»\.$ZÖ®¬Ŗ‰ó‹sV¶QÆ׳0„ žžh/”‡Ÿr Wåó…*­żU”ĖÕs ÉŪƒ2»?% >(2± Ī®ws-ūūū;ŃčÓ:OµHąć+rĮD6Łįńé%†<4•bMµÉ‹/[¶H'‘ vww“­³‚~s=¦H·ÕVķŠ)ˆGNvœ\‰˜ĶÖ1N•<‡Åj”sĆėRƒ¶ƒQŽę īyÖ5=ßą/­H7ö#ī”„+“„ÜGaļŖ&CD\tq·¹Ēv¹ö–Ł;t÷¹r¹œ jm8¾åęŹt\ĘŚsĆ»ī‡8mgó#OočWvž+t–bŠÅ 'sēų8±±)/¶¹ävą¬¼$ę{茞Ņ™q=œˆl1S6]źČ“Ikū±§7üLŠ+,¾v#āéÅīč¼Q³x–½óvŎ³®‡EßyÖbMŁ[wmmĖ°ųr”*O7‹·¢<‚_ī·#6 ŸäŽ™GuĻئ—³«Ž·6gŠ›Z^ŲElhXŅįc·ūJƒ)ŲoČO=0åjؽ[)IŠ)ym> rcq&s@Ą£h·n~ŠAūĘŚ8Ėœ'Ƥ›|‹†ķĪ; 'oGŪ^®ÅdæŻÅYbŻ”Xó‹R ^ŗŠī\n˜ÉĘ0žįq<čü…76s*°:× ±JYHL½óą^³”Ģł1ˆ\‰uÉ;‹R–M²ė` łTx |¦ót”uK‘r'e~ĒėIŁ#µšIq§ļ}Ō†“ŠīVÓŖtē”!~}ė«&ļL=…ŹoĖ`škz®źµ°ć°īįjF7gøźKŗŽ»š32“hP9$4—LņBŽYRĮŚČĀ4.£ß‘é…ĪR3¶šØńĒ\½ł¤€ķ Üė»yp„#†~©ā0©œĘ"ć†ė0j7GhōD#ÖÓĒß6„ŠƒAWq“ōØ&² “Nl ×īUOų±˜@ÆKELÖóž+a‡f{^*Š\šo¶ŖRk‰óęhķŹFJ™Sš‡qoōxŠCĘ0ŠsZæČt6ä«ō L—‹gü•õłåČэDėŪ›pŠc³)~@„Ž„ņßBpķó½…U܎9Ņj‹h7>Ž“O,Ž©„~¶£ˆßę"””×_Ų\#…P‡•Z8–óIä‚}Sӏ>UČķRĶ)6oˆ‘ē“¼HēC¦zÕæÖ1×īk–%čŒ-Ā˜×TpG»bBēšß t­“/QŠĖÕ"Iņė9>Y½$łm²rŪ.Ān6Mq§>…ŠėÜNu(ĒQż$ˆ$1|“ćVl1Š*ó"OS?„«ņ6= ś™DfņžD„ī2ī F[év:"ĢO“ĄQž2…ŠM’®ITˆņ!±!µÓ£e ęį÷ŚÓ{āk6ļLŒźŌ,$ZCēķ•—ūŠ‘C4!o££P¾sĻōAĻŹŗ]uTŁ1'JFy )=V©A>†÷ī…*ō Dq} ^Ș·qō€Ž¦Č‡ŲPŠÕv+æQnu°$Į'‚Ņ‹|bń²5ōŹł* \¤ä®½ÉŪ¤,?"¹ –…äX× “V6i<éN®ķ(Ņ[ŽS:Š±¶ ūÖ„):Š9ØuųןqGæš^ˆœµŒå“²¹ÖŌ8b+µ)dā÷>5Ż! rĮH";—āś6`‚7å`YōdŪ‰~•ófĢŠ ©TĒBeśˆéĘ±¶TR¤•½Īe,ā­„vü3" =·²Vzߒ¦@ų7tćšÆŗ kA;,rB–°µŗU?½Ė鿶*ļģR–\©›Ūm_ T¬8Ué·\7Ř;tTsŠoėq:})$r({ĘĢAV„ ‚TćgŽØš.4˜Hņķf”o2ljŽ³­źt “±ć5°x\dūa!HæA#pz!Ğ:O-CŸš¾–l‡ć7…<15“¦ Ÿ96įĖÅų”£ükóĮÄ|p?Ų,RŠ‹øy«•³ČöĖõvŃŗ…›$š~ (T`0Gõéhn}– ßøūtüØ`Ęøf>‘>)w :kwž‹gŲ“  u'ū`č| }!ĄUģ5¦YńļÖoŹ¶#—Ś^C„‰s C—āŁŅß,‘œqŽŪ%R²‰÷;­Y[•ÜÓ¼“xĄŅ‚NHń]ÖōV”­2!ę2TÓjķN«¦£|ŌeŪ @eŲʟæfŽ¾Śó[QštŠ¶Ūl›9©¹I¾¶ņĖ"›Cģ0xDĮhA‡Ö+ -š¶yƒŪ|=bŪVö^‚›+jL°Ęą?Ńźß#Žsą¶&Ųć÷J;ƗģBo~ŗiĄ2#€F/ŻšøMqz`’O¾ÅÄŠƒÖdÄØŚš”nķÉ5õ¢jŗ•éī!–“ƒ#†^擒YVž~=€^Ž EG÷n—Žy&>\RssÖŠCįŒ/Ō&š =£~Ķ³jću”³†4š“°T¼ß†Ž;Õé…ƒĖ“xå7Žpo÷#BӀ^įß3źžtJkłź,[Ė)’ä¹PØMøu~Kˆē ²zz·FŁ0§jśI“źuoĦ·Eķ‹õ©ō=š`>р>”<ī­üĀžźą¶’»ōzįF+Ō•bń¬”Hm¹ ®B&“ø™[!p'²Į“J„ł%!’Vę#,Ą/rĶŗrcC+é8¤éõ".÷t'†łrāüņ2›æ?RĖ)WkĻ8$yŠńåa$į”–·é›Bš¬·‰¶Ü<ķéÄ:8mŃĒIb¹--Ō×–Ä ŗ„ÓĘqģģģ„°źeua‘Žb‰’żD֙ć.Zc‡NŗĶĖŽ4W=/Æū‡oŁoļxĆ{čYp¬fąÕ«Wa–›@/ØÆMń¾Ś;F¶Ą©'W§Xį7įń:©;v2e}ŠżÓąŅĄöaŻYÖźG·ŸēŁ“‰§Q»ŒzM2B‹ćˆĀ~“ŃĮī·¤s9Æ%ŖhÓĖfÕćf ćFI?¾1C_±ŃōmČ³£!·Se$ę ŒaŽ>/źÓXœ)’ĮY$5ßQTÖĻžK!/ō—Z‰^‚*§~˜ń\L ŚĻ$¹ŌĒ!t=½;€œ[tHĪĘyt»3|ʍtĒx”óS£/4ååŹģ+$1ƒ^²¼NŒ­V÷;ļ8Ļ½ā°yŁY«qu·uīՕė™čdĒ XՉ@3[Ó„ā¹6ä‹Ķ¬vßmĻ­šG$¶mÅU$käwĻj±Ü÷k”XvI°²ēŽˆ»÷°žQ>O|K#Õ¼§¾iĢŠcŪĄEžóē4ö–|žÅ<öR™Żz°ˆņB1;|—ŗPße¹yŁņ^ēy-üÓAŸÖՉžŠ©rĮŠ{lŻżVŚyÜY=«¢v§ō,Zų C'_¬;VēĮ“N.åIM½śĘ§nŚī=t°rēŗBMĶ¹«³J7Ūö¦pĘ3¾œh¶L:ß'<æ@ė:ßźŪœč«Œ9-č(£4Ū:fō°{¾²Ė3é3hį' ± o²EvĀ²=•;}čAGR"XnWvŅÜ9b+kU­ŗnX”«»œŽX'{Ū¤”ėPi …w±¹Q¶śMŸŠ„ŽP]åiwääö#KŃlÜ Ó÷~=R4ičlŻüį:2LewNcōŽ•eÄĀCL+­‘Ü :Ī!żVšLB7;¤¦Æ&Š®éż’ĪšAļČ=^€™ÓĀšOįqKb*/c>«étŹ>fŌ&PD $ŽÓļD„QPfŠidRæ Ä]œ|ėŲkŚ9-»–xœŠö‘I{šöōGęģ=菌ļ)nŸAd.’|Š+DsĶ>C,a·M-MhąMK—&›ŽxŠ¬OdÉyāŪī¬‹w?žē9 ÖK JNDŗq¢Ŗ)C‚€4EķœĻuŠōēXÓÄop—üW1Ć!VÄQn—Ē†B$¤Ö_Ņ—"pc9«éc[Z}²ś~Ä^K=( ŃUL`ĮSM+@ĻQsĪõ]ŠŃ“4rŗt4¦š¤µēņrłƒŅˆŚdDK‚ižPwbék9ƒ¤œ­f’mģ ķ”w-†Žģ°vVÓĒQÓ3Žµ½½ķ v"ńų²jū8`YŽ‹ŠQü”•ū{ńDtńķė7īx¤eĪ×ōN­#õ¬‚ˆć„{§ ——ŌjhõgŠ”ĻåŒŻP ŗ¬z–øWKĆräK ×“ŒóV0Ś«H*Č.…›Ö¬4§lV•)M]ĶIāÓöfŠĒ]e(" »ĘZŌ –{³‚ÕY’\)!¹D"¾µå!@qč8Dč™Ū3.åRŹH'S½Ü¼@yrq åÕź¦ŻŽƒ-Q)_@J •›}M耶 `æ‚”g7W¬ŠøĢ :«äįŖ’”:ŗ”§|/F9—¢Äš0¼ŅˆTÖöĪ"{Ģ =K§?Āōég4öĪ =K§?Āōég4öĪ =K§?Āōég4öž.éø>AküIEND®B`‚Į3DdąąmBšh² š S šDAĮ’Ćart-minaiFigure 6š€bš3`.lքŖ„7ŌÄĢ4pŅ¦£’į2ļżnšŁ2`.lքŖ„7ŌÄĢ4pŅ¦£’‰PNG  IHDR:ęōv€PLTEh†¤\Ln¼µćsf»+JwśTK5$™›1cŃĖG“§Ū’’)†ž¶Ū×ōŗŚō„’’0Di„yÄÄčūÉĀź‚M=¦±ŹŪwrĄhZ“čåüGuQAص®PyعĖ“‰Ķ‘„\‚É„›ÖZJ¬§Įē²©ŻĀ¼ēXX²Ŗ¢Ł’’’- śüZ‰™Ó Šˆž•ÓļKéę?GB§E4¢wje ŒĄĶŁÕĻń0YƒŹļž@/xįŻ÷óń’ōń;µįæāųŽēwĆ{‘ĻŹīSRÆÕFT;3ŸØŸUON®’\DŒB<¤=,ˆ®Ėģ#Ž„žż8īź’÷õ: ƒ~‹Ģļģ<ŻŁBłö’’Ģ ‡Ļö’G6£be¹ōń6‰P@§§¤m³ŃšžbA™Ļ¾>Z„_Q°’fąęģŠŁćšóöĻŁāßåģļņõ·°ąŃēŗgYr`œLJ«O>¦¾Ļ®E4®J8¤K;„œ’YĀąįūų8’M>3f‡Ķ :bKGDˆH cmPPJCmp0712Hs¼0ŽIDATx^ķ‹_É—č…®™N,EŹķFl„ü˜`‹Gwq’Œ”ķŃјMōGÖ”GVó`ļ&÷Ŗ;מ×÷T7((n-š®Ļ ķēłÖ9õ:ēŌŠ„]JCŚÓø¾Ä–éæ•ō'śØgż!Fr¹‹M]^®|Õ¹TŠĖb}ØYŽĮO®™A²¼b½x¬æcČPl,֐d“ej|ŠjȊ.żųż¼œŖż%ü֚Ēž1ōµ d*öõråó8āZžł:5ōÉ5ó96>ćrø.W¾ø\Ė+SĖ.××hYfff¾¬ĄŃ3®“ńĖ©å/Ė_]ę‘[Jreœ~ąńqś”’ņrejÜ5u9®=ܐö9īZ”ÕĆ5¤Õ•!8vjȇÆL Ń/š­Ŗ?ć.zķūŌų |™¢ēܛRr Ņ¢@€ĘTl†VĒå˜ ŌfČ5õ žuy~ēŠĮpĪņ—ĖĻš7×שĻ3ĖĖ®1Oä‹ ®4WĘėäär%6s šĖŚ¤}:9ł“|śięrüäĖ `Ÿ‰Ębćšx§Ÿ¦¦Nc``§¾~Y†§]žōéD{®ÓŲgMīC±ÓOššżōr<öé46srJŪĒūR®€€Ķ:‚7¹¦NæR1Į»¹bŸ”jūŒkŹ555CĄŸ\š'P@öyüóų—ń˜é÷Y¾<…[ÅV> ­@bčd<6åśzzyJŁ.ŸŠJq9ōéņTvłt *ĮPlÜõiźŅ5>ąš_ž‚_A„™ŗ<]¦§’C¦ć§ššŽÓ*1żˆwrĀ•Ų—ĻP„–”]ŸšZ¦†÷™‰Å€IÅzĻœŖ$Č×ŲĢ8—küėēåĖ/¦~<J±Ńg¦ēÓćįO“žøč„Ģ+°é÷éÕ W@` 2Dh(¦¾Ņ÷Š!&šżŗ\›¢›,MCf“·œZM™2Æ!—`KĘc3PŸ?Ķøf–į~3€ćÓ µXµ@ūTõ n·„‡¬€žøĘįi(:קńC!Z‰h³C’ōž”‚ T¦–”Ņ•ŠŃźu Æ ²k_>ĒVfØi€†ę+­3S'.×å ­§f % ķZÆŲ'Ź’½%māÆ5„ÆĻ`’“gę “73ōŁąŽ'—Š˜€EŸ:™ū6µB+µtS€>)¤{«!®/®©°X3±/®Ó×é Ų…”°ńŸgĘ”ĮśźZ^åó25`ĖC®ÆŠĖśā_‚N] ³84CM2…(@Tk5č/”©¾2YĄ?vB[ hČAō±Ų'P„Ʊ“ńńƟąWSĖŸb±SØIŠęė¶iŽŃ?”GpoŌ‰sEWčcŽźŠƒvN”g oM<ü @æS[¦’ÓÆ¢z*C}Ģ£Ńn»¼\]=ĊžT}}Ø~½,ŌSӗÖõ)T—T1 dŗŗTłōać*ķ}ī=š”’“Ė@IĄ2P8žó?‡T» ”l …CUm 6“Ą€=Ž­!6“Ą€=Ns Į“ėOųFæT>ģ=Ģć4Bd¤Ŗ…RT‚OśŹ‰„ŖĘį»ōMĶ€`!Å$ļ ēĀFŹ^NQU…Ūūéé’ŲŪÓąŲ„/h³ŁX+Ī€pž•ƒI!åf‰ŖüĖ?F üćH_ž(•@3 ‘¤b”Č¹Ņ„Ȥ"yKDŻüב1(#’Ŗ»ōZU«Ó“ QQĀ¦óXČyŅ)‚½Ī:U¬*’w‘‘ķķ‘}GaÓnƒ{(Ņń—0ĘL8‰ˆŖŖŹŚżclū’õ?’yģŲŒ÷š~ōK¢y`+>%ų„a!bŃ’ło“0ŗ—y52¶˜±‡ˆ=«GF€č7Ó{c•>ĘJźœĆ{M[KzĆÄ8÷#©ļXÅ{•øcqlģ"³™čĶżąWéHįé‰;lĻķŚJŅƒŹŌ‹k£ß”D\rģQ$¶–tĖ¤K *aē·`rKMėžü±“«® ¶KGčˆJņė[2mź7wÉž“īńųŒ]ĢK k *ł¶>¬Il>™Ūw$–žżņĖ"ŖōĒĢ?Ņ}F÷@09œŲ“4ń'»c#oµY•żŻ[°¾}÷@`5‘ū°§-šRĆĆ}žk®Į>±iźŪź,ķ½8¬Z(é@ĄvĮh1Æmßć»KsÉn]Z1éčüO|«,&2 °Z2öĖāÅRfww:a€&īŲ¦ čd˜]šI '@Ąb~ōe•Č/“µt±ø’v{ldd{znɑAmedŃī·Ø½ƑѭJĶO8ĘčŌüb|ss32Ž„¹éżæa~ģ­¾ˆ26–±'ģ›é•¼]Ó:æą”YÜß_ŅšŠ‰Ē7扯ŻLĘ17M -ÓčĮą±®1¹ł]÷ś‚y’Ŗ ˜öķjvóĮŚ¼^QńĀśÓ‚N„JŗNŚTŲ‰D|NóŒŠĢÖ‹K™ĢnbZ]“q e¤ŗÉ0Āę%,#„€3Ęl>ņ0øÅj÷įa2é•ĪÅėµ¹I‰gØ-ƒŠcéÕž6Ų°gÆ e”=į4BÆŽn/:jˆ(|ŁéQ=įh9(ؤä,”R“ˆ ž>āģčüNp-koœ¶.#ūh\Ą†ųśĒžō’cwswŒ]ĮR$%;ĻPžĶ…–Će'–<„VĖré†'^·$rüĘ!Ś,=ķ«ŅnfiZkéßīėÖģ­zÕ®(Į '‡ˆĄ ÷†‹QĪ­rŃ([TŖCŠJ„‡@T,Æ­?o]õōĄeSv,MļWŚ–ķLÕhap#y"FXŹŲ/Š1)~öaŪ¬^–ąhė„Y“’€žqāq…ˆ£:KLņeY&HļYē{ ņ¤ĀÜģÕ żµz D%/Gē;ˆĒ—Ŗ°éŒŽAĆ²7T(—HQ0āQ$$ŅŸ˜ƒ|„‡L¤·@Tü|b­ƒ~ibw‘:oĶ=†%“ń€„œē|µĄ°„°5•ó0F VgĮ©ÕŅ@š“ĆķŅ¶óŪX˜qłb’Ł4xx9Ą‡eI$DhąÜ+•/šƒŖ{*¬ĒöžƒĪÆł:œˆļ>IÄiļ+3·=ņĒ+łG]žļ5KąˆŅI%®Žķć‰Āō…§aą~Õ~Č6źĘ»õˆŖĀp䛣®VżSÅ ­1y’®Ģ÷†¹ų7čČ5˜är¼¢‰6½³+?ĪBc€ØJžØ£Īo­š$āĶmm_@Ėāxü÷³„ÅjõĢÅÆWēā»#†ßgc#Ɩ“łį‹Ä/²/@T²šā©īˆŅU”‘0@ŃGńµSĮ]]u°OīŚłm=oP*‰ų±¦ P.6‡Čž±ĢÅÓA]×ęģõņĒ\IW Z]_wP/Š' 0žŲ讫„‹ģŹ‹åX/Y¤k'tA«Z` 9ؒķš¹śD›‹Ó I\hėŒ,ž@dćŪÅ9G”źķßĶ F¤o@Ø_üQ/–.ŅķžīĀ’¬hĶŃ„“ķÅ%“ >Ż č=0/āžéx.ž–®'žüY W‰÷Ž‹ĒąVōĒ«%t”uˆŸ”kÖ” ÓśD%ĆĢÅßņÓĻOj›ĶĶ @¼Š ĖR/,ć 0é'öŽ(ʤØBĻ•ßß3mŌTdś!õ‡ū †#¦Ūuż½ „ö¾›š«0mR.2“…1FwŠź+m.~”k" ’Ā3Żh=y6ēxRŪt±7¾ž”A”ėĻ»U‘&@T}Ģ8ņ ¼‰Ą­ė—鄇tŚg *‹ÆśÅwZm›/āWŠóJHĄą<^Ś­ ꔋ¼{/½ģū ‚BęŁīÖ«š”­{eŲMJfnńo:˜ĻƒĖpęÕ³ż¹Ż{Ųī;Uysń]M¢“R«tąßƒy:Į2—ŃœVGßĆh­ž¹ų‰§] G ”ŻaˆH”KŠ²hĶĖÜż‹D±ˆŠ?t5o !I@ƒ)Š4 ‹æ£ū5Cl …vŃł5DŸ!–«Ž@0]ߘ!ä²@TR^ŻyĆnˆŗūV'ņxń˜`‡9‚¾˜Öķ‚…į Ēą6÷–įČüčóŽvó@ānӎxWvĢ-źa؏/–Š“ŻDFīvpŌi¾ŻyÖQ1{¤åØéؘ¢&–ö’®¤÷؄<¼z #cūÆ“ł–‘żŽžÄ‚“ Į„ŹSOÉOKߎfLżā+A”¦ßŖ ź¦”A›W5€†<Ąb„Ó§æź}&“ŠRˆd¬¼µŸļB‹ŒĮ,W’Ą’œóWŸŗ±³uSi“×ėĪÅw¼„o($ čć›j¢’łcléŗGŒešzW&~OŠFk‰ ‡ā.œ‰¦+O×'BüYÓ©žeŽ¢Ž:›Ō8‚B;Ŗsi"™xՉå1Ś¼Vöh4c/ē„DŃjn6é”ĆLøą‡čĖ‹A B8 ¼ßa£’ŽkUĻ4š ‘ėØé%Œō6d{äŸKWĪłĄ0bņ#Ėę!…SŽĆ©2q²Nbŗ%h$R>ó¤Ł\JQ!÷»d’\…õz |L4:“ž ^)bš”y–q¼Y¼8yY–‘»uŅfŽ„rI\Ššß•ā*:xæŗS !YēNvŠdü:$§ćf£f½æųžQ õń]ĪėĪÜŠnė;'žYK*ĖdY"ŖEäXß;6‹ŁšŽW‚M+®5ä "”aÓUƒ#Jsń½¢MӇŽ%y¬g·s,AĪ—Q×Apś±Ā„˜ 9Ų‰F›ČķC aŻ/Ų?$Ģ ¶¬č¬ ”jŎvąŌk U)lī^@vŪ愊SY&Ģ!~¶ą †Ć"É{p©Ō­•Å•Ds„Ł\Įļ.E£zæ×|£®õü*Gń·ģŲD+y;3‰„¦ K~ž…ż¶āK2$WAXś~nü!{u¤A Xā£“T© —:sńW9j æB߀ŠuyH9'ŵ:¦ éō›öæökk‹A 4ś•śN«•Ą~bąˆbīū¢³ +÷¾ĆŌŗ &Zlp[Z•#“£ėKŻ¹8QūGĆ@n^³S ‰ÄŽ‹Ö9jnŃź'möbźSCµ¬0Xä9āh9?ZŒčp4sóHŒ`#Ā«ĀÖ­ŽY¤.A£1Mé/˜dÉģ¼uh]/~8µä²IĀ{mŗQĄpŲmˆś Ÿ"xĀ 8yäĀC§Ę CJ7ćC&@g ؚ‚ 9mWĪz eĶœ#JŸP !o‚?¤Ō.¼c_IPŽ»łR:äa•€\ßgy‚ĻSüGhfż8`$3b°Ś)ßĀb a”RĻĻKߔƚ!ČņÄT€y/„ļ=23ßw Š’dGž9Šōž>l…ŅRoÉ÷4Th ņ±Ą¬‡giäĻyŹaĒĖg…”7ŸóDƒJŅÉdńļRX–#%””ƱSö”²'é  Ģė)Å;׌!€5mŪÄ+¹ōM1HgiĀ•_ZQųXČwĒøā䯒Ėœäw材Āś„ g¶(äĪ}¢ Ŗr®śB¢Wņ.„|w Ī’'Čŗ„@ł L š qø’ Ń@3bš»SĖ‘¾Ū-'ƒH* -„(B¢†9Öé £l6ŽŠ>ŗ§ ?’w®¦ÓåO!‘R²Bų¤kČ*"²w2‡A©ņ²g‘\.7@”v k9Y$‘x\Ik×:k=Is‚€²”RV!9>p,¤łņ” 3Ź)­ĪJE˜gd+„)HQŲä]Ģķx„@PįÓaād>-‚†Ą°‹{ĮÕõæ[hŠE@ •<ƒŪąœŚ¢·…Q:Żį”R¬ģM åœ3‡Üe7/P (Ę+lĪ™(|¶¼CŪ¼Ūvs„Ū)»#IÅAļx…q‡½ŁŠ@O'6 6#ń[ń!ģœłC6«@o—2-z[®Ö/Ņ”]R×Ŗģ9ü,OB“ØY:ųĄā <0:+Šß`õl&õI>%IW‡ĄŚ‘l¦hź-ät{uQaŁhŽšÄ&15”6ƒžĻüB]’¹4ń ÅŲ¼\™āÖ§X“ZUļuVóz„61Ńp`ÆĻÕŌ•;ß­## Ņ£Ÿūõ'£ö­3ŚYńĢō/jsó M£öĖ“ćFŹĪ..müŌ»¢…¶·Zæ’õēŸæżłŪ# "¤ā‰Ÿžüī™ŌžŠš†?ęŠļWīõ…hŻ!3śÓŸæŃņóļVčČO?’®WfšQÉ\€éz » ĄVbe¬Ł<ó.h~ńķœŸāi<~ūĶ£u„Z°MˆĄŽŁž^’6„¹gcO[įōp§@hŽO›iģų£*+lV-jŗ‚Üvc\LÓģ‘Ēøß)ŠŽ¶ Į¬ė&ė‰ń†±ć#”ƒ]1YÕK`G z©ń®ėųmN¼[ 4_ü‹ÖŽŠØ’fQ£®ŽB;¬›Õ<Ļ#ÆśŸkšŽŠ5müāæ?śÕšn/4·4¤Ņ®Ę›ģæŗĪ|Ó¹k 0„Żj“ 1NGźÖ¤ŒmäUćMč.Zūsė{õDŚ^t=£sē@h‚Ę6~ńÖĢeiCĆĘ¢n.i3󯻓ųVO܅ˆˆGŽ%ĒqĻzwDĖQShUĆīČUDńŲułŃ—–ŅćJ֊'Pņ«TŠŹ,Qų Ž)ńB+ XvF!E#Ų,mCčĶĶQsk½ź^·ˆĆ&M°I&8vķ:––®ā…pnÖ BŽY„ĄŁēÜ ‘Ł¢(š5Cš[BJey Źqص‹NL%ņftķ–+Į}×Ē€äļ‹ Ķ‡ž‡£Ś Ń¢ ų>ĒA{)9<é!pHÆėžķF=ļM1eŚž·TŽc [i%²1ńō¦_üż¶JrTŅ<lWk6)1a“¢Ø"!ĢŠ ˜Iž9(āäõ,Åķ6Dł˜ė"i‰¤?½ĮŪ ļ!^">W™ęŗ؎„HŌ;™J;#AыņŽ “ĒÄĆJžh%”nµC•:;Tł7õ^Š,@O«y}ī A”õ]­ū µ*@¦arMųx’%’ EU"śY‹2Č׎ųn›¬Rš“©sv śĢwDKŠXæYŅ=rµYÓŲž…į)# Ö³’,Ņģ\ āŗÖ”A·%}é\.›.µ‰$jø[t›&Āȟµ|ńµ:rOØŖ3\°ŒµżŹń2nWŪ÷–ē–É¢‘¾l($·Ł&»_&‹j6õ‹Æ!r_$ Übé¦ät£xšI?įź°~jH§į®?Ż®;d2şŻØsĆ/ž¾œtB7%‡°?ņ÷ć9˜é°±ÖÅR”‘prh€Ŗ>A£u@ 4Ø~ķÜL5jp,ųCTR?jžšcÄ3Ų~&”˜¾m“ß  ”éōŒ­JMķüĮŽ­W -’éŃožtæČŌLn š§‡¼Ø#Ļ.4ēˆ‘żĪŪ·ˆH/“«Õ¢ōˆzĢ}øŹˆbĶGąCüēĻżŒ{ćµė˜«D—Ž4šŒh°¦[„%¹ƒ¹¬ė €ńu‚F‹€ÄŅÜģ’üõ†|—fėęé`¼s•Ķ–n·"Mõö6«ĻBżā«łā- ¢駊hx6—*@ŒhķvJ“gē‹—poÖ$|•£Ę* 4īAŅcøu¹Ämžkdæf{Ę«ęķqˆŖz}¾ō;-ejóŅo Ń4nisV©Ęjõ?4hÓ­śˆĮ^–JJn1’āƒ7– õÆWśDKŠHēā-’xņ3U‘?’jÓæģ…ž$vēļ™Ń  Q˜ˆI!ƞ}“Z-Ā„czmŃb-(ō=¶ #ü ”sYHØŖæ?śėvƒ®ÉµĮŌ »z–,~÷ÕJĪs""°śh•:¢X²”>śł§8»Š”Ä£æÕؗ…Cė}W«”r,Ÿ•™Ėyuē)+4DMš QĖubīĻO?Hņg@Žm &4$ S‹u“Y˜€ĆÆ’¼ ē¾W)Ÿė#ś¶÷īęš£fX“|ž³YU7ÆŠų\S@äb6[<Ø%‚‘·”ä\mīwžÕJļ¶öŠ4AćŽæ—’}oƃå¦m0@Ó-ś“īp­+Z²ž3H3~ŒßŅŠńdü¦åCOP×'&čõ‹V]«ķIƒ D•ĻƒļŹ5@°¼ś\rLÄƼ„ŠÉśØJ““}Ėī ‡£zyŻ_ćØ=å`Ļ¬ÕlÖ{k$©Df“š/F…I·¾°kI£NļSŅȧ±;Ö·ĻH ˜°³ēR¼®B6’s{*ē¼¼īČf9Ćś'ź5‹Õ<É#'˜eź3`Ė)p.Å"$ÖEa9ŃµCšŠhćqÜ%¦AŌ„ @2ŒzźC +{\ Ä: ėZ^~pŪÅå.  "Č\ŽB°KVż@äöKZdįhK+ošsnžĆÖŽ7±HĶælēün™ÉREV_ĮĮI~žt}t~/ß/Ė5˜@@ŲdÖĖ7Ž/«źŠU¢;–Ńw†Oyamk}ž•ś1G0Ø@”ĄĒÜw½Ņ¤- $8<ńāéjļ«d¶9P ńy¹6s"–iČ-”Ā:€ų’Ūz1’t£ŠĪ7Ę$‘ĮBX_2/¶³}MŻōD-8ņŹ–ę&æ==Śc ķā&Ģ0P gl³Š®ōF”Š¹Düu Ēļ!O)šēŚ»jI1‘†·>Ģę„ž H~Gō=ĄZ”~fĖ0 y‹źlĮ9£į‚§Ģæ/^7ml"øöbāé!Ū#$ƒ £¬/.ĻŽm£.8Ļ%9!É(˜ ĖB’*\‰łX‚H™åŽÖ·†_ĆŽāŻāˆĢpĪS‰Ų@Sś¬!Xu¦}|ąK¾ƒŻš“•"³ywõ¹~֗rxótk}tļ%lÕZ«Ū™įķ…Ķ µr·&K ÉĒ^?ō'gĮ¹‚/'}Ųb+ĄĪ†ó· ōdįéč‡yī%$Gh+õ ؆°^Ų‰'¼S“…Q ŃR„d·@ÄŌĮYW”žc‘6X‚.vaķÅčš!ģaÓ9’"–xvä¹Ó‘:–"Ī‰<åR”CE1`ŹéĮ“g£| ±Ą”a¹­£õį ¹uøź½Óm†@,N>sCNfa?Mł±€<ł šk.“!oöę_¬ļ=‡ø:Q”ĮŌXS‡Āś¬Ķt³āĀV™ Sč~Óa „ŁĮšE§ĮĪ²5gĀ(^ž¶7śbĶó²“~06ėółbwk²:o0dĀ[X[?šē {fRMNäa;ńÖ2és··s p&€`¹µ£¦×³‘Cł^¬ī›ŽL2ƒ ž™(Ēt=ktļ54'†é"ŒÜN\Š…ÓŠżæĖ©ĆBlv LE¢7{ėėó{o ›®āńB€HRI„ļ8`§k"Zš„ĀĀ0Ģ¬pØŠ6Š•ŽoØeNw Æ™;æŪ^V€ŠK€žpĆė/†XīÖŁ|ōWćhßŪŽļрĄ®² n£÷Śd]=Z$ń»¶õÜ£FI $ąŻĪ¼ą\ ŻóF½)“ė…į­‰y./6Å[dó‘^śē£i—…“ĮD/>[ó°Ī ØgŗzĀR÷ˆįC¶Y o Äļæź@~m°Yf³\'ķ–Ōļ!jŗ‘åę'¶†7`‹ē¦Ė ź“Ÿ+) Œ†E©”>0l::ĮXJķm®ļ½Ļ»›L¬Ņ‘†“erOčm¼øńōčĆ÷¦pc=Ė j„ iøįņ`¦gj[ŗ<@[Ļ~±>ĢÕ»GX$µķŲžcŃzĀt8?:ŗ¶ JW¦Ė" žśÉ_æ>išū£ŃLøGģĶÆCs‚“nQ6ś’’éu©žŚéf¢pŻļ·!5/ėYÆ÷Ø{Äsš¶c7^’÷æml,ŒI «£l M»] FƇ_Œ®qr%šq]īJŌĘN¶“˜.tøv“~¤‡ūNŲ@ŒUŖ¾EšKšxZl 髤^«y [=­Óćl“Õ^rJ5"ā}µ(‡~R±˜²·6śaķš„Üū­ė‡°Ā½ŠŹ‡÷ā›Ćį/Öø×-fźŪ_Æå6öIJžŽˆ…E,"ĀŌŹÄ(DĶŃiį>Ų.H{ Wń¾ōPŠFh®?Ż@×°×Ll €Ü<–OŠĘŽü‡õ§‡ē`Ü»ĖČ­l F¤tūˆšCo؇Ä0÷¦gį¦wµ“¢O.źæ“w$4ßn°]`™ńht Ö“ Š”7ĘĖŅ9@˜ų=)p$ ˆa8s±ø/TĪŅ—ć·^ķ}CliÜÕY6–Ä(ęWųH± ) q9ŽŠÉ@Pzć¹> ö——Ų 7·AZŻ·ń6–@ æõČ FŲĄńūr*,”YOż— &’üfotżh Ņ\tŁ¶“¢pL2„"N_nąHRį°Źd¹3†Ō§ Ó{Ć*,jM¬qy¹uģPk›fi!2éc#žü»B2;ž+ēÅč)¢`°Q” ø¦¾wįkÜ·#ēąYz„ĪėaėĆX1Ō0ĮNŚE_$Ķ |RPüŒ"”?b…™d˜³dCwAĶæ FņėóO ō±“ŽW÷@°˜å‘>ø…¹ß»ģŹ>]R¢%ÅSf¼łGö2ž2‚¦D*9¦™’&„ o ƚֹ‚ĮX‡ŗ§éˆˆĮ3G>­Ö¤!ōm ¹§ÄĻö@a‹čGAū.1Lk¤X‘7öÖ&&†ófgWŗBü9/£F6ŃėÆ$Rī×NŸ†ėu/¤ŁŸŲK\h!‘mŚ«”æ­ūĖą%ńĘ”st$o&‹D·@ˆœFN¦P—j¢|— JÉyžO‰š+§@{&E‘#õ@4%# {ø·õa}o!Žt}}āÅ|ƒģ%6*U”Ļ³J0ŠŅß#nĘœE&ņ3åŁ.Š‘$ƒMŃČŁ»@Š Åw 0å³waĘėWf!j H¾Gün>eė4¤¢ŌÉė›ēœ¼¶ō@”5HӖLVŁ …ō§z9įĄr#¹Ģ%!7R©äĀ™õńŽ‚ä¦kVŠß¹ććßłčFB±({Sežućä, ‰L¶!ĶÉ+!Ņ¼6v,&‹ö²`ŽUaĖß¼7°šKGøOŌqgÓ¹` ‚I™ A>“’OŹ¦¾ģ÷ŹŹ÷Ģ ­‹…ĻSŽœ³½‡@ŽÆŪŅ†BwB;pĖļ½!äĶ»gƒE!äACį˜;ĖÉĒ>Š!”³ēBŅ @°’ {ĀxĆJ„˜,jd²Ŗ€EH;©¹$ĒĶåŻ¼’ö”W0‡:›ŽxE9ķt—ņ±RĮ†nüŠ¶!˜u{ĆnFšųœé°?"« ³*Ņž—ōŽųl$łŽóÖö²nÜŻŅ‡v€¶±/äWĒ¢“”ŪĘ`6E÷Ą8€Y–ĪĮ5³z"J,å?Ā³łj{­UąWŚ/['Łµru”Xęµqø>ō¦ŸōĶ}ōj4®9b_­½ÓĘ1Hz¾ •oö8Äš«m•Œnž(:v„ŅČEŲ‡4g'žoę©4>ĆŅ+I¹:ŃwœÓ ü«ķD§Ջ Ĉ {t .š)pxd+&QbE’‡mdėŗ6 ŪĄe°œžMój0ē…Į%č‚?‹ņĪņa€’­!ŲėCH) ¼ ³AŲµ“,ā Ļäē€«'µ5¤×boq½‚rņ©l4 ŽøX‰2I––SÓö¶†XČįZŲR)”–/°āń (dtgxZ÷=“u‹”žȎ, (Ģ5¼ŗĖˆRLåšńl“e®øäw7?U’HŃø(Ü$›,EƗŽm ÖQ1S ˆ8Tō …Č+ńLÄRH$g¶É²Ćõ­` Üę`ÕÖ] §K†0} æ³õ;įa覶É2$&ė²X'kCw²“uŁ@¬“µ”;Ł@ ‰Éŗƒl ÖÉŚŠl †ÄdŻA6ėdmčN6Cb²ī ˆu²6t'ˆ!1Yw Ä:Yŗ“ И¬;Čb¬ ŻÉbHLÖd±Nֆīd1$&ė²X'kCw²“uŁ@¬“µ”;Y z؛ut–…'õņVé(‡)īč¬&iKZ׈B')=!4Ń|‘ Ļ±ˆÄt²qĀ4yųVbččV$¤uš*ų ož­H^O|«Y†©od_©ž!BpVQü«N_ĄųŻ ’Āfy!0[Š¢*Ź÷hQaxŒ ƒl }Ę{Ėįr«śbgČyŒ“·l\?č‘²«¤|§O”+8¤`ŌŸŒ4HęŻäŠ¼ óį½Ęļ„q*ųī ’+›‚ ņģpLģ£\lÅŽµ”Ł¢ń'§’Śa•ĀNuŖʘh5 XŽ8‘™ń(’ŹĀŻ|µ¹ĮZŽKAh…¤»ģŽ µB,ŠQČG® ē?*ł—KC{µÓĀč›BJī÷²»É¢W³*XH3B)Ū†`O˜ˆ²‰Ž(CŹölIxé3Ž†„ÜŖ(D$s9Ćż%/G…‘5, RŚ9˜“ģĖ Hƀ`i֝ ˜©“TEĪsétČøUץbæSĄaoŁé<7®ø-4ćNēxĆwĆwŁ W¢”¢†ū*9Óī¤ØšF1Žä&öö¬ ÜĪUs ŚJD†ō†ET¹®ī#2ģk‰ Ū8Q,ĄŲ^†ģ’Ęļ&Ņ{PWÉ°‚Š­vXņĒ€0jwįi#¬"V†œrˆmécŹd‡`Ł©l J®OēŁ@ś$ŲN/kéTr}:ĻŅ'ĮvzYH§’ėÓy6> ¶ÓĖŚ@:•\ŸĪ³ōI°^öi²Ī £pć÷NÅŲ»ó…ē@šäl¶P'I– ¼įÄŽ ¶Ó+= ‚7–‚yĻrL¦{ S½ »mcEböLŪ‰€˜ņ~čT¢]ž÷€¬œĻĘ`&³Ä€W’ż "~_HĪ—J0˜ēšÄ/u)ƞžž€€ä’n‰0‘,’"Yļ» ¾‹øŻ²3–FY_ÄׄpÖøkIO„lāb  >+3¹÷““ĀNå½Ļrla‡‡…+[A+ĘWMČ°§‡>$ „Ł¤ģwPŲ£yGvr N‡PšÓ)…M³”l4oxŖ§R6q±$]ņG’AŲ;%:+(H¢ÖQQ(ŗjÖcĻ„({sč’ć%čhVåŖØSuzÉBŁļ¢ūLÉ»Q–“óYĆ~w½Æł«< ĮąIŃ)O֝cÉ,8½FĻ$§Eó„":—_”7/Ėžœńp€`¹€µ•x 6«×¢žEĪĆŲP…ŸJöFé‰l;ŗČĆB'H“=žA°’¶Ŗ&čŚļ“_iæ„? vy@@[ŠFŸĪbTRg±HŠFoc1*)‹Ž³X$h£·±•”EĒż/œ’[ŖŁ_īIEND®B`‚‡9DdąąmBšh² š S šDAĮ’Ćart-minaiFigure 7š€bšĖ8C^ >mk/éņüCŲŹż’§8°1nšŸ8C^ >mk/éņüCŲŹż’‰PNG  IHDR:ęōv€PLTEhpČķžŗ²āh†¤ÖŃD'‘“.egYjri¼ƒyÄ’’2’YFŗŚō“ØŪ4#˜|rĮ†ž¶ŪÖō„ÉĆźDińƒgQAØ’’)·ÆO ‚’’’čåüi[µĪCV’‡ĢGuĀ»ęM=¦Ä½Ky²©Ż¤›Ö’ˆ[عĖ©Ä錁ČYJ¬|pcYY³2~«¢Ś’aAĄĶŁˆHC§‰šŌ ‰čä?ž•ÓE5¢œ³į’g>ęLO‹ē²²ÕĻńõń:;*yįŻ÷’Ź7 Œ0Yƒ‰ōń’üŸ=×ÉŅ„œV:2Ÿ<,RQÆ„A;£O@s®ĖģNL«īė’’\CĻŹīĢTj#śSIæāųŻIQO@§) `dø·;[ĀsŽś÷’|‰Ė—ŒĪ ›_P°†I8¤VFŖ ‰šPM›Š’fąęģĻŁćÓū’šóö³Ńš„æęĢĒ„-•LI“­Ńó{_˜]N¤& ź^dƒ”¹äKx†I‰3f†¼‰RdbKGDˆH cmPPJCmp0712Hs¼6¤IDATx^ķ} CŚĢ¶®†¶<Ö@Š±ZPQ”J[•Mć¾•Z[夭Ś–H=śŚī9Ž{[·łė÷™”A@ ~0ļ+U“Ézf}Ģš5kõwŪ•¢@5šĮ=Ļ ż·ų=ĀŽ=ĻŠ•ė­Œ ČńŒĒ3z|üśĄĘ„Ų»€t~”™ńō‚QĘÆ2 3Æ;OžĪß±HÆg«×dÜ2:4J9äµMū¼G_GĖßÄ»öķą× £žƒć×ūCĮ™ńƒŃŽƒĮń}ĻŠųąąŽąńė½ĮĮ™×£3ƒƒćŠ,ććć{ÆqõųąŽŠńčĢŽĢĮ`ć[Šäė!ś€‡†č‹żęńėŃ”ĮŃć!0-T™õ:4ųšNĮ^k®ōāŚŃŽA\žz“—žæJü34H{°žz?Féw®M+r ź÷öR@€ĘØgœNĒĻ Ų¦wp”ü`fļ zš?(4³w¼ĻF÷ĒgfĒG8S܇ņŚŪ;~ķßĒ ŽÜ£*ķ`oļ`f’`üxhmčxܳļń axūŻ¾vō`o£98 ¶Ē >ß·čŽėŁ?ĄCŠæ‡<ūžń½}ŖÆK;2kO<ä%č3ōzšœ˜†–r§€ą£A|†dūCūC{Cž†Ÿw|s`pŌóś ÷5,Š^ō1:x°¼O±Ł£“āø÷ąx,;³?ŠIŠėžĒƒC½ĄąųŠĢ(ŽĀ¤=ŽŸ”ŸÓ4`Šįu”8D/(~Ņš’ČNyķŁ£Sjz}¼wt†RĻ3īń“¢ōß”I( žń!“ĮĮ”ƒż™c:­kC0ÅLļŽńųxļž^ļĢąńA/nžŚCEĻ `ĄM³gof,²ƒĄ°÷{÷­;õŽļyåa|¾?3~¢c¦ß§×ć#:OiW3pcÓĀ«OĮ¤—bA1z@Ÿ«×A L,łuü2ÅY‡Œ[O9Ś;3NmœCŽ!K†<uCćƒć3øß8ą8· -°÷bŖ榀ąvø-½ä5ųdp£”W yp UBtQµC‡æĶ”„ ”Fg0é „JĻvŪ•¢@+ĒžgŁmWŠ]@®¦Ł¤ Č£ĄN—Cŗ€\1 \±įŌąBkæv[§(ĄD³)‰ålAźŌ`ŗ÷©ae;næ[–äøߝź"Ņ¹©Āā’tĖŖģ×ĆŖC1:7ž['& 1÷˜œĖ§ć¼„FˆŌmm”@Å$d’óø ĒŽK –Ģ"…į±nkrV1OAÅe HZ¤€HYēĘp·µœ™ Ķ$å*Ø©ų²—7†]ŪC)“l“…coy§†³.@Ģ<˜åĀŪįš¬Ūi)u)ė®HŚ`s:‘ōyæ/)é»~§C6 Aus€˜ÄŠ ‚WR4z»€üa@ĪŽ¾ HöPąŠõŹYÄ@“˜Š»Ė!ķA’!ŗą÷®¹ĀĆI$]@: HRvūåT*&øĆĆÕéŅI@ļU8Ū%Ć“Ŗˆté$ Xf{½Įp¶wé, ¦Yąāé“+ĖŅź]@: QøP(+²nŪ¤ć€„Tj÷viįY½2×!$ędYīrHgń`ū²ˆs)§»:äŹāŹŖh]‘ÕI@ #TjŠ“›žnPgą—†ÖÕ!C„čsĻŸ?Ÿ¹|Éø-Ä“čš½Ć¾`ū7åƒsB$SÜA š[ÕÖ5{Ūy^m —šcššXMĪwiķ«öŹD›w b/䂮P×¹ŲA<Ģź€˜¦‘‚ē$ūNŌĖ™QuEV{`bbJˆĄŠ‰xeÜ· H‡±cEŁ7ķŅq@jß° HĒĮ¦:{Kż–ÄeCUĮžgO.IōBŲ¦ńÖĖłV.p¬ˆDUџŠ+™:Ä$bŠ™cŸ¹BųLŲļÄ2Ķ>=F)gć€^G˜šEKū°CÓ²N!&åēwń™}méjśWvL*~ÄĮ™LīĪk¢\į aBv–8%䩌Å.ĆņŚr+܄ˆ‘b\v#,R(€²"}ō7‡<#HŽŃL¾2Kńį@°Ą9U‚%²Vą‰˜$$)ZKo o&EŪj%¢Ć±›ż‡¢†Så#cā–óŠźó³ćŚ2»µµõv/zćˆH¹€žĖ鐲 —U~w藠p²š§ŗWIf8nŒųŻˆ®5„Źs1’pJMq’źH1—qž¤Čqœ`˜†,˜N čŌg«Āb Źŗ[5øĀp°\ĄÕd˜WTē DŲŚśįl˜Kń{B"—¹œWeSÜÆBX\[N„y÷©YĮ›S(×HŪœcć«ĻŻń50LHÖ«ļr攬Ļ—ēüŖ©śsfŚĮsĆEQüI’R~m„UāĖérc– ˆ))Æpķ×!’!©ɚ&<“u¤˜?Uˆ¹C~•dä W‰ÉžDĀā¤$Ēåķ€ŪĶ‰¼©ĢJ·ó-ęĻfˆŠą)’ ØN§:/bź$ŅüĖŅnVĢår1M ź°ÕÆŗV ¦)$ÖŽź1@x‚k#²0Vc€o\\ŃoH¹°nņ‰g°¼”†Ņ”°*eS Ń>’ēՐæNŠ~ŗ%"ŚŲ°*r¢[2\Ičš°źtØŁ'CŠ€äH $ęĮ|Ņ«‘¤ĖÜ¼‘ØÉŌõs”~KI„żaNŲrPJ˜sņ~?ążD÷'ƒéP<0ļ•w“b @ §;ąwäāaEV3ŠŪ½šW§ŗ»“s‡Õ4œ²ˆ‘ĢN ^ō1²ĆĮÜ ŗ•ŒššÆO‡ä–du¾xĄ³šQ}ģ4Ķ!¦–Źå0żµM*dw4¢ćÅ,Ą€2ł-–åc"Æi¼f>–Ė„ˆ˜Å1&Ā…¦™ä‰®>Ė¾uĢ«&Ir„Ļ›<•žˆzÓĮ“ÄÜ Ć·S \ęŁę2×^‡\FdY™+¬|*0Œ¬kq,*MH?¶)ÖÆx§xµµ>±Ž‘Ż>Ž®ē$gŒvPœÜöz†",3’,śÜ(_r–ķŗC*QīŚ›½—¤9ŻSń-’’ķˆuĶ>O~¦åĖö›čŽįs©|ß¼| 7±SŲYŗžVÖž”"Õ„Ķé»dv``ą~ŽØł²Søš_Kl‹šVč0H½]Pé6łéÓ§ųy[ É,š|!ŁYõR“ŃėØŅ”śŻ°vĖįƒŃō­v«‰„]éxāFŹ5oe5Jä ®/A`E+=©§–—gß¾œĀ·¹¹¹ßļk¢„—S©Ót+†—ĄĆ²ŗģvŅ‹¾œZ~;9)|ūö ĮW柞|śćĒ`šéӝ;?ž’~žm & YBĒ²zoĒĀ°>@Št·Ä®%“Iņ^S“o' ’ļēæ©n½Įū§OŸžüżsļoMn}H-§’Ū–e%MÖDHĻ.ĒbLŸĆ­ę¢ų/FJå±4EńŻ»w&''Aę¹ē ķæžś (ü÷ĻŸæęęš¾ĻĘŽ„t]§zĆŽ(ć”’RÆ®CO"OČ·|aXā‘’ų±‰Č ©³¶KōCüü|’ž=hī¼śž9ŽÄŌäģģ;H}ŲF:4¶dP‰c”ĄŹ“H>üüżūżļßæg«YYÉ<OÆ%GŁėŚ˜½„ØŲZŖCüœŠż"Õ°P³Ø ėĖ³³@ć¹¹Źö|ną>›]ʕø,£•l(‹*4I@ÖåøćłPR|‰¤K`.D® „ߌšüéÜŽUƒ¤Āģ”ӒŠžT 䟝Ä«eł¼’Ńsó\š›FBCüé_(šÖŒ§ēcĖeOą³.aŲŁIx®Æ×^dIļܹófĢ·āømü[ –§ž\†å99łÖétZ–ēĻŸļ±6£@ PņSՋ=G@=Įēóš%y,ŁSļÄo6 n! Gs…'²¼ćėĀ!Ņ25,aZbŸ’D_^NMnŁ–ēļß?aļPńc›ž”žTõba°L‰Ļó?TzœŠžv@P ōpŅ­ įė¾R—RÅÕÄ x…Īūļayž| ńc[ž“o!¤N\e ˆzōN#³æžkŁ€ćļīšB iŅę?!ś!–Øå )ķk's©iöŌCĮ_ĆN>£SY—‚Żāźķ:ˆ,"‰Ā@*²ˆu®ųŖAPÆČ I$?,_W‘E$­°õūĮƒ§st‰Œę`{Z<É/ÕƒC°»ļMĀoąZ‚Äwā‡;Ÿž{'‰ĻŸžD{æõ'4BćŲ°I9q‡Ćį,\C@ˆQŲšūń×{į]ŃÉł‚Żšˆ“kœœ—’K‡#©F*Y”½Iņz10芼¬ČµļüųöN·7øķŻn–·āņlql+KtÅK‰Ó\°Ņ†7e`“Äo_E@€’īŪƒOOē>P×E‹IՙīŲ€p>Ó£OĢ^DuyS$.Øóž+š·W2’¾½’ėĒÜd¢„3T½Ä]j, s¹„ź<‰:1üĮtŖą•¤TÜb‘+Ę!ˆz÷ķē§Os³Z»ž¼a£Xcačwųt)źDĀ|\Ü°’ńŪ¹ßC!8”Ƅ²„¤J.ūńąĒóI¾x~ćSōµĘĀ0Ą%®˜“ˆ^y,!£:‚)¦­S/Å\HR(UōzÖ}Æv\(‘eēóOw¶R×[RŠ¦: Do8Öh; ”C„Dbƒ(Ī|qŖWB‡ĄŽŚę·~žxšt ē’nJ&‡h©d²PSe{źDˆRŹķĘY“vR:}VRF.zqrąĪƒßß ]ĻŚĮŸmč“%²$3› 8+Ž#œM Ķā¶XYłeÄ X?X2ÄɹOw~ ³“DĄMj,×I!½äV\_…s’ ōų­7{‰¾…x±lŻÕv;!ōÉģė )Ę¢ß¬Ę$œĘ^Ł¶¼Ä¬ŚŅz@hŗØ_…¹ķķmfÖ4zĄä? žģżÜģµ]Œ×œAL„NĻ2ą ¢£³ū!„’VcøŲ ēgæżųėé··ś “TYY…“ HøĆv“=ˆ”;÷óĪ§o 7OR]H| эšį÷u˜C Õ9vTž.ĘĢ}ŠµFõF$jšŃČ5Q5 ‘Å»ā8īĪłæv^dUįÉŠ—Oļ¼ŲJ6 `ˆ¬ō|łŅ£•ėŠXėaĮņ‹t:‘29Ļ!Xæs>æói®‘fŁüübzśÅ—•ėŪ¹XJ¹Ųįč÷³:&nŹłūĒ§Ÿ“­IOÕĀ—éu“é¾čµ°ė®Ņvv~µĆģ„]Ėtˆ$å [??żųķ›wāFV¾S<Ö×?ƬD¢W]™\5@N¬,HŖeøFī<–›’T„ -2żņQ__ĻŃŌŹĀ!`¹²ņ‹ HQh±œvķąTōŃæјY¬’ų­wž:—“—Ūż‹š}6ƒ¬æ|ō}śÅōżļŸ}.f¼r-ÆTž„„%ĻšæP’6bl!¾ü~bIk1žmNÜĖžHt„ēćś÷u(‘éõ#mes³§ļĖēūVūž°l®¬˜‘« Ł5&ŽÅ…°ņ«*MŚˆP<х ŽŸsņ—ęīįfĻĒé—=Ń¾—ė÷ń•RJžĶ£ž¾G¾\ńāćgŹ.S›¶» ĆD”™œž‚«z4i;yśm–Æ•ļ±.°°Ņ÷ņÅēž•ópūKž9i@eį0ŗ9Õ~yōђcTŒõl®\Tj4Ģ_žŻX‚f·;ߌȧŁĖI*‹Hß÷éļ€ƒĪś…¾£sZœ€WĢ•Ķ)šĖ*ÖīüųøLŃK„¶ĖHĖŗęLµ‹jTŲńrį“›ē2Õ³r¶‹÷Cj?/¤RV «uįĀ—–4"”ņ©#ؗ—ļÆOO„9v4`ž„™\ĆŹ2e!¦Õł£-TŖ@Ļ ćģLÕÓguĻ¹Čą€°2O¤ŌBS91v”ź…źżé/ī¶ĢdȱŽšÉl@Ä&+ Ģ<±­ē©š»€PīxA…Õ)‚õb]MÅŲį” 1vŌ×GĶäõūß_BæY¦X'”>[d ·¢øµŚĄ!$9š 'ĢŠŽ7/²¢‘Ķ¾ūėßįJ,'^“)c@Ė‹˜ŚŹŹĢ±—÷?ĀJ^·ĶäĶ¶›É5"e#;ēĖ"sw&‹QĶjÓ¢°ź;»_ųrŌää¦,CØūņł;äŲtÉLŽXr¬ÉNk _6 Ți-š­Õ"‹8qN¶Y$ģ1Bw|ń²gåšģėYŒg„f2ä5“?|Q2“6M Ņj9Vcač 8‚¾Nķ©#«ÄÜöešˆDV`YAwT™·ĶsHÅā%z-šÉP/ė÷a&ÓeåVūP>­2“kā‡Ć\‡ŽEK³Ÿ~³JĒŌc^EĮ÷GÉŠ­üĪe9¤¬7j&[Ėؗ¢™üĀR/0ĒĢ…x“€ ĖŠ$U‹QXm^J©O«&$¬ ĖIbŗå–Uł7[Į!gGBÅŲ”„^ś}¾’ĀöĀP½9AVߥ«\Ŋ:Qr‚‹¶Ždr …§?Ųu.z6auŗ*Ævu 9¤²{ĖL^ frO¼0/ Čؙ /ŒµŌ4”Y[ø;¼ŹfC”NŌĀ%ŚĄ§ĶĘęŅU95tWjh×vpH…™ `Ą++Ōki™Éėėß©z”fr”šcõs K‡"óˆnwtāX“eš^ÄÕ?§†īżéĻ=4°„ŻŚĘ!ēä˜mY^KĖL¾oy-§6-3¹.TŲJŻį– īÆcķ"Ž;Ī&ńw|ńˆ©;Jōj3‡œ…:“W6čņå%ŌĖōGŗŚ‡z±˜å‚™Ēęs7½ÖŪ_œ˜¼'łžįĖŠ]yT¹*ļØ©1\ŗ܇«›bŌ ó‘šÉ÷ļS3™nŠQ CŒ±tŽ«ńJ¼ib„Ÿži5‚D3ÕVM9ŗblz„ŽŠŖ^l¹“1Hkµ’ņ#vŦa&Ć;¶¹©bEXķœ¶b"e’ »ā铧żib‰ųą=Ė”\kž-LYĀ*RęB¼:¤Ęˆm·„µł½OåXŃLŽ–;a¢G}’Ń7U†H)³µ&Ņ±vĪܬ5®jš.7¬@"‘Ķ/§?ŁŪO eÓ<üƒR1ŗJ3ł>”>5“éf„ĶG‘žūÓėÓĖ6 J€äe'²Ų!É]EĮŖņĪ[É”„Õ¾ˆ“ÅĻ©GaVŒUłY ;ՇŠ¶Y|uŽįR—š–n·Ģä/ß-+yŻŚ¬œ¢æ­Æ\91„NDÖ. ķEk«ė„lĻŻŁb” d=rōpŖoĀŖĪŠŖlŠž¬ŪšrU9}4kwNž’™\ŒXZ·#2h+qHÉq"µ5ł <¼Ģź @¢›_īŽÓŻĄ‹ę*µAéīyēE]µésŗū²°`™ÉŠˆœ÷ÖĆŲ J vOõÖ‘E&ļ4fšZŪOX^l趉vmģ–šÉ‡=VņśśéöMYżynžsĘŪ˜QŽ;‘M}-ź›ž†°ź *°$Eõ1žóSŃ`pī§'cKĒū+Œ¦S*5š_vlHł²wW>SD¦šYe€ÄĒ aÕWQō°¼’Ks<¼ļQ‘ÕŠĄŠmLXÕsĶ«]ź«^©U>+¾kˆ!IŚįv“ŅNŠ—­Ņ-Ź»|Cƒh:źQŠ¼|š¬Ö#)?9QēŌŹ“Ļœ½ĆeiĢĆK ]*¬ź2t[€D± )§dgĆNd¶” ”æ ĀšlXļą3zµ$¬łŌX<äØnĮ¹cu€iŽ1Óŗ€äiž’";H¢Sš¹ ʘgĒŸādFW¦¾O™e"ąCŠ-å8„m…%Iņ9āįź$õčÖmčÖŁg]—!Óa!IKÆ&\Y#čņ†~9.Yó»×ś×“Hø6 įųņkšDpūTŁ©ņnāŠŃ}V’sĒ× wRL{ŻƔdÓ^’¦FY7ā ~>¾aģ”K!²šņ°œ,%@’ŁräĢz.—LĻD؇·Nƒ— +jčÖöčÖEąF/’bqąkVTņ[K²1Å,p¢—ׯü¼SwŖ2WHDZzÕT…yŌå¹`>Ž;hqh—äTv×”śĆ“ōź˜é ’Ž|IS$)3–ÉI$^¾2Ž¾¬p>”Ö!zŚ“g“,…FYōrÉųššÖĒ 0tķ°·źņp(½ĒŅvéU§Ū“×ü ·ĆI:Ēūd›ÜžRéU؃yT5-eü²*}ž”^5ŠA±ō*AéÕįįJÆŹj6JgųŹŅ«ÕŃ+ žÄZŚŃž *©^ƒ×^•?śS†.-½Ŗå]9NK䐞uļp¼(KÆŹņ¼.s¢]z•*‘y5•Ī巗³äW¼¢ōŖ!”—^8?7ŸŌףš9aQu]Ģ!4c‚ŖņĪƞ¶”Ķ“fļŌåįBXMÆ?:ź¤”[!Õ¤”(żįłą¶ā £ōźn`W=œtp!·#ł’ā.Y’Tw\óø…$©ČŚÉ؂ ś6bŠÆTzuw™ųvtųE2¦…)ÕLĪØ,½ŹąBbA·KńeŪQƒŹXFHĆÅEBģ/¾-üĮóg(½:V@“`6K/g‘»/Ø»Ŗš§6&kĆ"?Øķ„bŖÅś«ŗ¢‹”dĮ.½:–}ėD-\¢sR–^„ÕŠ›U»ˆ’Ŗoø\v³tˆ{‰“Åd[jPIāÓV–Ąš †.Våpö¬>UsQM~nĒ bwśR*½ Ć iŽJ„Wi:ZZ˜ĖC$œ·ˆ],½šu…-­o8C“—āć’%R!S1é€äē×\¬Ø±ų5­Ōi /Ūą-īqF#G–°Ŗgū©IRwģką›śŒ™Uł6K©«ŚĪ.Ź·Ū Ōk„4 f›Ų <ś‚£ž9ļÕŚy£†‚X€PÆ ŸYņœ¤Ö ÜX,–l ¾Y1¾Õ0xW°;š½'zī—£ś=ŗķ¤f§ūfRż‰%Wf'Y““örIT;ä³I@¤­Os¬CVYēe?߇°ŗ>ébZ C‡šń„_@‚č’|#āŚ†öo»jCӀ ¤a€Yųķ°t¤üŃџX¶–°ĶöĘąMĢ«ågCČņ¼iģ¤SŽ_RŖ”&–Ļ ”/Ój:“³’`; ®Š…fłj%²Īś5“¼”tg*2[iyŚjäć;ūč’ų¾V ļ!õ=Óż€f×\mR×7:¦R?c§I†£ŅŹl/f¶ĪŲa¶§¹žF=¼5bx£QXŗļ×$“R=ĻÜš551Œ$9qČGBFŁļ/’r“ń#³µUѵī{"¤”F otåĖōĒiDĮ”m`ÖŻõĶ¹° >čõŻāj†ˆnQÅ>MZV3p%7„Ō%jš2)=śžāĖTĻ£ūW%†źaĢ›)pm–6ØHjĶėõśµœ+­ŲZ¹a³WŚŖqˆ0é[æߍĄ×^¾_ö‡ˆņ'oĖ$>Ģ+§õC¬Ż~Ī½(Å„¼ĢŽ…©G/į°&vjo³ĮL`Ā9“œš9W„­d“6AH+Ą, kOŸ„r»Ų—mŃ)\Ā³ ^œ*Xæ_Œbļr[©Ż²·-āIžą“h{ DŽ^¾ųråy«9Hūś>Ņד`““_$UAkŒaė«zk’g†4D¢8åŃwæp»9„F ÷ü?}G%¢—1² '‘Hxę[q¤Z«Ž˜ž^¾E{«9A¾Ń§A£‘ĻBųš|ll#ÅtŒ4Ą!Ōą­š„!=ś8że„l×ćvsˆå©\«ˆ,ŌčŠiö÷B ŽŖ2†Nß?Ŗ{«9¤ &q`%čM\>q€Ä iX˜śüāŃT„c·Ė!ģf¼(Š!WEDD¹zÆWd‘ĀÕBč#Qßź3ĻnŅv9„!²¬ŻZIuž”^=kkÕ Į[-cßĀę—Šęg{ķr›C’<Ļė~īrf/ ŽŖ‡ķÅG•}Ø.‡°8„‘ŲzÉĖĢ¶W‡ąŠZoÄÄā£jE.‡ŌH‚)YQó—āĖĆ{®‡…ĶG8Ó\=-n—C˜:„G\–ŪĶ<P‡Hoįį=§&,Wbłā£ģŠ.‡ŌČ¹č¢;“—9§ƒ÷ē¹d)p%bńĮŠH„®’c‘ÕWĆĖĢĝU±A{ ‘ECĪĘšbmžyśŃ&#"1¢æyõ÷W7#^±I|Ł€8y¾bv{”ȂĮ{.EuŌģY_ļcķ ’䯇÷ž~ļįÄ8šÓ$łZ’µZõCÖ\‰K¬Ōµó! Ų }ń’tu8ńšä^ž#ĀöeR±\.gbØÖ.ąb…4T<ˆ«ļ•®ÄŠ~ÉJĻæżķo{„Y[õ Z?’®~¬|Y©$Oó••ļ>ó," w¾UāÕjisZś±ēļƒ¶WÆī¾™X]Ō MˆqõiŲŅ2²’&¹˜ąŠĒ›Ī—E ŽŹ^+ŽįŒ+±ģI¢‡‹wBdŻƒČz3ņģ~6ņ¤uŠę“ŗE¼Āā‚†÷hē–%"ÖäÄšž¬ōøGk,>hĘ»Å‘WļM<"öFōÅÕž7w)*ÆīŽ<*ŖMŠŅÉŽTgĢ4±²lEŠ6µ‘ ļŸV¼VT"ė8T4š_ĻśómāÕ½»«R4‹©åWŸ<~e1Ķć'ż‹Sy«¶ZSĻym¾ÄJ¤¼äłŹqJs+u’üżé]yŒāĀŃgø«kœ“…¬ŗ7²jQzas¤‚ā4ŪŌźÄ`·XšeŠÖļŗ¹Ø°8dx—óĖ8EÕLVRxxĖcxÉĪ}œßł°ęldańĶ³‡÷ž,w‘#SĻĶešä ØōOŒX2ģŁcĄ2ucAa™½įC~Æ"7”CČ·;BŽQĖ•XķN$²½śųŽĆgś‰-U 9+3?µH5 mÆC³ą(DCY£ÆƒÜŖįķUUQń0¢EjÄö(rjšbcĘ1T1EżU!«N?ebÓŅJ„šå®%Ć YV“7Źc"©y™‹+ŽB£ CėŠŚÉ‚Š^|Ta˜¹OجZ­L p EXØ [\xņŲ²Ža†õ/źuēņ¾ālĀ$ē÷ŗĖfĆ:„¼§‡Ö¢SWU6#ŃՑ{_M”TĒ ‘źÄŗŚŖB8XčšåŽ½gwG&V“Ō8¾ę |–••šøóó’Fcri8õšbķ]Ķ•źż`Ž»«ŪēiW? E F‹wiT³XÖ1Õ,‹SŪ‘3/‘sżŚœ"epH^}ų?“kHdIśĻ'ļĀ u%ž5vé’üŁĆWoV«’Ø1@Jc£Ęqt±’IŃ:~üÖqžT†E!Żśó×ÄĆ“²Ų+i š½$‰†KE«Å1DVß¼¢²Šį£j¢ CaH,šŸŒ<{H5Ėć7ż‹e•čhš‡™it®–Ra[Y¦‘Ujœ¬ę:A ļV(”g HÅ“ŒDóż0Zļ®ę™.ĆKR2Ž#Ū°Žéš…¶g'ū©Ž¹÷päz,&k"Wäž;3‘ŖBCŠWQW"å߉.,öĆ_U\’3¦å%9‘a“4Ėćg–ul7Ę6žÕbfl/Ęp€VźõšŚio{>¾ØŒcUĻž,Vc8æ*ƲRo–bHL|hĀ +āqobŖ,Ŗ¼ŁNŪž=öŽįæ4bĢSčē8Dz÷ą·Ņ@D},¢Ębnn»żS%#k‡œšŃ@e¤„Č«»OVÆüĘW’GKĆy§§ī`k"žųa9Ē€ŒŌŌĢ}L‰qŃk5 t<‹¶y3A=”÷F&u˜ÅŽä¢‘¶ės¶Aź†x¢Āi[1†3B`šZ…@ģÅĒ©M=\}»źĶb]+6bF&^AŒĄĆ’„Ļ:åģ/óšŠbRĒUļCš&ī-Å#‚ļ§®D˜¹X’?ėŸŖ­:NEL uH©S²€ĶČU«@g”*ølØ'æóJī­ŌYžl2ć©/r‘=¼•G¢¢‘d’³{Ułŗgc;8»,‹#‡EEĶÆüT’]ŲĆÄŠ©»ø]Ņ§©~™ĪE’åUC®–UŽŗQ…Č*ĘšF·ūPƧ˜µ2]Ċ¬^YU|{Įqå‚°,Z®É{#šK^)拵AµĮvŠ6źņö“w¶”>¬| öā#Š%9ŻźØWVu{€‡S¶J¹ Pązij>·žK5¢NP¦ĶķŖGdI³žė(׃ĪV>ģø37`qˆ+„¦}ņłÕŽĀ•ŽŽ™³ā£żX’Ć}XZuśAjŻÆ>9ĮµOUJ§ b†‘‚^÷×e8k' •ļp$źĖęöģ”‘ÅĶÜNÖ‡”¤×‚©/Z”ĘÆOl"ü«c1s„>ę„[§[+u©šßO’õńcŸ½$ŸźÜØD²1)vNėnk«o R ‡WW:“žgś²PĆ$ē¢€zŃŹ¹ˆŚ‰’{YÕī’ććē ˜¹w'ō?j,ÖFØa95ˆ°ĻIĆš“·Ś‘ ®[øU’č8eLn9žõ_žēł’z±žw*«V“WQuœ<@SRś6”ˆ¾H$NFL¬R¾i?»¼1@L’<Æ8÷ūüßhƒ{AObI~ÅĢܳ$hžCŠ* äŸXq#żSÉv®ēkĘöŅP Š‡ć½ŗ4ß&ü?hNšū’öšī“Ķ…ņŌ€m¬ņ?'æk`Wž¢pA[;€‡lqdNÖąźĮĀB²ßöF"t5‚ .ZŅČ~ŗś:ØAž²˜™ņ-Tnö’a—JÄø(m¾“²ęßŃ/ž³ ]i,QL$uāĶ<žÖžÖI’žjZį*ŠĀßyėŖӏŠoUķ@“:8ūŃł;XœšZ}<µø8- ĮNAśē? 8ŁU ‘,ü3j=čÉÓŁ#(>ŻÉGÅq–‘æŚ4ØņtŃQĮeµp4“ƒ³ā Y€¤ˆ]Xā’ ~EÉŖ²āŽMź(¹8¦:·ƒ¤8Å/JT6v% kaEŁQÅŌ œĀ„Œ āPgV Č|©ƒ|õBŠ; ēO;‹(‚4fu(v±:Č©Åķ,ĮĀźc«<~²@G`žv`X˜§š§,[°K!«øēéøa<‚āX((ń’zl}Mü}ŗ:Qd4ŚAĢt¦ƒd²Ų=Źš)Š`l ^+uąÓ ~%\Qµ ō’½W. I*„üq^ŅmY’ė¼ŲÆ5~mī£²n›īĄņčZN}ę8| \«O艈WŲžĻ/ĀÉŻ*HL‘…Ā•ētˆ–Č©N·!l2żęyžĘL‹kx5Żą²T Żž_lŻ"…½§ōx‘'¶2 ˆČ ŕ’’ūß©•õļ·9ē64ÄLŠ˜–»oZńÅŽS/äĘĘĘĪnį¢&ĶØæZ’õÆŌ;±ņ:א .2B#Ū:ųBĢrK"¾X{ź!>•E“ĻÕ1“µ !F(f4T ļā§»¶Wąō =æ ®7ż«ęå6øX{źį˜ģ†Õė®0{Ė)va6 kKŽfŽˆÆņ ®KDį±DV^Ӓ“µ ‘r3xæé„é8žB ā7«y­¹ ®]'§„źrHÕIC#¾&¬ˆÆĒtƒ«±ØK0ĶŽ &i" ‡ylĻC„Ļ+ĮįÄi>².‡“z^Šløy¤e„1±=’KȇŸœ"Rˆw+qŅļ؈‚8QWdµœČ‚ˆļRod1QĪā "§€˜’“‘Ué\E–ā8ŗ€ćLĪār&P§āOk‹•¾œ5”¬ ®~ė°m'j¤ 3äp:|1V: [wv†u‚ˆæ2Ÿ8hMß d·€"by`Im`ÓLł_&³c [ÆŌU%F•E&äwˆ\l>«¦ĘāŁs'#«c»™¬j"[€8œN§SČÅUu>[ˆ‰JĢ 3¬„č³ŠL•åfÆŚ[Wņ™k ń[?D՝£Ņc7—·Ö„¬"øróĮ¬’ $¶YOOśˆ¬±€šȎĆį’JPpėŠ3čĻó»Õżp©0IŽsłŗĀ €4feNČ<ģ4äĢŽ”vwĢ”ģ“ ÉķŹT©ęłTAEčtŌ„,}¢$¼” °–L@Ȯꮟŗ¹õ"«“Ņ°"XĒģeē@%g¶Œņ§:³Õż58„ÄĒÄ°ź v•śe¤į«ÖŒŅrĢō»lQ-”:»A—ĮĆö“Tiģ”įl@rK9Žó6^ŠårpėæĶVź{øBuk™R­«CŚ3wj"Ļg‚ –«hĻoUÆl‘Lģīīŗ+õO6 p.Ś\õÖYķAŠˆ”(pßp ŖöŒņõZ’ōqŠGńū»ū!ž @ņ²S€÷ÅŒu†…„%²TqĢ0²±®Čź,L׉ņģJRęė|÷Šg‡aéø€m«m±®TćņĶ¾å“U-Guŗfog'X óövv“·ąn @ōø€üpÄDņ«īĀ°£Ó€ae²'\®ź½]ēbŪ@b®ŌsŹ’Ē5Ļ $ķz{Ū…ӗeH|!Ü½]„Ž.ŅWļ—ķ~·w‰;H¾Ļߞ“^mj @jS¦MŽ^Ih ’ÜŽT„mj0  Ó.@œm˜Ķ†Š@œm˜; bK°9v½iG1uéĻ"‰9˜\r.Ś× ›Ē!DąüéR‡ż–S„ ‚ąž Č"¢wćWFIʅ_ó~»`ź‡“a@Ņ­Ö!8‡}vXžK üHŪ)¹‘s>•!j֝ņJR*®S$¤Š²!µ¾©N¤¶ouS…|«»DŖ³ÕšżhÆčĖ ķ«¢!Į†a,'v2~+·ƒ4, ·”ĶśŚŃi0ŌŽ^[=Ō’ó_“=yņdb„t ·* I·—#$øęŪ.%ć§ęV’&Zn}‹µ¾Ė±±¶tŚ†^Sh’µOˆTDS"‚įSš¦¬mĖ.;×FDK«EĄµėŚćL±[¶Ids)MɈ\Fmƒ2ļvYÕ”ĒIż€ß©‰įp¦z2š.EŪB ¦©Ń† v鶌č–wŹ¤VZZ|ƒ}ĘįRDląķ+”ßņŽm÷TiŁ€œ!2Ń䍶 "؛”Ķā,ńņXĖĒŖć°ŸÄ bk;ęqTŅåŌɁ·ŗє]æƵƒ±]dĆK­&‰¹3žLkĒJŌłŒJRī jT5;OĪœÓbī]Ų*~Z/ †C1t/#ūß%F(ńń„–s^`^[;V)÷dT ;.Zą¦5M %<‚”qNu8]õ¢ŗ³’`¤Ņj~xÄš n֑śf»%A’röä ›ķ„ā{(łēßU“ QŅ•ÖĶ¢§§*¦C8øVB¹n@¼DŚoõŠD’żŪé kóųæZ;Tbģ%]J*åēž/‰6‘üÄĆĶ»wKéNźd€ģ¶ö)M“Oȱ„£Å -.šc.fāÆęˆH¾å€˜&Iy6ŌŌI¢Ėz1Ā8Ī±ÕÜÓ0æ„s~’Wv²‚ęī–’šT‰›yRæ¹N) łō†Ź£īis=TżåÆØņ'4Ø[śąL°’,7?B$ påZ,²477ęˆŪŪj-kR  ‡k6Ģµt“\PÕĀÜlXŁ.·^@°Č°ņ§\ź©5”ÕŻ’B&iµAHv x·…°ĆŚjYĖę$¢ūĀ¾“éS7 HB^£üĪeŲŅ“BHņ\ÖÉĖŒšä»čøŕķ8’²^ė¤%OŌķä" t¹ˆBž¼ H‡ ~Ńķŗ€\D”Ž¤Ćæčv]@.¢P‡?ļŅa‚_t». QØƟwé0Į/ŗŻÄ:eB_™QŽŚpśä"š^źóÉ+21W`WƟ ¦wYXkyhdQ¹1€˜¼‡ĆA<[22ńÉ ·°¼&Č Įü*ęćÜ5ZŒÜ@4‚%4aƒ˜ł ¢$)Ė!ה&č†lĒ!é6qÉĶÄ“ņwŅ8rT““š~…6G:©ÕŃdmĀĀźöŅN2u®ļ. £u]wźR™:wQĪŃŗ®;u©‹L»Ø Hēh]םŗ€ŌE¦Ī]ō’—üŖ€ŲIEND®B`‚ų4DdąąŪšh² š S šDAĮ’Ćart-minaiFigure 8š€bš<4ÉĀģdNEÓ#WĶ«’ÕR’47knš4ÉĀģdNEÓ#WĶ«’ÕR’‰PNG  IHDRĀfÉKj€PLTEi[µYJoXJ­,eH:¤h†¤žWI†ž¶ÓĶGŗ²āHx’ž5”§Ś…ÉĆźŗŚō €ēäüĀ»ę“ˆĢDi¤›Ö†zÅŚÕō,”o`gŖ¢Ł{di»’’’’’-ØĘėGu±©QŠų’"‹Ø¹ŹĄĶŁ€tĀˆŒÉpc¹ž•Ó&Ž±©Żvi½’e>źę>RBØ Œ=+œ‰/~ ‰6$™ōń’zm¾ˆy_įÜ÷ÕĻń3!—Œ0Yƒ=5 UU±›’Y- –ļė’Ūź”ĒĮJ‰šÖ„½ßöĪÉī\M®ˆB1 ¤šWßIPrk9'š’’`U°—Ī/•D4vkT’˜Æ噔ćÄÅ|pĄ„ś÷’{ˆĖ „ŻŲC ”ÆŹė8.š ˆ‚tbµņš;‘åį@ ‚FE¹/'–šŠ% ’f`PÆąęģŠŁćĻŚāšóöź’ŠŒ’–:³Ńš\Uü’j^a·jpætg±3f‡<ēRÕbKGDˆH cmPPJCmp0712Hs¼2IDATx^ķ}cāʵÆJä8Jī؃°@є}Neƒ>[ ²˜ń&”i#ƚ ÷öR'}]oß¾»wéÅ®_Ž}_ÖæžĪģ›Y,˜]c3š™ó›3sęĢ™sø«mzäą¢öļžēéļŃÆaŸvĪó{¼wŃü!„W‡łüžÕÕńåÉQŚŻBųĘĄ5„‡ł`ʃu†ššų1ō§oć5„;ł˜Gw†īGīļķS.<Ņmų >£ÆWūćĀ§?M³·sĀt:_CøŸæ¼:¾Ų£ī\īļ\ī\ä÷vwĻwƎĻww÷ww/`…<888?†Ü»ē{Wū‡ē‡—»ńA„Ń@±?Ž£/0$ööčĖšĆ«ćż½Żż«=˜`IŽ^÷vé€ŚŻ‰F×äŻßŁ…ģĒū;ō ¼»ęŃ½]ś„čżžŽ1¼Ł§eœ®!¼¼vv(„€ß~ž€łĆü.°ęĪī>…čņp>ŪĶĆ éįłÕ|·{¹qpxø{C”Ė/`>?æ:Ī\Ą |xŌ>¼¹éB˜I/öF{łŻ} ķõN(C=kv÷w÷÷(„šÕ.|L _ģ]ģļåcSčąFĶī~žųrēd©xĘžīåÅÕ ‡ēt]ķ\^Ć“px±Ćf'æ#ęjwo°{°wøĮ0Ūæŗ8¤ßÓH0  EšŗO!ߣFßÄnā#)pįqžœŪChvö)&@ƒ|P­B€eD įež`ŅīīŽåÅįexi/Œwøs~up°sq¾sø{u¹•ēé„xĄA„02ņē‡‡Ąf@óÅĪÕīETÓĪĮy ¤ó|qx5\ęĻ÷ö.A‘ß?¼„™ĘH;Ćsņ _AŚ '8ŽöyĆ=ąõVŠž ÷­@ø?¢ō=a‡æV•†›ŠŃVtø¾‰Ŗ=<¼Ž¤Ž4āxŲŖ•6jUē¹£µ0FŃHœY›DłuĆSl÷`#±F|øńßčĀ¦ÖZvžūmzäŲBųČü’ą¼ņ6=j x\9ܦGMņĀG4~ įcGp į£Gp įĀˆїčךu›~B ,a-Dd`lŽŠ·2„~w‹įOą2Ĥ9ĶĘNīMF$ŽtDo‹įO‰įā\ˆŗj:ƒIš'8]Ū¤Xć·>.ƐČly!–t1@DŖFžłōū%§āŖR®źÉ =wb„,Ī…C»Gå ĀkŹ|ūäɓoéĖŻō?ß’Õ2Ó7’žZQāø=x”Ēž”Ęē¹eAxvd…Ä7ÄŸ‹Ō?żį‹/¾ųķoéė­ōՓ߼·Ģōž7_VV”T}e^ ÅAńį² Ž#•ęk['­ZƒBˆŪ’õåĖĻ¾’——ūģVzłńGß=}yūÓŽæ’ĶĖ§ '45e 2ż –O †t_Ę;_Š¬Qža©©EGóœ„Chźµjœƒ+9³®G\Ž9@żīė’¼›~ 3ėG·ÓĒOēž¾’ĶxzjķˆęĶ4_¤ öpŪ<|”k }Uxųßłj"}šäćĻꆹ›÷—ž>²Ųä*§|ÅHóW,b„Bł®äįbˆJe\­{—4 pĖ£Ć6’CŗŌNÉąRX—^Ōé‚TD^k x}ń:€ü* 0³čõĀ“» 旕Ÿ’ūĖ‰¤};?„čƅ“öĶÆ>üš÷S0äÜń)+Ž ė61AbŠt€‰a ™¢&ŲRK‘e[Ä|`Ł¶Ä[¦ ŸGvė¤¤bŅļ¤ä KHZ!) >®²dö„,qEÕĪbG¦\>NķYą÷$üģėŌäń)@8·fnįušéĖ÷~õžÆ>|zkŻ‚Ö÷'¦¬xZyĮĪIÆOrwÓ­\Ŗd·ōž†Ø䍄N¶öœėüØ ÖiöGŪF!6LģyųĖ“;ț¾®6B>ļĀ’Ņ©%:|Ä Pu äæžžó‰ōĒo’ōļŸN›÷NRńĆ÷ŽūÕ{ŸNróļ”)c~.TNS<—k«ĘŅI?ŻqqSĶtjn½AL“‰eč¢ØŌ’PHĢ FE'm n Urķę5„µŠjzøyRļC+9X­ÖĀgżz2żćŪß~żõ/ߝZ}öįź{°:;ƒł!ģ6!YUĪRē~ħ{©”Į×+”!É~֓n ģƒH(ŪA…Ė¢[M¤|­Ø45Ō䇶$:·­"ķŁ­ōæ¾żÓ›Ļłģ^œE†Ÿš‡™©µߛü÷ž{Oa…ŖĢ?1ĄŒŁvj\+żĀØws©nnµĻ²V®BdÓHćŗó„Toå¢K0‘r*įÓ\›+éŅ›‚–±ßŌįš¹é¢r¤”SĻīæš%䌌z@ÉÕć śķßżńüńgo’l)’¾dĘM,©/?|’½—!j,”'w:>DmI­ąA2Źe]2-„gįĮĄS ĮN©£‹]Ų> /‡łN¦Ów5]RKø¬ūÕ"|Ü(5½ŒtĻźŲ‚sEé42=$ĪÜɏ¾»£„»5ÓĪūö{f'3¢ß’šåg/;æø£™ź X˜3¤£}ąĶŸōH•Ššt·w“Šņ='Ņ"Œņ7ōóQżäļvÖSWµ©XĀPūx2}õä󅓈£ĀŸ’õū)»–žöa¤0ųę>­ĮļY25Ļ}‹«U}żĄp6¶M«[]ŃÖ>ö¦bJIżŚĖ/žDz¦E“÷/’łOs&Uś×‡ŅœOż§ś—_܃!B0qŽŸ`kŠČ`t ꙓ@ųē™™fg@Öļžś_V‘žz8÷sł}ÄHńÓŲ¶yƒ µÕ‚ɳ¦=ąoļ½’įßę|ņ×óB8śFA°O–må“Y œS+6 Ā‡EŃa*?];ó@Č"’N©bs üĆ·Æ żś“Oē¤> ™ī‡pĖ…“ļéĒŃQŌGæ~×:ō¼ļNŚr!ĆčĖŌ<č«_k‹ŸBŒ=„ā‰<÷(Ų(„[.œEĶHQńɓæ|°ÄōIl²£ =Ųrį,“ī’ž‹_/1żŪ“_Ē7 øw-œ{zųśūæ-<³ü÷„^LÅ –Žō’¬-1=}õ*>„™©ē…0‘¾7Æ„Ą×™yKŽ•ūoĖ6Z„s1M+ųņÕ«—£–²‹¹÷Aų«¹­u~žÆs}[šŸĒ—„e!® Āł§ąi Ų«W?~:J¬Ś»{,ŲžĀ!’¼éēyKŽ•ć .Ā—ÆŽZ>~ĢȇH›nĮ6y¶kmķL¬üÓ2?¢µp©>żĶˆŅ_=a…04¦ī h×Ęhg ŃżEÆ9ļéĻŲ!\ÄüijK(„ /ńĖ·ę~kįM+ß1„æūńĖEӋĒ³©X 3†į_>łź“O¾cŲéÆ`"żśē‹§öfŠ3o¹š»_æ‚Onq,dĮ6}žŸ_,žžļÄnus6o)Z„Ė«gōńó‡ŸjpßaŖ‚m‘Łaį…šŽ|”[Ł§Ććį’}õ)Zŗ8ĆÖŗ¹¶R=żīŸĢHÆąØkŗvf)8,š-„lÄ+~ņźÓ§:÷7F-Ą”‡ŽĢD§Ww÷±ŃÅ0śs}qJĶƏ¶²A~ņźgßżó?÷«6īöc‹ėņŌ~~Z*{·?-§¦=RÉKRNLܹ„2&&pß Ć+rį¾.}6vōxė2Ü%%Qņ³$U·…6µä†ļüŹbÅ~N‡ÄBFæóƒ?}ņŃ¼Ņ+¢^®Mfƌ¼l®łŗ2‡5ž—ž|ōwœ’äń¼ÉEV÷¹3œŹåy,Ė$Ø)½.ƒį/²\®Ótą>“£Ć­ńla]ļT0õ§ĶöōégOõĮĒsCص”¶Ųµj†l#)ėˆ]×O ŁnS0jŽpZIĮ»Ž•–ø8°Ą.ÜéõJ~ ó]ä4[µ Ā ŸÉäu½N:’‘Š‰M]km¹0ĘHčpĻ=‘Zł\®&ZŗIPĪ­ė|J“ |ū“•¦÷ įŠh)Å÷E„6¼"Š ąeĮ}'pj1Ø;ÄĢ¶D•Žņmz֑†›¼_!i}īĘ į;Ījø晛 éDJŌ¾`Š[¾/Ń~žT9ćśō–Æį“¶Ż‡[¾žč–ÆšĄ(„ž ¬‚[ŃEķŃŃ(EƈÖ×ä–ļ;ʅ½zŌUBšp;±ø‹ą“ÆXöŠÅF„Ņ% m¶`b·ķĮ–ĻØ ²R†ķ_薰ė"·b•‘F7€X€ ÅEÅ »ąŁ«[ĘŲ¶g(c‡÷š£l'Rv§Z°­ Böfm!d§ÕT×AI€:Ėœé0mł1h½¢¬ÓŽ|?„ˆ„%×-•©öü”§øŃ{ō‚_"Q}ÉĻDn4ļMɀpŚ]{€š«§qœĻyXu?m[ /f܆euł¬ų ÆĪD@ˆ”)9ĀfmL|’›eĻņ‹AVna-$”õ Óćd@XššE?„i_ŻqKżŠO¾Z3#}ƒ¦› Mp1L„÷ø”½¾ ÅöūÕŗAHƒ“eCŠŗ%}-œnĮ†nū~Č84\7‘ÅŸĖӀ˜·dµČÕūEĮ‘{õeĻ ?łóō¼[^;½¬ÉGČŲ =ņ×v»E—ć‘qV"&RLY cŽ£µƒĀū”²ż~QĒ»‚“¾ŖŚł ØŁŖ©%Ā{®ˆĘAq !„Ų ¼™A·VB0²#z–ų‰9‰ąĀ°:q‡(r7y×BTČ՝\Ūø„ó¾Et;›Ž*Ā֙GÓ»w¤6凅–p§bķ D „#żÖĘĢ= ˜drœš‹bąžsBS»±ßyŃEāT¬­8Ӓŗ–¢ĢuT˜k*£ Ö…kS0”RĻī”Įw£­Œ5Mwf«7kĒ…-]-[{Ō‘*gJƒßa}šbH,B¼›ĢSl1›²~j!.-BŠDp—¢X€[q`Ö¢Å0āĢŌSūĒ!\ D±“ŠIBZ+(rQ;s-Īܳ)&Žaö$®…”׶sv§oēnņ~Õpq¼ŽS$ƒ ©łÓ¢hż&R„µ’“1Ą»-ŠLö5i˜DʼnIJI„hŚaSL¶\?.dķ@2 \Ž‚mādƒ•€ä[šČwōäF ‘HĆŽ2l|7žF_Arq1\ZmD;‹R"øp) ¶›)>A/*»0„(%kB:s¶ lKŲT?žĶXśĖGk!:k¶¹¦››1Å$ƒ  Ē|ĶlćÖn/’°–Žˆ)c.ˆ'~"]†‚m‚HŸ}²jM¾ĘużQnĮ…ĖP°­!„ą!%-€G†ķZ8‡X²\"„[D„ʌC¤Dpį2lkȅŹ›¦ū¦Õ§Ü6om2 Ō'|ŃĻĮv·Š¬öÓł£tŗY±›Še(Ų֐ Ė^ŸŽĢEļ˜‰ąĀū‚ĢĶŽėĮ…ŲčõzÕį±`²! ‹+Ų֐ Ćb­f ‚=Ćåq"ø0”ā *Ņcū‡O “¢ę^‚‚m ¹iµ39PŁ€‰“żąŹųKāz¬…!ö›LFŸĶč¦W‰˜HŖ` ‘)›²,ƒæ©Ä‹3÷DN‹Ļ}×%ք ĮÄ©[F3¼%$Äü)™kaˆR¹#CØÉēĀÕH¤ GY8ģ–×<É8­4ÜŌNüD®@Įöpł½hś‹ÅlBĮÉ8.Į$BŌZüŠčä¦āVs¾łč‹‚EŚŃ‹®ß7Bk†ÜW°AßżliA. Q;ŻĢ5mźž6ń ¶ģ’O*Ā…ƒĄŅ,¶bq=w3¶öK0ȏĖØ ł¶`Ć5É(Cœ$ž —½©`Ą‡!ĖĀ¢ '6mšż½–¬`cĄ‡!ĖĀBō 2/AhšäCøtŪ’yąM<:[w<”ļŻŗ)¼8„J[®×ōūb‚*J†Ž”Ÿ5Ł0šĢCYP'_Ƨ«Ś©±µ"/ģ£[hP‹ž„˜]wĖ/ !N7åöVĮ¶ xĆāHĪāÖJM »Ō6m¢s ōNÕO² F•ĢÉ] …”ec¼ÆZ"E¦I°ė·šeCr|e„Œoe…^=ąóżŽÆ•ź©wGźX BÄ«p;Ą–“ ¶„ļ oń.Źœ RóŽ<×}£Ź-š%ā“ėü—}ŁMk”ĄÉRIŸŻfų!<ɅžČ jęe+Ųn“ ™¶Õ(bķČKŁjMvk°2Õ!“ŖĆ,[ČńˆŻńūŗ(„õŠ“6Āe+ŲīB”ńPØ5•&Ot¹”³p¶ /n;•."ūDķ‘/—Ļ…uTµąĀpåiæaj–»S÷»¦dÖĻ2’^ēł¼*‹åV:“[śZxRėVüŽ„ś&L¤K?/¼³ö(‘-g±U 9×ć”0ÅAš_×i ­‘ā P—Õ›ā>{Į‰”Ļūõ£šŸknĀÖžĒĪKŁOŒvCqsh[¹äž¤;ĀČŲzŖŁb†?’ėw¢zOv,[ūš$‘ 63ōįüpJ„ą{uV?—Č‘ĢZ YėI„īŠl¬ŌœĢ·8„ŃĄœ“)®~-œ ĆE!D8(‚2Ƶ×bV­`› Į…–”ÜSĆuŻŚF\]õ¾šŻ@˜©åÓ¹ZMÜkīŹŒū[óA°h©E'Ņb±°9WD“)‘ĀaÓ =¤&|ßWÉg’9‘†HĢårG§„ 8©X½‚m®9uщ4ņüKv° &Ō‚-r)‹„Ū¼n”}Ć?1‘¢Ō Mš\L“p”…¹9ą-A?½uRał’$ą3³ę­„“a2ř ’ HQ<‘· „D«Ń s£h1\<䣤*Ų)ń˜žTŽ%ģčg!ń|ćzƉąĀ„*ŲBħsžŃ­„ĖM!m(õ‘”ÉÕMŲ­%82^xń˜ūÉT°…gMŒ“'iœÆVŅ‘BX ’l¦JSaÉ7ōęFc®‚ÉÜŅ+¢ĄdŅ­+¢@M(H0‘ś'C.“Č(8ģ\Ä[‹B(™ 6ø"`¬Õ&]ŹbŃ ­#«/7— ˜MÓāŚæūĮµų¦¢p$wŅ·®ˆĀĢź× X“üZ8-!āĢ²ļŚ/ž…! qCļš·– T”q0ų3IĪÖ>± 6šėŽ¹Ł4RĻŒö‹ÉŲT,!ģroā) s!Ņ¾_gHš‰€¶ö³n3Æ”™\BT9õŹfT” ©`CDKĆmʙVˆÉ€0‰jndm_ą8®½G¾Ih³.Ū'Ā¤žŗŗ(țĮ…Ė~7KÖdū~A‰*!øµ)kacĘEX6’/;×Ā"©™3Ūg¾‰˜H“Ŗ`C:6ÓįER,ŲŒ$^€•‹;Dpab-Ų˜¦öd@˜P‰”N¢ˆŚŒ&_˜T[Ø“‹†Śi"-ŲĄu—(óy3· Ī,Ŗ`;R¢ p‹pė.I(XA¦E÷…Ø{ōƒ_@Ņ q{+Ī¬»Ń#…0Är­Öķē¾Ü5woF”ĘÕĮōŠ“†0Äķ2”[—ķoW™.DÉT°‹¾…ĖŲœaa™ »‰Ō‘ź¹|Ī÷żŪ~gɅ ÕĪ'9#u2˜å!\˜P1¶ØõÓF˜?%ӂ ¶ö\Rz#lgVæp>‰vQ‰Yy§R*•6!NEB-ŲPå"EĶ²ĒOČya;‘”FĄ^a&€IqZ’Ä+¢0yćtžččع kaRřPń”ŠemĀZVŖ`óL1•™åĶ#ūB”LķLˆź¦ķµš;“L©'DŻAāFœ&Ó)RN1øé7ā¼0™B g_RķŚFx¼H¦˜Æµ13ćbS2¶öˆŸIw>„Ų2K-Ø`óÅFWQŗMŲT$RĮ†I“źõzĪ߉Ā\'Š _k…-Pro†š;”WD=Kjyš&ĻŠ[$bkŸP[¶žÆ‹¢ß¼=ŀ‡Ė(${Ž=)jngŅ‰ü2e’žµ 8ķš o‹jŲ5rXLqÜ tĮ… U°!¬u|KÜĘY‘ĢūżNVK„É4B ±‘«ÕkG)z ‡OčHiwIŅDšLķ ²NOüŖ#œ[s#Æāē§gYI6­ĆDD‹IØUswŚXøe Œ±Ū4‰ģ·åa“ˆŁä<ž˜M åBķØՓ5æ:¹é-›M£zeLü(“!6JMŚ,Wś Hf+/šLGążznŅ™%օ"!ÅBƒśĀD„ LäQ„K¼‡ŗ\c‚ >5õŒī™uNMGqdaČŻ w»r¾gŖ`±}!*‚× Ńŗ¦•9Ēq ķŒ3 ưɀ0‰‡Mˆ? Īźż»Ź_jZ ŲĮQT’Ān%Ā“:"Ž4›ß“Į…ĪIņN*ŠI=gŪ'ĀD*ŲŠIŗńwŻo46Ć[Į¢ MÆ5mČĶ¦d6µQŚßÜIU°E²ēĢÅ0kaB!œ-Œ&ēČ7© 66 Į…H›a-ĖF‹eēZL;ĆܚD@ Ün„IŌĪl!d¦Ąź2n'Ņ“ŻN¤1ˆµ–Y©`c¦t"ÄŌJd XFa2lŒ&äČ7™ęOŒ&ƒ ·2Ā½¶ŁPÄ+¢¬äNnl¬pÆo¾ķ¾p}±alŁVĮĘHØõĶ¶…p}±alŁv"e$ŌŚfCŻ”]óš„­š›TšåEžżYKĢ¹…01·ka b­gÖ­vf=q‰ŃŖ-„1ˆµ–Y· ¶µ„%N£¶ ¶8ŌZĻ¼ÉtÄHėDع·G¾ŒhÆq¶Ž“¼ū…ĢäN&ń®żfAˆ”­‚ńõĢøU°­'.qZ•Š˜Ml$HĘZøÕĪ°”½Ę¹ōŃ8ŽMÓ·'ģtGĮö°‰Zk™s«`[KXb5*©Įļ˜ˆ qf{äĖö:gŚn*Ö¦¶mlLdZćL[ŪƒĆÖ“ķ©=®sÅ=֙逼NõńKÄ_ ćöœļĘ#ä^×­}9¦e¤3ÜĄŻ& b_»Ž­`‹Ū hćIlkću…Š+ÄŽØuBœāćR+¶‚-n/Āl¼~Ɯ Ń(XLü‹ŚŽ­Ø ³¦TIŅŠ !rcN aÜ^@/cŻUCˆ»=wøāÄŽŚĒķüOa7eÜ^¬„8³’žĆĀ­˜8³¦†ĒĻ…XŠq© ˜ėŽ—2ž*W cĪa6ÜH7ž8 »<Ž“ņfŒxBq{uōā6 yFYen‰yåóˆų\”Ć+±R#cÅŹÆš„…Ž“,n';Ķ+gc6*v/%næ„Õ—€– a£ ""SÜÉ NjWćå?įŒ8‡¼'FĢ& '^£q{ĶŠŁo(ўĖVa/Z ‹QŌ­©#o”uõ¼ņOQGÜ~{“ńč— !Ū¤X[K_-3‘G›a©†„«ØŅä y“¤y, _.„!j›śZŗ³~,xĢŃĪ%C¢2DŽŚ¦Ÿ’Ė†š¦ķ„˜żĄń  ėĄĻŒÕ`*ˆcBŲG¢%bTY” 1 ŠęDŪÄŽŖa‘ńJV!2‡XQ7‚j'Ņ:ö †‚—EŠ7&ó<°gF]Se<ß@V_0*öÖ³\1…„’„{ŒÄĀ¼j»+Į½.±"QOt…L Ć&¤éĒ™ƒ=©“ņfĘEš(„¤ą§:9ViĖ³Å2²źŽ‘fĀi¹B*×Ć²}ā³£JĪi§Ū(ÄBŽbƒó5Īhš¤ŸŌÆ+Y„5ž4š¬C+R‹›¢Bå“L²"+„HIēU„ź.&éµ¼ō©P&“ĀĶ€hĪ/ĪoÕK„™zŽ«6‡R=”É!13ˆČ}>§‘Œ0źĒj DŻ#żj~Ā ©zĻlŁŪĢ|ŽHA Ė¼G¬S&ž° Ie,ź•­ØQB$c»~—ü Ė0A•&B~‹Bt!d¹ó\čW}`ß(­Ā IĀ²Ļ¾V”¾āÖćFh’Ų?qšGtX·›& u£yĮŠåz&.¶cF„=»YJåB\¹nü>ę…5MH74©Ž¢Ö ć–X×,I’óם_„Żf<.Df®`UŁUīØ ½F\ŽōB$7#Sķ(4pŹ/ā†ŲmŖn2yq&EÜQĒƒōÆqA-ź«0Ä5—“ŽĪ˜ŗѓļ9@^v‘zAH*]d®BH²jŒ]@X&v‡!ĖR ņ|v\‰lk!jųl*U§ļ±±!ę}*éŪ*Y„Ą ß×ćX €`R 9µš²žćXÅXŁ:BˆÓ’Ŗ²īBŅĻpė˜µ. ×bīHVÕ,ĪųzŽm&½&”0Ęå¼Ē¶Ŗ¹EŚAŌłQ‘A¢T!ÅŅń±}s!ŌjN—ź|é4h4¹7RŸØö.ķµ%O4Y¤– żĻŚ\‘¬ņi°KÕ4]zĘźŹ‘Ėóõv*WW™Ļ~ę%ū2Ėm.„øķĖ29©g¬ĀQøuOM8ÓwSy?ĒdCøLyÖCXĮģ‡Óš¦ƒøXéYGJ±č“žėŗüˆ–Āq#Ähtk8 g”rńęØū1õķį”Š~¾b1ßĀ­¦Īå2D•Śżt¹->’(Ådeäq7[¤į–7Ąp×!ćT9­‘¢·ś5īĪNx‘9ą–ŃtŅ-”āæPD^ĒZøöH†ńˆ†źĶDŠK§6QD —µ!ėa įJś į‚ōĢµ®KŹ©ųČc²ēz§ą0V]„½Œī$Į #zŸ)ŗõXŅ[Y<ń$Ķµåȟ2M!hēyŒ BŻĶ–d¹  _ Ū{Ųėī8„¼¤ •/Jp u¶ÖŲ„ē :ļfōNĄ7ü»•żzõ4±­ƒPÕŖ¶ź“Iˆ,½S+DöTå`øęs[0*5qĀēIbéņˆ:öB^ÕĪ¤¦bóHl¹)˜HĪFĄ&=ÓsM®Q’R‚Rg½ōˆØšØ›z!j4ģŚåĄN”¾…[µM-gĄe ųįŽ Į±tģTu‡“×ų±­żšč,²¾1c¦ūĮį™Śš+ų&¦ŃuņH¶n=Ś\ķĢŗ!1w{¶ĪMŗu)ø…p]˜»ćkį]%éÜj&©9ŲuQŽX‡åō~¾ö"ĶŅżčé“]ģ)RŌÄ)A Äźm uWĆN©Hq6Ѧ·–•V!e¢ƒćµ·ŪTĮA¶Ė=‡łn¹ŹĮU¾L ķ²a”Q)ÓfĘ·tPų¶Ū“Ńc‘5@ø­3¹> H+0ŗŌønz`öcīv²ćĪsŽn*JB§/[>ĖĄ@E1“cŖE‘ÉY}Ž¶ø›Ō•ž§śUł—BTQn&ćüą‚3¦és³9…]BӔ”x&¤~č³CČŪZĖn l¶8j8LŲL]eB »rö։Ž˜÷'TéiŌ·ŽÖ—«FIÖCW••‚ .>šN§:m9‹9¹Ļ:£,ųŃäŽĢź¦÷dÕõl]®0¶ 5T9ӕU¹?&Ģ(‹:įķŽĪĢS”†Šmę^Œ–B‡Uˆåļ™ęøžśķ¦Eö1„zŗÄš¹īŒķÄŚ}jA< Č®NÅTO<ö=ńĄž‡X1ÜW`‹ö-Ž?RXuąüŽ‹ĮR”†øČŽ‹µŲ€›GŠmZ•v&R”3rH$­¼@¬ęŒµa¬$ļ4)…Ŗ2³¶ uUAÕJPóV)œŅxŒ½'āAEÅ8» TźŠcŪ¼qķLV—ÜŠ@× ’žÕÅZ¹¾NØ«ĄŸ z`ߊ-^t±# AJPĮÓaYė†–&Ā–VŃßś®D°y±p)Ļ¼£ŗ° -²«{Į\WĒ©fY\„1&<Ļęm4r³ ›©§][ōZ‚ÅŖ  †Č¹>AƳłsåó–zŽ™w;n ÷ŻV_ēŪB6kn?Ćs -{.¤yÆņ&Wxvn•z¶Ÿ1» ³ą£Ā˜y"oȚl3Å wyRĶ0C¢Hg虡ØS„Ė19,*DeUų¢TMoƒēOµ@*[ST#ĖÜ ˜&Į\/oż*Rƛ4fĶ]·EĮ“~čŗT:®eģēv«^qO2rV¶ģk}° 6]¤iĻÉ=,ŁkĻŽŲ\†ūń9Ćp[‘Ō™A–Ł`ń 英.2ĻYXļų$«3CŽ*RØ ]b³ź)€ ]5ąŒ”ŹlūŒKŖeI½U„“IIž”‹ ƒōz óq;Råuæ JZ»āˆ™œ Ūf›Æ˜¦.g{Hv±%ø æ€ÓņŠj€y‰¤‰Ģ©-’FĘŪSėŲņķtš.— Ž*³žÄlS?kudēŒ™X„k“Œ\`lÄļć3ŚYO5ø !gģ»Ī²Ö”KŪW?MgĢˆk\G ZŹNU@ē*ź’‹»]W{ž?A łj(.Œ-ĢgP>t{Ŗó‚³ū&ø. x­TBØU ™·L‡IE&bŠ²ŁĢŸØAs†ē„×:«: T90zÕßj„F;}RPD>ō™wų…(a€%Ö](€DˆĖ“oP3I¹}+Z'éDŸ®ę–=O-õ²rpŅé“]³`5GµŅ.Ó1œzU…y(Ū¶zDpõ_Vy$”péØ*vģĄU{GØ0f‚„®%"ā3oÕ9lBI‰½ó%‰:iŒ<åeLµ5¾ÖŲŠ@˜RC œ­³+ĪŖ„Y»ĪčĒ¬LŠĻå86PŁÖUwĢ®l\G*ˆvW"\µŻ®zņBČfĄœŪļņčH³CĻV‡Óm³Ā'¼HšÆUĪ H…āąIŗR™B žUȒ–ĻŖm=:é 69"¶ŃPõ<~k0Œ¬šbitFŁUU‚ŗ`zĢ*`C9NČH¬Jkœ Ā—µ`3kæ0LÓDzģw*0Ų‘ŗ9Žø›SbĘ[ a¢c7›ŗ­–…Š„.*·ZÅb£UÖ4ó-E+Y ņ‡–āAUkTZž×™§Ū‚łø¬ .²<žāź-±e¾+–xę†`@5Œl1ŹØTmƒžu­…Öķ.H_.óFjŽ•jŹĄšŹV1lœŠ»D¬‰n¼Pd’ĄžŠüÉx›&mg"Š±ŸįÕśa˜®čæ” ’żŠč÷Š*šqåkŌfÓš7ŹĻŽõ9 Œ DŲI5ģsœFÅ/0ģGœ6Ż!TLķĢ=zhńaē³!ŪģĖ”@L—Séö)Ė¤ĄĀeRó*phfDV`¢D MsŪFollowedHyperlink >*phf`^`` MsŪ Normal (Web)¤d¤d[$\$B*CJOJQJ^JaJphPžo"P MsŪ titlenopullB* CJOJQJ^JaJph3fLžo2L MsŪ titlepullB* CJOJQJ^JaJph3fZžoBZ MsŪ centercol¤d¤d[$\$B*CJOJQJ^JaJphVžoRV MsŪ questionform¤,B*CJOJQJ^JaJphøžobø MsŪquestionforminline[¤–$d%d&d'd-DMĘ ’īīīNĘ333OĘ333PĘ333QĘ333B*CJOJQJ^JaJphdžord MsŪquestiontext12¤d¤d[$\$B*CJOJQJ^JaJph`žo‚` MsŪ answertext10¤d¤d[$\$B* CJOJQJ^JaJphf`žo’` MsŪ answertext12¤d¤d[$\$B* CJOJQJ^JaJphfdžo¢d MsŪanswerexplanation ¤i¤iB*CJOJQJ^JaJphfžo²f MsŪincorrectquestion¤<#5B*CJOJQJ\^JaJphłcfžoĀf MsŪincorrectanswer¤d¤d[$\$B* CJOJQJ^JaJph™džoŅd MsŪtocbg!¤d¤d-DMĘ ’Ŗ»Ż[$\$B*CJOJQJ^JaJphTžoāT MsŪheader¤d¤d[$\$B*CJ#OJQJ^JaJ#phZžoņZ MsŪ errortext¤d¤d[$\$B*CJOJQJ^JaJphĢ3XžoX MsŪnotetext ¤d¤d[$\$B*CJOJQJ^JaJphĢ3TžoT MsŪtext14!¤d¤d[$\$B*CJOJQJ^JaJphTžo"T MsŪtext12"¤d¤d[$\$B*CJOJQJ^JaJphTžo2T MsŪtext10#¤d¤d[$\$B*CJOJQJ^JaJph^žoB^ MsŪ text14serif$¤d¤d[$\$B*CJOJQJ^JaJph^žoR^ MsŪ text12serif%¤d¤d[$\$B*CJOJQJ^JaJph^žob^ MsŪ text10serif&¤d¤d[$\$B*CJOJQJ^JaJphlžorl MsŪrightbuckethead'¤d¤d[$\$#5B*CJOJQJ\^JaJph’’’Ržo‚R MsŪright(¤d¤d[$\$B*CJOJQJ^JaJphFžo’F MsŪtitle)¤d¤d[$\$B* CJ#aJ#phf^žo¢^ MsŪsubtitle*¤d¤d[$\$#5B* CJOJQJ\^JaJphfbžo²b MsŪ buckethead+¤d¤d[$\$#5B*CJOJQJ\^JaJphXžoĀX MsŪbucket14,¤d¤d[$\$B*CJOJQJ^JaJphXžoŅX MsŪbucket12-¤d¤d[$\$B*CJOJQJ^JaJphXžoāX MsŪbucket10.¤d¤d[$\$B*CJOJQJ^JaJphVžoņV MsŪcredits/¤d¤d[$\$B*CJOJQJ^JaJphZžoZ MsŪcmetag0¤d¤d[$\$#5B* CJOJQJ\^JaJph™VžoV MsŪresults1¤d¤d[$\$B*CJOJQJ^JaJphZžo"Z MsŪ rctoctext2¤d¤d[$\$B*CJOJQJ^JaJph\žo2\ MsŪ rcheadtext3¤d¤d[$\$B*CJOJQJ^JaJphZžoBZ MsŪ videoicon4¤d¤d[$\$B*CJOJQJ^JaJphTžoRT MsŪbyline5¤d¤d[$\$B*CJOJQJ^JaJphfff\žob\ MsŪboxhead6¤d¤d[$\$#5B*CJOJQJ\^JaJph^žor^ MsŪ boxheadthin7¤d¤d[$\$B*CJOJQJ^JaJphXžo‚X MsŪtextdark8¤d¤d[$\$B*CJOJQJ^JaJph\žo’\ MsŪ textdark109¤d¤d[$\$B*CJOJQJ^JaJphZžo¢Z MsŪ body10top:¤d¤d[$\$B*CJOJQJ^JaJph^žo²^ MsŪ sectionhead;¤d¤d[$\$B*CJOJQJ^JaJphdžoĀd MsŪsectionsubhead<¤d¤d[$\$B*CJOJQJ^JaJphZžoŅZ MsŪ body12top=¤d¤d[$\$B*CJOJQJ^JaJph`žoā` MsŪ body12bottom>¤d¤d[$\$B*CJOJQJ^JaJphZžoņZ MsŪ body14top?¤d¤d[$\$B*CJOJQJ^JaJph`žo` MsŪ body14bottom@¤d¤d[$\$B*CJOJQJ^JaJphNžoN MsŪ titlefontA¤d¤d[$\$B* CJ#aJ#phf\žo"\ MsŪ headertextB¤d¤d[$\$B*CJ#OJQJ^JaJ#ph®žo2® MsŪ qacontainer_C¤į¤į$d%d&d'd-DMĘ ’ŻŻŻNĘOĘPĘQĘB*CJOJQJ^JaJphXžoBX MsŪ questionintroD¤iB*CJOJQJ^JaJphLžoRL MsŪqatableE¤B*CJOJQJ^JaJphXžobX MsŪquestionF¤d¤d[$\$B* CJOJQJ^JaJph&MTžorT MsŪanswerG¤d¤d[$\$B*CJOJQJ^JaJphzžo‚z MsŪresponsequestionheaderH¤d¤d[$\$#5B* CJOJQJ\^JaJph&M^žo’^ MsŪresponsequestionI¤iB* CJOJQJ^JaJph&Mdžo¢d MsŪresponseanswerJ¤d¤d[$\$B*CJOJQJ^JaJphnžo²n MsŪuseranswerheaderK¤d¤d[$\$#5B*CJOJQJ\^JaJphłcRžoĀR MsŪ useranswerL¤iB*CJOJQJ^JaJphłc¬žoŅ¬ MsŪpollboxeM¤d¤d$d%d&d'd-DMĘ ’’’’NĘOĘPĘQĘ[$\$B*CJOJQJ^JaJphXžoāX MsŪ pollheaderN¤-#5B*CJOJQJ\^JaJphZžoņZ MsŪ polltableO¤d¤d[$\$B*CJOJQJ^JaJphfžof MsŪpollrespondentsP¤d¤d[$\$B*CJOJQJ^JaJph~žo~ MsŪresponsediscussionheaderQ¤d¤d[$\$#5B*CJOJQJ\^JaJphbžo"b MsŪresponsediscussionR¤iB*CJOJQJ^JaJphPžo2P MsŪ yourscoreS¤iB* CJ OJQJ^JaJ ph&MTžoBT MsŪ scoringtextT¤„B*CJOJQJ^JaJphXžoRX MsŪ incorrecttextU¤„B*CJOJQJ^JaJphłcXžobX MsŪ correctanswerV¤;B*CJOJQJ^JaJphdžord MsŪ proceedlinkW¤d¤d[$\$#5B*CJOJQJ\^JaJphģ=2’’’’„!’’ z™‚!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’  z™!’’  z™!’’  z™!’’  z™!’’  z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™!’’ z™ŽQ ę9#H+(6’HlT^lzpęt_…l‘Æ¢z°$µ’Ē„Łgę…óŖ¼"2ģ=E/#{Żb{  . { •‚{p|Œ$ö¶„ō$ż’S¤Źāų7gƒ™²d¤Ó2gŽÓ’ @ i ‘ ² ś : x Ä Ņ R & • Ō Õ " # q r ¤¦°ĪTV`GŽ£¹ŗŪšńż'BC^rsŽ”¢µĮĀä&':STp‚„—\×Ų#%C*¾*H+Ć+L,ī.õ0¬3(6<ģ>BgE’HaIJhNČQŹQŌQlTēTŽUVŽ[[ __jbƒbČiŌi$ktkykk›k¤k³k“kĮkĒkćkękčkékökžkllll$l(lFlJlMlNl[lcl{ll‚lƒlŒll¦lŖl­l®lølĮlÓl×lŚlŪlälźlmmmmmm-m1m4m5mAmJm^mbmemfmrm{m‡m‹mŽmmšm¢m®m²mµm·m¼mŠmėmõm n!n"n/n:nAnDnHnQnTn`ncnnnon|n‡nn“n—n n£n®nÆn¼nĘnĶnŠnŌnŽnįnķnšnūnün ooo o$o-o/o8oDoFoOoYoZocomovoyo~o‡o‰o’oožoØo²oŗo½oĄoŹoĢoÕoįoćoņoōoppppp"p,p/p3ppKpLpUp_phpkpppyp{p„pŽpp›p„p­p°p“p½pæpČpŌpÖpßpépźpöpqq qqqqq*q,q5q?q@qKqUq[qgqmqqqsq|q„q’q”qœq„q³q¶qĄqĮq€sūsętx5{”~ō_…Ś…¾‡Ō‰KŽ’8”u–Jšź›””1£\¤ÜØz°õ°5²°²ī³”ŗ2½Dæ^æĀČ²ĢĻĢGĻ7Ö²ŲŪbŽwą¦ą÷įłį āņāZäeęgę‹ęH菼ķķķcńeńpńHó…ó‡ó’ó[ōÖōhõ9öśö°÷µų%łąłgś½ś8ūü‡üżž‘ž’«’Ŗ w4WÆe0Séė ƒ 6 ß ™ U ś m ¦×¼rHĖcčæa™/Ūa<ŌŽBH ‘ !y!"½"t# $Õ$S%>&ū&Š'o(a)ļ)ń*¬+¬,Y-ø.¬/!01‰1Ž12s34É4o5(67Ņ7f8Č8*9Š9d:ö:«;|<1=ė=ī=$v:$$v:$v:$$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:u:$v:u:$v:u:$v:ėt$v:$v:$ $v:$v:$v:$v:$$v:$v: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u: v:a v:u:$v:$$v:$Å/V$v:$v:$v: $v:$Žg($v:$/E1$v:$v:$v:$v:$v:$v:$v: $v:$v: $v:$v:$v: $v: $v:$v:$$v:$fŲ9$v:$v:$v:$v: $v:$v: $v:$v:$v:$v:$v:$v:›v:Sv:« v: v:üv:ėt›v:Sv:« v: v:üv:ėt›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:›v:Sv:« v: v:üv:ėt›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:ėt›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:u:›v:Sv:« v: v:üv:u:›v:‘v:¼v:™v:łv: v:`Æ›v:‘v:¼v:™v:łv: v:u:¼v:u:¼v:u:›v:‘v:¼v:™v:łv: v:u:¼v:u:›v:‘v:¼v:™v:łv: v:u:¼v:u:¼v:u:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:u:‘v:¼v:u:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:u:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:u:‘v:ėt‘v:u:‘v:u:›v:‘v:¼v:™v:łv: v:u:‘v:u:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:u:‘v:¼v:u:›v:‘v:¼v:™v:łv: v:u:‘v:¼v:u:‘v:¼v:u:›v:‘v:¼v:™v:łv: v:ėt‘v:¼v:™v:ėt‘v:¼v:™v:u:¼v:u:$v:$X3$v:$v:$v: $v: $v: $v:$ -$v:$v: $v: $v:$v:$v: $v:$v: $v:$v:$v:$v: $v:$v:$ -$v:$†4$v:$v:$v:$v:$v:$v:$v: $v:$v:$v:$v:$v:$v: $v:$v:$v:$v:$v:$$v:$v:$v:$v:$$v:$v:$v:$v:$ $v:$v:$$v:$v:$v:$$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$v:$¬$ż’S¤Źāų7gƒ™²d¤Ó2gŽÓ’ @ i ‘ ² ś : x Ä Ņ Q R & • Ō Õ " # q r ¤¦°ĪTV`GŽ£¹ŗŪšńż'BC^rsŽ”¢µĮĀä&':STp‚„—\×Ų#%C*¾*H+Ć+L,ī.õ0¬3(6<ģ>BgE’HaIJhNČQŹQŌQlTēTŽUVŽ[[ __jbƒbČiŌi$ktkykk›k¤k³k“kĮkĒkćkękčkékökžkllll$l(lFlJlMlNl[lcl{ll‚lƒlŒll¦lŖl­l®lølĮlÓl×lŚlŪlälźlmmmmmm-m1m4m5mAmJm^mbmemfmrm{m‡m‹mŽmmšm¢m®m²mµm¶m·m¼mŠmėmõm n!n"n/n:nAnDnHnQnRnSnTn]n^n_n`nanbncnknlnmnnnon|n‡nn“n—n n”n¢n£n«n¬n­n®nÆn¼nĘnĶnŠnŌnŽnßnąnįnźnėnģnķnīnļnšnųnłnśnūnün ooo o$o-o.o/o8oAoBoCoDoEoFoOoVoWoXoYoZocomovoyo~o‡oˆo‰o’ošo›oœoožoØo²oŗo½oĄoŹoĖoĢoÕoŽoßoąoįoāoćoīoļošońoņoóoōoüożožo’oppp p p p pppp"p,p/p3ppGpHpIpJpKpLpUp_phpkpppypzp{p„p‹pŒppŽpp›p„p­p°p“p½p¾pæpČpŃpŅpÓpŌpÕpÖpßpępēpčpépźpöpqq qqqqqq'q(q)q*q+q,q5qq?q@qKqUq[qgqmqqqrqsq|q„qq‘q’q“q”qœq„q±q²q³q“qµq¶q½q¾qæqĄqĮq€sūsętx5{”~ō_…Ś…¾‡Ō‰KŽ’8”u–Jšź›””1£\¤ÜØz°õ°5²°²ī³”ŗ2½Dæ^æĀČ²ĢĻĢGĻ7Ö²ŲŪbŽwą¦ą÷įłį āņāZäeęgę‹ęH菼ķķķcńeńpńHó…ó‡ó’ó[ōÖōhõ9öśö°÷µų%łąłgś½ś8ūü‡üżž‘ž’«’Ŗ w4WÆe0Séė ƒ 6 ß ™ U ś m ¦×¼rHĖcčæa™/Ūa<ŌŽBH ‘ !y!"½"t# $Õ$S%>&ū&Š'o(a)ļ)ń*¬+¬,Y-ø.¬/!01‰1Ž12s34É4o5(67Ņ7f8Č8*9Š9d:ö:«;|<1=ė=ī=˜0€€€(0€€€˜0€€˜0€€(0€€˜0€’80€’© 0€S€© 0¤S© 0¤S© 0¤S€© 0ųS© 0ųS© 0ųS© 0ųS© 0ųS© 0ųS© 0¤S€© 0dS” 0dS© 0€S€© 0S” 0S© 0€S€© 0ŽS© 0ŽS© 0ŽS© 0ŽS© 0ŽS” 0ŽS© 0€S€© 0² S© 0² S” 0² S© 0€S€© 0Ä S ™0€S4 ˜0€S€80€’€©0€&  ™0€& 4 ©0€&  ™0€& 4 ©0€&  ™0€& 4 ©0€&  ™0€& 4 ˜0€& €˜0€& €(0€€€˜0€¦€˜0€¦˜0€¦0€¦(0€€˜0€V80€V©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ©0€G ©0€G ™0€G4 ˜0€G€(0€€˜0€„˜0€„˜0€„€˜0€„€˜0€„˜0€„0€„˜0€„€˜0€„€˜0€„€˜0€„€˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„(0€€˜0€ŹQ0€ŹQ˜0€ŹQ€80€ŹQ€˜0€ŽU80€ŹQ˜0€Ž[80€ŹQ˜0€ _80€ŹQ˜0€jb80€ŹQ˜0€Či80€ŹQ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ˜0€$k©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k ©0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k ©0€$k ©0€$k ©0€$k © 0€$k © 0€$k ™0€$k4 © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ™0€$k4 ˜0€$k€˜0€$k€˜0€$k€˜0€$k€˜0€$k˜0€$k˜0€$k˜0€$k0€$k˜0€$k€˜0€$k€˜0€$k˜0€$k˜0€$k˜0€$k˜0€$k˜0€$k˜0€$k80€ŹQ˜0€”˜0€”˜0€”˜0€”0€”˜0€”€˜0€”€˜0€”€˜0€”€˜0€”˜0€”80€ŹQ˜0€Dæ˜0€Dæ˜0€Dæ80€ŹQ˜0€²Ģ˜0€²Ģ˜0€²Ģ˜0€²Ģ˜0€²Ģ˜0€²Ģ80€ŹQ˜0€wą0€wą(0€€€˜0€łį€˜0€łį˜0€łį0€łį(0€€€˜0€gꀘ0€gę˜0€gę0€gę(0€€€˜0€ķ€˜0€ķ€(0€€€˜0€eń€˜0€eń0€eń(0€€€˜ 0€‡ó€˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0 €‡ó˜ 0 €‡ó˜ 0 €‡ó˜ 0 €‡ó˜ 0 €‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0€‡ó˜ 0 €‡ó˜ 0!€‡ó˜ 0"€‡ó˜ 0#€‡ó˜ 0$€‡ó˜ 0%€‡ó˜ 0&€‡ó˜ 0'€‡ó˜ 0(€‡ó˜ 0)€‡ó˜ 0*€‡ó˜ 0+€‡ó˜ 0,€‡ó˜ 0-€‡ó˜ 0.€‡ó˜ 0/€‡ó˜ 00€‡ó˜ 01€‡ó˜ 02€‡ó˜ 03€‡ó˜ 04€‡ó˜ 05€‡ó˜ 06€‡ó˜ 07€‡ó˜ 08€‡ó˜ 09€‡ó˜ 0:€‡ó˜ 0;€‡ó˜ 0<€‡ó˜ 0=€‡ó˜ 0>€‡ó˜ 0?€‡ó˜ 0@€‡ó˜ 0A€‡ó˜ 0B€‡ó˜ 0C€‡ó˜ 0D€‡ó˜ 0E€‡ó˜ 0F€‡ó˜ 0G€‡ó˜ 0H€‡ó˜ 0I€‡ó˜ 0J€‡ó˜ 0K€‡ó˜ 0L€‡ó˜ 0M€‡ó˜ 0N€‡ó˜ 0O€‡ó˜ 0P€‡ó˜ 0Q€‡ó˜ 0R€‡ó˜ 0S€‡ó˜ 0T€‡ó˜ 0U€‡ó˜ 0V€‡ó˜ 0W€‡ó˜ 0X€‡ó˜ 0Y€‡ó˜ 0Z€‡ó˜ 0[€‡ó˜ 0\€‡ó˜ 0]€‡ó˜ 0^€‡ó˜ 0_€‡ó˜ 0`€‡ó˜ 0a€‡ó˜ 0b€‡ó˜ 0c€‡ó˜ 0d€‡ó˜ 0e€‡ó˜ 0f€‡ó˜ 0g€‡ó˜ 0h€‡ó˜0€€$ż’S¤Źāų7gƒ™²d¤Ó2gŽÓ’ @ i ‘ ² ś : x Ä Ņ Q R & • Ō Õ " # q r ¤¦°ĪTV`GŽ£¹ŗŪšńż'BC^rsŽ”¢µĮĀä&':STp‚„—\×Ų#%C*¾*H+Ć+L,ī.õ0¬3(6<ģ>BgE’HaIJhNČQŹQŌQlTēTŽUVŽ[[ __jbƒbČiŌi$ktkykk›k¤k³k“kĮkĒkćkękčkékökžkllll$l(lFlJlMlNl[lcl{ll‚lƒlŒll¦lŖl­l®lølĮlÓl×lŚlŪlälźlmmmmmm-m1m4m5mAmJm^mbmemfmrm{m‡m‹mŽmmšm¢m®m²mµm¶m·m¼mŠmėmõm n!n"n/n:nAnDnHnQnRnSnTn]n^n_n`nanbncnknlnmnnnon|n‡nn“n—n n”n¢n£n«n¬n­n®nÆn¼nĘnĶnŠnŌnŽnßnąnįnźnėnģnķnīnļnšnųnłnśnūnün ooo o$o-o.o/o8oAoBoCoDoEoFoOoVoWoXoYoZocomovoyo~o‡oˆo‰o’ošo›oœoožoØo²oŗo½oĄoŹoĖoĢoÕoŽoßoąoįoāoćoīoļošońoņoóoōoüożožo’oppp p p p pppp"p,p/p3ppGpHpIpJpKpLpUp_phpkpppypzp{p„p‹pŒppŽpp›p„p­p°p“p½p¾pæpČpŃpŅpÓpŌpÕpÖpßpępēpčpépźpöpqq qqqqqq'q(q)q*q+q,q5qq?q@qKqUq[qgqmqqqrqsq|q„qq‘q’q“q”qœq„q±q²q³q“qµq¶q½q¾qæqĄqĮq€sūsętx5{”~ō_…Ś…¾‡Ō‰KŽ’8”u–Jšź›””1£\¤ÜØz°õ°5²°²ī³”ŗ2½Dæ^æĀČ²ĢĻĢGĻ7Ö²ŲŪbŽwą¦ą÷įłį āņāZäeęgę‹ęH菼ķķķcńeńpńHó…ó‡ó’ó[ōÖōhõ9öśö°÷µų%łąłgś½ś8ūü‡üżž‘ž’«’Ŗ w4WÆe0Séė ƒ 6 ß ™ U ś m ¦×¼rHĖcčæa™/Ūa<ŌŽBH ‘ !y!"½"t# $Õ$S%>&ū&Š'o(a)ļ)ń*¬+¬,Y-ø.¬/!01‰1Ž12s34É4o5(67Ņ7f8Č8*9Š9d:ö:«;|<1=ė=ī=˜0€€(0€€˜0€˜0€(0€€˜0€’80€’© 0€S© 0¤S© 0¤S© 0¤S© 0ųS© 0ųS© 0ųS© 0ųS© 0ųS© 0ųS© 0¤S© 0dS© 0dS© 0€S© 0S© 0S© 0€S© 0ŽS© 0ŽS© 0ŽS© 0ŽS© 0ŽS© 0ŽS© 0€S© 0² S© 0² S© 0² S© 0€S© 0Ä S ™0€S ˜0€S80€’©0€&  ™0€&  ©0€&  ™0€&  ©0€&  ‘0€&  ©0€&  ‘0€&  ˜0€& ˜0€& €(0€€˜0€¦˜0€¦˜0€¦˜0€¦(0€€˜0€V80€V©0€G ©0€G ™0€Gü ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G“ ©0€G ©0€G ‘0€G“ ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ©0€G ©0€G ‘0€G ˜0€G(0€€˜0€„0€„˜0€„0€„˜0€„˜0€„0€„˜0€„0€„˜0€„0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„˜0€„(0€€˜0€ŹQ0€ŹQ˜0€ŹQ00€ŹQ˜0€ŽU80€ŹQ˜0€Ž[80€ŹQ˜0€ _80€ŹQ˜0€jb80€ŹQ˜0€Či80€ŹQ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$kü ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k ˜0€$k©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ™0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ©0€$k ‘0€$k © 0€$k ©0€$k ©0€$k ©0€$k © 0€$k © 0€$k ‘0€$k © 0€$k ©0€$k ©0€$k ©0€$k © 0€$k © 0€$k ‘0€$k © 0€$k © 0€$k ©0€$k © 0€$k © 0€$k © 0€$k ‘0€$k ˜0€$k€0€$k˜0€$k€0€$k˜0€$k€˜0€$k€˜0€$k€˜0€$k€0€$k˜0€$k€0€$k˜0€$k€˜0€$k€˜0€$k€˜0€$k€˜0€$k€˜0€$k€˜0€$k€80€ŹQ€˜0€”€˜0€”€˜0€”€˜0€”€0€”˜0€”€0€”˜0€”€0€”˜0€”€˜0€”€80€ŹQ€˜0€D怘0€D怘0€Dæ€80€ŹQ€˜0€²Ģ€˜0€²Ģ€˜0€²Ģ€˜0€²Ģ€˜0€²Ģ€˜0€²Ģ€80€ŹQ€˜0€wą€˜0€wą€(0€€€˜0€łį€˜0€łį€˜0€łį€˜0€łį€(0€€€˜0€gꀘ0€gꀘ0€gꀘ0€gę€(0€€€˜0€ķ€˜0€ķ€(0€€€˜0€eń€˜0€eń€˜0€eń€(0€€€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0 €‡ó€˜ 0 €‡ó€˜ 0 €‡ó€˜ 0 €‡ó€˜ 0 €‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0€‡ó€˜ 0 €‡ó€˜ 0!€‡ó€˜ 0"€‡ó€˜ 0#€‡ó€˜ 0$€‡ó€˜ 0%€‡ó€˜ 0&€‡ó€˜ 0'€‡ó€˜ 0(€‡ó€˜ 0)€‡ó€˜ 0*€‡ó€˜ 0+€‡ó€˜ 0,€‡ó€˜ 0-€‡ó€˜ 0.€‡ó€˜ 0/€‡ó€˜ 00€‡ó€˜ 01€‡ó€˜ 02€‡ó€˜ 03€‡ó€˜ 04€‡ó€˜ 05€‡ó€˜ 06€‡ó€˜ 07€‡ó€˜ 08€‡ó€˜ 09€‡ó€˜ 0:€‡ó€˜ 0;€‡ó€˜ 0<€‡ó€˜ 0=€‡ó€˜ 0>€‡ó€˜ 0?€‡ó€˜ 0@€‡ó€˜ 0A€‡ó€˜ 0B€‡ó€˜ 0C€‡ó€˜ 0D€‡ó€˜ 0E€‡ó€˜ 0F€‡ó€˜ 0G€‡ó€˜ 0H€‡ó€˜ 0I€‡ó€˜ 0J€‡ó€˜ 0K€‡ó€˜ 0L€‡ó€˜ 0M€‡ó€˜ 0N€‡ó€˜ 0O€‡ó€˜ 0P€‡ó€˜ 0Q€‡ó€˜ 0R€‡ó€˜ 0S€‡ó€˜ 0T€‡ó€˜ 0U€‡ó€˜ 0V€‡ó€˜ 0W€‡ó€˜ 0X€‡ó€˜ 0Y€‡ó€˜ 0Z€‡ó€˜ 0[€‡ó€˜ 0\€‡ó€˜ 0]€‡ó€˜ 0^€‡ó€˜ 0_€‡ó€˜ 0`€‡ó€˜ 0a€‡ó€˜ 0b€‡ó€˜ 0c€‡ó€˜ 0d€‡ó€˜ 0e€‡ó€˜ 0f€‡ó€˜ 0g€‡ó€˜ 0h€‡ó€8ń!€-źCē]¶wœzƒ’B»„Éōēˆ/£­·¹ŗĘó  ¤QŌq¤¹!š!"B"r"”"Į"#&#S##Ć3ŗlv8vfvvŅvżv*wWw„wµwŽwx;xrx”x¤x°x³x¾x×xšxóxžxy.y1y=y@yKycy}yˆy”yŸy©y½y×yāyķyzz%z1z>zBzLzPzZz^zrzŒz—z›zÆzÉzŌzŽzõz {{${/{9{P{c{n{z{…{{„{Į{Ģ{ā{ģ{|||K~‚Ē³üś 8!±4Ķ.ˆ/¤¦§Ø©Ŗ«¬®Æ°±²³“µ¶ø»¼½¾æĄĮĀĆÄÅĒČÉŹĖĢĶĪĻŠŃŅÓŌÕÖ×ŲŁŚŪÜŻŽßąįāćäåęēčéźėģķīļšńņōõö÷ųłśūüżž’   ˆ/„\ÓÕC*ŗ*¼*H+æ+Į+lTćTåT€s÷słs_…Ö…Ų…z°ń°ó°5²¬²®²ģ=C’¬C’¬C’¬C’¬C’¬C’¬C’¬C’¬’’ "µ9t²#µ9ŒŠ$µ9dØ%µ9l†&µ9¶'µ9D¹.µ9nś/µ9<Ÿ0µ9 ŒČ1µ9“2µ9t$3µ9$    œ–œ–_—_—"£"£ī=    $ $ ©–©–d—d—/£/£ī= B*€urn:schemas-microsoft-com:office:smarttags€country-region€= *€urn:schemas-microsoft-com:office:smarttags €PlaceName€= *€urn:schemas-microsoft-com:office:smarttags €PlaceType€9 *€urn:schemas-microsoft-com:office:smarttags€place€ ä<ģ   cnķō#%79KWb“øķüBHwŲ ā ’ ? M  ‹ Ņ Ż ß ģ š  % / 8 A B O b k ® ² ³ ŗ *·¾ī&ARŪźgŹ=Ī=ī=ųśŻßNPS[R Ø Ą Ē & . ‰”›OQ  GOhl׹įõ<E¼ĀĒĻƒ!…!’"#''Ł'ä'¾*Ē*Č*G+Ć+Ģ+P2R2Ć7Å7Ņ8Ū8Ž@—@'H0H’HIaIfI²L“L+N-NaRcRēTšTÅUĖUŠUŲU'V8V8WSWˆ[Š[ ^$^mcoc‘j“j$k,kūstĄtĒtšwœw,{.{’{”{Ī~Ł~RTł‚ƒ„„Y…[…Ś…ć…ž‡Ŗ‡Æ‡ø‡2ˆ4ˆŠ‹Ņ‹ū‘ż‘2”4”i v Ų£Ś£ö¤ų¤x؀Øt°v°õ°ž°ā±ź±°²¹²›³£³}“Ņ7Y8_8¹8Į8Į9É9V:]:é:š: ;;œ;¤;n<u<"=*=Ż=å=ī=:::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::ī=§2żźVĄ’’’’’’’’’(-$æ’’’’’’’’’„Š„˜žĘŠ^„Š`„˜ž.€„ „˜žĘ ^„ `„˜ž.€„p„˜žĘp^„p`„˜ž.€„@ „˜žĘ@ ^„@ `„˜ž.€„„˜žĘ^„`„˜ž.€„ą„˜žĘą^„ą`„˜ž.€„°„˜žĘ°^„°`„˜ž.€„€„˜žĘ€^„€`„˜ž.€„P„˜žĘP^„P`„˜ž.„Š„˜žĘŠ^„Š`„˜ž.„ „˜žĘ ^„ `„˜žCJOJQJo(o„p„˜žĘp^„p`„˜žCJOJQJo(§š€„@ „˜žĘ@ ^„@ `„˜ž.€„„˜žĘ^„`„˜ž.€„ą„˜žĘą^„ą`„˜ž.€„°„˜žĘ°^„°`„˜ž.€„€„˜žĘ€^„€`„˜ž.€„P„˜žĘP^„P`„˜ž.(-$§2ż’’’’’’’’’’’’‚ EōV³tEōV%>UōfÕ.ŠŠddb$… ōfÕ.ŠŠddS0BEōVėR“ōfÕ.ŠŠddĀŌ+EōVīm,ōfÕ.ŠŠddōfÕ.EōV3S0BŠŠddĒn5@Z\mGŠŠddólAFEōVZ\mGEōVeMIS0BŠŠdd{*\PEōVń'ļTōfÕ.ŠŠddEōVć4laEōV4?·cZ\mGŠŠddŲgßlōfÕ.ŠŠdd«quZ\mGŠŠddÄh zEōV]`ź|EōVzńEōVåsxB|+¤MsŪ¤Q R • Ō Õ " # q r Ž£¹ŗŪšńż'BC^rsŽ”¢µĮĀä&':STp‚tkykk›k¤k³k“kĮkĒkćkękčkékökžkllll$l(lFlJlMlNl[lcl{ll‚lƒlŒll¦lŖl­l®lølĮlÓl×lŚlŪlälźlmmmmmm-m1m4m5mAmJm^mbmemfmrm{m‡m‹mŽmmšm¢m®m²mµm¶m·m¼mŠmėmõm n!n"n/n:nAnDnHnQnRnSnTn]n^n_n`nanbncnknlnmnnnon|n‡nn“n—n n”n¢n£n«n¬n­n®nÆn¼nĘnĶnŠnŌnŽnßnąnįnźnėnģnķnīnļnšnųnłnśnūnün ooo o$o-o.o/o8oAoBoCoDoEoFoOoVoWoXoYoZocomovoyo~o‡oˆo‰o’ošo›oœoožoØo²oŗo½oĄoŹoĖoĢoÕoŽoßoąoįoāoćoīoļošońoņoóoōoüożožo’oppp p p p pppp"p,p/p3ppGpHpIpJpKpLpUp_phpkpppypzp{p„p‹pŒppŽpp›p„p­p°p“p½p¾pæpČpŃpŅpÓpŌpÕpÖpßpępēpčpépźpöpqq qqqqqq'q(q)q*q+q,q5qq?q@qKqUq[qgqmqqqrqsq|q„qq‘q’q“q”qœq„q±q²q³q“qµq¶q½q¾qæqĄqĮqī=–žžž–žžžžžžžžžž–žžžžžžžžžžž–žžžžžžžžžžžžžžžžžžžžžžžžžžžžžžžž–’@€ė=ė=Ø$øė=ė=dLM°\°]°Ē°Čd:ģ=@@@T@¬@@f@Š@@Ņ@Ø@@X@’’Unknown’’’’’’’’’’’’G‡z €’Times New Roman5€Symbol3& ‡z €’Arial7‡ŸGeorgia?5 ‡z €’Courier New;€Wingdings"1ˆšŠhŸź›F ź›Fs/y¢As/y¢A!š  ““4J=J=3ƒšHX)š’?ä’’’’’’’’’’’’’’’’’’’’’MsŪ2’’Pulmonary Hypertension Jason Carter Jason Carter  ž’ą…ŸņłOh«‘+'³Ł0Œ˜øÄÜčō ( H T `lt|„äPulmonary HypertensionJason CarterNormalJason Carter1Microsoft Office Word@FĆ#@oęłōÅ@X2 śōÅs/yž’ÕĶ՜.“—+,ł®0 hp|„Œ” œ¤¬“ ¼ ßäA¢J= Pulmonary Hypertension Title  !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ ”¢£¤„¦§Ø©Ŗ«¬­®Æ°±²³“µ¶·ø¹ŗ»¼½¾æĄĮĀĆÄÅĘĒČÉŹĖĢĶĪĻŠŃŅÓŌÕÖ×ŲŁŚŪÜŻŽßąįāćäåęēčéźėģķīļšńņóōõö÷ųłśūüżž’     ž’’’ !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghijklmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ ”¢£¤„¦§Ø©Ŗ«¬­®Æ°±²³“µ¶·ø¹ŗ»¼½¾æĄĮĀĆÄÅĘĒČÉŹĖĢĶĪĻŠŃŅÓŌÕÖ×ŲŁŚŪÜŻŽßąįāćäåęēčéźėģķīļšńņóōõö÷ųłśūüżž’      !"#$%&'()*+,-./0123456789:;<=>?@ABCDEFGHIJKLMNOPQRSTUVWXYZ[\]^_`abcdefghiž’’’klmnopqrstuvwxyz{|}~€‚ƒ„…†‡ˆ‰Š‹ŒŽ‘’“”•–—˜™š›œžŸ ”¢£¤„¦§Ø©Ŗ«¬­®Æ°±²³“µ¶·ø¹ŗ»¼½¾æĄĮĀĆÄÅĘĒČÉŹĖĢĶĪĻŠŃŅÓŌÕÖ×ŲŁŚŪÜŻŽßąįāćäåęēčéž’’’ėģķīļšńž’’’óōõö÷ųłž’’’ż’’’ż’’’ż’’’ż’’’ż’’’ż’’’ż’’’ž’’’ž’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’Root Entry’’’’’’’’ ĄF \&śōÅ€Data ’’’’’’’’’’’’ėŸ1Table’’’’jžWordDocument’’’’42SummaryInformation(’’’’’’’’’’’’źDocumentSummaryInformation8’’’’’’’’ņCompObj’’’’’’’’’’’’q’’’’’’’’’’’’ž’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’’ž’ ’’’’ ĄFMicrosoft Office Word Document MSWordDocWord.Document.8ō9²q